{
  "Xis": "RESIDENT\nTeaching Video NeuroImages:\n& FELLOW\nSECTION\nDystonic posturing in anti-NMDA\nSection Editor\nMitchell S.V. Elkind, receptor encephalitis\nMD, MS\nChenjieXia,MD A 27-year-old woman presented with odd behavior, pathophysiology of paroxysmal dyskinesias in anti-\nFranc¸oisDubeau,MD seizures, and left arm paroxysmal dyskinesia, more NMDAreceptorencephalitis.1ExtensiveEEGmon-\nspecifically dystonic posturing (video 1 on the Neu- itoring of this patient almost certainly rules out an\nrology® Web site at www.neurology.org), with no ictal origin. Involvement of dopaminergic pathways\nAddresscorrespondenceand electrographic correlate on EEG. The diagnosis of hasrecentlybeenhypothesized.2\nreprintrequeststoDr.Chenjie\nXia,NeurologyDepartment, anti-NMDAreceptorencephalitiswasconfirmedby REFERENCES\nMontrealNeurologicalInstitute detectingserumandCSFanti-NMDAreceptoranti- 1. IizukaT,SakaiF,IdeT,etal.Anti-NMDAreceptoren-\nandHospital,3801University\nbodies. No ovarian teratoma was found, despite its cephalitis in Japan: long-term outcome without tumour\nSt.,Montreal,QuebecH3A2B4,\nremoval.Neurology2008;70:504–511.\nCanada associationwiththissyndrome.Sheimprovedmini-\nchenjie.xia@mail.mcgill.ca 2. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-\nmally with steroids, IV immunoglobulin, and plas-\nNMDA-receptorencephalitis:caseseriesandanalysisof\nmapheresis, but eventually responded to rituximab\nSupplementaldataat the effects of antibodies. Lancet Neurol 2008;7:1091–\nwww.neurology.org (video 2). We have not yet fully grasped the 1098.\nFromtheMontrealNeurologicalInstituteandHospital,Montreal,Quebec,Canada.\nDisclosure:Theauthorsreportnodisclosures.\ne80 Copyright © 2011byAANEnterprises,Inc.\nTeaching Video NeuroImages: Dystonic posturing in anti-NMDA receptor encephalitis\nChenjie Xia and François Dubeau\nNeurology 2011;76;e80\nDOI 10.1212/WNL.0b013e3182166dde\nThis information is current as of April 18, 2011\nUpdated Information & including high resolution figures, can be found at:\nServices http://n.neurology.org/content/76/16/e80.full.html\nSupplementary Material Supplementary material can be found at:\nhttp://n.neurology.org/content/suppl/2011/04/16/76.16.e80.DC1\nReferences This article cites 2 articles, 1 of which you can access for free at:\nhttp://n.neurology.org/content/76/16/e80.full.html##ref-list-1\nSubspecialty Collections This article, along with others on similar topics, appears in the\nfollowing collection(s):\nParaneoplastic syndrome\nhttp://n.neurology.org//cgi/collection/paraneoplastic_syndrome\nPermissions & Licensing Information about reproducing this article in parts (figures,tables) or in\nits entirety can be found online at:\nhttp://n.neurology.org/misc/about.xhtml#permissions\nReprints Information about ordering reprints can be found online:\nhttp://n.neurology.org/misc/addir.xhtml#reprintsus\nNeurology ® is the official journal of the American Academy of Neurology. Published continuously since\n1951, it is now a weekly with 48 issues per year. Copyright Copyright © 2011 by AAN Enterprises, Inc.. All\nrights reserved. Print ISSN: 0028-3878. Online ISSN: 1526-632X.",
  "Odriozola-Grijalba": "CorrespondenCia\ndiscinesias faciales y bucolinguales, distonías El estudio autoinmune en sangre mostró po-\nEncefalitis antirreceptor de NMDA de la extremidad superior derecha y movimien- sitividad de anticuerpos antinucleares, antipero-\nen un niño de cuatro años tos de ‘contar monedas’. xidasa (62,8 UI/mL; normal: 0-9 UI/mL) y anti-\nLa interacción con el medio fue disminuyen- tiroglobulina (49,4 UI/mL; normal: 0-4 UI/mL).\nMercedes odriozola-Grijalba a, inés Galé-ansó a,\ndo, precisó alimentación por sonda nasogástri- Los anticuerpos antirreceptor de NMDA en el\nJavier López-pisón a,c, Lorena Monge-Galindo a,c,\nca, presentó limitación de la marcha hasta im- LCR resultaron positivos mediante la técnica de\nJuan p. García-Íñiguez b,c, paula Madurga-\npedir la bipedestación, y desapareció el control inmunofluorescencia sobre células HEK293 trans-\nrevilla c, Francesc Graus d\nde esfínteres. El lenguaje fue disminuyendo has- fectadas con la subunidad NR1 del receptor NMDA.\na Unidad de Neuropediatría. b UCI Pediátrica. Hospital\nta presentar un mutismo completo 13 días tras Las ecografías abdominal, tiroidea y testicu-\nUniversitario Miguel Servet. c Grupo de Investigación\nNeurometabólico. Instituto Aragonés de Ciencias de la el comienzo de los síntomas. lar fueron normales.\nSalud. Zaragoza. d Servicio de Neurología. Hospital Clínic. Aparecieron episodios de sacudidas de co- El paciente permaneció ingresado 17 días.\nBarcelona, España. misura bucal autolimitadas de menos de un mi- Tres semanas después de los primeros síntomas\nCorrespondencia: Dr. Javier López Pisón. Unidad de nuto. Junto al deterioro progresivo del nivel de presentó un único episodio de crisis tonicoclóni-\nNeuropediatría. Hospital Universitario Miguel Servet.\nconciencia, presentaba episodios de agitación. ca generalizada que cedió con diacepam rectal.\nP.º Isabel La Católica, 1-3. E-50009 Zaragoza.\nA las dos semanas de evolución se trasladó a La mejoría fue progresiva, pero fluctuante, de\ne-mail: jlopezpi@salud.aragon.es\nnuestro centro, donde ingresó en la Unidad de los movimientos orofaciales, estado estuporo-\naceptado tras revisión externa: 28.04.11. Cuidados Intensivos. No precisó en ningún mo- so, alteraciones del sueño y episodios de agita-\nCómo citar este artículo: Odriozola-Grijalba M, Galé-Ansó I, mento asistencia respiratoria. ción, y recuperó paulatinamente las distintas\nLópez-Pisón J, Monge-Galindo L, García-Íñiguez JP, Madurga- El estudio bioquímico general, función tiroi- funciones: alimentación enteral, habla, memo-\nRevilla P, et al. Encefalitis antirreceptor de NMDA en un\ndea, lactato, amonio, cobre, ceruloplasmina, ho- ria anterógrada y marcha. Al alta hospitalaria\nniño de cuatro años. Rev Neurol 2011; 53: 58-60.\nmocisteína, aminoácidos en plasma, ácidos gra- deambulaba de forma autónoma, obedecía ór-\n© 2011 revista de neurología\nsos de cadena larga, mucopolisacáridos y ácidos denes, emitía frases coherentes, recordaba su-\norgánicos en orina fueron normales. Las reso- cesos pasados y personas, y manipulaba correc-\nLa encefalitis letárgica autoinmune o encefalitis nancias magnéticas (RM) realizadas a los 7 y 15 tamente con ambas manos. Tras ocho meses\nanti-NMDA (N-metil-D-aspartato) es una entidad días del inicio fueron normales. El electroence- de seguimiento, el paciente está asintomático.\npoco conocida, caracterizada por alteración del falograma mostró una lentificación difusa que\ncomportamiento con agitación, trastornos del evolucionó a la normalización. La encefalitis asociada con anticuerpos contra\nmovimiento y disfunción autonómica, asociada A su ingreso se realizó una punción lumbar los receptores NMDA del neurópilo del hipo-\na anticuerpos frente a antígenos de superficie con la que se obtuvo un líquido cefalorraquídeo campo es una entidad recientemente descrita;\ndel neurópilo del hipocampo, concretamente los (LCR) claro, con 13 células nucleadas, glucosa y en los últimos 20 años se han descrito enferme-\nreceptores de NMDA [1]. proteínas normales. dades similares catalogadas como ‘discinesia y\nSe presenta un nuevo caso de encefalitis El segundo día de ingreso, una vez confirma- deterioro neurológico de etiología desconoci-\nanti-NMDA en un niño de 4 años de edad y sin da la negatividad de la reacción en cadena de la da’, ‘encefalopatía coreiforme inmunomediada’\ntumor asociado, se revisa la bibliografía de esta polimerasa (PCR) del virus del herpes, se inició o ‘encefalitis juvenil aguda no herpética’ [1-3].\npatología en la edad pediátrica y se analizan las un tratamiento con metilprednisolona intrave- La patogenia aún no está clara, pero una teoría\ndiferencias de presentación con respecto a los nosa (30 mg/kg/día durante cinco días), y 48 ho- descrita por Likuza et al postula que una inhibi-\nadultos. ras después se añadieron inmunoglobulinas in- ción de los receptores NMDA en las neuronas\ntravenosas (2 g/kg). Presentó mejoría progresi- gabérgicas presinápticas causa una reducción de\nNiño de cuatro años de edad con antecedentes va, con un aumento del nivel de conciencia y una la liberación de ácido γ-aminobutírico (GABA), y\nfamiliares de hipotiroidismo en la familia ma- disminución de los movimientos coreiformes que esto determina la desinhibición de la transmi-\nterna, remitido a nuestro centro por presentar se hizo evidente al tercer y cuarto día tras el ini- sión postsináptica de glutamato con un aumen-\nuna alteración del comportamiento de dos se- cio de los corticoesteroides. Después de la metil- to de su liberación en las áreas prefrontales y\nmanas de evolución, con agresividad, amena- prednisolona intravenosa, se trató con prednisona subcorticales que contribuye al desarrollo de\nzas de autolisis, lenguaje inapropiado, apatía y oral: seis semanas con 60 mg/m2/día, seis sema- psicosis y discinesias de modo similar a la esqui-\nactitud desafiante, que inicialmente se atribu- nas a días alternos con 40 mg/m2 y seis semanas zofrenia [4].\nyeron a una separación temporal de la madre. con disminución gradual hasta la suspensión. Inicialmente fue identificada en mujeres jó-\nAdemás, presentaba un trastorno del sueño En el estudio microbiológico se detectó la venes como síndrome paraneoplásico asociado\ncon imposibilidad del descanso nocturno. Refe- presencia de Haemophilus influenzae en el fro- a un proceso tumoral subyacente, principalmen-\nría febrícula y faringoamigdalitis previas al co- tis faríngeo, y el estudio serológico, incluyendo te teratoma ovárico, y, en menor medida, en\nmienzo de la clínica. un estudio de ADN mediante PCR de virus her- varones, asociado a teratoma testicular y carci-\nValorado inicialmente en psiquiatría, recibió pes simple, virus varicela zóster, citomegalovi- noma microcítico de pulmón.\ntratamiento ansiolítico y antipsicótico, pero la rus, herpes 6 y virus de Epstein-Barr, resultó ne- Hay series de casos recientes en pacientes\nsintomatología continuó progresando con la gativo, lo que permitió la retirada de la terapia sin tumor asociado, sexo masculino y población\naparición, desde el séptimo día tras el inicio, de con cefotaxima y aciclovir. pediátrica [5-8].\n58 www.neurologia.com Rev Neurol 2011; 53 (1)\nCorrespondenCia\nLa clínica neuropsiquiátrica es característica, El origen autoinmune indica el uso de tera- El protocolo de nuestro servicio ante una en-\ncon una fase prodrómica, una fase aguda y un pia inmunosupresora con corticoesteroides, in- cefalopatía aguda o subaguda incluye la con-\nperíodo de recuperación prolongado. En la gran munoglobulinas, plasmaféresis y, en ocasiones, servación de 1-2 cm3 de LCR para valorar estu-\nmayoría de casos, se describe una clínica psi- rituximab o ciclofosfamida, aunque la respuesta dio de anticuerpos antirreceptor de NMDA. Ade-\nquiátrica llamativa que induce a enfocar la pato- a este tratamiento es muy variable y la recupe- más, recoge el siguiente razonamiento: ‘las en-\nlogía desde un punto de vista psiquiátrico. Los ración es lenta y sin clara correlación con una cefalitis autoinmunes, que pueden tener RM\nsíntomas iniciales son alteración del comporta- respuesta positiva inicial [5,9-10]. El éxito de la normal, son argumento de tratamiento precoz\nmiento, desinhibición, agitación, agresividad y inmunoterapia parece ser mayor cuando se aso- con corticoesteroides e inmunoglobulinas en en-\ndeterioro progresivo del lenguaje. En muchos cia a resección tumoral, disminuyendo la posibi- cefalopatías agudas de causa no aclarada, in-\npacientes, existen pródromos similares a los de lidad de recidiva, que puede darse en un 15-25% cluso antes de la realización de la RM’.\nnuestro caso, en forma de viriasis y febrícula. de los pacientes y se relaciona con valores eleva-\nComún a todos los casos es la aparición de dos de anticuerpos en el LCR, aunque éstos se En conclusión, la encefalitis anti-NMDA es una\ndiscinesias orofaciales, movimientos distónicos encuentren disminuidos en el plasma [5,10]. Se entidad recientemente descrita, más frecuente\ny coreoatetósicos de cara y miembros que hacen pueden producir una o varias recaídas entre 1 y en niños de lo que se pensaba previamente.\nplantear el diagnóstico diferencial con crisis fo- 96 meses tras la recuperación [5]. Presenta un curso clínico fácilmente reconoci-\ncales [5]. A lo largo de la evolución aparecen Probablemente, como consecuencia de una ble cuyo diagnóstico tiene gran implicación pro-\nfrecuentemente crisis epilépticas generalizadas. activación del sistema inmunitario de patogenia nóstica y en su manejo, por lo que ante una\nEs habitual la lentificación difusa en el elec- aún no aclarada, no es raro encontrar la asocia- historia clínica con signos similares a los descri-\ntroencefalograma. El LCR suele mostrar pleoci- ción entre distintos anticuerpos en el plasma; tos debería solicitarse la determinación de los\ntosis linfocitaria e hiperproteinorraquia, pero los más frecuentes, antinucleares y antipero- anticuerpos contra el receptor de NMDA, aun-\ntambién puede ser normal. La RM puede variar xidasa [5]. El hallazgo de anticuerpos antitiroi- que la espera de la confirmación no debe retra-\ndesde la normalidad hasta la visualización de deos en el plasma de nuestro paciente planteó sar el inicio del tratamiento.\nhiperintensidades temporales o atrofia de dife- el diagnóstico diferencial con encefalopatía de\nrentes áreas. El diagnóstico lo confirma la de- Hashimoto o más correctamente denominada\nBibliografía\ntección de anticuerpos contra la subunidad NR1 ‘encefalopatía sensible a corticoesteroides aso-\ndel receptor NMDA. ciada a tiroiditis autoinmune’, descrita en adul- 1. Dalmau J, Tuzun E, Wu HY, Masjuán J, Rossi JE,\nVoloschin A, et al. Paraneoplasic anti-N-methil-\nLa peculiaridad de nuestro caso es que se tos en el año 1966, poco frecuente en niños\nD-aspartate receptor encephalitis associated with\ntrata de un paciente de cuatro años de edad, pero de características clínicas similares a la en- ovarian teratoma. Ann Neurol 2007; 61: 25-36.\nvarón y sin patología tumoral asociada. El cua- cefalopatía anti-NMDA, respondedora a la tera- 2. Sebire G, Devictor D, Huault G, Aicardi J, Landrieu P,\ndro clínico en niños es similar al de los adultos, pia con corticoesteroides y de curso prolongado Tardieu M. Coma associated with intense bursts of\nabnormal movements and long-lasting cognitive\naunque hay diferencias en la asociación tumo- [11-13]. La detección en sangre de anticuerpos\ndisturbances: an acute encephalopathy of obscure\nral, presentación neurológica y frecuencia y ma- antitiroideos (principalmente antiperoxidasa) con- origin. J Pediatr 1992; 121: 845-51.\nnifestación de algunos síntomas. firma el diagnóstico. En nuestro caso, la cifra 3. Hartley LM, Ng SY, Dale RC, Church AJ, Martinez A,\nDe Sousa C. Immune mediated encephalopathy\nEn la revisión de 81 pacientes realizada por de anticuerpos antiperoxidasa detectada fue de\nsyndrome in childhood. Dev Med Child Neurol 2002;\nFlorance et al [5], 32 eran menores de 18 años 62,8 UI/mL, mientras que, aunque los niveles\n44: 273-7.\ny, de ellos, sólo 6 eran varones. Ningún varón pueden ser variables, la mediana descrita en la 4. Linuza T, Sakai F. Anti-NMDA receptor encephalitis:\nasoció patología tumoral. La revisión muestra bibliografía revisada es de 250 UI/mL [12]. Cabe clinical manifestations and pathophysiology. Brain\nNerve 2008; 60: 1047-60.\nuna relación directamente proporcional entre destacar que en ninguno de los casos revisados,\n5. Florance NR, Davis RL, Lam C, Szperka C, Zhou L,\nla edad y la asociación tumoral, que se ve dis- dado lo reciente del descubrimiento, se realizó de- Ahmad S, et al. Anti-N-methyl-D-aspartate receptor\nminuida en la infancia con respecto a los adul- tección de anticuerpos contra el receptor NMDA. (NMDAR) encephalitis in children and adolescents.\ntos, así como una menor frecuencia de tumor No queda claro, por tanto, que se trate de una Ann Neurol 2009; 66: 11-8.\n6. Ramos-Rivas M, Rojas-Velasco G, Acuña-Hidalgo R,\nen el sexo masculino. entidad claramente diferenciada [14-17].\nMárquez-Valero OA, Arellano-Bernal RH, Castro-\nEn la población pediátrica se describe una Algunos autores describen un término glo- Martínez E. Encefalitis límbica paraneoplásica: una\ndisfunción del sueño en forma de insomnio y bal denominado ‘meningoencefalitis inflama- entidad de difícil diagnóstico. Rev Neurol 2009; 48:\n311-6.\nterrores nocturnos, y también es más propio de torias autoinmunes no vasculíticas’, que incluye\n7. Herrero S, Guerrero AL, Gámez G, Fernández-Buey\ndicha edad la pérdida del control de esfínteres encefalitis límbicas paraneoplásicas, no para- MN, Conde A, Rodríguez M, et al. Encefalitis por\n[5,9]. Una serie de cuatro casos en niñas entre neoplásicas, encefalopatías asociadas con el lu- anticuerpos contra el receptor de NMDA. Descripción\ntres y ocho años [9] muestra clínica común con pus eritematoso sistémico y el síndrome de Sjö- de una paciente sin tumor asociado y revisión de la\nbibliografía. Rev Neurol 2010; 50: 661-6.\nalteración comportamental, discinesias orofa- gren, y la encefalopatía de Hashimoto. En todas\n8. González-Soltero ME, Gámez-Leyva G, Gavilán-Iglesias\nciales, pérdida completa del lenguaje, insomnio ellas, la detección de anticuerpos, la asociación T, Portilla-Cuenca JC, Casado-Naranjo I. Nuevo caso\ngrave y enuresis. En los adultos, las manifesta- con otros trastornos autoinmunes, y la respues- de encefalitis antirreceptor de NMDA sin tumor\nasociado. Rev Neurol 2011; 52: 250.\nciones autonómicas más frecuentes son la hipo- ta a corticoesteroides avalan un proceso inmu-\n9. Poloni C, Korff C, Ricotti V, King M, Roulet E, Mayor-\nventilación central con necesidad de ventilación nitario, la mayoría de fisiopatología aún no co-\nDubois C. Severe childhood encephalopathy with\nmecánica y alteraciones del ritmo cardíaco. nocida [13]. dyskinesia and prolonged cognitive disturbances:\nwww.neurologia.com Rev Neurol 2011; 53 (1) 59\nCorrespondenCia\nevidence for anti-N-methyl-D-aspartate receptor sarrollar una enfermedad sintomática crónica sado el SUMMA 112, se activó un código ictus y\nencephalitis. Dev Med Child Neurol 2010; 52: 78-82. en forma de afectación gastrointestinal o car- se la trasladó a urgencias, donde se objetivó un\n10. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X,\ndíaca. La cardiomiopatía crónica es la manifes- bajo nivel de conciencia, desviación oculocefáli-\nLai M, et al. Anti-NMDA-receptor encephalitis:\ncase series and analysis of the effects of antibodies. tación más frecuente de la enfermedad, que ca hacia la derecha que no sobrepasaba la línea\nLancet Neurol 2008; 7: 1091-8. causa insuficiencia cardíaca, dilatación cardía- media, disartria moderada, hemianopsia ho-\n11. Gayatri NA, Withehouse WP. Pilot survey of Hashimoto’s ca, varios tipos de arritmias y, como consecuen- mónima izquierda y paresia faciobraquiocrural\nencephalopathy in children. Dev Med Child Neurol\ncia de todo ello, ictus isquémicos embólicos, izquierda con una puntuación de 21 en la escala\n2005; 47: 556-8.\n12. Castillo P, Woodruff B, Caselli R, Vernino S, Lucchinetti etiología de la enfermedad cerebrovascular bien NIHSS. El hemograma y la coagulación fueron\nC, Swanson J, et al. Steroid-responsive encephalopathy conocida en los países en los que la enferme- normales, el electrocardiograma mostró una fi-\nassociated with autoinmune thyroiditis. Arch Neurol\ndad es endémica [2]. brilación auricular con bloqueo de rama izquier-\n2006; 63: 197-202.\nAunque tradicionalmente era una enferme- da y la tomografía computarizada (TC) no pre-\n13. Mocellin R, Walterfang M, Velakoulis D. Hashimoto’s\nencephalopathy: epidemiology, pathogenesis and dad rural transmitida por la picadura de varios sentó signos de sangrado o isquemia, y tan sólo\nmanagement. CNS Drugs 2007; 21: 799-811. géneros de chinches redúvidos que habitaban en una arteria cerebral media derecha hiperdensa.\n14. Fatourechi V. Hashimoto’s encephalopathy: myth\nlas casas, en las que diversos animales sal vajes o Al haber transcurrido menos de tres horas\nor reality? An endocrinologist’s perspective. Best\nPrac Res Clin Endocrinol Metab 2005; 19: 53-66. domésticos actuaban como reservorios naturales, desde la última vez en que la paciente fue vista\n15. Byrne OC, Zuberi SM, Madigan CA, King MD. por una parte, la posibilidad de otras formas de sana, con sospecha de ictus isquémico cardio-\nHashimoto’s thyroiditis, a rare but treatable cause transmisión sin necesidad de insectos vectores embólico y sin ningún criterio de exclusión, se\nof encephalopathy in children. Eur J Paediatr Neurol\n(transfusión sanguínea, congénita o transplacen- realizó una fibrinólisis sistémica con rtPA con\n2000; 4: 279-82.\n16. Vasconcellos E, Piña-Garza JE, Fakhoury T, Fenichel taria, trasplante de órganos o infección acciden- control ecográfico, que transcurrió sin compli-\nGM. Pediatric manifestations of Hashimoto’s tal en el laboratorio) y por otra, la migración en caciones, pero sin mejoría clínica ni de la oclu-\nencephalopathy. Pediatr Neurol 1999; 20: 394-8.\nlos últimos 20 años de pacientes asintomáticos sión. Quedó monitorizada en la unidad de ic-\n17. Sawka AM, Fatourechi V, Boeve BF, Mokri B. Rarity\nof encephalopathy associated with autoimmune desde las zonas rurales a las urbanas, y desde los tus; a las 24 h presentó en la TC un área hipo-\nthyroiditis: a case series from Mayo Clinic from 1950 países de Iberoamérica a Europa y Norte américa, densa corticosubcortical en el territorio de la\nto 1996. Thyroid 2002; 12: 393-8. hacen que esta enfermedad infecciosa deba con- arteria cerebral media derecha, y en el estudio\nsiderarse una enfermedad de la globalización [3]. sonológico, una oclusión de la arteria afecta,\nEn concreto, en España, como resultado de sin signos de ateromatosis en el resto de vasos.\nEnfermedad de Chagas y código ictus: la enorme emigración de personas originarias Se decidió anticoagular con heparina de bajo\nun caso importado de dichas zonas endémicas, se puede esperar peso molecular al valorar un riesgo embólico\nun número creciente de pacientes que mani- elevado.\nantonio Martínez-salio a, patricia Calleja-Castaño a, fiesten la enfermedad de Chagas, como lo de- A las 48 h, la paciente empezó a sufrir episo-\nM. dolores Valle-arcos a, Carmen sánchez- muestra la obligatoriedad de las pruebas de dios de taquicardia y bradicardia; posterior-\nsánchez a, Jaime díaz-Guzmán a, efrén salto-\ncontrol serológico para la tripanosomiasis en mente, un deterioro del nivel de conciencia con\nFernández b\nlos donantes de sangre a partir del año 2005, fibrilación auricular y respuesta ventricular rápi-\na Unidad de Ictus. Servicio de Neurología. b Servicio la alta prevalencia de serología positiva encon- da, hasta producirse una parada cardiorrespira-\nde Microbiología. Hospital Universitario 12 de Octubre.\ntrada en embarazadas bolivianas [4] y la previ- toria con asistolia, de la que se recuperó gracias\nMadrid, España.\nsión de ictus isquémicos en pacientes jóvenes a las maniobras de reanimación cardiopulmo-\nCorrespondencia: Dr. Antonio Martínez Salio. Servicio\nsin factores de riesgo vascular clásicos [5]. Pre- nar avanzadas, atropina y adrenalina. Ingresó\nde Neurología. Hospital Universitario 12 de Octubre.\nCtra. Andalucía, km 5,400. E-28041 Madrid. sentamos el caso de una paciente boliviana con en la UVI con ventilación mecánica mediante\nesta enfermedad diagnosticada tras la activa- traqueostomía, sufriendo dos episodios hipo-\ne-mail: amsalio@yahoo.com\nción de un código ictus, que creemos que es de tensivos. Una nueva TC no mostró cambios res-\nTrabajo publicado como póster en la Reunión Anual de\nla Sociedad Española de Neurología, Barcelona, 2010. interés para considerar esta posibilidad en los pecto a la previa, evolucionando a una muerte\nneurólogos españoles dedicados al tratamiento encefálica a las 24 h. A pesar de la sospecha\naceptado tras revisión externa: 25.03.11.\nde esta emergencia neurológica. diagnóstica de una enfermedad de Chagas, la\nCómo citar este artículo: Martínez-Salio A, Calleja-Castaño\nfamilia autorizó la donación, por lo que se reali-\nP, Valle-Arcos MD, Sánchez-Sánchez C, Díaz-Guzmán J,\nSalto-Fernández E. Enfermedad de Chagas y código ictus: Mujer de 48 años de edad, originaria del depar- zó un doble trasplante renal, con profilaxis a los\nun caso importado. Rev Neurol 2011; 53: 60-1. tamento de Cochabamba, Bolivia, residente en receptores. En el quirófano se advirtió una mio-\n© 2011 revista de neurología España desde hacía cuatro años, con antece- cardiopatía dilatada no observada en la radio-\ndentes familiares de un hermano con marcapa- logía simple. Con posterioridad se recibió un\nLa tripanosomiasis americana o enfermedad de sos y personales de un estudio por arritmia en estudio serológico con inmunocromatografía\nChagas es una zoonosis causada por el proto- su país de origen, sin tratamiento ni seguimien- negativa, ELISA (enzyme-linked immunosorbent\nzoo Trypanosoma cruzi. Es un gran problema de to médicos. Fue encontrada por sus compañe- assay) positiva y finalmente reacción en cadena\nsalud pública en América Central y Sudamérica, ras de piso con un cuadro de somnolencia exce- de la polimerasa (PCR) positiva para enferme-\ndonde se estima que el 8% de la población es siva, dificultad para la articulación del lenguaje dad de Chagas. El motivo del fallecimiento se\nseropositiva [1], de la cual un 10-30% va a de- y debilidad en las extremidades izquierdas. Avi- atribuyó a una causa cardíaca. Los receptores\n60 www.neurologia.com Rev Neurol 2011; 53 (1)",
  "Agrawal - Wassmer, 2010": "Postscript\nLETTERS encephalopathy or Sebire’s syndrome actu-\nally had anti-NMDAR encephalitis. Indeed,\nit is very important to consider anti-NM-\nSuccessful treatment of anti- DAR encephalitis as a diagnostic possibility\nN-methyl-d-aspartate receptor in any child with encephalopathy.\nThe clinical improvement appeared to\nlimbic encephalitis in a 22-month- be strongly time related to plasmapheresis\nold child with plasmapheresis in our patient, suggesting that a reduction\nin circulating antibodies can be an effective\nand pharmacological intervention, even in patients with a longer\nimmunomodulation history than that described by Schimmel\net al. This indicates the importance of con-\nsidering immunosuppressive therapy when\nWe report the case of a previously healthy\nthere is high suspicion of an immune-\n22-month-old girl who presented with the\nmediated central nervous system disorder\nfull clinical spectrum of anti-N-methyl-d-\nand other investigations have proved neg-\naspartate receptor (NMDAR) encephalitis\native, even when the serum is negative for\nwith seizures, agitation, stupor, autonomic\nthe antibody tests currently available. With\ninstability, dysphagia and relentless choreo-\nthe advent of new investigation techniques,\nathetoid movements.\nit is all the more important to avoid the pit-\nSchimmel et al describe a 12-year-old\nfalls so common in evaluating patients with\ngirl with typical clinical symptoms of the\nencephalopathy. The clinician must perform\nrecently described NMDAR encephalitis.1\na complete and critical review of the medical\nTheir patient was the youngest reported\nhistory along with a comprehensive exami-\ncase with this condition to date.\nnation. The challenge is to know and eval-\nThe symptoms in our patient began\nuate the differential diagnosis. Failure to do\n1 week after a meningitis C booster vac-\nso can result in a misdiagnosis which may\ncination. Cerebrospinal fl uid (CSF) exam-\nlead to unnecessary care, long-term therapy\nination on admission showed raised\nwithout clinical resolution, or even death.\nlymphocyte count and oligoclonal bands\nwith no oligoclonal bands in a paired blood Shakti Agrawal,1 Angela Vincent,2 Leslie Jacobson,2\nsample. All other investigations includ- David Milford,1 Rajat Gupta,1 Evangeline Wassmer1\ning PCR for human herpes virus 1 in CSF, 1Department of Paediatric Neurology, Birmingham Children’s\nbrain MRI, EEG, blood and urine tests for Hospital, Steelhouse Lane, Birmingham UK B4 6NH, UK\ncommon inborn errors of metabolism and\n2Neurosciences Group, Weatherall Institute of Molecular\nautoantibody screening were normal or\nMedicine, University of Oxford, John Radcliffe Hospital,\nnegative. The child did not respond to ini-\nOxford, UK\ntial treatment with antibiotics, acyclovir,\nsteroids and intravenous immunoglobulins. Correspondence to Dr Shakti Agrawal, Department of\nNeurology, Birmingham Children’s Hospital, Steelhouse\nThe working diagnosis was autoimmune\nLane, Birmingham B4 6NH.\nencephalopathy, also known as Sebire’s\nencephalopathy.2 However, 4 months after Provenance and peer reviewed Not commissioned; not\nthe onset of her symptoms the patient externally peer reviewed.\nshowed no signs of improvement and Patient consent Obtained.\nremained severely encephalopathic, hypo-\nAccepted 13 September 2009\ntonic, unable to sit, see or communicate\nArch Dis Child 2010;94:312. doi:10.1136/adc.2009.164889\nwith her surroundings and had marked\nchorea. At this stage plasmapheresis was\ncommenced. After 20 cycles of plasmaphe- REFERENCES\nresis and further immunosuppression with 1. Schimmel M, Bien CG, Vincent A, et al. Successful\nmycophenolate mofetil, the patient made treatment of anti-N-methyl-D-aspartate receptor\na remarkable recovery and continues to encephalitis presenting with catatonia. Arch Dis Child\n2009;94:314–16.\nmake progress. Now aged 3 years, she has\n2. Sébire G, Devictor D, Huault G, et al. Coma\nsingle words, good receptive language and\nassociated with intense bursts of abnormal\nis walking with mild ataxia. Blood samples\nmovements and long-lasting cognitive disturbances:\ntaken before plasmapheresis were found an acute encephalopathy of obscure origin. J Pediatr\nretrospectively to be positive for anti-NM- 1992;121:845–51.\nDAR antibodies. 3. Dalmau J, Rosenfeld MR. Paraneoplastic syndromes\nEncephalitis is caused by infection or by of the CNS. Lancet Neurol 2008;7:327–40.\nimmune mechanisms. In adults, immune- 4. Dalmau J, Tüzün E, Wu HY, et al. Paraneoplastic anti-\nmediated encephalitis with specifi c anti- N-methyl-D-aspartate receptor encephalitis associated\nwith ovarian teratoma. Ann Neurol 2007;61:25–36.\nbodies against NMDAR has recently been\ndescribed.3 4 Many of the published cases are\nof young women with an associated ovarian\nteratoma. Our case shows that the condition\ncan affect very young children and in our\nexperience these are often female (S Irani,\nL Jacobson, A Vincent, manuscript in prepa-\nration). It is possible that children described\nin the past as having an autoimmune\n312 Arch Dis Child April 2010 Vol 95 No 4\n1177__aacc116644888899,, aacc117733884499,, aacc117711994422,, aacc117744116699,, aacc117766112233 && aacc117766665511..iinndddd 331122 33//1177//22001100 22::3377::4422 PPMM\nArch\nDis\nChild:\nfirst\npublished\nas\n10.1136/adc.2009.164889\non\n24\nMarch\n2010.\nDownloaded\nfrom\nhttp://adc.bmj.com/\non\n28\nMay\n2018\nby\nguest.\nProtected\nby\ncopyright.",
  "Novillo-López, Graus": "TREATMENT-RESPONSIVE SUBACUTE LIMBIC\nENCEPHALITIS AND NMDA RECEPTOR ANTIBODIES IN A\nMAN\nMaría Elena Novillo-López, Jeffrey E. Rossi, Josep Dalmau, et al.\nNeurology 2008;70;728-729\nDOI 10.1212/01.wnl.0000305981.53537.d9\nThis information is current as of February 25, 2008\nThe online version of this article, along with updated information and services, is\nlocated on the World Wide Web at:\nhttp://www.neurology.org/content/70/9/728.full.html\nNeurology ® is the official journal of the American Academy of Neurology. Published continuously\nsince 1951, it is now a weekly with 48 issues per year. Copyright . All rights reserved. Print ISSN:\n0028-3878. Online ISSN: 1526-632X.\nClinical/Scientific\nNotes\nMar´ıaElenaNovillo- TREATMENT-RESPONSIVE SUBACUTE LIM- tientwasdiagnosedwithlimbicencephalitisand\nLo´pez,MD BIC ENCEPHALITIS AND NMDA RECEPTOR treated with carbamazepine 200 mg/8 hours,\nJeffreyE.Rossi,BS ANTIBODIESINAMAN methylprednisolone (1 g/day for 5 days and 60\nDisturbances of memory, behavior, cognition,\nJosepDalmau,MD, mg/dayforthenext2weeksfollowedbyprogres-\nand seizures can result from immune-mediated\nPhD sivetapering),andIVimmunoglobulins(0.4g/kg\nencephalitides. These disorders can be paraneo-\nJaimeMasjuan,MD for5days).Theseizuresresolvedaftercarbamaz-\nplasticornotandmayassociatewithseveralanti-\nepine was started, and the memory deficits and\nbodies.1 Recently, a treatment-responsive\ndisorientationprogressivelyimprovedduringthe\nparaneoplastic encephalitis that associates with\n4 weeks of hospitalization. Follow-up 4 months\nantibodies to NR1/NR2 heteromers of the\nafterdischargedemonstratedimprovementofthe\nNMDA receptor (NMDAR) was reported.2 Pa-\nMRI (figure, B), a normal neurologic examina-\ntientswereyoungwomenwithteratomas,usually\ntion, and the patient was planning to return to\noftheovary,whopresentedwithprominentpsy-\nwork.\nchiatric symptoms, and less frequently with fea-\nIncubation of live rat hippocampal neuronal\nturesoflimbicencephalitis.Wereportamanwith\ncultures with the patient’s serum and CSF re-\ntreatment-responsive limbic encephalitis and an-\nvealedantibodiesthatlabeledthecellsurfaceand\ntibodiestoNR1/NR2heteromers.\nneuronal processes (figure, C). Using previously\nreported techniques,2 the target autoantigens\nCase report. For 3 months this 53-year-old man\nwere identified as the NR1/NR2 heteromers of\nhad progressive short-term memory deficits and\ntheNMDAR(figure,DthroughF).Immunoblots\ndisorientation that forced him to leave his job.\noftheseproteinswererecognizedbycommercial\nDuring the month before hospital admission he NR1orNR2antibodiesbutnotthepatient’santi-\nhad multiple episodes compatible with partial bodies(notshown).LimitedamountofCSFpre-\ncomplexseizures.Hehadnopastmedicalhistory vented analysis of intrathecal synthesis of\nof interest. The neurologic examination only re- antibodies.Serumantibodytiters(usingserialdi-\nvealed short-term memory deficits and impair- lutionsonrathippocampalimmunohistochemis-\nment of temporal orientation. Blood cell count, try) showed a tenfold decrease at the 4-month\ngeneral chemistry, B12, folic acid, thyroid func- follow-up(from1:4,000to1:400).\ntion test, thyroglobulin antibodies, RPR, Lyme\nserology, antibodies to double stranded DNA, Discussion. Experience suggests that up to 40%\nand SSA/Ro and SSB/La were unrevealing. CSF of patients with limbic encephalitis do not have\nanalysisshowed5WBC/(cid:1)L(100%lymphocytes)\nclassic antineuronal or VGKC antibodies.1,3 Re-\nand normal glucose and protein concentration. cent studies show that many of these “seronega-\nSerum and CSF disclosed the same oligoclonal tive patients” actually have antibodies against\nIgG bands. Paraneoplastic antineuronal and neuronal cell surface antigens mainly concen-\nVGKC antibodies were negative. EEG demon- tratedinthehippocampus.4Oneoftheseantigens\nstrated bilateral temporal lobe epileptic activity. corresponds to extracellular epitopes of NR1/\nMRIofthebrainrevealednoncontrastenhancing NR2 heteromers of the NMDAR. All patients\nT2andFLAIRhyperintensitiesinvolvingtheme- previously reported with these antibodies were\ndialaspectofthetemporallobesandnonspecific youngwomenwithteratoma,andtheantibodies\nhyperintensities in the frontal lobes (figure, A). reacted with cells expressing interacting NR1/\nUltrasound of the testis, CT of the chest, abdo- NR2 subunits (functional channel), but not with\nmen and pelvis, and body [18F] fluorodeoxyglu- immunoblots of these cells or NR1/NR2 pro-\ncose were normal. A transient elevation of the teins.2 The associated syndrome usually presents\nprostate-specific antigen led to a biopsy of the with psychiatric manifestations (less frequently\nSupplementaldataat\nwww.neurology.org prostatethatrevealednomalignantcells.Thepa- withshort-termmemorydeficits)andmayevolve\n728 Neurology70 February26,2008\ndouble stranded DNA antibodies that crossre-\nFigure MRIandpatient’santibodies\nact with an epitope present in both NR2A and\nNR2Bsubunits.7Inallthesedisorders,theanti-\nbodies are detectable by immunoblot of single\nNR2 subunits and therefore differ from those\nof our patient, suggesting different syndrome-\nepitopeassociations.\nThepresentcasebringsintoconsiderationthe\nNR1/NR2 heteromers of NMDAR as autoanti-\ngensoflimbicencephalitis,paraneoplasticornot.\nRecognition of encephalitides associated with\nthese antibodies is important because despite\ntheirseverity,theyoftenrespondtotreatment.\nFromtheDepartmentofNeurology(M.E.N.-L.,J.M.),Hos-\npitalRamo´nyCajal,Madrid,Spain;andDivisionofNeuro-\noncology (J.E.R., J.D.), Department of Neurology,\nUniversityofPennsylvania,Philadelphia.\nDisclosure:Theauthorsreportnoconflictsofinterest.\nReceivedFebruary18,2007.AcceptedinfinalformMay30,2007.\nAddress correspondence and reprint requests to Dr. Josep\nDalmau, Department of Neurology, 3 W. Gates (Division\n(A)MRIFLAIRatsymptompresentationshowspredominanthyperintensitiesinthemedialtem- of Neuro-oncology), University of Pennsylvania, 3400\nporallobesandinsularregion,andsmallerareasofabnormalsignalinthefrontallobes.(B)MRI SpruceStreet,Philadelphia,PA19104;josep.dalmau@uphs.\nFLAIRatfollow-upshowssignificantimprovementofthetemporalandinsularregionabnormali- upenn.edu\nties.(C)Reactivityofthepatient’sCSFwiththecellsurfaceofculturesofrathippocampalneu-\nrons.Nucleiaredemonstratedwith4=,6-diamidino-2-phenylindole(DAPI,bluestaining).(D–F) Copyright © 2008byAANEnterprises,Inc.\nConfirmationthatthepatient’santibodiesselectivelyreactwithNMDARisshownusingHEK293\ncellsexpressingNR1/NR2AheteromersoftheNMDAR.Thereactivityofthepatient’sCSF 1. AncesBM,VitalianiR,TaylorRA,etal.Treatment-\n(green,D)co-localizes(yellow,E)withthereactivityofacommerciallyavailableNR2Aantibody responsive limbic encephalitis identified by neuropil\n(red,F).Inaddition,panelEshowsabackgroundofnon-transfectedcells(bluenucleistainedwith antibodies:MRIandPETcorrelates.Brain2005;128:\nDAPI)thatarenotreactivewiththepatient’santibodiesorNR2Aantibodies.Similarstudiesusing 1764–1777.\nHEK293cellsexpressingNR1/NR2Bdemonstratedthatthepatientalsohadantibodiesagainst\n2. Dalmau J, Tu¨zu¨n E, Wu H-Y, et al. Paraneoplastic\ntheseheteromers(seefiguree-1ontheNeurology®Websiteatwww.neurology.org).C–F,Immu-\nanti-N-methyl-D-aspartatereceptorencephalitisasso-\nnofluorescenttechnique,C(oillens(cid:1)800),D–F((cid:1)400).ThecommercialNR2Aantibodywas\nciatedwithovarianteratoma.AnnNeurol2007;61:25–\nusedat1:50dilution(UpstateBiotechnology,LakePlacid,NY),patient’sCSFat1:10,andAlexa\nFluorsecondaryantibodiesat1:2,000(MolecularProbes,OR),asreported.2 36.\n3. GultekinSH,RosenfeldMR,VoltzR,EichenJ,Posner\nto life-threatening complications including sei-\nJB,DalmauJ.Paraneoplasticlimbicencephalitis:neu-\nzures, hypoventilation, and autonomic instabil- rological symptoms, immunological findings and tu-\nity. Patients usually recover after removing the mourassociationin50patients.Brain2000;123:1481–\nteratomaandimmunotherapy. 1494.\nSeveralnotablefindingsofourpatientarethat 4. Bataller L, Kleopa KA, Wu GF, Rossi JE, Rosenfeld\nMR,DalmauJ.Autoimmunelimbicencephalitisin39\nhe is a man, with classic features of limbic en-\npatients:immunophenotypesandoutcomes.JNeurol\ncephalitis, and all studies for cancer have been\nNeurosurgPsychiatry2007;78:381–385.\nnegative to date. Furthermore, he had dramatic\n5. TakahashiY,MoriH,MishinaM,etal.Autoantibod-\nclinical and radiologic improvement that associ-\nies and cell-mediated autoimmunity to NMDA-type\natedwithadecreaseofNMDARantibodytiters. GluRepsilon2inpatientswithRasmussen’sencephali-\nAntibodies predominantly reacting with in- tisandchronicprogressiveepilepsiapartialiscontinua.\ntracellular (C-terminal) and less frequently Epilepsia2005;46:152–158.\nN-terminal linear epitopes of NR2 subunits 6. MochizukiY,MizutaniT,IsozakiE,OhtakeT,Taka-\nhashiY.Acutelimbicencephalitis:anewentity?Neu-\n(without requirement of NR1) have been re-\nrosciLett2006;394:5–8.\nported in several disorders, including epilepsia\n7. DeGiorgioLA,KonstantinovKN,LeeSC,HardinJA,\npartialis continua, Rasmussen encephalitis,5\nVolpe BT, Diamond B. A subset of lupus anti-DNA\nandsomecasesofnon-herpeticlimbicencepha-\nantibodiescross-reactswiththeNR2glutamaterecep-\nlitis identified in Japan.6 Furthermore, some torinsystemiclupuserythematosus.NatMed2001;7:\npatientswithneuropsychiatriclupushaveanti- 1189–1193.\nNeurology70 February26,2008 729\nTREATMENT-RESPONSIVE SUBACUTE LIMBIC ENCEPHALITIS AND\nNMDA RECEPTOR ANTIBODIES IN A MAN\nMaría Elena Novillo-López, Jeffrey E. Rossi, Josep Dalmau, et al.\nNeurology 2008;70;728-729\nDOI 10.1212/01.wnl.0000305981.53537.d9\nThis information is current as of February 25, 2008\nUpdated Information & including high resolution figures, can be found at:\nServices http://www.neurology.org/content/70/9/728.full.html\nSupplementary Material Supplementary material can be found at:\nhttp://www.neurology.org/content/suppl/2008/02/22/70.9.728.DC\n1.html\nReferences This article cites 7 articles, 3 of which you can access for free at:\nhttp://www.neurology.org/content/70/9/728.full.html##ref-list-1\nCitations This article has been cited by 7 HighWire-hosted articles:\nhttp://www.neurology.org/content/70/9/728.full.html##otherarticl\nes\nPermissions & Licensing Information about reproducing this article in parts (figures,tables)\nor in its entirety can be found online at:\nhttp://www.neurology.org/misc/about.xhtml#permissions\nReprints Information about ordering reprints can be found online:\nhttp://www.neurology.org/misc/addir.xhtml#reprintsus",
  "Suri-Suri": "Ann Indian Acad Neurol. 2013 Apr-Jun; 16(2): 169–171.\ndoi:  10.4103/0972-2327.112456\nPMCID: PMC3724067\nPMID: 23956557\nYoung girl with abnormal behavior: Anti-N-Methyl-D-Aspartate receptor immune encephalitis\nVinit Suri, Sushma Sharma, Rohan Gupta, Nilesh Jadhao, and Kunal Suri\nDepartment of Neurology, Indraprastha Apollo Hospitals, New Delhi, India\nFor correspondence: Dr. Sushma Sharma, Department of Neurology, Indraprastha Apollo Hospital, New Delhi, India. E-mail: moc.liamg@321amhsusrd\nReceived 2013 Jan 1; Revised 2013 Jan 20; Accepted 2013 Jan 21.\nCopyright : © Annals of Indian Academy of Neurology\nThis is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.\nGo to:\nAbstract\nAnti N Methyl D Aspartate receptor immune encephalitis (Anti NMDARE) is a recently defined, under-recognized and often misdiagnosed disease, which typically occurs in young females and may be associated with an underlying tumor, usually ovarian teratoma. If diagnosed early, initiation of immunotherapy and tumor removal (if present) may result in recovery. We report a case of a 17 years old girl with Anti NMDARE who was initially misdiagnosed as Functional psychosis, Neuroleptic Malignant Syndrome and Sepsis syndrome. To the best of our knowledge, this is only the second case of anti NMDARE being reported from India. This case report underscores the need for a greater awareness of this entity across multiple specialties, e.g., general medicine, psychiatry and neurology, to ensure a heightened diagnostic suspicion, which can lead to timely diagnosis and adequate therapy of this treatable disease.\nKeywords: Immune encephalitis, N-Methyl-D-Aspartate, psychosis, neuroleptic malignant syndrome\nGo to:\nIntroduction\nAnti-N-Methyl-D-Aspartate receptor immune encephalitis (Anti-NMDARE) is an immune-mediated syndrome that remains under-recognized despite a growing body of literature. We describe an interesting case of a young girl with anti-NMDARE who was initially misdiagnosed as functional psychosis, Neuroleptic Malignant syndrome (NMS), and Sepsis syndrome.\nGo to:\nCase Report\nA 17-year-old, school-going girl developed acute onset of behavioral change, initially manifested as extreme politeness and obedience (as against her pre-morbid gregarious personality), progressing within a few days to excessive and irrelevant talks accompanied with features of disinhibition. Frank psychotic features emerged within 10 days, including verbal and physical aggression, muttering to herself, and marked delusional thoughts with a tendency to run amok. A diagnosis of acute functional psychosis was made by a psychiatrist and oleanzapine was started. The behavioral syndrome persisted, albeit with mild reduction of psychomotor activity. After a few days, she developed stiffness of whole body along with akinesia and mutism. She was evaluated further by neurologist and psychiatrist. Magnetic resonance imaging (MRI) Brain revealed few scattered, non-diffusion restricted, non-contrast-enhancing T2 and Fluid Attenuated Inversion Recovery sequence (FLAIR) hyper intensities in periventricular and centrum semi-ovale region. Cerebrospinal fluid (CSF) examination revealed no cells, normal protein, and normal glucose levels. CSF viral markers, Venereal Diseases Research Laboratory test, gram stain, acid fast bacillus stain, India ink, cryptococcal antigen, and bacterial, mycobacterial and fungal cultures were negative. Electroencephalogram showed a non-specific diffuse theta delta slowing. She had low grade fever and serum Creatinine Phosphokinase was raised to 1800 U/dl. A diagnosis of NMS due to oleanzapine was considered and dantrolene and hydration were started. Other than a slight reduction of rigidity, no other improvement was noticed. Clinical worsening continued over next 2 weeks, with increasing mental obtundation and persistent akinetic mute state. About 4 weeks after disease onset, frequent bouts of tachypnea, tachycardia, hypotension, and sweating were noticed, which deteriorated over next 48 h to gasping for breath, associated with oxygen desaturation in blood, necessitating endotracheal intubation, and mechanical ventilation. At this stage, patient was brought to our center. Widely fluctuating heart rate and blood pressure were noted, with stimulus-induced sinus tachycardia, tachypnea, and diaphoresis, necessitating sedative infusion. A provisional diagnosis of sepsis syndrome due to bilateral aspiration pneumonia was considered by the treating physician. She received critical care and medical support and was re-evaluated by neurology team for her underlying progressive illness. A possibility of immune encephalitis was considered at this stage. MRI Brain was repeated; similar changes as noted before were found [Figure 1]. Besides work up for infectious meningoencephalitis (which turned out normal again), CSF samples were also sent for anti-NMDA receptor antibody, anti-Voltage gated potassium channel VGKC, and anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antibody levels. Vasculitic work up (anti nuclear antibody, anti-double stranded DNA, anti phospholipid antibody, lupus anti-coagulant, cytoplasmic and perinuclear anti neutrophilic cytoplasmic antibody) was normal. Anti-thyroid peroxidase antibody and anti-thyroglobulin antibody were negative. Computed tomography (CT) scan of chest, abdomen, and pelvis revealed neither ovarian teratoma nor any other malignancy. Patient had two episodes of tonic-clonic seizures, unrelated to any transient metabolic abnormality. While the immune CSF markers were still awaited, it was thought prudent to empirically treat her with immunomodution. She received intravenous immunoglobulin (IVIG), 20 g/day, for 5 days. Within a few days, first signs of improvement of sensorium were noticed with ability to spontaneously open eyes and fixate gaze. The clinical course was further complicated by sequential development of ventilator-associated bilateral pneumothorax, on right side followed by left, necessitating bilateral intercostal tube drainage. During the stage of improvement of sensorium, she developed severe oro-lingual dyskinesias which subsided over next 10 days. Patient was gradually weaned off the ventilator within 2 weeks after receiving IVIG. The anti-NMDA antibody in CSF was meanwhile reported to be positive, whereas anti-VGKC and anti-AMPA antibodies were negative, thus confirming the diagnosis of anti-NMDARE. The patient had a remarkable and quick neurological recovery, with full recovery of sensorium with normal higher mental functions, within 4 weeks of receiving IVIG, with subtle, steadily resolving distal acral lower motor neuron deficit due to overlap of critical illness polyneuropathy. The need for follow-up and periodic screening for teratoma has been explained to the patient and her parents.\nGo to:\nDiscussion\nAnti-NMDAR encephalitis, first defined in 2007 by Dalmau J et al., has been reported from India only once, in 2010.[1,2] Predominantly described in young females with a constellation of symptoms, including personality changes, autonomic dysfunction, extra pyramidal features, and seizures, it may be either an idiopathic or a paraneoplastic syndrome, the latter being associated commonly with ovarian teratomas (in about 60% of young females) and rarely with other neoplasms, e.g., mediastinal teratoma, hodgkin’s lymphoma, testicular tumor or small cell lung carcinoma (in 1-2% of patients, mainly in males).[3]\nClinical syndrome follows well-defined phases. Following a prodromal flu-like illness, neuropsychiatric symptoms such as agitation, psychotic symptoms, behavioral changes, and progressive unresponsiveness occur. Next, a dysautonomic phase ensues, with central hypoventilation, cardiac arrhythmias, hypo or hyperthermia, apneic spells, blood pressure fluctuations, and seizures. This is followed by a hyperkinetic phase with dyskinesias, bruxism, lip and tongue biting, dystonia, complex stereotyped movements, and ophisthotonus and oculogyric crisis, in various combinations. Next follows the phase of gradual recovery wherein the neurological syndrome gradually subsides, sometimes leaving behind its sequelae.[2,4,5] The clinical course in our patient conformed well to these typically described phases of clinical evolution.\nPathogenesis wise, antibodies against NR1-NR2 subunits of NMDA receptors, present in serum and CSF, predominantly block gamma amino butyric acid containing neurons, leading to disinhibition of excitatory pathways and increased extracellular glutamate. Resultant fronto-striatal syndrome is characterized by psychosis, catatonia, mutism, and dystonia. Disinhibition of brainstem central pattern generator accounts for orofacial dyskinesias and involuntary movements of the limbs and trunk. Blockade of NMDAR in the dopaminergic, cholinergic, and noradrenergic systems may explain the dysautonomia whereas a direct effect of the antibodies on the ponto-medullary respiratory network may lead to respiratory dysfunction. Since ovarian teratomas express NR1; immune cross-reactivity probably accounts for association with anti-NMDARE.[6]\nCranial CT scan is usually normal. MRI brain may be normal or may demonstrate non-specific, non-contrast-enhancing white matter hyper intensitiesin the T2-weighted or FLAIR sequences (as seen in our patient). CSF may be initially abnormal, with moderate lymphocytic pleocytosis and normal or mildly increased protein concentration in up to 80% of patients. CSF anti-NMDAR antibodies are highly positive and titers correlate with disease process.[3,6,7]\nAlthough no standard of care exists, experts recommend eradication of associated malignancy and immunomodulation. Immunotherapies include corticosteroids, IVIG, plasmapheresis, rituximab, cyclophosphamide, and azathioprine, of which corticosteroids, IVIG, or plasmapheresis constitute the first line approach.[3,8,9] Since plasmapheresis is not without risks, especially in dysautonomic state, and corticosteroids carry the risk of aggravation of usually co-existing infection, IVIG appears to be a safer option. However, systematic comparisons between the three first line modalities are not yet available.[9] Decision to choose one modality or the other may therefore be made on a case-to-case basis, keeping the clinical condition of patient, cost, and availability factors in mind.\nRelapses may occur in 20-25% of patients, especially in those without teratoma; in such patients continued immunosuppressants (mycophenolate mofetil or azathioprine) for at least 1 year after discontinuation of initial immunotherapies is recommended.[3] Besides, periodic screening for tumor is recommended if it is not found on first presentation. The extent and frequency of screening depends on patient’s age and sex. In female patients aged 12 years or older, approach similar to that of paraneoplastic syndromes is appropriate (e.g., MRI of the abdomen and pelvis every 6 months for 4 years), but in young children (<12 years) and male patients the need for repeat screening is not clear. If detected, the tumor should be promptly removed to speed up improvement and decrease relapses.[3,9]\nThe important outcome determinants, identified in a recently published observational cohort study, include stay in an intensive care unit (a marker for the severity of disease) and the time from symptom onset to initiation of treatment.[9] Latter underscores the need for early diagnosis and prompt treatment.\nIn conclusion, this case report highlights several important issues. Since most of the initial manifestations are likely to mimic functional psychosis, neurologists and psychiatrist should be aware of this entity. Intensivists and internists diagnosing NMS in patients on anti-psychotic medications should also have a high index of suspicion for this entity. Absence of hyperpyrexia and lack of good response to dantrolene should alert towards an alternate possibility, other than NMS. A greater awareness of auto-immune encephalitis, including NMDARE across various specialties would prevent potential diagnostic pitfalls which lead to non-diagnosis and misdiagnosis of this disease which probably is more under-recognized than rare.\nGo to:\nFootnotes\nSource of Support: Nil\nConflict of Interest: Nil.\nGo to:\nReferences\n1. Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36. [PMCID: PMC2430743] [PubMed: 17262855]\n2. Maramattom BV, Philip C, Sundaram PS. Idiopathic anti-NMDA-receptor encephalitis in a young Indian girl. Neurol India. 2010;58:671–2. [PubMed: 20739825]\n3. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74. [PMCID: PMC3158385] [PubMed: 21163445]\n4. Davies G, Irani SR, Coltart C, Ingle G, Amin Y, Taylor C, et al. Anti-N-methyl-D-aspartate receptor antibodies: A potentially treatable cause of encephalitis in the intensive care unit. Crit Care Med. 2010;38:679–82. [PubMed: 20016378]\n5. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al. Anti-NMDA receptor encephalitis in Japan: Long-term outcome without tumor removal. Neurology. 2008;70:504–11. [PMCID: PMC2586938] [PubMed: 17898324]\n6. Maramattom BV, Jacob A. N-methyl D-aspartate receptor encephalitis: A new addition to the spectrum of autoimmune encephalitis. Ann Indian Acad Neurol. 2011;14:153–7. [PMCID: PMC3200034] [PubMed: 22028524]\n7. Florance-Ryan N, Dalmau J. Update on anti-N-methyl-D-aspartate receptor encephalitis in children and adolescents. Curr Opin Pediatr. 2010;22:739–44.[PubMed: 21045695]\n8. Chapman MR, Vause HE. Anti-NMDA receptor encephalitis: Diagnosis, psychiatric presentation, and treatment. Am J Psychiatry. 2011;168:245–51.[PubMed: 21368306]\n9. Titulaer MJ, McCracken L, Gabilondo I, Armangué T, Glaser C, Iizuka T, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: An observational cohort study. Lancet Neurol. 2013;12:157–65. [PMCID: PMC3563251] [PubMed: 23290630]\nGo to:\nFigures and Tables\nFigure 1\n\nFLAIR magnetic resonance imaging brain revealing few periventricular (a, arrows) and centrum semiovale (b, arrows) white matter hyper intensities",
  "Kim, Park - Lee, 2018": "Anti-NMDAR Encephalitis in a 13-Year-Old Female:\nA 24-Month Clinical Follow-Up\n1 2 1 1\nEunsil Kim, MD , Eu Gene Park, MD , Jiwon Lee, MD , Munhyang Lee, MD, PhD ,\n3 1\nJihye Kim, MD, PhD , Jeehun Lee, MD, PhD\n1Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul;\nCase Report 2Department of Pediatrics, Uijeongbu St. Mary’s Hospital, The Catholic University School of Medicine, Seoul;\n3Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University\nJournal of Epilepsy Research\npISSN 2233-6249 / eISSN 2233-6257 School of Medicine, Seoul, Korea\nAnti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a rare autoimmune disorder manifesting\nas seizures, movement disorders, and psychiatric changes. However, there have been few case reports\nconcerning this disorder in South Korean children. The current case report describes a pediatric patient\nwith anti-NMDAR encephalitis. A 13-year-old female patient developed clonic movements of the right\narm followed by aphasia, paresthesia, and right-sided hemiparesis. The electroencephalogram (EEG)\nresults indicated electroclinical seizures arising from the left temporal area. Brain magnetic resonance\nimaging (MRI) revealed high signal intensity and cortical swelling in left temporal lobe. Anti-NMDAR\nantibodies were detected in the cerebrospinal fluid (CSF). The patient was treated with intravenous\nimmunoglobulin and high-dose methylprednisolone and showed partial improvement in language skills,\nReceived April 13, 2018\nAccepted June 25, 2018 paresthesia, and motor power. The brain MRI and EEG results also indicated improvement. However,\nCorresponding author: anti-NMDAR antibodies persisted in the CSF. After four doses of rituximab, the patient exhibited\nJeehun Lee, MD, PhD\ncomplete recovery of language and motor skills, and was seizure free under treatment with antiepileptic\nDepartment of Pediatrics, Samsung Medical\nCenter, Sungkyunkwan University School of medication. There were no residual anti-NMDAR antibodies in the CSF at her 24-month follow-up visit.\nMedicine, 81 Irwon-ro, Gangnam-gu, Seoul\nThis case report elucidates the benefits of early intervention using rituximab to improve neurological\n06351, Korea\nTel. +82-2-3410-0910 deficits and achieve baseline recovery in patients with anti-NMDAR encephalitis. (2018;8:41-48)\nFax. +82-2-3410-0043\nE-mail; jhlee0101@skku.edu Key words: Autoimmune, Encephalitis, Child, NMDA receptor antibody\nIntroduction guideline for the optimal management of patients with this disease,\nparticularly in children.6,7 Here, we report a case of anti-NMDAR\nAnti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is a encephalitis in a 13-year-old female treated with rituximab. This case\nwell-described clinical disorderin children and adults,1 and is one of the report may contribute towards elucidating the benefits of early inter-\nwell-known contributors to encephalitis in children.2 This autoimmune vention using rituximab to improve neurological deficits, reduce the\ndisease is becoming increasingly recognized in the pediatric pop- amount of residual anti-NMDAR antibodies in the CSF, and achieve\nulation,3 yet the pathophysiology in most cases of anti-NMDAR ence- baseline recovery in patients with anti-NMDAR encephalitis, who\nphalitis remains unknown. However, a few cases of this disorder have show only a partial response or are refractory to first-line therapies.\nbeen thought to have a paraneoplastic origin.4,5 Children with an-\nti-NMDAR encephalitis initially present with prodromal symptoms of Case\nneuropsychiatric abnormalities in behavior, speech, and mood, which\nare often accompanied by personality change, memory loss, and A 13-year-old female was referred to Samsung Seoul Hospital\nseizures. A definitive diagnosis requires the detection of NMDAR anti- with frequent clonic movements of the right arm and leg followed by\nbodies in the cerebrospinal fluid (CSF).6 Early diagnosis and prompt right-sided weakness, paresthesia, and acute onset of aphasia. One\ntreatment can improve outcomes; however, there is no consensus month prior, she had clonic movements of the right arm and leg last-\nThis is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/)\nwhich permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.\n42 Journal of Epilepsy Research Vol.8, No.1, 2018\ning about 2 minutes without loss of consciousness. The results of tains to diffuse cerebral dysfunction (Fig. 1). T2-weighted brain MRI\nelectroencephalography (EEG) and brain magnetic resonance imag- revealed multifocal high signal intensity lesions and cortical swelling\ning (MRI) were unremarkable at initial presentation. She was pre- involving bilateral temporal lobes, including the limbic system, which\nscribed levetiracetam for the prevention of seizures. were more promient in the left hemisphere (Fig. 2).\nTwo weeks after the initial presentation, the patient experienced\nClinical course during initial admission\nright leg weakness along with right hand and right foot paresthesia\nand was referred to Samsung Seoul Hospital. Upon admission, the The patient was empirically treated for acute bacterial meningitis\npatient experienced fever and her temperature had risen to 38°C. and acute encephalitis with intravenous vancomycin (60 mg/kg/day\nShe exhibited clonic movements of the right arm, was inarticulate divided in 4 doses), cefotaxime (160 mg/kg/day divided in 4 doses),\nand could neither verbalize nor understand others. and acyclovir (30 mg/kg/day divided in 3 doses) until the tests for mi-\nShe was born from non-consanguineous parents at the 38th week croorganisms yielded results. Additionally, azithromycin (10 mg/kg/day)\nof gestation by spontaneous vaginal delivery at an appropriate gesta- was administered because mycoplasma pneumoniae infection was\ntional age. There was no history of significant illness, the results of her suspected, as the mycoplasma pneumoniae antibody titer was 1:640.\ngeneral physical examination were normal, and there was no evi- For the treatment of seizures, diphenylhydantoin (4 mg/kg/day) and\ndence of an external injury. She was alert and the results of her cranial levetiracetam (20 mg/kg/day) were administered. From the 2nd\nnerve examination were also normal. She exhibited decreased hospital day, intravenous immunoglobulin (400 mg/kg/day for 5 days)\nright-sided motor power (motor grade IV) and right-sided paresthesia. was introduced considering the differential diagnoses (limbic ence-\nThere were no pathological reflexes. phalitis, viral encephalitis, autoimmune encephalitis, and acute dis-\nseminated encephalomyelitis) based on brain MRI results. On the 10th\nInitial clinical course\nhospital day, antibiotic treatments were ceased because the bacterial\nThe patient exhibited continuous right-sidedclonic movements at cultures exhibited no growth of bacterial organisms. Despite the neg-\nthe time of transfer. The clinical impression was an epilepsiapartialis ative polymerase chain reaction results for herpes simplex virus (HSV1\ncontinua because the EEG revealed continuous slow waves in the left and HSV2), acyclovir was continued for 14 days for the complete treat-\nhemisphere and frequent spikes or sharp wave discharges from the ment of possible herpes virus encephalitis.\nleft temporal areas and identified multiple electroclinical seizures On the 15th hospital day, the CSF tests for autoimmune antibodies\narising from the left temporal area (Fig. 1). The seizures were- revealed the presence of anti-NMDAR antibodies (Table 1). Following\ncontrolled with intravenous lorazepam (5 mg). She was admitted to this result, methylprednisolone pulse therapy was commenced at\nthe general ward and treated with antibiotics (cefotaxime, vancomy- 790 mg once daily (15 mg/kg/day) for three consecutive days. To de-\ncin, and azithromycin), an antiviral agent (acyclovir), antiepileptic termine the etiology of the anti-NMDAR encephalitis, particularly a\ndrugs (levetiracetam and oxcarbazepine), and dexamethasone. possible paraneoplastic origin, chest and abdomen-pelvis computed\ntomography (CT) scans were performed. On abdomen-pelvis CT, a\nLaboratory findings\nsmall, low, attenuated lesion was noted in the right adnexa. For fur-\nThe complete blood count was normal. Antinuclear antibodies, ther evaluation, an abdomen-pelvis MRI was performed; the lesion\nrheumatoid factor, immunoglobulins, complement, thyroid function was concluded to be multiple follicles of both ovaries, and there was\ntest, and α-fetoprotein were within normal limits. There was no re- no demonstrable tumorous lesion (Fig. 3).\nmarkable elevation of anti-viral antibody titers from serum and CSF Between the 21st and 25th hospital day, there was a significant\nsamples, including herpes simplex virus, enterovirus, and Japanese B improvement in the patient’s condition regarding speech, motor\nencephalitis virus. The CSF analysis did not indicate pleocytosis or power, and paresthesia. The lesions observed on brain MRI\nother biochemical abnormalities and was negative for cultures of decreased in extent, but high signal intensity with cortical swelling\nbacteria and viruses (Table 1). The initial EEG demonstrated electro- involving the temporal lobes and the limbic system, predominantly in\nclinical seizures arising from the left temporal area. The follow-up the left hemisphere, was still observed on fluid-attenuated inversion\nEEG revealed intermittent and generalized slow waves, which per-\nCopyright ⓒ 2018 Korean Epilepsy Society\nEunsil Kim, et al. Anti-NMDAR Encephalitis in a 13-Year-Old Female 43\nA\nB\nC\nFigure 1. (A) One month after initial presentation (on admission): regional sharp waves from the left temporal lobe (arrows) and cerebral dysfunction in the\nleft hemisphere. (B) Follow-up EEG after methylprednisolone pulse therapy: diffuse or severe regional cerebral dysfunction in the left fronto-centro-temporal\nareas; no epileptic discharges. (C) Follow-up EEG after rituximab therapy: diffuse cerebral dysfunction in the left fronto-centro-temporal or left\ntemporo-parieto-occipital area; no epileptic discharges. EEG, electroencephalogram.\nwww.kes.or.kr\n44 Journal of Epilepsy Research Vol.8, No.1, 2018\nTable 1. Results of laboratory tests\nTest performed Results (reference, if applicable)\nClinical laboratory studies\n9.68 x 1,000\nWBC (cells/μL)\nNegative\nC-reactive protein\n67 (0-27)\nErythrocyte sedimentation rate (mm/hr)\n25.2\nSerum ammonia level (mmol/L)\nCSF findings\nLymphocytes 89 (40-80)\n% of cell count with differential (%)\n82 (45-60)\nGlucose (mg/dL)\nNegative\nEnterovirus PCR\nNegative\nHerpes simplex virus PCR\nNo bacterial seen, no growth at 48 hour\nCulture with gram stain\nNegative\nOligoclonal band\n1,280 (759-1,549)\nIgG serum (mg/dL)\nNegative\nAnti-nuclear antibody\nNegative\nAnti-ds DNA antibody\nNegative\nAnti-cardiolipin antibody\n5 (0-14)\nRheumatoid factor (IU/mL)\nPositive\nNMDA autoantibody\n33.5 (0-60)\nThyroglobulin antibody (U/mL)\n0.7 (0-10.0)\nα-fetoprotein (ng/mL)\nWBC, white blood cell; CSF, cerebrospinal fluid; PCR, polymerase chain reaction; NMDA, N-methyl-D-aspartate receptor.\nA B\nC D\nFigure 2. Magnetic resonance imaging (MRI) of the brain. (A) Initial brain MRI: FLAIR hyperintensities and cortical swelling involving the temporal lobe,\nincluding the limbic system, predominantly on the left side. (B) Follow-up brain MRI after 14 days in the hospital: improved interval. (C) Follow-up brain MRI\nafter 2 months in the hospital: no interval change. (D) Follow-up brain MRI after 9 months following rituximab therapy: no interval change. FLAIR,\nfluid-attenuated inversion recovery.\nCopyright ⓒ 2018 Korean Epilepsy Society\nEunsil Kim, et al. Anti-NMDAR Encephalitis in a 13-Year-Old Female 45\nA B C\nFigure 3. Evaluation of anti-NMDAR encephalitis etiology. (A) There was no remarkable tumorous condition in the chest CT. (B) Abdomen CT: 1 x 0.5 cm\nhypodense lesion in the right adnexa (arrow). (C) Abdomen-pelvis MRI: multiple follicles of both ovaries without a demonstrable tumorous lesion (arrow).\nNMDAR, N-methyl-D-aspartate receptor; CT, computed tomography; MRI, magnetic resonance imaging.\nrecovery (FLAIR). The follow-up EEG on the 21st hospital day re- relapses.8\nvealed continuous slow waves in the left fronto-centro-temporal At the last visit (24 months after symptom onset and 18 months\nareas without epileptiform discharges. after rituximab treatment), the patient maintained a seizure-free\nThe patient was discharged on the 25th hospital day and was pre- state and performed well in school, with no demonstrable tumor\nscribed clobazam, valproic acid, diphenylhydantoin, and oxcarbazepine. lesion in the follow-up tumor screening. Therefore, the remaining an-\nThe patient’s receptivity to communication appeared to be improved, tiepileptic drug, oxcarbazepine, was discontinued.\nbut her speech, particularly word variety, sentence length, and\nword-finding ability, remained slightly below baseline. Discussion\nClinical follow-up after initial admission\nAnti-NMDAR encephalitis, originally described in 2005 as a para-\nBy the time of the outpatient follow-up visit, approximately one neoplastic syndrome in a group of women with ovarian teratoma,\nmonth after discharge, the patient showed near complete resolution was linked to the presence of anti-NMDAR antibodies and was offi-\nof sensory aphasia, motor weakness, and paresthesia symptoms and cially defined in 2007.5 Approximately 40% of reported patients with\na partial resolution of calculation disability and motor aphasia anti-NMDAR encephalitis are < 18 years of age.6 A recent study\nsymptoms. However, anti-NMDAR antibodies were still present in the compiling data from more than 577 patients with anti-NMDAR ence-\nCSF (weakly positive antibody reactivity). Four months after dis- phalitis found that 37% of them were in the pediatric age group.9\ncharge, despite the nearly complete resolution of clinical symptoms, Most children with anti-NMDAR encephalitis present with seizures or\nthere were no remarkable improvements in brain MRI and EEG re- movement disorders10 rather than psychiatric symptoms such as\nsults, i.e., no interval change inresidual high signal intensity lesions anxiety, agitation, paranoia, and visual or auditory hallucinations,\ninvolving the left temporal lobe, including the limbic system, on brain which are more predominant in adults with anti-NMDAR\nMRI; and generalized continuous slow waves onthe EEG. As a sec- encephalitis.5,11\nond-line therapy to treat the persistent presence of anti-NMDAR an- The patient in this study presented with epilepsia partialis con-\ntibodies in the CSF, rituximab (a monoclonal anti-CD20 antibody), tinua, which is rarely reported in pediatric anti-NMDAR encephali-\n375 mg/m2 per dose weekly was administered four times in total. tis,12,13 along with motor aphasia and unilateral sensory changes.\nEight months after discharge, the patient achieved symptom-free According to a recent study, the first neurological symptoms ob-\nstatus. The EEG revealed localized intermittent slow waves in the left served in young children with anti-NMDAR encephalitis included\ntemporal areas, and the brain MRI indicated decreased extents of seizure (72%), particularly focal seizure (42%), with a median onset\nhigh signal intensities in the left temporal lobe (Fig. 2). She was sus- of 15 days before other encephalitis symptoms appeared; other pa-\npected to be at risk of a relapse based on the EEG and the brain MRI tients mostly exhibited behavioral disorders (26%).14 Thus, in pa-\nresults, and a third CSF study was conductedbecause change- tients presenting a novel onset of altered mental status, seizures, or\nsinanti-NMDAR antibody titers in the CSF correlate with clinical behavioral changes, anti-NMDAR encephalitis should be systemati-\nwww.kes.or.kr\n46 Journal of Epilepsy Research Vol.8, No.1, 2018\ncally considered in the absence of other apparent etiologies. nal changes throughout the brain.18\nWith early diagnosis and effective treatment, patients with The majority of anti-NMDAR encephalitis cases are idiopathic in\nanti- NMDAR encephalitis have a relatively good prognosis and can pathophysiology; however, a significant minority can be attributed to\nachieve baseline recovery and complete resolution at follow-up a paraneoplastic origin.19 Regardless of tumor presence, patients with\nexamination.4,15 According to the California Encephalitis Project, the anti-NMDAR encephalitis should be treated with first-line im-\nnumber of young patients with anti-NDMAR encephalitis was greater munotherapy, typically corticosteroids, intravenous immunoglobulin\nthan that of patients with viral encephalitis.16 Thus, anti-NMDAR (IVIG), or plasmapheresis. The patients without tumors have an initial\nencephalitis must be considered and should be part of the differential response rate of 48%.4 In pediatric patients, first-line immunotherapy\ndiagnosis in young patients with limbic encephalitis. is effective in only half of the patients diagnosed with anti-NMDAR\nIn this case, the EEG revealed regional epileptiform discharges and encephalitis because pediatric patients are less likely to have causa-\nslow waves, which are frequently described in children with anti- tive tumors compared to adults.20 If there is no response to the\nNMDAR encephalitis as well as in adults.17 This patient initially pre- first-line immunotherapy, rituximab or cyclophosphamide are usually\nsented unremarkable changes in the brain MRI, but the following recommended for the treatment of clinical symptoms and prevention\nMRI (after the presentation of motor aphasia and epilepsiapartialis of relapse.4,5,10,20,21\ncontinua) indicated increased signals on T2-weighted FLAIR MRI se- In this patient, the anti-NMDAR antibodies in the CSF were pres-\nquences involving the temporal lobes, including the limbic system, ent without a causative tumor. After detection of anti-NMDAR anti-\npredominantly in the left hemisphere. The findings of the brain MRI in our bodies in the CSF, methylprednisolone pulse therapy was added to\npatient were consistent with findings of anti-NMDAR encephalitis.12,18 the initial IVIG treatment considering the incomplete resolution of\nIn most cases (89%), brain MRI results are normal or reveal non-spe- the clinical symptoms. Although remarkable clinical improvements\ncific focal changes at the initial presentation, as in this case.6 Another were observed after high-dose steroid treatment, there were residual\nstudy reported that most patients with NMDAR encephalitis (66%) anti-NMDAR antibodies in the CSF. After the additional rituximab\nhad normal brain MRI findings, and the remaining 44% had a wide therapy, the patient no longer reported any symptoms (Fig. 4).\nvariation in the distribution and degree of T2-FLAIR hyperintense sig- Despite a prolonged presence of abnormalities in the brain MRI and\nFigure 4. Clinical course of this patient―a 13-year-old female diagnosed with anti-NMDAR encephalitis. NMDAR, N-methyl-D-aspartate receptor; IVIG,\nintravenous immunoglobulin. *Antibiotics: vancomycin, cefotaxime, azithromycin.\nCopyright ⓒ 2018 Korean Epilepsy Society\nEunsil Kim, et al. Anti-NMDAR Encephalitis in a 13-Year-Old Female 47\nEEG, there was no demonstrable tumor lesion in the follow-up tumor review. J Clin Apher 2015;30:212-6.\nscreening test. A CSF study was performed because changes in an- 2. Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children:\nti-NMDAR antibody titers in the CSF correlate with clinical relapses,8 clinical phenomenology, therapeutics, and emerging challenges. Curr\nOpin Neurol 2017;30:334-44.\nand anti-NMDAR antibodies were not present in the patient’s CSF.\n3. Zhu WW, Liao WP, Yi YH, Song XW. Efficacy and safety of cyclo-\nAmong patients with anti-NDMAR encephalitis who do not respond\nphosphamide as a sequential immunotherapy drug for anti-N-meth-\nto first-line therapy (i.e., steroids, intravenous immunoglobulin), yl-D-aspartate receptor encephalitis in children. Zhongguo Dang Dai\nthose receiving second-line immunotherapy (i.e., rituximab) achieve Er Ke Za Zhi 2017;19:668-71.\na better outcome than those who do not receive second-line agents.7 4. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon\nR. Clinical experience and laboratory investigations in patients with an-\nPatients receiving second-line immunotherapy also experience fewer\nrelapses than those not receiving such therapy.9 Accumulating data ti-NMDAR encephalitis. Lancet Neurol 2011;10:63-74.\n5. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor ence-\nsuggest that rituximab is an effective treatment for anti-NMDAR en-\nphalitis: case series and analysis of the effects of antibodies. Lancet\ncephalitis in both children and adults.22\nNeurol 2008;7:1091-8.\nAnti-NMDAR-encephalitis is mediated by immunoglobulin G anti- 6. Irani SR, Bera K, Waters P, et al. N-methyl-D-aspartate antibody ence-\nbodies against the GluN1 subunit of the neuronal NMDA receptor. phalitis: temporal progression of clinical and paraclinical observations\nThe inflammatory neuronal dysfunction is thought to be initially re- in a predominantly non-paraneoplastic disorder of both sexes. Brain\n2010;133:1655-67.\nversible but potentially progresses to permanent neuronal destruc-\n7. Hallowell S, Tebedge E, Oates M, Hand E. Rituximab for Treatment of\ntion if untreated, due to prolonged inflammation and NMDA-medi-\nRefractory Anti-NMDA Receptor Encephalitis in a Pediatric Patient. J\nated glutamate excitotoxicity.18,23 Thus, rituximab may be a favora-\nPediatr Pharmacol Ther 2017;22:118-23.\nbletreatment option for patients who have residual anti-NMDAR an- 8. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at di-\ntibodies in the CSF and for those who do not respond to im- agnosis and during follow-up of anti-NMDA receptor encephalitis: a\nmunosuppressive therapy (i.e., corticosteroids andIVIG).7,24 retrospective study. Lancet Neurol 2014;13:167-77.\n9. Goldberg EM, Titulaer M, de Blank PM, Sievert A, Ryan N.\nIn summary, this report discusses the case of a 13-year-old female\nAnti-N-methyl-D-aspartate receptor-mediated encephalitis in infants\nwith anti-NMDAR encephalitis, which was idiopathic in etiology. She\nand toddlers: case report and review of the literature. Pediatr Neurol\nreceived first-line (i.e., steroid and intravenous immunoglobulin) and\n2014;50:181-4.\nsecond-line (i.e., rituximab) immunotherapy, and 18 months after ini-\n10. Lin JJ, Lin KL, Hsia SH, et al. Anti-N-methyl-D-aspartate receptor en-\ntial presentation, normalcerebral function was restored and there cephalitis in Taiwan--a comparison between children and adults.\nwereno residual anti-NMDAR antibodies in the CSF. Patients with Pediatr Neurol 2014;50:574-80.\nanti-NMDAR encephalitis typically present with psychiatric symp- 11. Brenton JN, Kim J, Schwartz RH. Approach to the management of pe-\ndiatric-onset anti-N-Methyl-d-Aspartate (anti-NMDA) receptor ence-\ntoms and partial seizures, and it is important that they receivean ear-\nphalitis: a case series. J Child Neurol 2016;31:1150-5.\nly diagnosis and prompt treatment for an improved prognosis. The\n12. Kim EH, Kim YJ, Ko TS, Yum MS, Lee JH. A young child of anti-NMDA\nmedical history, combined with brain MRI, EEG, and CSF examina-\nreceptor encephalitis presenting with epilepsia partialis continua: the\ntion, was helpful in the diagnosis of anti-NMDAR encephalitis. Our first pediatric case in Korea. Korean J Pediatr 2016;59(Suppl 1):S133-8.\ncase suggests that in patients who have residual anti-NMDAR anti- 13. Kumakura A, Miyajima T, Fujii T, Takahashi Y, Ito M. A patient with\nbodies or in those who do not tolerate first-line immunotherapy, rit- epilepsia partialis continua with anti-glutamate receptor epsilon 2\nantibodies. Pediatr Neurol 2003;29:160-3.\nuximab could be considered as a treatment option. Thus, physicians\n14. Favier M, Joubert B, Picard G, et al. Initial clinical presentation of\nmight consider the early initiation of second-line immunotherapy in\nyoung children with N-methyl-d-aspartate receptor encephalitis. Eur J\ncertain cases of anti-NMDAR encephalitis.\nPaediatr Neurol 2018;22:404-11.\n15. Nunez-Enamorado N, Camacho-Salas A, Belda-Hofheinz S, et al. Fast\nReferences and spectacular clinical response to plasmapheresis in a paediatric\ncase of anti-NMDA encephalitis. Rev Neurol 2012;54:420-4.\n1. DeSena AD, Noland DK, Matevosyan K, et al. Intravenous methyl- 16. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The frequency of\nprednisolone versus therapeutic plasma exchange for treatment of an- autoimmune N-methyl-D-aspartate receptor encephalitis surpasses\nti-N-methyl-D-aspartate receptor antibody encephalitis: a retrospective that of individual viral etiologies in young individuals enrolled in the\nwww.kes.or.kr\n48 Journal of Epilepsy Research Vol.8, No.1, 2018\nCalifornia Encephalitis Project. Clin Infect Dis 2012;54:899-904. 2013;12:157-65.\n17. Huang Q, Wu Y, Qin R, Wei X, Ma M. Clinical characteristics and out- 21. Salvucci A, Devine IM, Hammond D, Sheth RD. Pediatric anti-NMDA\ncomes between children and adults with anti-N-Methyl-D-Aspartate (N-methyl D-aspartate) receptor encephalitis. Pediatr Neurol 2014;50:\nreceptor encephalitis. J Neurol 2016;263:2446-55. 507-10.\n18. Kelley BP, Patel SC, Marin HL, Corrigan JJ, Mitsias PD, Griffith B. 22. Bien CG, Vincent A, Barnett MH, et al. Immunopathology of autoanti-\nAutoimmune encephalitis: pathophysiology and imaging review of an body-associated encephalitides: clues for pathogenesis. Brain 2012;\noverlooked diagnosis. AJNR Am J Neuroradiol 2017;38:1070-8. 135:1622-38.\n19. Armangue T, Titulaer MJ, Málaga I, et al. Pediatric anti-N-meth- 23. Bravo-Oro A, Acosta-Yebra D, Grimaldo-Zapata IP, Reyes-Vaca G.\nyl-D-aspartate receptor encephalitis-clinical analysis and novel findings Reversible cortical atrophy secondary to anti-NMDA receptor antibody\nin a series of 20 patients. J Pediatr 2013;162:850-6.e2. encephalitis. Rev Neurol 2015;60:447-52.\n20. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prog- 24. Iizuka T, Ishima D, Kaneko J, Nishiyama K. Clinical spectrum and\nnostic factors for long-term outcome in patients with anti-NMDA re- treatment strategy in anti-NMDA receptor encephalitis: current status\nceptor encephalitis: an observational cohort study. Lancet Neurol and issues. Rinsho Shinkeigaku 2014;54:1098-102.\nCopyright ⓒ 2018 Korean Epilepsy Society",
  "Lu - Lu, 2016": "NeurolSci(2016)37:149–151\nDOI10.1007/s10072-015-2385-9\nLETTER TO THE EDITOR\nBrainstem and vestibulocochlear nerve involvement in relapsing–\nremitting anti-NMDAR encephalitis\nTingting Lu1 • Wei Cai1 • Wei Qiu1 • Xiaobo Sun1 • Zhengqi Lu1\nReceived:17June2015/Accepted:18September2015/Publishedonline:26September2015\n(cid:2)Springer-VerlagItalia2015\nBackground antipsychotic agents. Dexamethasone 10 mg daily was\nadministered and tapped gradually. The patient experi-\nSince first reported in 2007, anti-N-methyl-D-aspartate enced a period of reduced consciousness and then com-\nreceptor (NMDAR) antibodies have become an increas- plainedofshortnessofbreathandhyperhidrosis.However,\ningly recognized cause of autoimmune encephalitis (AIE). she gradually returned to baseline conditions in 1 month\nUsually, the disease is mono-phasic. The main symptoms and was asymptomatic between December 2013 and\ninclude progressive psychosis, memory impairment, February 2014 while using antipsychotics and prednisone\nmovementdisorders,seizures,dysautonomiaanddecreased 10 mg per day.\nlevel of consciousness [1]. Brainstem symptoms are rarely In March 2014, after a few days of cough and expec-\nnoticed. We reported a case of relapsing–remitting anti- toration, she complained of blurred vision as well as tin-\nNMDAR encephalitis, wherein presented with dizziness nitus and hearing loss in the right ear. She then felt\nand hearing loss related to brainstem and right vestibulo- vertiginous and could not walk stably. On admission, her\ncochlear nerve injury in relapse. temperature was 100.9 (cid:3)F. Neurological examinations\nrevealed right supertemporal and left supernasal visual-\nfielddefects,coarsehorizontalnystagmusinbotheyes,and\nCase hearing loss in the right ear. During hospitalization, the\npatient again complained of shortness of breath and\nIn September 2013, 10 days after cough and expectoration hyperhidrosis. Routine blood and CSF tests were still\nwithmildfever,a16-year-oldfemalebecamealerttolight unremarkable. Oligoclonal bands were negative in the\nand sound and suffered from optical and auditory halluci- CSF. Brain MRI scan revealed abnormal areas in the left\nnation,hypochondriacideaofepilepsy,aswellasadecline temporal lobe, left hippocampus and parahippocampal\nin concentration, calculation capability and memory. Her gyrus,rightcerebellumandrightbrachiumpontis.Notably,\nelectroencephalogram (EEG) revealed diffuse slowing the right vestibulocochlear nerve was hyperintensified on\nwaves. Routine blood tests, cerebrospinal fluid (CSF) T2 flair images (Fig. 1a–d).\nexaminationsandbrainmagneticresonanceimaging(MRI) Considering the likelihood of AIE, high doses of\nshowed no notable alteration. The patient was diagnosed methylprednisolone were administered. After anti-\nwith viral encephalitis and treated with antiviral and NMDARantibodies1:1positiveweredetectedintheCSF,\nanti-NMDAR encephalitis was confirmed. Bilateral cystic\nadnexal masses were identified using computerized\nT.LuandW.Caicontributedequallytothispaper.\ntomography (CT) scan (Fig. 2). The patient gained near-\n& ZhengqiLu complete recovery, experiencing only horizontal nystag-\nlzq1828@aliyun.com mus and slight unsteady gait on discharge. For mainte-\nnance, methylprednisolone was gradually tapped to 8 mg\n1 DepartmentofNeurology,TheThirdAffiliatedHospitalof\neveryotherdayandazathioprine50 mgperdaywasadded.\nSunYat-senUniversity,No.600TianheRoad,Guangzhou,\nGuangdongProvince,China No sign of relapse has been found so far (Fig. 1e, f).\n123\n150 NeurolSci(2016)37:149–151\nFig.1 Magnetic resonance images of the patient in relapse before brachium pontis on T2 flair. The right vestibulocochlear nerve was\nand after immunotherapy. a, b Before immunotherapy, hyperinten- also involved, as indicated by the arrow. c, d T1 contrast demon-\nsifiedlesionswereobservedinthelefttemporallobe,lefthippocam- strated slightly enhance in the abnormal regions. e, f Three months\npus and parahippocampal gyrus, and the right cerebellum and right afterimmunotherapy,thehyperintensifiedlesionsreturnedtonormal\nThepatientwasadmittedfordizzinessandhearingloss;\nhowever, after reviewing her medical history, a special\n‘‘viral encephalitis’’ was noticed. It was characterized by\nlimbic system symptoms that lacked signs of meninges\ninvolvement, shared common features, such as suspected\nhypoventilation and autonomic dysfunction with the pre-\nsent illness, and was responsive to steroids. We believed\nthe patient suffered from AIE with a relapsing–remitting\ncourse. Detected anti-NMDAR antibody in the CSF led to\nthe diagnosis of anti-NMDAR encephalitis.\nRelapses occur inapproximately 25 %ofanti-NMDAR\nencephalitis cases. The typical manifestation in relapse is\nmildsymptomsconsistentwiththefirstepisode[1].Toour\nknowledge, our case is the first one which presented with\ndifferent symptoms in the two episodes. Consistent with\nFig.2 Cysticadnexalmassesrevealedbycomputerizedtomography,\nthedistributionofNMDARs,neuro-inflammationhasbeen\nasindicatedbyarrowsonbothsides\nproved to affect the pons and cerebellum in anti-NMDAR\nencephalitis by PET/SPECT [2]. Nevertheless, brainstem\nDiscussion symptomsarerareinclinicalpractice.Onlyoneothercase\nwith ophthalmoplegia accompanied by flaccid paraplegia\nWe reported the first case of relapsing–remitting anti- hasbeen reported. Inthatcase,ophthalmoplegiawasmore\nNMDARencephalitispresentingwithtypicalsymptomsof likely to be a part of Miller-Fisher syndrome during the\npsychotic disorders and cognitive impairment in the first course of anti-NMDAR encephalitis [3, 4]. Our patient\nepisode butdizzinessandhearinglossrelated tobrainstem complained of hearing loss and vertigo. Brain MRI indi-\nand cerebellar as well as vestibulocochlear nerve injury in catedinflammatoryalterationintherightvestibulocochlear\nthe second episode. nerve and the circular region. NMDAR expression is\n123\nNeurolSci(2016)37:149–151 151\nproved in the cochlear nuclei [5]. The abnormal signal in References\ntherightvestibulocochlearnervecouldbesecondarytothe\ncochlear nuclei and vestibular nuclei insults. Both cases 1. Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C,\nIizukaT,HonigLS,BenselerSM,KawachiI,Martinez-Hernandez\nwere relapsing–remitting. We speculated that brain stem\nE,AguilarE,Gresa-ArribasN,Ryan-FloranceN,TorrentsA,Saiz\nand cerebellum involvement may be associated with a\nA, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013)\nhigher probability of relapse. Treatment and prognostic factors for long-term outcome in\nThe first-line immunotherapy for anti-NMDAR patients with anti-NMDA receptor encephalitis: an observational\ncohortstudy.LancetNeurol12(2):157–165\nencephalitis, including steroids, intravenous immunoglob-\n2. Jensen P, Kondziella D, Thomsen G, Dyssegaard A, Svarer C,\nulin and plasmapheresis, could prevent disability and\nPinborg LH (2015) Anti-NMDAR encephalitis: demonstration of\nrelapses. However, the recommendation for chronic neuroinflammation and the effect of immunotherapy. Neurology\nimmunotherapy is still undetermined. Our patient respon- 84(8):859\n3. Dalmau J,Tuzun E, WuHY, Masjuan J,RossiJE, VoloschinA,\nded well to high-dose steroids, but relapse still occurred\nBaehringJM,ShimazakiH,KoideR,KingD,MasonW,Sansing\nafterinfectiondespitelow-dosesteroidmaintenance,which\nLH,DichterMA,RosenfeldMR,LynchDR(2007)Paraneoplastic\nimplies that the immunotherapy regimen should be care- anti-N-methyl-D-aspartate receptor encephalitis associated with\nfully considered. ovarianteratoma.AnnNeurol61(1):25–36\n4. Ishikawa Y, Ikeda K, Murata K, Hirayama T, Takazawa T,\nYanagihashi M, Kano O, Kawabe K, Takahashi Y, Iwasaki Y\n(2013) Ophthalmoplegia and flaccid paraplegia in a patient with\nConclusion anti-NMDA receptor encephalitis: a case report and literature\nreview.InternMed52(24):2811–2815\n5. Rubio ME, Fukazawa Y, Kamasawa N, Clarkson C, Molnar E,\nOccasionally, the presentation of anti-NMDAR\nShigemotoR(2014)Target-andinput-dependentorganizationof\nencephalitis is atypical and incomplete, thereby increasing\nAMPA and NMDA receptors in synaptic connections of the\nthe difficulty for correct diagnosis. Our experience indi- cochlearnucleus.JCompNeurol522(18):4023–4042\ncates that dizziness and hearing loss could be components\nof the disease and highlights the involvement of cranial\nnerves and the brainstem.\nCompliancewithethicalstandards\nConflictofinterest Theauthorsstatethattheyhavenoconflictof\ninterest.\n123",
  "Halbert, 2016": "270 Journal of Neuroscience Nursing\nAnti-N-Methyl-D-Aspartate Receptor\nEncephalitis: A Case Study\nRoger Kelsey Halbert\nABSTRACT\nAnti-N-methyl-D-aspartatereceptorencephalitisisanautoimmunesyndromethatpresentswithpersonality\nchanges,autonomicdysfunction,andneurologicdeterioration.Mostpatientswiththissyndromeprogress\nfrompsychosistoseizuretocatatonia,oftenassociatedwithabnormalmovements,autonomicinstability,\nandhypoventilation.First-linetreatmentconstitutesresectionoftheassociatedneoplasm,corticosteroids,\nintravenousimmunoglobulin,andplasmaexchange.Second-linetreatmentincludesrituximaband\ncyclophosphamide.Acaseofconfirmedanti-N-methyl-D-aspartatereceptorencephalitisispresentedthat\nillustratesthediagnosticandtreatmentchallengesassociatedwiththissyndromeandunderscoresthe\nnursingimplicationsofmedicalmanagementduringimmunosuppression.Thiscasestudyrecommends\nsurfacecoolingandapharmaceuticalregimenformanagementofautonomicstorming,whichisahallmark\nofthisdisorder.\nKeywords:anti-NMDAreceptorantibodies,autonomicstorming,encephalitis,immunosuppressivetherapy\nA\nnti-N-methyl-D-aspartatereceptor(anti-NMDAr) patients can be quite challenging for the neurocritical\nencephalitis is an autoimmune syndrome that careteam.\npresentswithavarietyofsymptoms,including\npersonality changes, autonomic dysfunction, and neu-\nLiterature Review\nrologicdeterioration.Itiscommonlyassociatedwith\nNMDArs play crucial roles in neuroplasticity, mem-\nmatureovarianteratomas.Asawarenessofthedisorder\noryformation,andlearning,andtheirdysfunctionhas\nincreases,recentstudiesindicatethatthediseaseisalso\nbeenassociatedwithexcitotoxicityleadingtonervecell\noccurring in younger teenagers and children (Brenton,\ndeath, schizophrenia, epilepsy, and dementia (Dalmau\nSchwartz,&Madoo,2015). Most patients with anti-\netal.,2007).Movementdisordersareahallmarkfeature\nNMDAr encephalitis develop a multistage illness that\nofthissyndrome,consistingmainlyoforofacialdyski- progresses from psychosis, memory deficits, seizures,\nnesias,choreoathetosis,and dystonia (Jones, Benseler,\nand language disintegration into a state of unrespon-\n&Moharir,2013).Orofacialdyskinesiasmayconsist\nsivenesswithcatatonicfeaturesoftenassociatedwith\nof chewing,tongue thrusting,lip smacking,and facial\nabnormalmovementsandhemodynamicinstability,re-\ngrimacing(Tham&Kong,2012).Patientsmaydevelop\nquiringventilatorandothersupportivecareinaninten-\ndystoniaandoculogyriccrisesaccompaniedwithtachy-\nsivecareunit(ICU;Day,High,Cot,&Tang-Wai,2011).\ncardia and hypertension, suggestive of autonomic\nPatientstreatedwithtumorresectionandimmunotherapy\nstorming(Jones et al., 2013). This autonomic nervous\n(corticosteroids, intravenous immunoglobulin [IVIg],\nsystem dysfunction can also include hypersalivation,\norplasmaexchange)respondfastertotreatmentandless\nsweating, hypoventilation, and increased pulse, respi-\nfrequentlyneedsecond-lineimmunotherapy(cyclophos-\nratory rate, blood pressure, and temperature (Brenton\nphamideorrituximaborboth)thandopatientswithouta\net al., 2015). Clinical presentation usually progresses\ntumorwhoreceivesimilarinitialimmunotherapy.These\nfrom a prodromal phase (headache, fever, cough) to\npsychiatric symptoms (anxiety, insomnia, mania, delu-\nsions) to decreased responsiveness (agitation, mutism,\nseizures) and finally to dyskinesia and autonomic\nfeatures(Ryan et al., 2013).\nAfter the prodromal phase, patients are often mis-\ndiagnosedwithpsychosis.Whentheclinicalpresentation\nrapidly progresses to delirium, seizures, and catatonia,\nthe diagnosis of anti-NMDAr encephalitis should be\nS\nC\nYDUT\nESA\nQuestions or comments about this article may be directed to\nRogerKelseyHalbert,RNBSNCNRNSCRN,atroger.halbert@\nynhh.org.HeisaClinicalNurseintheNeuroscienceIntensive\nCareUnit,YaleNewHavenHospital,NewHaven,CT.\nTheauthordeclaresnoconflictsofinterest.\nCopyrightB2016AmericanAssociationofNeuroscienceNurses\nDOI:10.1097/JNN.0000000000000232\n& &\nVolume 48 Number 5 October 2016 271\nstronglyconsidered.Diagnosisissupportedbycharacter- summary,shewasnotedtobe‘‘agitatedandpsychotic’’\nisticfindingsonmagneticresonanceimaging(MRI)and andwastransferredtoapsychiatricunit.Fivedaysinto\nbycerebralspinalfluid(CSF)studies(Gulyayeva,Massie, her stay, she presented with worsening mental status,\n&Duhamel,2013).InvestigationofCSFcanshowlym- lethargy,andtrismus.ShewastreatedwithIVcogentin\nphocyticpleocytosis,anincreaseinintrathecalprotein, and flumazenil with positive and immediate effect.\nand oligoclonal bands; final diagnosis is based on the Thirty minutes later, she experienced a generalized\ndetection of NMDA antibodies in the serum or CSF tonicYclonicseizure,wasintubatedforairwayprotec-\n(Wandinger,Saschenbrecker,Stoecker,&Dalmau,2011). tion,andwasadmittedtotheirmedicalICU.\nOnce antibodies to the NMDAr are identified, pri- She was initially loaded with Keppra and started\nmaryemphasisisplacedoneradicationoftheassociated onPrecedexforsedation.Seizurescontinueddespitein-\nmalignancy or suppression of the immune reaction. creasesindosagesofKeppraandDilantin.Ativanpushes\nOvarianteratomasoccurinanestimated60%offemale andVersedandpropofoldripswereutilized.Herseizures\npatients who present with this syndrome (Wandinger stopped,andshehadaninitialMRIofthebrain,which\net al., 2011). First-line therapy for anti-NMDAr en- wasreadasnormal.Multiple,repeatelectroencephalo-\ncephalitis istumor resection(if applicable) and immu- grams (EEGs) showed slowing without epileptic dis-\nnotherapy. Patients with this disorder usually require charges.ShewasgraduallyweanedfromPrecedexand\nventilatory support and intensive care for seizuresand propofol, but unfortunately, her seizures reemerged.\nautonomicinstability,whichcandelaytumorremoval. Versedandpropofoldripswererestarted,andseizure\nOn the basis of previous experience from Josep controlwasachieved.Abouttwoweeksintoheradmission,\nDalmauanddatafrom his review,there isnostandard neurologywasconsultedforasecondopinion.Theyrec-\nof care that exists. However, the preferred first-line ommendedacomputedtomography(CT)ofthechest/\ntreatmentisconcurrentIVIg(0.4g/kgperdayfor5days) abdomen/pelvistoruleoutaparaneoplasticprocess.This\nandmethylprednisolone(1g/dayfor5days)orplasma revealedanovarianmassthatwasresected5dayslater\nexchange (Dalmau, Lancaster, Martinez-Hernandez, and confirmed to be a teratoma. She was empirically\nRosenfeld,&Balice-Gordon,2011). In some patients, treatedwithIVmethylprednisoloneandIVIg.\ntumor removal results in noticeable neurological im- A tracheostomy and percutaneous endoscopic\nprovementinamatterofdaysorweeks.Ifnoresponse gastrostomy tube were placed. A repeat MRI showed\nisseen,thentherecommendationistostartsecond-line nonspecificedemainthebilateralmedialandtemporal\ntherapywithrituximab(achimericmonoclonalantibody lobes.ShewasmaintainedonpropofolandVerseddrips\nthatdestroysBcells,whicharefoundinexcessivenum- forcontrolofarm,leg,andfacetwitching.Atthispoint,\nbers in autoimmune disorders, dosage = 375 mg/m2 4 weeks after her initial hospital admission, she was\neveryweekfor4weeks)andcyclophosphamide(apro- transferredtoourneuroscienceICUforfurtherwork-up\ndrug,whichisconvertedinthelivertoactiveformsthat andtreatmentforaconfirmeddiagnosisofanti-NMDAr\nhave chemotherapeutic effects, dosage = 750 mg/m2 encephalitis.\ngiven with the first dose of rituximab), followed by Thepatient’sneurologicexaminationwassignificant\nmonthly cycles of cyclophosphamide (Dalmau et al., forcomawithnoresponsetovoiceornoxiousstimuli,\n2011). This treatment is discontinued when patients intactbrainstemreflexes,involuntaryorofacialandupper\nhavehadsubstantialclinicalrecovery,whichisusually extremity movements, and hyperreflexia with nonsus-\naccompaniedbyadecreaseofCSFandserumantibody tainedclonus.\nconcentrations. Once improvement is noted, most pa- Thestandardtreatmentinterventionsforanti-NMDAr\ntientscontinue toimprove over weeks or months until encephalitiswerestarted.AsFigure1shows,ourpatient\nfull recovery, and no maintenance immunotherapy is receivedallfivemodesofimmunosuppression.Ofnote,\nneeded.Abouttwothirdsofpatientswithnonneoplastic the initial hospital did not administer the full dose of\nNMDAr antibody encephalitis recover with first-line methylprednisolone and did not administer it concur-\nimmunotherapy(Dalmau et al., 2011). rentlywiththeIVIg.Inaddition,thesecondovarywas\nremovedprophylacticallyinthethirdmonthoftherapy\nCase Study givenherpersistentcomatosestate.\nA 33-year-old woman who was in her usual state of\nhealthpresentedtoalocalemergencydepartmentwith Diagnostics\ncomplaints of headache, fatigue, myalgias, and cough MRIsofthebrainperformedduringthefirstmonthof\nfor4days.Shewasthoughttohaveaviralillnessand treatment showed T2/FLAIR signal hyperintensities\ngivenadoseofAtivanforanxiety.Shereturnedtothe within the medial temporal lobes bilaterally. EEG\nlocal emergency department the following day with monitoring continued throughout therapy and consis-\nconfusion.Herfamilyreportsthatshewas‘‘actingcrazy’’ tently showed marked generalized slowing consistent\nand did not know who people were. Per discharge withaglobalormultifocalcerebraldysfunction,extreme\nCASE\nSTUDY\n272 Journal of Neuroscience Nursing\nFFIIGGUURREE 11 Response to Treatment\ndeltabrushpatternconsistentwithanti-NMDArenceph- temperature would quickly rise to a sustained 42-C\nalitis(Schmittetal.,2012)andabundantrhythmicdelta (108-F).IVacetaminopheninadditiontostandingoral\nactivity suspicious for nonconvulsive seizures. EEG acetaminophen would be administered to assist with\nconsistentlyruledoutcorrelationbetweenthedyskinetic treatment of hyperthermia. During these storming\nmovementandseizureactivity.SubsequentMRIandCT episodes, the patient frequently bit her tongue or lips\nbrain scans identified atrophy. In the fifth month of repeatedly, would flex her neck so significantly as to\ntherapy, ictal and interictal single-photon emission CT occludeherairway,andwouldviolentlyflailherupper\nscans were performed in an attempt to identify a po- andlowerextremities,oftendisconnectingherselffrom\ntentialseizurefocusbutwereunrevealing.Intheninth the ventilator. All vital signs would become markedly\nmonthoftherapy,apositronemissiontomographyscan elevated, with sustained heart rate 9 140, respiratory\noftheheadandbodywasperformedtoruleoutasec- rate 9 40, and systolic blood pressure 9 160. A three-\nondaryneoplasm,whichwasalsonegative. step pharmacological protocol was developed for au-\ntonomic storming management thatconsistedof 2-mg\nNursing Implications Versed IV push; then, if needed, 1-mg propofol IV\nMedicalmanagementduringimmunosuppressionther- push;andthen,ifneeded,50-mgpentobarbitalIVbolus\napyprovedverychallenging.Attemptstominimizethe infusion. The dose of the pentobarbital bolus had to be\nautonomicstormingwithcontinuousinfusionsofhigh- progressivelyincreasedto100mgandthento150mgfor\ndoseVersedandketamineweremostlyineffective.Sei- positiveeffect.Physicalrestraintswerenotused.\nzuremanagementduringthesemonthswasalsochal- Nursingcareprovedtobeachallengebecauseofthe\nlenging.Multipleantiepilepticdrugswereadministered storming, seizures, increased secretions, hyperthermia,\nandtitratedtosupratherapeuticlevels,adjustedwith and increased length of stay. For the entire 10 months\nrecommendationsfromtheepilepsyteam. thatthispatientwasadmittedtotheneuroscienceICU,\nShewasneverabletobeweanedfromtheventilator herfamilymaintainedavigilantpresence,anddiligent\nasevidencedbytachypneaandlowtidalvolumesduring effortsweremadetoprovidesupportandincludethem\nbreathing trials. Oral secretions were substantial and inherdailycareandrounding.\nprovedachallengewhentheywouldfalluponthesub-\nclaviancentralline.Manycreativeideaswereinstituted Outcomes\ntoprotectthissubclaviancentralline.Forseveralmonths, Sheshowednoimprovementinhersymptomsafterthe\nshehadaBlomtracheostomywithasubglottalsuction- first-linetreatment(ovaryremoval,methylprednisolone\ningcatheter,andbetween500and1000mlofsecretions (cid:1)5, four rounds of IVIg (cid:1)5). The second ovary was\nwerecollecteddaily.Thishelpedquantifysomeofher removed to rule out a secondary neoplasm, and the\ninsensiblefluidloss.Inaddition,anExu-Dryabsorbent second-line therapy was initiated. The initial doses of\ndressingwasplacedaroundhertracheostomytoprevent rituximabandcyclophosphamideresultedinasignif-\nmacerationoftheskinaroundthestoma. icantneutropeniaandexacerbationofcolitis,whichin-\nArectal probe provided continuous monitoring of terruptedenteralfeeding.Shewasthenstartedontotal\ncoretemperature.Theonsetofanautonomicstormfre- parenteral nutrition. After her white blood cell count\nquentlystartedwithabriskriseincoretemperature.She normalized,aseconddoseofcyclophosphamidewas\nwasonacoolingblanketbutfrequentlyrequiredsurface administered, again with no signs of clinical improve-\ncooling to maintain normothermia, because her core ment.Plasmaexchangetherapywasbegunatthistime.\nS\nC\nYDUT\nESA\n& &\nVolume 48 Number 5 October 2016 273\nSerumandCSFsamplesweresentevery6weeksfor References\nanalysis toDr. JosepDalmau, creditedfor discovering Brenton, J., Schwartz, R., & Madoo, L. (2015). Anti-NMDA\nthesyndromein2007,whoalsohaddevelopedatech- receptorencephalitis:Areview.ContemporaryPediatrics,\nniqueforquantifyingantibodytiters.Bytheeighthmonth\n32(7),14Y19.\nDalmau,J.,Lancaster,E.,Martinez-Hernandez,E.,Rosenfeld,M.R.,\noftherapy,antibodylevelswereseentohavereduced\n&Balice-Gordon,R.(2011).Clinicalexperienceandlabo-\nto75%andthento50%inthefollowingmonth.She\nratoryinvestigationsinpatientswithanti-NMDARenceph-\nhadbeensuccessfullyweanedoffVersedandketamine alitis.LancetNeurology,10(1),63Y74.\nandnolongerpresentedwithgrosshemodynamicfluc- Dalmau, J., T[z[n, E., Wu, H. Y., Masjuan, J., Rossi, J. E.,\ntuations.However,therewasnoevidenceofimproved Voloschin,A.,ILynch,D.R.(2007).Paraneoplasticanti-\nN-methyl-D-aspartate receptor encephalitis associated with\nlevel of consciousness. She remained comatose, with\novarianteratoma.AnnalsofNeurology,61(1),25Y36.\nintermittentorofacialdyskinesias.\nDay,G.S.,High,S.M.,Cot,B.,&Tang-Wai,D.F.(2011).Anti-\nInthetenthmonthoftherapy,thepatientdeveloped\nNMDA-receptorencephalitis:Casereportandliteraturereview\nahemorrhagiccystitis,mostlikelyasasideeffecttothe of an under-recognized condition. Journal of General\ncyclophosphamide.Herbladderrupturedintotheperi- InternalMedicine,26(7),811Y816.\ntoneum,andshewentintocardiacarrest.Sherequired Gulyayeva, N. A., Massie, M. J., & Duhamel, K. N. (2014).\nAnti-NMDAreceptorencephalitis:Psychiatricpresentation\nemergentlaparoscopicdecompressionandmultiplewash-\nanddiagnosticchallengesfrompsychosomaticmedicineper-\noutsurgeriesandremainedonvasopressors.Atthispoint, spective.PalliativeandSupportiveCare,12(2),159Y163.\nthefamilyelectedtowithdrawcare,andsheexpired.\nJones,K.C.,Benseler,S.M.,&Moharir,M.(2013).Anti-NMDA\nreceptorencephalitis.NeuroimagingClinicsofNorthAmerica,\n23(2),309Y320.\nConclusion\nRyan, S. A., Costello, D. J., Cassidy, E. M., Brown, G.,\nDespiteaggressivefirst-andsecond-lineimmunothera- Harrington,H.J.,&Markx,S.(2013).Anti-NMDAreceptor\npies,thispatient’sclinicalpresentationremainedlargely encephalitis: A cause of acute psychosis and catatonia.\nJournal of Psychiatric Practice, 19(2), 157Y161.\nrefractory.Medicalmanagementofthepatientthrough-\nSchmitt, S. E., Pargeon, K., Frechette, E. S., Hirsch, L. J.,\noutanextendedstayinanICUbecameachallengefor\nDalmau,J.,&Friedman,D.(2012).Extremedeltabrush:\nthe doctors and nurses. Efforts to stabilize the patient\nAuniqueEEGpattern inadultswithanti-NMDAreceptor\nduring episodes of autonomic storming led to the de- encephalitis.Neurology,79(11),1094Y1100.\nvelopment of a protocol that included surface cooling Tham, S. L., & Kong,K. H.(2012). A case of anti-NMDAR\nand sedation. The diverse nature of this syndrome en- (N-methyl-D-aspartatereceptor)encephalitis:Arehabilitation\nperspective.NeuroRehabilitation,30(2),109Y112.\ntailedamultidisciplinaryapproach.Earlydiagnosiswill\nWandinger,K.P.,Saschenbrecker,S.,Stoecker,W.,&Dalmau,J.\nimpactclinicaloutcomes;however,moredatamustbe\n(2011).Anti-NMDA-receptorencephalitis:Asevere,multi-\nobtainedtoestablishstandardsofcareforthisrecently\nstage,treatabledisorderpresentingwithpsychosis.Journal\nacknowledgedsyndrome. ofNeuroimmunology,231(1Y2),86Y91.\nCASE\nSTUDY",
  "Almuslamani - Mahmood, 2015": "CASE REPORT\nFirst Bahraini adolescent with anti-NMDAR-Ab\nencephalitis\nAhood Almuslamani, Fatima Mahmood\nABSTRACT\nAnti-N-methyl-D-aspartate-receptor (NMDA-R)\nencephalitis is a new autoimmune, often paraneo-\nAddress for Correspondence:\nplastic disorder that presents with complex neuro-\nAhood Almuslamani\npsychiatric symptoms. It was first described in 2007\nDepartmentofClinicalNeurosciences,SalmaniyaMedical\nbyDalmauetal.Ourpatientpresentedwithheadache,\nComplex, Manama, Bahrain\nEmail: omeslimani@health.gov.bh, behavioral changes and then seizures with hallucina-\naalmuslamani@gmail.com tions. She was initially misdiagnosed to have\nschizophrenia and was prescribed antipsychotics.\nShedeterioratedanddevelopedfurtherseizureswith\nhypoventilation and choreoathetosis. Her blood\nhttp://dx.doi.org/10.5339/qmj.2015.2 investigations were positive for mycoplasma IGM.\nª2015Almuslamani,Mahmood,licenseeBloomsburyQatar Her CSF studies showed high white cell counts,\nFoundationJournals.Thisisanopenaccessarticledistributed predominantlylymphocytes,andhighanti-NMDA-R\nunderthetermsoftheCreativeCommonsAttributionlicense titre.HerbrainMRIscansshowedhighT2andFLAIR\nCCBY4.0,whichpermitsunrestricteduse,distributionand intensitiesinthegreyandwhitematteroftheleft\nreproductioninanymedium,providedtheoriginalworkis\ncerebellarhemispheresuggestiveofacutedissemi-\nproperlycited.\nnatedencephalomyelitis.Sherespondedtotreatment\nwithantibiotics,multipleantiepileptics,steroidsand\nneededfivesessionsofplasmapheresis.Therewasno\nCitethis article as: AlmuslamaniA,Mahmood F.\nFirstBahraini adolescentwith anti-NMDAR-Ab underlyingmalignancyonrepeatedscanningofthe\nencephalitis, QatarMedicalJournal2015:2 abdomen.Sheneededaroundoneyearforfull\nhttp://dx.doi.org/10.5339/qmj.2015.2\nrecoverywithintensiverehabilitation.Theobjectiveof\nthispaperwastohighlighttheoccurrenceofthisfairly\nnew,challenging,easilymissed,not-so-rareformof\nencephalitisoftenoccurringintheabsenceoffever.\nKeywords: anti-N-methyl-D-aspartate receptor\nantibody (anti-NMDAR-Ab), encephalitis, central\nnervous system (CNS), acute disseminated\nencephalomyelitis (ADEM)\nINTRODUCTION\nAutoimmune encephalitis is an exciting group of\ndisorders that is eminently treatable and should be\nconsidered in the differential diagnosis of any child\npresentingwithapictureofencephalitiswithnoother\nQATARMEDICALJOURNAL 1\nVOL.2015/ART.2\nFirstBahrainiadolescentwithanti-NMDAR-Abencephalitis AlmuslamaniandMahmood\nexplanation. Encephalitis with anti-N-methyl-D- Other systems examination were unremarkable. She\naspartate receptor antibody (anti-NMDAR-Ab) has developedfurtherseizureswithshallowbreathing,for\nbeen recognized as the most frequent autoimmune which she was intubated and started on midazolam\nencephalitis in children after acute disseminated infusion, intravenous phenytoin and phenobarbitone.\nencephalomyelitis (ADEM).1 It was first described in Her EEG showed generalized delta rhythm with\n2007 by Dalmau and colleagues2 and since then, sharplycontouredwavesovertheleftfrontotemporal\nhundredsofcaseshavebeenreportedworldwide.Itis region. Valproic acid, levetiracetam and clonazepam\noften a paraneoplastic disorder that presents with were all needed for seizure control. She was worked\nneurological, psychological and autonomic nervous up forcauses of neuropsychiatric diseases such as\nsystem disturbances. Through an illustrative case infectious and autoimmune encephalitis with exten-\nexample, we report an initially missed classic case of sive laboratory investigations including complete\nanti-NMDAR-Ab encephalitis. This is the first blood counts, ANA, anti-dsDNA, C3, C4, serum\nadolescenttobedescribedinBahrainandtheArabian copper, ceruloplasmin, urine porphobilinogen and all\nGulf region. were normal pending the result of anti-NMDAR-Ab.\nHer serological tests for herpes, influenza, EBV, CMV\nand RSV were negative except for mycoplasma IgM.\nCASE PRESENTATION\nShe was started empirically on IVacyclovir and\nA 13-year-old Bahraini girl initially presented to a ceftriaxone along with oral clarithromycin. She\nprivate hospital with a two day history of agitation received1g/kg/doseofintravenousimmunoglobulins\nand new onset of severe continuous bitemporal (IVIG) once daily for two days. Cerebrospinal fluid\nheadache associated with slurring of speech. She had (CSF)analysisshowedpleocytosiswithWBCcountof\nno history of fever, trauma, drug intake or migraine. 60 cells/high power field (normal 0-5 cells/high\nShehadnootherpastmedicalhistoryofsignificance. power field) and 96% lymphocytes (normal 60-70%\nHer birth and developmental histories were normal. lymphocytes) with normal glucose and protein\nShealways performedwellin school.Her motherhad concentrations. CSF oligoclonal bands were negative.\nalonghistoryofageneralizedseizuredisorder,which Polymerase chain reaction (PCR) analysis of the CSF\nwas controlled with medication. Herother family forenterovirus, CMV, herpes, EBVand mycoplasma\nmembers were healthy. She was investigated for a wasnegative.Theantibioticswerediscontinuedwhen\npossible cranial lesion and/or seizure, with a brain CT her blood and CSF cultures returned negative.\nscan and an electroencephalogram (EEG) performed, Acyclovir was then discontinued upon obtaining\nboth of which were normal. The following day she negative PCR viral study of her CSF. Her brain and\nreportedbothvagueauditoryandvisualhallucinations entire spine magnetic resonance imaging (MRI) scans\nas well as fatigue. She wasseen by a psychiatristand showedanon-sectorallesionthatwasofahighsignal\nprescribed antipsychotics for psychosis. Over the intensity in both T2 and FLAIR involving the grey and\nfollowing few days, hercondition worsened with a whitematteroftheleftcerebellarhemispherewithno\nnew onset of generalized tonic clonic seizures lasting spinal involvement, suggestive of ADEM and less\nfor two minutes. She then presented to the likelyofaninfectiousprocess(Fig.1).Havingexcluded\nemergency department at our hospital and required infection and presuming \"autoimmune etiology\"\npediatric intensive care unit admission for monitoring we proceeded with an empiric trial of steroids and\nand further work up. Upon examination, she was intravenous pulse methyl prednisolone 30 mg/kg/\nafebrile.Herbloodpressure,heartrateandsaturation dose every six hours for five days which was given\nwere within normal limits. She was opening hereyes followed by maintenance with oral prednisolone.\nspontaneously and obeying simple commands with Anti-NMDAR-Ab assay from CSF, IgG isotype\noccasional inappropriate speech. Her Glasgow Coma resultwas1:16(referencevalue1:1).Itwasobtained\nScale was 13. Her pupils were constricted bilaterally by qualitative indirect immunofluorescence testing\nwith sluggish reaction to light. Fundoscopy was done at Bioscientia Institut für Medizinische\nnormal. Her muscle tone was decreased with Diagnostik(IngelheimamRhein,Germany).Theresult\ngeneralized diminished deep tendon reflexes. was obtained three weeks after admission. Anti-\nHer plantar responses were equivocal. Hergait NMDAR-Abs were not identified in her serum.\nwas normal. She had no signs of incoordination. High anti-NMDAR-Abs confirmed our suspicion of\n2 QATARMEDICALJOURNAL\nVOL.2015/ART.2\nFirstBahrainiadolescentwithanti-NMDAR-Abencephalitis AlmuslamaniandMahmood\nFigure1.MRIbrainscanT2imagesshowingareasofhighintensitiesinthegreyandwhitematteroftheleftcerebellar\nhemispheresuggestiveofacutedisseminatedencephalomyelitis(ADEM).\nanti-NMDAR-Ab encephalitis. She was extubated was focusing on patient stabilization and intubation\naroundthattimeandnotedtobeinacatatonicstate; together with the neurologists for seizure control.\nmute, with reduced level ofcommunication and poor Other specialist roles were involved in managing\nappetiteforfoodwithperiodsofoccasionalagitation. complications and rehabilitation including psychia-\nShe was responsive to pain, turning in bed with trists, physiotherapists, occupational therapists,\ndystonicposturing,somechoreoathetoidmovements speech therapists and nutritionists. Each specialists'\nofthelimbsandfacialgrimacing.Shewasaccordingly individualized evaluation and recommendations were\nstarted on trihexyphenidyl for dystonia and halo- obtained regularly as well as a general consensus on\nperidol for chorea and periodic agitation. Despite patient care. Over the following two months, she\nongoing physiotherapy over a period of four weeks, showed signs of improvement with seizure\nshe developed spasticity in her lower limbs for which control, decreased spasticity and improved speech.\nbaclofen was added. Her dystonia and choreoathe- She continued to have occasional choreoathetoid\ntosis did not improve; accordingly she was given five movements. Her Modified Rankin Scale scored 4\nsessions of plasmapheresis over ten days. A repeat (moderatelyseveredisability,unabletoattendtoown\nMRI scan of her brain and entire spine showed bodily needs without assistance, and unable to walk\ncomplete resolution of the signal abnormality in the unassisted). Anticonvulsants were weaned offover\nleftcerebellarhemispherewith nospinalinvolvement the following six months. She was followed up in the\n(Fig. 2). She developed paralytic ileus with abdominal outpatient clinic and noted to improve remarkably\ndistension and was investigated with repeated with disappearance of the extrapyramidal symptoms,\nultrasound and CTscans of herabdomen, but neither regaining normal functional mobility with good recall\nshowed any evidence of a tumor. Her family refused\nandfluentspeech.HerModifiedRankinscorereduced\na follow up CSF study for anti-NMDAR-Abs.\nto stage 1 (no significant disability, able to carry\nAmultidisciplinaryteamapproachwasneeded.During out all usual activities, despite some symptoms) in\nthe acute stage of the disease, the intensivists' role one year and reached stage 0 (no symptoms) in\nQATARMEDICALJOURNAL 3\nVOL.2015/ART.2\nFirstBahrainiadolescentwithanti-NMDAR-Abencephalitis AlmuslamaniandMahmood\nFigure2.ArepeatMRIbrainshowingcompleteresolutionofthesignalabnormalityintheleftcerebellarhemisphere.\ntwo years time. She continued to have no evidence hyperthermia,centralhypoventilation(66%),\nof malignancies. unexplainedpyrexia,apneicspellsandbloodpressure\nfluctuationscomplicatethisphase,andadmissioninto\nDISCUSSION intensivecareisnecessary.Byphasefour(hyperkinetic\nphase),movementdisorderssuchasorofacial\nAnti-NMDAR-Ab encephalitis is a new autoimmune,\ndyskinesias,bruxism,lipandtonguebiting,dystonia,\noften paraneoplastic disorder, in which patients have\ncomplexstereotypedmovements,opisthotonus,\nCSF and serum antibodies to a restricted epitope\nregionoftheNR1subunitoftheNMDAreceptor.3Ina oculogyriccrisesandchoreicmovementsareobserved\nseriesofover400patients,itwasfoundthatatleast\ninaround86%ofpatients.5Phasesfourandfiveare\n80% of sufferers were females,4 with a preceding usuallycombinedandduringthesephases,patientsare\npaper finding 20% of sufferers under the age of 195 oftenunresponsiveforlongperiodsoftimeandliewith\nand a smaller series finding the mean age of eyesopen,muteormumblingincoherentlyinastate\npresentation at 18.5 years.6 resemblingcatatonia(wakefulunresponsiveness).7\nAnti-NMDAR-Abencephalitisisnotedtoevolveover The presentation of anti-NMDAR-Ab encephalitis in\nfivephases.Intheinitial\"prodromalphase,\"thepatient childrencanbedifferentfromthatreportedinadults.8\nsuffersfroma\"flulike\"illness.Inthesecond\"psychiatric Armangueetal.,foundthat60%ofchildrenpresented\nphase,\"behavioraldisturbances,psychosis,hallucina- with seizures, abnormal movements, and focal\ntions,anxiety,agitationandparanoiasupervene; neurological deficits. They noted that children older\ntempertantrumsorhyperactivitydominateinchildren. than 12 presented more often with psychiatric\nUsually,mostpatientsareevaluatedbypsychiatristsat symptoms (45%) compared to those younger than\nthisstage.Bystagethree,theneurologicalnatureof 12 (33%).8 Previous experiences with large series of\ntheillnessisevident.Patientsdevelopaltered predominantly young adults demonstrated that 70%\nsensorium(88%)andseizures(76%).Frankdysauto- presented with psychosis and other psychiatric\nnomia(70%),includingcardiacarrhythmias,hypo-or symptoms.5\n4 QATARMEDICALJOURNAL\nVOL.2015/ART.2\nFirstBahrainiadolescentwithanti-NMDAR-Abencephalitis AlmuslamaniandMahmood\nDifferential diagnosis of patients who present with GABAergic neurons, leading to a disinhibition of the\nan encephalitis picture include herpes simplex excitatory pathways and increased extracellular\nencephalitis, non-paraneoplastic autoimmune glutamate. The resulting frontostriatal syndrome is\nlimbic encephalitis and other causes of autoimmune- characterized by psychosis, catatonia, mutism and\nrelated encephalopathies, including systemic lupus dystonia. The brainstem central pattern generator,\nerythematosus cerebritis, antiphospholipid antibody whichisnormallyinhibitedbytheGABAergicsystems,\nsyndrome, Sjögren’s syndrome, and Hashimoto’s isdisinhibited,leadingtotheorofacialdyskinesiasand\nencephalopathy, as well as primary central nervous the involuntary movements of the limbs and trunk.\nsystem and systemic angiitis. Our patient was The ubiquitous presence of NMDAR in the dopamin-\nmisdiagnosed to have primary psychosis when she ergic, cholinergic and noradrenergic systems and the\nwas in phase two and was started on antipsychotics. resultant hypofunction may explain the dysauto-\nShe then deteriorated and was admitted to hospital. nomia.Finally,adirecteffectof theantibodiesonthe\nHer findings of unilateral epileptiform discharges in nucleus of the Kölliker-Fuse or the pontomedullary\ntheEEGandlymphocyticpleocytosisintheCSFwere respiratory network could explain the respiratory\nsuggestive of viral encephalitis. At this stage, anti- dysfunction.11\nNMDAR-Ab encephalitis was a more likely diagnosis\nRoutine brain MRI is frequently negative and if\nsince the patient did not respond to treatment and\nalterations are observed, they are of limited\nher illness was complicated by a movement disorder.\nconsistency and do not correspond well to clinical\nHer diagnosis was only confirmed after receiving the\nsymptoms,12 ranging from periventricular white\nhigh titres of anti-NMDAR-Ab in the CSF. Serum\nmatterchanges similar to demyelination, to hyper-\nNMDA receptor antibody titres are of a lesser value\nintensities in the white matterof the hippocampi,\ncompared to CSF antibody titres as the sensitivity of\ncerebellarorcerebral cortex, frontobasal and insular\nNMDA receptor antibody testing was found to be\nregions,basalganglia,ponsand,inrareoccasions,the\nhigherinCSFthaninserum.9Shedevelopedparalytic\nspinal cord on fluid-attenuated inversion recovery/\nileus with abdominal distension, which could be due\nT2 sequences.13,14,15,16 Interestingly, a significant\nto autonomic disturbances related to her primary\nreductionofhippocampalfunctionalconnectivitywas\ndisease. The use of antipsychotics or the autonomic\nobserved in patients with NMDAR encephalitis.17\ndisturbances could explain her constricted pupils.\nWe unfortunately were unable to do serial anti- EEG is abnormal in 75% of patients, with diffuse or\nlocalized slowing in the frontal or temporal regions\nNMDAR-Ab levels; these have been reported to\ncorrelate with clinical severity over time in and a possible finding of paroxysmal sharp waves.\npatients.10 Scmittetal.,reportedextremedeltabrushinonethird\nof patients with anti-NMDA-R encephalitis.18\nInoursearchforapathogen,therewasevidenceofa\nmycoplasma infection. It has been reported that in Patients with anti-NMDAR-Ab encephalitis respond\nabout 50% of patients, mycoplasma pneumonia toimmunotherapy.First-lineimmunotherapyincludes\nserum IgM is positive. Although the significance of intravenous methylprednisolone and immuno-\nthis is unknown, infections may trigger an auto- globulins, which aim to suppress/modulate immune\nimmune encephalitic process akin to PANDAS responseorplasmaexchangeandattemptstoremove\n(pediatric autoimmune neuropsychiatric illness\nantibodiesandotherinflammatorycytokines.5Ifthere\nassociatedwithstreptococcalinfections)mediatedby is no clinical improvement and CSF titres remain high\nantistreptococcal–antineuronal antibodies.6 A poss- at one month, then one can consider rituximab,\nibleseasonaltriggerwashypothesizedfornon-tumor cyclophosphamide or both as second-line therapies,\nNMDAR encephalitis, as a subset of studied patients where both aim to suppress the antibody\nwithouttumorshadtheironsetofsymptomsprimarily production.10 Recovery can take more than\nin warm months.11 18 months.12\nThe pathophysiology behind the anti-NMDAR-Ab The finding of anti-NMDAR-Ab should lead to a\nencephalitiscanhelpusbetterunderstandourpatient search fora tumor, which if present, is almostalways\nsymptoms. NMDA receptors are widely distributed anovarianteratoma thatcontainsnervoustissueand\nacrossthebrainandtheirblockadeproducesdifferent expressesNMDAR.19Youngerpatients(,18yearsof\neffects. Anti-NMDAR-Abs predominantly block the age) are less likely to have tumors (27-31%) as\nQATARMEDICALJOURNAL 5\nVOL.2015/ART.2\nFirstBahrainiadolescentwithanti-NMDAR-Abencephalitis AlmuslamaniandMahmood\ncompared with older patients, where the frequency CONCLUSION\nis 55-60%.20 Some patients (usually older than\nGeneral physicians, pediatricians and psychiatrists\n12years)dohaveateratoma,andasoccursinyoung\nshould be familiar with anti-NMDAR-Ab encephalitis\nadults,thetumormaybedetectableafterthepatient\nas they might be the first to encounter these cases.\nhasrecoveredfromencephalitis.21Ifatumorisfound,\nAnti-NMDAR-Ab encephalitis requires a multidisci-\nremoval is important because it speeds recovery and plinary approach to patient management. Infectious,\ndecreases relapses.5,22 An interesting correlation was inflammatory and otherorganic causes should be\nfound between anti-NMDA antibodies titres and excluded before diagnosing a primary psychiatric\nteratomas wherein serial antibody titres in CSF and disorder and in diagnosing neuropsychiatric diseases\nserum were found to be higher in patients with as this is an example of a classically missed case. It is\nteratoma than in patients with no tumor.9 feasiblydiagnosable,andpotentiallyafatalconditionif\nleft unrecognized. Finding high CSF anti-NMDAR-Ab\nOur patient was screened almost every six months\ntitresdiagnosethisconditionandserialserumandCSF\noveraperiodoftwoyearswithabdominalultrasound\nantibody titres can help in managing and under-\nandCTscans,lookingforpossiblehiddenmalignancies\nstanding the prognosis, particularly in relation to\nand all were normal.\ntumordevelopment. Its course can span a period of\nRelapsing disease affects 20-25% of patients with\nmonths to years from symptoms to complete\nanti-NMDAR-Ab encephalitis.4 Clinical relapses can\nrecovery. An aggressive and prompt treatment\nbe monosymptomatic and less severe than the\nrenders a favorable prognosis even after prolonged\ninitial presentation.23 It was found that antibody\nhospitalization. Anti-NMDAR-Ab encephalitis should\ntitres in CSF and serum were higher in patients\nbe considered in cases ofencephalitis in the absence\nwith poor outcome than in those with good\nof fever and those of unclearetiology.\noutcome. The same study reported that titre\nchange in CSF was more closely related with DISCLOSURE\nrelapse than that of serum.9 Titulaer et al., found\nThe authors report no conflicts of interest in this\nthat two independent predictors of good outcome\nwork.\nincluded lower severity of symptoms assessed as\nno need for ICU support, and prompt initiation of ABBREVIATIONS\nimmunotherapy and tumor removal, if\nappropriate.12 They also noted that lower fre- CSF: cerebrospinal fluid\nquency of neurological relapses (12% vs. 20-24% EEG: electroencephalography\nreported in previous studies)10,23 is likely due to IVIG: intravenous immunoglobulin\nbetter recognition of the disorder, earlier treat- MRI: magnetic resonance imaging\nment, and increasing use of second-line NMDAR: N-methyl-D-aspartate receptor\nimmunotherapy.12 PCR: polymerase chain reaction\nREFERENCES\n1. GranerodJ,AmbroseHE,DaviesNW,ClewleyJP,WalshAL, receptorencephalitisassociatedwithovarian\nMorgan D,Cunningham R,ZuckermanM,MuttonKJ, teratoma.Ann Neurol. 2007;61:25–36.\nSolomon T,WardKN, Lunn MP,Irani SR,VincentA,\n3. Gleichman AJ,SpruceLA,DalmauJ, SeeholzerSH,\nBrown DW,Crowcroft NS, UKHealth Protection\nLynchDR.Anti-NMDAReceptorEncephalitisAntibody\nAgency(HPA) Aetiologyof Encephalitis StudyGroup.\nBindingIsDependentonAminoAcidIdentityofaSmall\nCauses ofencephalitis and differencesin theirclinical\nRegionwithinthe GluN1 Amino Terminal Domain.\npresentations in England: amulticentre,population\nJ Neurosci. 2012;32:11082–11094.\nbasedprospective study.LancetInfectDis.\n2010;10:835–844.\n4. DalmauJ, LancasterE,Martinez-Hernandez E,\nRosenfeld MR,Balice-Gordon R. Clinical\n2. DalmauJ, TuzunE,WuHY,Masjuan J, Rossi JE,\nexperienceand laboratory investigationsinpatients\nVoloschinA,BaehringJM,ShimazakiH,KoideR,KingD,\nwith anti-NMDARencephalitis. LancetNeurol.\nMason W,Sansing LH, DichterMA,Rosenfeld MR,\n2011;10:63–74.\nLynch DR.Paraneoplastic anti-N-methyl-D-aspartate\n6 QATARMEDICALJOURNAL\nVOL.2015/ART.2\nFirstBahrainiadolescentwithanti-NMDAR-Abencephalitis AlmuslamaniandMahmood\n5. DalmauJ,GleichmanAJ,HughesEG,RossiJE,PengX, receptorencephalitis. JNeurosci.\nLaiM, Dessain SK,Rosenfeld MR,Balice-Gordon R, 2010;30:5866–5875.\nLynch DR.Anti-NMDA-receptorencephalitis:case\n14. TaguchiY,TakashimaS, NukuiT,Tanaka K.Reversible\nseriesandanalysisoftheeffectsofantibodies.Lancet\nNeurol. 2008;7:1091–1098. \"brain atrophy\" in anti-NMDAreceptorencephalitis.\nInternMed. 2011;50:2697.\n6. GableMS,GavaliS,RadnerA,TilleyDH,LeeB,DynerL,\n15. ConsoliA,RonenK,An-GourfinkelI,BarbeauM,MarraD,\nCollins A,Dengel A,DalmauJ, Glaser CA. Anti-NMDA\nCostedoat-ChalumeauN, Montefiore D,Maksud P,\nreceptorencephalitis: reportof ten cases and\nBonnotO,DidelotA,AmouraZ,VidailhetM,CohenD.\ncomparisonwithviralencephalitis.EurJClinMicrobiol\nInfect Dis. 2009;28:1421–1429. Malignantcatatonia due to anti-NMDA-receptor\nencephalitis in a17-year-old girl: case report.Child\n7. KleinigTJ,ThompsonPD,MatarW,DugginsA,KimberTE, Adolesc PsychiatryMent Health.2011;5:15.\nMorrisJG,KneeboneCS,BlumbergsPC.Thedistinctive\n16. Chan SH, Wong VC,Fung CW, Dale RC,VincentA.\nmovementdisorderofovarian teratoma-associated\nencephalitis.Mov Disord.2008;23:1256–1261. Anti-NMDA receptorencephalitis with atypicalbrain\nchanges onMRI. Pediatr Neurol. 2010;43:274–278.\n8. Armangue T,Titulaer MJ, Málaga I, BatallerL,\n17. FinkeC,Kopp UA,Scheel M, PechLM, Soemmer C,\nGabilondo I, Graus F, Dalmau J, SpanishAnti-N-\nSchlichtingJ,LeypoldtF,BrandtAU,WuerfelJ,ProbstC,\nmethyl-D-AspartateReceptor (NMDAR)Encephalitis\nPloner CJ, PrüssH, Paul F.Functionaland structural\nWork Group. Pediatric Anti-NMDARencephalitis-\nbrainchangesinanti-N-methyl-D-aspartatereceptor\nClinical analysis and novel findings in aseries of\n20 patients. JPediatr. 2013;162(4):850–856. encephalitis. AnnNeurol. Aug;.\n2013;74(2):284–296.\n9. Gresa Arribas N, Titulaer MJ,TorrentsA,Aguilar E,\n18. SchmittSE,PargeonK,FrechetteES,HirschLJ,DalmauJ,\nMcCrackenL,LeypoldtF. Antibody titres atdiagnosis\nFriedmanD. Extremedeltabrush: A unique EEG\nand during followup ofantiNMDAreceptorencepha-\npatterninadultswithanti-NMDA receptorencepha-\nlitis: aretrospective study.LancetNeurol. Feb;.\nlitis. Neurology.2012;79:1094–1100.\n2014;13(2):16777.\n19. TuzunE,ZhouL,BaehringJM,BannykhS,RosenfeldMR,\n10. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S,\nDalmauJ. Evidenceforantibody mediatedpatho-\nZandi MS, Friese MA, Galea I, Kullmann DM,\ngenesisin anti-NMDARencephalitisassociatedwith\nBeeson D, Lang B, Bien CG, Vincent A. N-methyl-\novarian teratoma.Acta Neuropathol.\nD-aspartate antibody encephalitis: Temporal\n2009;118:737–43.\nprogression of clinical and paraclinical observations\nin a predominantly nonparaneoplastic disorder of 20. Florance-RyanN,DalmauJ.Updateonanti-N-methyl-\nboth sexes. Brain. 2010;133:1655–1667. D-aspartatereceptorencephalitis in children and\nadolescents.Curr Opin Pediatr.2010;22:739–744.\n11. AdangLA, Lynch DR,PanzerJA.Pediatricanti-NMDA\nreceptorencephalitisisseasonal.AnnalsofClinicaland 21. Iizuka T,Sakai F,Ide T,Monzen T,Yoshii S, Iigaya M,\nTranslational NeurologyAnnals ofClinical and SuzukiK,Lynch DR,SuzukiN, HataT,DalmauJ.\nTranslational Neurology.2014;1(11):921–925. Anti-NMDA receptorencephalitis inJapan:long-term\noutcome without tumor removal. Neurology.\n12. Titulaer MJ,McCrackenL,Gabilondo I,Armangué T,\n2008;70:504–511.\nGlaser C,Iizuka T,Honig LS,Benseler SM, KawachiI,\nMartinez-Hernandez E,Aguilar E,Gresa-Arribas N, 22. SabinTD,Jednacz JA,Staats PN. Case records of the\nRyan-FloranceN, TorrentsA,Saiz A,Rosenfeld MR, MassachusettsGeneralHospital.Case 26-2008.\nBalice-Gordon R,Graus F,DalmauJ. Treatmentand A 26-year-old woman with headache and behavioral\nprognostic factorsfor long-term outcome in patients changes. NEnglJMed.2008;359:842–853.\nwithanti-N-Methyl-D-Aspartate (NMDA)receptor\n23. Gabilondo I,Saiz A,Galan L,Gonzalez V,Jadraque R,\nencephalitis:a cohort study.LancetNeurol. 2013\nFebruary;12(2):157–165. SabaterL,Sans A,Sempere A, Vela A,VillalobosF,\nViñals M, VillosladaP, Graus F.Analysis of relapses in\n13. HughesEG,PengX,GleichmanAJ,LaiM,ZhouL,TsouR, anti-NMDARencephalitis. Neurology.\nParsons TD,LynchDR,Dalmau J,Balice-Gordon RJ. 2011;77:996–999.\nCellularand synapticmechanisms ofanti-NMDA\nQATARMEDICALJOURNAL 7\nVOL.2015/ART.2",
  "Beatty - Khot, 2014": "Clinical Pathological Conference\nTheNeurohospitalist\n2014,Vol4(1)34-41\nThe Diagnostic Conundrum and Treatment\nªTheAuthor(s)2013\nReprintsandpermission:\nDilemma of a Patient With a Rapidly sagepub.com/journalsPermissions.nav\nDOI:10.1177/1941874413496792\nProgressive Encephalopathy nhos.sagepub.com\nChristopher W. Beatty, MD1, Claire J. Creutzfeldt, MD2,\nArielle P. Davis, MD2, Zachary Hoffer, MD3, and Sandeep P. Khot, MD2\nKeywords\nencephalitis, paraneoplastic,tuberculosis meningoencephalitis, anti-N-methyl-D-aspartate receptor encephalitis\nA45-year-oldmanoftheYakamaNationtribewithoutsignif- His clinical progression and episodes of depressed con-\nicant medical history had an abrupt onset headache that sciousnesspromptedtransfertoourinstitutionforfurthereva-\nprogressedoveraweek.Hepresentedtoanemergencydepart- luation. On arrival, repeat CSF analysis revealed a persistent\nmentandanoncontrastheadcomputerizedtomography(CT) neutrophilic pleocytosis and hypoglycorrhachia (Table 1,\nwasunremarkableexceptformildethmoidsinusdisease.One columnDayofIllness27).Intravenousacyclovir,ceftriaxone,\nweeklater,thepatientdevelopedneckstiffness,feverto101.6 vancomycin, and enteral doxycycline were initiated. As CSF\ndegrees F, chills, and body aches. The patient’s partner cultures, antibodytests, and viral polymerase chainreactions\nreportedepisodesofconfusionwithauditoryandvisualhallu- (PCRs)returnednegative,thesetreatmentswereagaindiscon-\ncinations,seeingthingsonthewall,andthinkinghewascov- tinued. Continuous electroencephalogram (EEG) monitoring\neredinchocolate. over a 3-day period revealed diffuse slowing but no epilepti-\nAfter2.5weeksintothecourseofillness,thepatientsought form activity. Contrast-enhanced CT of the chest, abdomen,\ncare from his primary care physician who referred him to a and pelvis and testicular ultrasound were normal. Whole-\nlocal emergency department. In the emergency department, body [18F]-fluorodeoxyglucose positron emission tomogra-\nthepatientwasafebrilethoughillappearingwithdiaphoresis. phy (FDG-PET) scan from the base of skull to upper thighs\nHehadfluentspeech,normalcomprehension,andintactmem- revealed no evidence of primary malignancy or metastases.\nory and concentration. He was noted to have an unsteady Anonlesionalbrainbiopsyfromtherightfrontallobedemon-\ntandemgaitandpositiveRombergsign.Therestoftheneuro- stratednonspecificfindingsofscatteredrareperivascularlym-\nlogic examination wasunremarkable. phocyticinfiltrateswithnoevidenceofneoplasmoraspecific\nHe was admitted tothe hospital where cerebrospinal fluid infection (Figure 2).\n(CSF)analysis revealed a significant neutrophil-predominant Duetothepersistent CSFpleocytosis, hypoglycorrhachia,\npleocytosis with a low glucose (Table 1, column Day of Ill- andelevatedprotein,aswellasbrainimagingwithbasallep-\nness 17). An infectious etiology was suspected, and empiric tomeningeal enhancement, antituberculous medications and\ntreatmentwasinitiatedwithintravenousadministrationofcef- dexamethasone were started and continued for an 8-week\ntriaxone, vancomycin, acyclovir, and dexamethasone. Exten- course. The patient had no known exposure to tuberculosis\nsive serum and CSF infectious and autoimmune workup was (TB).TheCSFfungalculturesandbroad-basedPCRtestsfor\nunrevealing (Table 2). Repeat imaging with a contrast- fungalelements andTB were negative (Table 2).\nenhanced brain magnetic resonance imaging (MRI) about 3 Sixweeksafterthesymptomonset,thepatientprogressed\nweeks after symptom onset demonstrated hyperintensities in to a deep coma, unresponsive to both verbal and painful sti-\nthe deep gray and white matter as well as basal leptomenin- muli and with no purposeful movements. He also began\ngealenhancement(Figure1).Anatypicalviralmeningoence-\nphalitiswaspresumedandantibiotics,antivirals,andsteroids\nwere discontinued. 1DepartmentofNeurology,UniversityofWashington,Seattle,WA,USA\nThe hospital course was characterized by a progressive 2DepartmentofNeurology,HarborviewMedicalCenter,Seattle,WA,USA\nencephalopathy, and approximately 1 month after initial 3DepartmentofPathology,UniversityofWashington,Seattle,WA,USA\nsymptom onset, the patient began having episodes of unre-\nCorrespondingAuthor:\nsponsivenessconcerningforseizuresandrequiredintubation.\nChristopherW.Beatty,DepartmentofNeurology,UniversityofWashington,\nInbetweentheepisodes,hewasdrowsyandfollowedsimple\n4800SandpointWayNE,Seattle,WA98105,USA.\ncommands. Email:cwbeatty@uw.edu\nBeatty et al 35\nTable1.CerebrospinalFluidAnalysis.\nDayofIllness\n17 27 31 38 47 79 150 NormalValues\nRedcells/μL 15 1 20 5 0 0 0 None\nWhitecells/μL 1046 493 329 143 39 14 4 0-5\nNeutrophils,% 67 69 56 07 01 00 00\nLymphocytes,% 25 27 38 67 86 94 75\nMonocytes,% 08 04 6 26 13 06 25\nProtein,mg/dL 127 111 101 95 55 51 41 15-45\nGlucose,mg/dL(%ofserumglucose) 36(28) 37(36) 34(32) 56(39) 51(54) 59(39) 51(52) 40-80\nTable2.Blood,Urine,andCerebrospinalFluidTesting.\nDayofIllnessWhen\nTesting Fluid Result TestPerformed\nCoccidioidesimmitis(IgG/IgM) Blood Negative 17,31\nCryptococcusantigen CSF Negative 17,30\nHistoplasmaantigen BloodandUrine Negative 31\nMycoplasmapneumonia(IgG/IgM) Blood Negative 30\nToxoplasmagondii(IgG/IgM) CSF Negative 27\nTreponemapallidum(FTA-ABS) BloodandCSF Negative 30\nTreponemapallidum(VDRL) Blood Negative 27,30\nTreponemapallidumRPR Blood Negative 27\nHerpessimplexvirusPCR CSF Negative 17,30\nCytomegalovirusPCR CSF Negative 27,30\nBartonellahenselae Blood Negative 27\nBrucella Blood Negative 27\nBorreliaBurgdorferi(IgG/IgM) BloodandCSF Negative 27\nEpstein-Barrvirus(IgG/IgM) BloodandCSF Negative 27,30\nHumanherpesvirus6PCR CSF Negative 30\nVaricellazostervirusPCR CSF Negative 30\nHumanimmunodeficiencyvirus(RNAPCR) Blood Negative 48\nHumanimmunodeficiencyvirus(Westernblot) Blood Negative 18,48\nArbovirus(IgG/IgM) CSF Negative 17\nEnterovirusPCR CSF Negative 17,30\nParechovirusPCR CSF Negative 30\nWestNilevirus(IgG/IgM) CSF Negative 27,30\nInfluenzaAandB(opticalimmunoassay) Nares Negative 17\nMycobacteriumtuberculosisPCR CSF Negative 17,38\nMycobacteriumtuberculosis(QuantiferonGold) Blood Negative 20,33\nAcidfastBacilliculture CSF Negative 30\nMycobacteriumaviumPCR CSF Negative 38\nAspergillusfumigatusPCR CSF Negative 37\nCreutzfeldt-Jakob(14-3-3,andtauamount) CSF Negative 30\nCytology CSF Negative 27,30,37\nAnti-nuclearantibody Blood Negative 27\nExtractablenuclearantigenpanel(dsDNA,SM,ribosomalP, Blood Negative 27\nchromatin,RNP,SmRNP,Scl-70,centromereB,SSA,SSB,andJo-1)\nParaneoplasticantibodypanel(antineuronalnuclearantibody,anti-glial CSF Positiveforunidentified 38\nnuclearantibody,Purkinjecellcytoplasmicantibody,amphiphysin anti-neuronalantibody\nantibody,andCRMP-5IgG)\nAbbreviations:CSF,cerebrospinalfluid;FTA-ABS,fluorescenttreponemalantibody-absorption;Ig,immunoglobulin;VDRL,VenerealDiseaseResearch\nLaboratory;RPR,rapidplasmaregain;PCR,polymerasechainreaction;dsDNA,double-strandedDNA;SM,Smithantibody;RNP,ribonucleoprotein;SSA,\nSjo¨grenantibodyA;SSB,Sjo¨grenantibodyB;CRMP-5IgG,Collapsinresponsemediatorprotein5.\nexhibitinglimbandorofacialchoreoathetoidmovementswith weretrialed—includingbenzodiazepines,propranolol,baclo-\ndystonia. He had severe dysautonomia, including hyperther- fen, trihexyphenidyl, and botulinum toxin injections to the\nmia, tachycardia, and hypertension. Multiple medications masticatory muscles—which hadlittle improvement.\n36 The Neurohospitalist 4(1)\nFigure1.Magneticresonanceimaging(MRI)scansofthebrainonday27ofillness.AandB,Fluidattenuatedinversionrecovery(FLAIR)axialimages\nofthelesionsinthemedialrighttemporallobe(thinlongarrow),rightbasalganglia(shortthickarrow),inferiorleftfrontallobe,andleftcaudate\nnucleus(longthickarrow).C,T1postcontrastaxialimagedemonstratingleptomeningealenhancementinvolvingthemedulla(shortthinarrow).\nAdiagnostictest result wasobtained. the temporal lobe with a typically mild CSF pleocytosis,\ncan be either infectious or autoimmune. Limbic encephalitis\nDifferential Diagnosis classically involves the rapid development of irritability,\ndepression, sleep disturbances, hallucinations, and short-\nDiscussant: Sandeep Khot term memory loss.2 Our patient’s clinical presentation\nNeurohospitalistsoftenencountercasesinwhichseizuresand was suspicious for subacute-onset limbic encephalitis, and\nencephalopathycanfollowacomplexclinicalcourse.Thiscase he was appropriately started on acyclovir. Patients with\ndemonstrates the difficulty in diagnosis, where a clinical HSV-1 encephalitis typically progress rapidly with dep-\nsyndrome involves fluctuating symptoms over many weeks ressed consciousness, focal neurologic deficits, and evidence\nandovermultipleclinicalinstitutions.Thepatient’spresenta- of hemorrhagic inflammation on MRI and CSF evaluation.3\ntiontoourinstitutionwascharacterizedpredominantlybyepi- The MRI finding of medial temporal lobe abnormalities was\nsodesofdepressedconsciousnesswithconcernforsubclinical particularly concerning for HSV-1 infection, although basal\nseizures.Hewasappropriatelystartedonantiepilepticmedica- ganglia involvement and basal meningeal enhancement were\ntionsandmonitoredwithcontinuousvideoEEG.However,the atypical (Figure 1). Given that the HSV PCR can be falsely\ninitialdevelopmentoffeverandneck stiffness with headache negative when obtained within the first 72 hours of disease\nwas highly suspicious for infectious meningitis. In our onset, restarting acyclovir and repeating the PCR testing\npatient, the presence of these symptoms in the setting of were appropriate.\nan altered level of consciousness, possible seizures, and Although the initial suspicion in our patient was for an\nhyperintense signal within the temporal lobe suggested the infectiousmeningoencephalitis, thefindingsofnegativeCSF\ndevelopment of encephalitis. Patients with encephalitis typi- testingandthedevelopmentofnewsymptomssuchasdyski-\ncally have fever and headache along with confusion, beha- nesiasanddysautonomialedtofurtherconsiderationforauto-\nvioral abnormalities, depressed level of consciousness, immune limbic encephalitis. The diagnoses of autoimmune\nfocal neurologic deficits, or new-onset seizure activity.1 limbicencephalitiscanbebroadlycategorizedintothoseclas-\nEncephalitis can be characterized as either infectious or sicsyndromesassociatedwithantibodiestointracellularneu-\nnoninfectious, with or without associated CSF inflammation. ronalantigens(anti-Hu,anti-Maproteins,andlessfrequently\nHistorically, the most common identifiable causes of anti-CV2/CRMP5 andamphiphysin), whichare oftenassoci-\nencephalitis have been infectious, including reactivation of ated with a tumor, and antibodies to cell membrane antigens\nlatent herpes virus infection, including herpes simplex virus (voltage-gated potassium channel, N-methyl-D-aspartate\n1 (HSV-1) and varicella zoster virus, tick-borne bacterial receptor,andothersthatremainuncharacterized),whichmay\ninfections, and arthropod-borne viral infections, including\normaynotberelatedtoatumor.2Cancerscreeningwithbody\nWestNilevirus.1 Noninfectious etiologies are typically auto- CT, testicular ultrasound, and FDG-PET scan were obtained\nimmune disorders, which may or may not be related to an to evaluate for the presence of a tumor, and paraneoplastic\nunderlying tumor. Limbic encephalitis, an inflammatory dis- antibodytestingwasobtainedinboththeserumandtheCSF.\norder with demonstration of MRI and EEG abnormalities in TheseverityofCSFpleocytosisinourpatientwasunusualfor\nBeatty et al 37\nFigure2.Nonlesionalbrainbiopsy.A-D,Hematoxylinandeosin-stainedsectionsshowactivatedmicroglia(blackarrowheads).B,Background\nneurons(whitearrowheads)areidentified.ScalebarinA¼250m;B-D¼100m.\nautoimmuneencephalitis,wheretypicallyonlyamildtomod- TheTBmeningitisisthemostsevereformofextrapulmonary\nerate lymphocytic pleocytosisis found. TB with a broad and nonspecific presentation of disease,\nnecessitating a high index of suspicion among providers and\nmaking an early diagnosis difficult. Characteristically, CSF\nDiagnostic challenges\nshows a lymphocytic pleocytosis, an elevated protein level\nAsinthiscase,thelackofaspecificdiagnosisleavestheclin- greater than 100 mg/dL, a low CSF glucose with a ratio of\nician uncertain how to predict or alter the course of the CSF-blood glucose <0.5 or some combinations of these\ndisease.Theclinicalpictureofrapidlyprogressivecomasug- findings.4\ngestedeitherinfectiousorautoimmune-mediatedencephalitis, Neuroradiologic findings in TB meningitis include menin-\nbut the CSF profile was more concerning for an infectious geal inflammation, basal exudates, infarcts, or hydrocepha-\netiology. Further immunosuppression for presumed autoim- lus.5,6 Parenchymal involvement can present with a localized\nmune or paraneoplastic limbic encephalitis was considered tuberculoma,abscess,orcerebritis,aswellasischemicstroke,7\nthough not initiated early on due to concern for potential TB typically involving the deep gray matter of the thalamus or\nmeningoencephalitis. basal ganglia.8 Our patient developed hyperintense lesions on\nT2andfluidattenuatedinversionrecovery(FLAIR)sequences\nwithinthebasalgangliaandmedialtemporallobethoughwith-\nDiagnosis of TB meningoencephalitis\noutevidenceofischemia.\nInfectious causes of meningoencephalitis are frequently con- The demonstration of Mycobacterium tuberculosis in CSF\nsideredinthedifferentialdiagnosisofprogressiveencephalo- smear or culture is required to confirm the diagnosis, though\npathy with CSF pleocytosis. Most bacterial, fungal, and both the methods are insensitiveand can be associated with a\nspecificviraletiologiesofmeningitiscanbeevaluatedbyanti- treatmentdelay.ThesensitivityofCSFcultureforTBmenin-\nbody or PCR testing or CSF cultures. The TB meningitis is gitis in most Western countries is only between 52% and\nparticularlydifficulttodiagnosedefinitively,giventheinsen- 78% and may take up to 6 weeks.9 Diagnostic tests such as\nsitive testing for acid-fast bacilli (AFB) in CSF. The CSF nucleicacid amplification,includingPCR, are alsolimitedby\npleocytosisandhypoglycorrhachia,aswellasbasalmeningeal low sensitivity (60%) for CSF AFB.10Tuberculinskintesting\nenhancementonbrainMRI,raisedconcernforTBmeningitis. orinterferon-greleaseassays,suchastheQuantiferon-TBgold,\n38 The Neurohospitalist 4(1)\nhavelimitedutilityforarapiddiagnosisanddonotdistinguish developmentofbehavioralandpsychiatricsymptoms,includ-\nbetweenpriorexposureandactivediseasenorconfirmcentral ing agitation, hallucinations, bizarre behavior, and speech\nnervoussystemTB.InsuspectedcasesofTBmeningitis,treat- problems. The language disorder can vary from a reduction\nmentwithantituberculosismedicationsshouldbepromptlyini- in speech output and echolalia to mutism.19 After 10 to 20\ntiated while awaiting definitive diagnostic testing, because days of initial symptoms, patients enter the second phase of\ntreatment delay has been associated with poorer outcome.11 illness.18Patientsmaydeveloporofacialandlimbdyskinesias,\nThe use of dexamethasone has also been shown to decrease catatonia, and adecreased level of consciousness.14,18,19 Sei-\nmortalityinthetreatmentofTBmeningitis.12 zures, autonomic instability, and central hypoventilation,\nwhichmaynecessitateintubation,canoccurduringthisperiod\nas well.14,18,19 Dissociative responses to stimuli, such as\nDiagnostic Results\nresistingeyeopeningthoughremainingunresponsivetopain-\nApproximately 6 weeks after the symptom onset, serum and ful stimuli, have also been described in this latter phase of\nCSFanti-N-methyl-D-aspartatereceptor(NMDAR)antibodies illness.19\nreturned positive by indirect immunofluorescence. The CSF The time course of our patient’s symptoms was unusual.\nalsodemonstratedanonspecificantineuronalantibody.Given The subacute development of confusion and hallucinations,\nthepositiveanti-NMDARantibodiesinthesettingofthelater about2to3weeksaftertheonsetofheadaches,wasintermit-\nclinicalfeaturesoffacialdyskinesias,rigidity,andautonomic tent and quickly overshadowed by episodes of unresponsive-\ninstability,5 plasmapheresis treatmentswere completed over ness and later by a severe encephalopathy. The patient’s\n2 weeks. The patient had slow improvement in the abnormal movement disorder and autonomic dysfunction were not\nmovements and dysautonomia over the following month. He apparent until 40 days of illness. Such a delayed course of\nremained unresponsive to commands or a painful stimulus symptoms has been rarely reported with anti-NMDAR\nthough was noted to resist eye opening and occasionally encephalitis.18\nattend to the examiner. He had completed a 2-month course The majority of patients with anti-NMDAR encephalitis\nofantituberculoustreatment,andthesemedicationsweredis- will recover fully or be left with mild deficits over time.\ncontinuedbeforecompletionofafullcourseofthetherapyin Recoveryisoftenhastenedbyimmunosuppressivetreatment.\nfavor of an alternative diagnosis. Rituximab infusions were Thebestoutcomesareseenwhentreatmentisinitiatedwithin\nsubsequently initiated(weekly 800mgfor 4weeks). 40daysoftheonsetofdisease.18Inourcase,theconcernfor\ninfectionmadeearlyimmunosuppressionadangerousoption.\nAnti-NMDA Receptor Encephalitis Patients typically require a prolonged hospitalization with a\nusual duration of 3 to 4 months of inpatient management\nDiscussant: Christopher Beatty (rangeof1-14months).14,19Inaretrospectivereviewofcases\nAnti-NMDAR encephalitis, first described in 2007,13 is a prior to the description of the disease where patients were\nwell-characterized autoimmune condition with specific auto- subsequently confirmed to have anti-NMDAR encephalitis,\nantibodies to the NMDAR. The majority of anti-NMDAR recovery without immunosuppressive treatment took more\nencephalitis cases are associated with an underlying tumor, than 3 years.21 Immunotherapy and tumor removal result in\nfrequently an ovarian teratoma.14 The actual incidence of a good recovery (slight disability or better on the modified\nanti-NMDAR encephalitis is unknown, although multiple Rankinscale)in81%ofthepatientswithanti-NMDARence-\nstudieshavedemonstratedthatitisacommoncausativeagent\nphalitiswithamedianfollow-upof24months.20Themajority\nofpreviouslyundiagnosedcasesofencephalitis.15-17Approx- of symptoms from the disease may resolve, though many\nimatelythree-quartersoftheaffectedindividualsarewomen, patients continue to have difficulty with executive function,\nand a tumor is detected in up to 59% of the adult memory, and disinhibited behavior.14,19,22 Relapses occur in\npatients.14,18,19 In adult men, anti-NMDAR encephalitis is 12% of the cases and are more common in patients without\nrelatedtoneoplasminonly6%ofthepatients.20Themechan- anocculttumor.20Theestimatedmortalityrateinthisgrueling\nisminitiatingthedisorderinthosepatientswithoutneoplasm disease is 7%at 24months.20\nis unknown.\nDiagnosis and Treatment\nClinical Course and Complications\nSeveral descriptions19 exist in the literature of milder or\nAnti-NMDAR encephalitis can present with symptoms simi- incomplete forms of anti-NMDAR encephalitis, a forme\nlartoinfectiousencephalitis,thoughpatientsusuallydevelop frusteofthedisorder,suchasisolatedpsychiatricsymptoms,\na characteristic sequence of symptoms.14,18,19 The typical seizures, or dystonia. These pure monosymptomatic syn-\nclinicalcourse,seeninupto70%ofthepatients,beginswith dromes occur in less than 5% of anti-NMDAR encephalitis\nprodromalsymptomsofheadache,fever,nausea,diarrhea,or cases,19 though patients may also present with a predomi-\nupper respiratory tract symptoms.19 The clinical picture will nant symptom, such as headache in our case, with milder\ncommonly progress within the following 2 weeks,19 with the manifestations of other elements of the syndrome such as\nBeatty et al 39\nFigure3.Magneticresonanceimaging(MRI)scansofthebrainonday150ofillness.AandB,Fluidattenuatedinversionrecovery(FLAIR)axial\nimagesdemonstratingintervalimprovementinthepreviouslyvisualizedlesionsatpresentation.C,T1axialpostcontrastimagewithcomplete\nresolutionofbasalleptomeningealenhancement.\nconfusion or hallucinations. Some of the classic behavioral antibodyproduction.14,19,23Therehavebeenconflictingstud-\nsymptoms of anti-NMDAR encephalitis may have also been iesonwhetheranti-NMDARantibodytitersareassociatedwith\novershadowed in our patient by symptoms of higher cortical diseaseseverity.18,25\ndysfunction, decreased level of consciousness, or refractory Priorstudiesexaminingthepresenceofanti-NMDARantibo-\nseizures, as has been described in cases of limbic diesinthesettingofviralmeningoencephalitishavefoundlittle\nencephalitis.2 tonocross-reactivity,14,15thougharecentstudysuggeststhatan\nTheCSFfindingsinourpatientwerealsounusualforanti- inflammatorycascadeinthesettingofaviralmeningitiscould\nNMDAR encephalitis, and suggested a potential infectious leadtofalse-positivetestresults.26Earlyinourpatient’scourse,\netiology.InitialCSFevaluationinanti-NMDARencephalitis wesuspectedthatthepositiveanti-NMDARantibodieswerethe\ntypicallyrevealsonlyamildpleocytosiswith25to35cells/mL, resultofaninflammatorycascade,whichwassupportedbythe\nthoughthehighestreportedvalueis480cells/mL.14TheCSF nonspecificCSFantineuronalantibody.Ashedevelopedsymp-\nproteinmaybemildlyelevated,rangingfrom20to70mg/dL, toms with more characteristic of anti-NMDAR encephalitis,\nand CSF glucose is typically normal.14,15 To our knowledge, including dyskinesiasand dysautonomia, heappearedtoenter\nthisdegreeofCSFpleocytosis,hypoglycorrhachia,andpersis- thesecondphaseofillnessalbeitwellafterthetypical10to20\ntent elevation of protein more than 100 mg/dL has not been days.18.Thepathogenicmechanismofanti-NMDARencephali-\nreportedinanti-NMDAR encephalitis. tis without an occult tumor remains unclear. The degree of\nAbnormalities on EEG are found in 80% to 100% of the pleocytosispresentinourcasecouldbetheresultofanuniden-\npatients with anti-NMDAR encephalitis, often with diffuse tifiedinfectiousetiologywithexposedantigensresultinginan\nslowing, although epileptiform discharges can also be autoimmuneresponse.Alternatively,couldtheseverityofCSF\nseen.14,15,18,20,23 Brain MRI abnormalities are seen in up to pleocytosis, higher than previously reported, be solely related\n50% ofthepatients.19Mostcommonly,abnormal FLAIRand toanti-NMDARencephalitis?Cliniciansshouldconsideranti-\nT2 signal can be seen in the medial temporal lobes,24 similar NMDARencephalitisinpatientswithasignificantCSFpleocy-\ntothoseseeninourpatient,orthecerebralcortex.14Somereports tosisthatisnotrespondingtotypicalinfectioustreatment.\nhavealsodescribedcontrastenhancementinthemeninges.14,19 Initial treatment of anti-NMDAR encephalitis should in-\nBrain biopsy is generally not thought to be helpful with cluderemovaloftheoffendingtumorinparaneoplasticcases\ndiagnosis.Inafewpatientswho haveundergone biopsydur- and immunosuppression in all cases. First-line immunosup-\ning the course of illness, specimens have shown nonspecific pressionincludescorticosteroids,intravenousimmunoglobulin\nmild perivascularcuffing andmicroglial activation.14 (IVIG),plasmaexchange,orsomecombinationoftheseinter-\nConfirmatorytestingforanti-NMDARencephalitisiscon- ventions.19Evidencesuggeststhatdualtherapywithcorticos-\nducted through an indirect fluorescent antibody method in teroids and either plasma exchange or IVIG is superior to\ncommerciallaboratories.Testingisperformedonbothserum steroidsalone.18Iffirst-linetherapyfails,furtherimmunosup-\nandCSFwithhighertitersintheCSFcomparedtotheserum pression with rituximab or cyclophosphamide is considered\nduring active disease.14,19 In rare cases, the serum has been secondline.14,18,19,23,27Inmanypatients,second-linetherapies\nnegative,buttheCSFhasbeenpositive,suggestingintrathecal havebeenusedtopreventrelapses.20\n40 The Neurohospitalist 4(1)\nCase Follow-Up 8. BeattieGC,GlaserCA,SheriffH,etal.Encephalitiswiththala-\nmic and basal ganglia abnormalities: etiologies, neuroimaging,\nThepatientshowedgradualimprovementinhislevelofalert-\nand potential role of respiratory viruses. Clin Infect Dis. 2013;\nness and responsiveness approximately 3 months into his\n56(6):825-832.\nillness, although he developed considerable agitation. Multi-\n9. Greenlee J, Carroll KC. Cerebrospinal fluid in central nervous\nple sedating medications for dysautonomia and abnormal\nsysteminfections.In:ScheldMW,WhitleyRJ,MarraCM,eds.\nmovementswerestopped.Thepatientbeganmouthingwords\nInfections of the Central Nervous System. Philadelphia, PA:\nbutwithconfusedandperseverativespeech.Heoftenrequired\nLippincottWilliams&Wilkins;2004;18.\nrestraintsandneurolepticmedicationsforsevereagitationand\n10. DinnesJ,DeeksJ,KunstH,etal.Asystematicreviewofrapid\ntoensuresafety,bothforthepatientandthehospitalstaff.He\ndiagnostic tests for the detection of tuberculosis infection.\nbegantointermittentlyrespondtosimplecommands.Afinal\nHealthTechnolAssess.2007;11(3):1-196.\nCSF analysis obtained nearly 2 months after initiation of the\n11. VerdonR,ChevretS,LaissyJP,WolffM.Tuberculousmeningitis\nrituximabinfusionswasnormal(seeTable1).Arepeatbrain\ninadults:reviewof48cases.ClinInfectDis.1996;22(6):982-988.\nMRIwasalsoobtainedwithsignificantintervalimprovement\n12. Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone\nand resolution of contrast enhancement (see Figure 3). He\nfor the treatment of tuberculous meningitis in adolescents and\nremainedhospitalizedatourfacilityforabout4monthsbefore\nadults.NEnglJMed.2004;351(17):1741-1751.\ndischargetoaskillednursingfacility.Hewascognitivelyslow\n13. DalmauJ,TuzunE,WuHY,etal.Paraneoplasticanti-N-methyl-\nwith poor memory and recall. Abnormal movements were\nD-aspartate receptor encephalitis associated with ovarian tera-\ngone. Monthly rituximab infusions were continued, and he\ntoma.AnnNeurol.2007;61(1):25-36.\nbecame independent in all activities of daily living, returning\n14. Dalmau J, Gleichman AJ, Hughes GH, et al. Anti-NMDA-\nhomeabout6monthsaftertheonsetofinitialsymptoms.Aneu-\nreceptor encephalitis: case series and analysis of the effects of\nropsychologicalevaluationabout9monthsaftersymptomonset\nantibodies.LancetNeurol.2008;7(12):1091-1098.\ndocumentedcognitiveandpersonalitychangesthoughnomood\n15. GableMS,SheriffH,DalmauJ,TilleyDH,GlaserCA.Thefre-\nproblems.Specifically,testingrevealedpoorfocuswithconcen-\nquencyofautoimmuneN-methyl-D-aspartatereceptorencepha-\ntration, memory difficulty, and occasional child-like behavior\nlitis surpasses that of individual viral etiologies in young\nthatwasalsonotedbythepatient’spartner.After10monthsfrom\nindividualsenrolledintheCaliforniaEncephalitisProject.Clin\ntheonsetofhisillness,thepatienthasbeenunabletoreturnto\nInfectDis.2012;54(7):899-904.\nworkduetotheseverityofhiscognitivedeficits.\n16. Gable MS, Gavali S, Radner A, et al. Anti-NMDA receptor\nencephalitis: report of ten cases and comparison with viral\nDeclaration ofConflicting Interests\nencephalitis. Eur J Clin Microbiol Infect Dis. 2009;28(12):\nTheauthorsdeclarednopotentialconflictsofinterestwithrespectto 1421-1429.\ntheresearch,authorship,and/orpublicationofthisarticle.\n17. Pruss H, Dalmau J, Harms L, et al. Retrospective analysis of\nNMDA receptor antibodies in encephalitis of unknown origin.\nFunding\nNeurology.2010;75(19):1735-1739.\nThe authors received no financial support for the research, author- 18. IraniSR,BeraK,WatersP,etal.N-methyl-D-aspartateantibody\nship,and/orpublicationofthisarticle. encephalitis: temporal progression of clinical and paraclinical\nobservationsinapredominantlynon-paraneoplasticdisorderof\nReferences bothsexes.Brain.2010;133(pt6):1655-1667.\n1. RoosKL,GreenleeJE.Meningitisandencephalitis.Continuum 19. DalmauJ,LancasterE,Martinez-HernandezE,RosenfeldMR,\n(MinneapMinn).2011;17(5):1010-1023. Balice-GordonR.Clinicalexperienceandlaboratoryinvestiga-\n2. TuzunE,DalmauJ.Limbicencephalitisandvariants:classifica- tionsinpatientswithanti-NMDARencephalitis.LancetNeurol.\ntion,diagnosisandtreatment.Neurologist.2007;13(5):261-271. 2011;10(1):63-74.\n3. WhitleyRJ.Herpessimplexencephalitis:adolescentsandadults. 20. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and\nAntiviralRes.2006;71(2-3):141-148. prognostic factors for long-term outcome in patients with anti-\n4. HristeaA,OlaruID,BaicusC,MorotiR,AramaV,IonM.Clin- NMDA receptor encephalitis: an observational cohort study.\nical prediction rule for differentiating tuberculous from viral LancetNeurol.2013;12(2):157-165.\nmeningitis.IntJTubercLungDis.2012;16(6):793-798. 21. IizukaT,SakaiF,IdeT,etal.Anti-NMDAreceptorencephalitis\n5. SutlasPN,UnalA,FortaH,SenolS,KirbasD.Tuberculousmenin- inJapan:long-termoutcomewithouttumorremoval.Neurology.\ngitisinadults:reviewof61cases.Infection.2003;31(6):387-391. 2008;70(7):504-511.\n6. GalimiR.Extrapulmonarytuberculosis:tuberculousmeningitis 22. FinkeC,KoppUA,PrussH,DalmauJ,WandingerKP,Ploner\nnew developments. Eur Rev Med Pharmacol Sci. 2011;15(4): CJ.Cognitivedeficitsfollowinganti-NMDAreceptorencephali-\n365-386. tis.JNeurolNeurosurgPsychiatry.2012;83(2):195-198.\n7. BernaertsA,VanhoenackerFM,ParizelPM,etal.Tuberculosis 23. Florance NR, Davis RL, Lam C, et al. Anti-N-Methyl-D-\nof the central nervous system: overview of neuroradiological Aspartate Receptor (NMDAR) Encephalitis in Children and\nfindings.EurRadiol.2003;13(8):1876-1890. Adolescents.AnnNeurol.2009;66(1):11-88.\nBeatty et al 41\n24. SansingLH,TuzunE,KoMW,BacconJ,LynchDR,DalmauJ. 26. Pru¨ssH,FinkeC,Ho¨ltjeM,etal.NMDAreceptorantibodies\nApatientwithencephalitisassociatedwithNMDAreceptoranti- in herpes simplex encephalitis. Ann Neurol. 2012;72(6):\nbodies.NatClinPractNeurol.2007;3(5):291-296. 902-911.\n25. HansenHC,KlingbeilC,DalmauJ,LiW,WeissbrichB,Wan- 27. Ishiura H, Matsuda S, Higashihara M, et al. Response of\ndinger KP. Persistent intrathecal antibody synthesis 15 tears anti-NMDA receptor enchephalitis without tumor to immu-\nAfterrecoveringfromanti-N-methyl-D-aspartatereceptorence- notherapy including rituximab. Neurology. 2008;71(23):\nphalitis.JAMANeurol.2013;70(1):117-119. 1921-1923.",
  "Uzawa - Kuwabara, 2012": "Clinical Neurology and Neurosurgery 114 (2012) 402– 404\nContents lists available at SciVerse ScienceDirect\nClinical Neurology and Neurosurgery\nj o ur nal homep age: www.elsevier.com/locate/clineuro\nCase report\nAnti-N-methyl d-aspartate-type glutamate receptor antibody-positive limbic\nencephalitis in a patient with multiple sclerosis\nAkiyuki Uzawaa,∗, Masahiro Moria, Yukitoshi Takahashib, Yoshitsugu Ogawaa, Tomoyuki Uchiyamaa,\nSatoshi Kuwabaraa\naDepartment of Neurology, Graduate School of Medicine, Chiba University, Chiba, Japan\nbDepartment of Research, National Epilepsy Center, Shizuoka Institute of Epilepsy and Neurological Disorders, Shizuoka, Japan\na r t i c l e i n f o\nArticle history:\nReceived 30 June 2011\nReceived in revised form 26 October 2011\nAccepted 29 October 2011\nAvailable online 5 December 2011\nKeywords:\nMultiple sclerosis\nAnti-N-methyl d-aspartate (NMDA)\nreceptor antibody\nAnti-glutamate receptor antibody\nEncephalitis\nPsychosis\n1. Introduction\nMultiple sclerosis (MS) is an autoimmune demyelinating dis-\nease of the central nervous system. Although it often coexists with\nother autoimmune diseases, its association with anti-N-methyl d-\naspartate receptor (NMDAR) antibody-positive encephalitis, which\nis characterized by fulminant prominent neuropsychiatric manifes-\ntations, seizures, dyskinesias and autonomic instability [1], is rare.\nIn this study, we describe the case of a Japanese female MS patient\nwho developed with anti-NMDA type glutamate receptor (GluR)\nantibody-positive limbic encephalitis. The simultaneous manifes-\ntation of both diseases has never been reported to the best of our\nknowledge.\n2. Case report\nA 33-year-old Japanese woman developed left optic neuri-\ntis (ON) at the age of 30. She experienced some demyelinating\n∗\nCorresponding author at: Department of Neurology, Graduate School of\nMedicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba 260-8670, Japan.\nTel.: +81 43 226 2129; fax: +81 43 226 2160.\nE-mail address: a-uzimp1204@graduate.chiba-u.jp (A.\ninflammatory\nUzawa).\nepisodes, including the development of 2 left optic\nnerve lesions, 3 different spinal cord lesions and 1 brainstem\nlesion between the ages of 31 and 33 years. Intravenous high-dose\nmethylprednisolone pulse (IVMP) therapy was effective for treating\nthe acute inflammatory episodes. The patient’s relapses, in addition\nto the observation of clinical lesions on magnetic resonance images\n(MRI), led to the diagnosis of MS according to 2005 McDonald’s\ncriteria.\nAt age 33, the patient developed fatigue and fever. Three weeks\nafter manifestation of prodromal symptoms, she developed epilep-\ntic seizures and lost consciousness following psychobehavioral\nsymptoms; she was then admitted to our hospital for further inves-\ntigation. Upon admission, she was conscious and responsive, but\npresented with mild cognitive deficits (verbal and performance\nIQ of 88 and 78, respectively, as determined by the Wechsler\nAdult Intelligence Scale-R), manic, persecution complex and over-\ninterfering to others. Neurological examination revealed loss of\nvisual acuity, left abductor muscle weakness, mild left hemipare-\nsis and left hypoesthesia below the C4 and T7 dermatomal areas.\nCerebrospinal fluid (CSF) parameters on admission were as follows:\ncell count, 3 cells/mm3; protein level, 35 mg/dl; immunoglobulin\nG index, 0.700; positive for oligoclonal bands and no evidence of\nany active viral infections. Laboratory findings were unremarkable\nand negative for antinuclear, anti-SS-A/B, anti-thyroid peroxidase\nor anti-aquaporin-4 antibodies. Brain MRI demonstrated hyperin-\ntensity of the bilateral medial temporal lobes, some periventricular\novoids on FLAIR images and multifocal white matter lesions with\ngadolinium enhancement (Fig. 1). Spinal cord MRI revealed a\nsolitary C2 lesion. Epileptic discharges were not noted on some\ntimes of electroencephalograms. She was diagnosed with lim-\nbic encephalitis instead of an MS exacerbation and was treated\nwith IVMP (1 g/day for 3 days) followed by oral prednisolone\n(30 mg/day). The aetiology of the patient’s psychobehavioral symp-\ntoms and seizures was further examined, and it was determined\nthat antibodies against the GluR(cid:2)2 subunit were in her CSF, but not\nthe serum. Systemic computed tomography/MRI/ultrasonography\ndid not detect any tumours. Although she presented with epileptic\nseizures and required ventilatory support 2 months after admis-\nsion, her symptoms were ceased not immediately but slowly. She\nwas discharged without neurological deficits, psychobehavioral\nsymptoms or epileptic seizures 6 months later.\n0303-8467/$ – see front matter© 2011 Elsevier B.V. All rights reserved.\ndoi:10.1016/j.clineuro.2011.10.047\nA. Uzawa et al. / Clinical Neurology and Neurosurgery 114 (2012) 402– 404 403\nFig. 1. Brain MRI performed on admission showing a high-intensity lesion on FLAIR images of the bilateral medial temporal lobes (A); some MS plaques (ovoid lesions) are\nnoted around the lateral ventricle (B and C); an image obtained with gadolinium enhancement (D) is also shown.\n3. Literature review\nThe coexistence of ON or neuromyelitis optica (NMO) with anti-\nNMDAR or anti-GluR antibody positive encephalitis has attracted\nattention recently. Four previously reported cases [2–5] and the\npresent case are summarized in Table 1. Among these 5 patients,\n2 were diagnosed with NMO, 2 with ON and 1 with MS. All 5\npatients were female, and this predominance fits the clinical char-\nacteristics of their respective diseases. In all cases, anti-NMDAR or\nanti-GluR antibodies were detected in the CSF. The symptoms of\nthe 3 patients with ON or MS preceded the development of anti-\nNMDAR encephalitis. Interestingly, no patient developed tumours\nand showed poor clinical prognoses.\n4. Discussion\nThe early clinical course of this patient was typical of MS\nand the later course was compatible with anti-NMDAR encephali-\ntis. The patient’s fulminant neuropsychiatric manifestations\nseizures,\nand\nincluding the lesions that were present in the bilateral\nmedial temporal lobes on MRI and positivity for the anti-GluR(cid:2)2\nantibody in the CSF, are atypical of MS, which encouraged\nthe diagnosis of anti-NMDAR encephalitis with overlapping MS.\nGluR(cid:2)2 (NR2B) is a subunit of NMDAR that is predominantly\nexpressed in the hippocampus and forebrain and is involved\nin memory function. The mild cognitive impairment of the\npresent case appears to have been caused by lesions in these\nareas.\nAntibodies against NR1/NR2B heteromers are specific to\nNMDAR-associated encephalitis, with or without ovarian teratoma,\nwhereas GluR(cid:2)2 antibodies are also found in some other disor-\nders, such as Rasmussen’s encephalitis and progressive epilepsia\npartialis continua, and may lack syndrome specificity. Hence, the\ndetection of anti-GluR(cid:2)2 antibodies in the present patient’s CSF\nmay be related to her epilepsy or the destruction of her central ner-\nvous system. However, an activated autoimmune system in such\npatients may be related to the production of anti-NMDA antibod-\nies; previous cases [4,5] and present case have manifested ON or\n404 A. Uzawa et al. / Clinical Neurology and Neurosurgery 114 (2012) 402– 404\nTable 1\nCharacteristics of patients with presenting with NMO, ON or MS with anti-NMDA or anti-GluR receptor antibody positive encephalitis.\nAuthors Age/sex Disease Onset Anti-NMDAR\nAb in\nEpilepsy\nCSF\nNMO-IgG/\nanti-AQP4\nSpinal\nAb\nlesion Optic nerve Tumour\nlesion\nPrognosis\nHonda [2] 39 years/F NMOSD NA Anti-GluR(cid:2)2 Absent Anti-AQP4 Ab (+) + (>3VL) − − Good\nKruer [3] 15 years/F NMO NMDA → NMO Anti-NMDAR Present NMO-IgG (−) + (>3VL) + − Good\nMotoyama [4] 10 years/F ON ON → NMDA Anti-NMDAR Present Anti-AQP4 Ab (−) − + NA Good\nIshikawa [5] 12 years/F ON ON → NMDA Anti-GluR(cid:2)2 Present NA − + NA Good\nOur case 34 years/F MS MS → NMDA Anti-GluR(cid:2)2 Present Anti-AQP4 Ab (−) + (<3VL) + − Good\nNMO: neuromyelitis optica; NMOSD: neuromyelitis optica spectrum disorder; MS: multiple sclerosis; ON: optic neuritis; NMDAR: N-methyl d-aspartate receptor; GluR:\nglutamate receptor; Ab: antibody; AQP4: aquaporin 4; NA: not available; VL: vertebral segments in length.\nMS before the development of anti-NMDAR encephalitis. A previ-\nous review reported that 59% of anti-NMDAR encephalitis patients\nhave tumours and 36% of patients without tumours showed severe\ndeficits or died [1]. Most noteworthy were the facts that all reported\ncases [2–5] and present case who presented with ON, NMO or MS\nwith anti-NMDAR encephalitis did not present with tumours, and\nthat those cases demonstrated good recoveries. Positive outcomes\nmay be possible following the use of intensive immune-modulating\ntherapies.\n5. Conclusion\nWe reported the first case of a patient who developed anti-\nNMDA glutamate receptor antibody-positive encephalitis with\ngood recovery during the course of MS. There may be a possi-\nble linkage between these diseases, and concurrent autoimmune\nresponses may be important for the development of autoimmune\nencephalitis. Anti-NMDAR encephalitis should be recognized as\nrare\na\nmanifestation that can occur in MS patients who develop psy-\nchiatric symptoms and seizures. However, further investigation of\npatients with related disorders and analysis is needed.\nReferences\n[1] Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-\nreceptor encephalitis: case series and analysis of the effects of antibodies. Lancet\nNeurol 2008;7:1091–8.\n[2] Honda K, Yuasa T. A case of anti-aquaporin-4 and anti-glutamate receptor anti-\nbodies positive myelitis presented with modest clinical signs. Magn Reson Med\nSci 2008;7:55–8.\n[3] Kruer MC, Koch TK, Bourdette DN, Chabas D, Waubant E, Mueller S, et al. NMDA\nreceptor encephalitis mimicking seronegative neuromyelitis optica. Neurology\n2010;74:1473–5.\n[4] Motoyama R, Shiraishi K, Tanaka K, Kinoshita M, Tanaka M. Anti-NMDA recep-\ntor antibody encephalitis with recurrent optic neuritis and epilepsy. Rinsho\nShinkeigaku (in Japanese) 2010;50:585–8.\n[5] Ishikawa N, Tajima G, Hyodo S, Takahashi Y, Kobayashi M. Detection of\nautoantibodies against NMDA-type glutamate receptor in a patient with recur-\nrent optic neuritis and transient cerebral lesions. Neuropediatrics 2007;38:\n257–60.",
  "McIvor - Moore, 2017": "The Clinical Neuropsychologist\nISSN: 1385-4046 (Print) 1744-4144 (Online) Journal homepage: http://www.tandfonline.com/loi/ntcn20\nSpontaneous recovery of memory functions in an\nuntreated case of anti NMDAR encephalitis – a\nreason to maintain hope\nKatherine McIvor & Perry Moore\nTo cite this article: Katherine McIvor & Perry Moore (2016): Spontaneous recovery of memory\nfunctions in an untreated case of anti NMDAR encephalitis – a reason to maintain hope, The\nClinical Neuropsychologist, DOI: 10.1080/13854046.2016.1245358\nTo link to this article: http://dx.doi.org/10.1080/13854046.2016.1245358\nPublished online: 20 Oct 2016.\nSubmit your article to this journal\nArticle views: 7\nView related articles\nView Crossmark data\nFull Terms & Conditions of access and use can be found at\nhttp://www.tandfonline.com/action/journalInformation?journalCode=ntcn20\nDownload by: [Ryerson University Library] Date: 23 October 2016, At: 00:17\nThe CliniCal neuropsyChologisT, 2016\nhttp://dx.doi.org/10.1080/13854046.2016.1245358\nSpontaneous recovery of memory functions in an untreated\ncase of anti NMDAR encephalitis – a reason to maintain hope\nKatherine McIvora and Perry Moorea,b\naDepartment of Clinical neuropsychology, The Walton Centre nhs Foundation Trust, liverpool, uK; bschool of\nMedicine, university of liverpool, liverpool, uK\nABSTRACT ARTICLE HISTORY\nObjective: Anti N-methyl-D-aspartate receptor (anti-NMDAR) received 27 June 2016\nencephalitis is an autoimmune disorder that was only fully discovered accepted 29 september 2016\nrecently and neuropsychological outcome data remains sparse. We\nKEYWORDS\npresent the case of BA, a 19-year-old male, which illustrates the\nanti-n-methyl-D-aspartate\ncognitive outcome in an untreated case over a time period of over\nreceptor; encephalitis;\n2½ years. Method: We conducted three cognitive assessments, memory; assessment;\nincluding tests of memory and executive functioning, over this time recovery\nperiod and considered the evidence for reliable change in memory\nfunction using the Wechsler Advanced Clinical Solutions (ACS) serial\nassessment package. Results: Our findings revealed mild memory\nproblems 6 months post-discharge with, at best, static and potentially\ndeclining memory functioning at follow-up assessment 12 months\npost-discharge. However, the results of testing at 30 months post-\ndischarge revealed significant improvements in immediate and\ndelayed memory index performances. Conclusions: Our report of a\ncase of anti-NMDAR encephalitis provides evidence for spontaneous\nimprovements in memory functioning occurring more than 2 years\nafter initial assessment and also demonstrates both the utility and\npotential limitations of the ACS serial assessment software when used\nin a relatively typical clinical assessment situation.\nIntroduction\nAnti N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis\nAnti N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune disorder\nthat mainly affects young, female patients (Dalmau, Lancaster, Martinez-Hernandez,\nRosenfeld, & Balice-Gordon, 2011). The condition is often associated with cancerous tumors,\noften found in the ovaries, although cases are also reported in the testes of males (Eker\net al., 2008). This condition is considered the most common paraneoplastic encephalitis\n(Dalmau et al., 2011) and is caused by a patient’s altered antibodies, which reduces surface\nNMDARs and leads to the reduction in NMDAR-related synaptic function. NMDA receptors\nare found throughout the brain but are concentrated in the hippocampus (Day, High, Cot,\n& Tang-Wai, 2011) and are thought to have specialist functions in terms of memory and\nlearning (Kruse et al., 2014; Lo et al., 2010).\nCONTACT Katherine Mcivor katherine.mcivor@thewaltoncentre.nhs.uk\n© 2016 informa uK limited, trading as Taylor & Francis group\n2 K. MCIvOR AND P. MOORE\nAnti-NMDAR encephalitis has a number of distinct stages; prodromal, psychiatric, unre-\nsponsive, and hyperkinetic (Iizuka et al., 2008). Chapman and vause (2011) summarized how\nthe condition evolves over time. Initially, patients experience a short-lived flu-like illness. A\npsychotic phase follows, which often starts with anxiety or depression but progresses to\nsevere behavioral and personality disturbance, delusions, paranoia, and hallucinations. It is\nnot uncommon therefore for a primary psychiatric disorder to be mistakenly diagnosed.\nUnresponsiveness with hypoventilation, autonomic instability, and dyskinesias generally\nfollows. The principal cognitive symptom is severe amnesia, which has been found to be\nassociated with medial temporal atrophy on imaging (Martin-Mozon, Trujillo-Pozo, & Romero,\n2012). The diagnosis often relies on the presence of specific autoantibodies to the N-methyl\nD-aspartate receptor being detected (Dalmau et al., 2011).\nAuthors in the field call for early identification of this condition, with clinicians being alert\nto a sudden decline in cognitive ability without delirium (vahter et al., 2014). They also\nhighlight the need for immediate and aggressive treatment, of which tumor resection and\nimmunotherapy appear the most effective (Dalmau et al., 2007; Uchino et al., 2011). However,\neven with effective treatment, recovery appears slow and this has been attributed to treat-\nments being unable to produce a rapid and sustained control over the immune response\n(Dalmau et al., 2008).\nMost of the research involving anti-NMDAR encephalitis is in its infancy given that the\ncondition was only fully discovered in 2007 (Dalmau et al., 2007). Research in the area is\nlimited to a small number of case studies and case series with restricted neuropsychological\ndata that indicate primary cognitive difficulties in memory and executive functioning\n(Dalmau et al., 2007; Finke et al., 2012; Lebon et al., 2012; Marcos-Arribas, Almonacid, &\nDolado, 2013; Martin-Mozon et al., 2012; vahter et al., 2014).\nIn terms of recovery, some authors report encouraging findings in terms of patients return-\ning to normal cognitive functioning. Acién, Acién, Ruiz-Maciá, and Martín-Estefanía (2014)\nreport that 80% of people with anti-NMDAR encephalitis and a detectable tumor recovered\nover a 3-month hospital stay. Dalmau et al. (2008) assessed recovery in terms of return to\nactivity and Mini Mental State Examination (MMSE) score, upon which they report that 75%\nof 100 patients treated with tumor resection or immunotherapy, recovered or only had mild\nobservable deficits in attention, planning, and impulsivity. This study was limited by the lack\nof more comprehensive neuropsychological assessment data. Further, a case study by Martin-\nMozon et al. (2012) reported their patient completely recovered intellectual function after\n6 years follow-up, which included intermittent memory rehabilitation. They concluded that\ncognitive dysfunction is transient and full recovery is possible over an extensive period of\ntime. However, the authors determined change through higher test scores and changes in\nbehavioral function, rather than by statistical analysis.\nIn contrast, continuing cognitive impairments have been found in other studies where\nmore comprehensive neuropsychological testing has assessed outcome. Finke et al. (2012)\nstudied nine patients with anti-NMDAR encephalitis, the majority of which had received\nimmunotherapy treatment. At follow-up (median 43 months), impairments in memory and\nexecutive functioning remained in around 90% of patients. The most severe deficits were\nshown in patients with delayed or inefficient treatment. A further case reported by vahter\net al. (2014) also reported persistent memory problems in a patient, who received immuno-\ntherapy, after 12 months.\nTHE CLINICAL NEUROPSyCHOLOGIST 3\nHinkle et al. (2016) reported on three adolescent females with anti-NMDAR encephalitis,\nwho all received anti-epileptic drugs and steroid treatment within a month of symptom\nonset. A flexible neuropsychological battery was completed that covered most cognitive\nand emotional domains. Testing took place at the acute stage (4–6 weeks after symptom\nonset), post-acute stage (2–6 months), and chronic stage (6–13 months). All three patients\nshowed marked improvements in cognitive function, defined as a change of 2 or 3 standard\ndeviations in testing, with subtle deficits remaining in language (i.e. naming, comprehension\nand fluency), executive function, fine motor skills, and memory. Interesting, each patient\nthought that their cognitive function had returned to their own baseline, which the authors\nfelt highlighted the importance of repeated, detailed neuropsychological assessment. They\nrecommended that testing continued beyond the 2-year mark if deficits are identified at the\nchronic stage.\nA number of cases have claimed spontaneous recovery of anti-NMDAR encephalitis and\nassociated cognitive impairment in patients that did not receive treatment. Evoli et al. (2012)\nfound that their patient fully recovered (apart from a mild semantic fluency impairment) at\n42 months follow-up and concluded that this may be a self-limiting condition. However, the\npatient in this case had not progressed to the late, severe stage of the illness. Furthermore,\nIizuka et al. (2010) report that four Japanese women with the condition showed complete\nphysical and cognitive recovery over three or more years, though further examination of\nthis case series revealed that neuropsychological assessment was limited to an equivalent\nof the MMSE and patients had indeed received treatment in the form of antiviral medication,\ncorticosteroids, immunotherapy, and antiepilepsy treatments during the course of their\nillness.\nIn summary, the current evidence appears to indicate that spontaneous recovery of\nneuropsychological functioning is less likely when no treatment has been provided or when\nthe condition is severe. Additionally, the evidence for recovery is more limited when com-\nprehensive neuropsychological evaluation is used to assess outcome rather than brief screen-\ning tools.\nSerial assessment of cognitive functioning\nAlthough single time-point assessments remain the mainstay of neuropsychological exam-\ninations, repeated assessments are a valuable, and in some cases common, approach to\nmonitoring disease progression, recovery following neurological insult, or the impact of\ninterventions. This is reflected in the recent American Academy of Clinical Neuropsychology\npolicy paper that recommends neuropsychologists become more informed about the oppor-\ntunities and challenges involved in serial assessment (Heilbronner et al., 2010).\nMethods for assessing reliable change in test scores share the common logic that observed\nchanges in test scores are likely the result of both true change (the actual improvement or\ndecline in cognition function) and error resulting from confounding variance consequent\nto the tests themselves, the testing situation, and the person completing the tests. A number\nof approaches have been employed in the evaluation of reliable change. The reliable change\nmodel of Jacobson and Truax (1991) uses a scale’s standard error of measurement and test–\nretest reliability to estimate the standard error of the differences. This method has been\nfurther developed (Chelune, Naugle, Luders, Sedlak, & Awad, 1993; Iverson, 2001) to include\nthe mean practice effect. An alternative to these unidimensional methods is the use of\n4 K. MCIvOR AND P. MOORE\nmultiple regression-based formulas to predict scores at a second time point from time point 1\nperformance. Such formulas may also incorporate additional predictors, such as demo-\ngraphic variables, as well controlling for regression towards the mean. The Wechsler Advanced\nClinical Solutions (ACS) package (Pearson Clinical Assessment, 2009) is one such solution,\nwhich provides clinicians with the ability to employ a standard regression-based model in\norder to evaluate change over 2 time points and works in conjunction with the existing\nWechsler Adult Intelligence Scale (WAIS-Iv) (Wechsler, 2008) and Wechsler Memory Scale\n(WMS-Iv) (Wechsler, 2009) software package.\nThere has been little research into how cognitive function in adults changes over time\nafter anti-NMDAR encephalitis. Most reported cases cover a short follow-up period, have\nlimited neuropsychological data or do not measure improvement through statistical analysis.\nWe present a case of NMDAR encephalitis where a comprehensive neuropsychological\nassessment was carried out at 3 time points (over 30 months) and reliable change was deter-\nmined through regression analysis. The patient showed spontaneous recovery of memory\nfunction over time, despite not receiving any specific treatment for anti-NMDAR encephalitis.\nThe apparent improvements observed in testing were assessed using regression-based\nchange formulas derived from WMS-Iv validation data and calculated using the Wechsler\nACS software package.\nCase study\nBA was a 19-year-old Caucasian, right-handed male, previously healthy with no prior psy-\nchiatric history. He achieved normal developmental milestones. He was thought to be of\naverage ability at school and went on to obtain a qualification in photography at college.\nHis initial symptoms began in December 2011 and included poor appetite, disturbed\nsleep, and having problems in interpersonal relationships. Depression was suspected and\nhe was treated with anti-depressants by his GP. He then went onto to develop psychotic\nsymptoms including thinking his parents were poisoning him and his older sister had pos-\nsessed him. He was admitted to a psychiatric hospital in March 2012 and treated with\nanti-psychotic medication (Olanzapine) and Benzodiazepines. On the ward he was seen by\nan occupational therapist, physiotherapist, and a dietician, although his engagement with\nthese professionals was minimal. An MRI brain scan and lumbar puncture were reported as\nnormal.\nBA was then transferred to a general hospital due to his physical health needs and his\ncondition worsened, including exhibiting involuntary movements, seizures, mutism, and\norofacial dyskinetic movements. His sleep functioning was severely compromised and\nNeuroleptic Malignant Syndrome (NMS) was suspected, as he had significantly raised CPK\nlevels (1000–1500). He was transferred to a specialist tertiary neurosciences hospital in April\n2012. His family was reluctant to start treatment for NMS so he was kept under observation\nand treated with Iv fluids and fed through a nasogastric tube. Treatment at this stage was\nsupportive and focused on improving diet and sleep. His MRI scan was normal and his EEG\nsuggested diffuse non-specific encephalopathy, with no evidence of seizure syndrome. With\nsupportive treatment his condition improved, with him then sleeping and eating to excess.\nHe was discharged after 1 month.\nTHE CLINICAL NEUROPSyCHOLOGIST 5\nAdditional investigations revealed deranged liver function, fluctuating CPK levels, positive\nserology for Epstein-Barr virus, and positive monospot test suggested an infection 8 weeks\npreviously. An HIv test was negative. No tumors were ever discovered, despite extensive\ninvestigations. His NMDA antibodies were found to be positive at the point of discharge and\nhe was therefore diagnosed with anti-NMDAR encephalitis retrospectively. NMDA antibody\nlevels were monitored over time and remained positive.\nBA was assessed at 6 months (Time 1) and 12 months (Time 2) after inpatient discharge.\nHe was re-referred for neuropsychological assessment as an outpatient at 30 months (Time 3)\nto clarify if his cognitive impairments had plateaued or improved.\nReported symptoms\nAt Time 1 and Time 2, BA and his mother reported problems with retrieving information and\nforgetting his way around in less familiar places. His memory problems were reported to\nhave resolved at Time 3 and his mother felt he was ‘back to normal’. By this time, he had\ncompleted a NvQ level 2 in care work with no difficulty and learnt to drive.\nNeuropsychological assessment\nMethodology\nCognitive assessment involved the administration of The Test of Pre-morbid Function (ToPF)\n(Wechsler, 2011), The Wechsler Memory Scales, 4th edition (WMS-Iv) (Wechsler, 2009), two\nsubtests (Trail Making Test and verbal Fluency Test) from the Delis Kaplan Executive Function\nSystem Test (D-KEFS) (Delis, Kaplan, & Kramer, 2001) and the Hospital Anxiety and Depression\nScale (HADS) (Zigmond & Snaith, 1983). The WMS-Iv was administered at all three time-points\nas memory dysfunction was the main presenting neuropsychological symptom. In addition,\nsubtests from the D-KEFS and the HADS were administered at Time 1 and 3. The ToPF was\nadministered at Time 3. Table 1 indicates the tests completed at the three different time\npoints. We hypothesized that, given the reported improvement in memory, there would be\nspontaneous recovery of memory function between Time 2 and 3. Therefore, the ACS pack-\nage was used to examine reliable change in memory scores only.\nTest behavior\nWhen BA was seen for testing he was pleasant and cooperative. There were no specific\nconcerns regarding his understanding or motivation to comply with the testing situation.\nAt Time 1 and 2, he appeared fatigued in testing. He had insight into the fact that his per-\nformance had improved over time.\nTable 1. Tests administered at separate time points.\nTest administered\nTime 1 (6 months) TopF, WMs-iV, D-KeFs Trail Making Test, D-KeFs Verbal Fluency, haDs\nTime 2 (12 months) WMs-iV\nTime 3 (30 months) WMs-iV, D-KeFs Trail Making Test, D-KeFs Verbal Fluency, haDs\nTest of pre-morbid Functioning (TopF), Wechsler Memory scales, 4th edition (WMs-iV), Delis–Kaplan executive Function\nsystem (D-KeFs), Trail Making Test and Verbal Fluency Test, hospital anxiety and Depression scale (haDs).\n6 K. MCIvOR AND P. MOORE\nTest results\nA ToPF (Wechsler, 2011) was completed and supported the view that he had an average\npre-morbid IQ (estimated IQ = 100).\nMemory\nThe serial assessment memory scores are reported in Table 2. BA’s auditory memory index\n(AMI) was assessed to be in the low average range at Time 1 and 2. However, this did not\nreflect the expected improvement in auditory memory scores as part of a serial assessment.\nUsing the ACS serial assessment methodology, his obtained AMI score at Time 2 was signif-\nicantly lower than predicted (p ≤ .05). By Time 3, his AMI score had increased to the average\nrange, however, as this was comparable to his predicted score based on the obtained Time 2\nscore, this was not deemed to be a statistically significant change.\nHis scores for visual Memory showed greater variability as he scored in the average range\nat baseline (Time 1) and the low average range at Time 2. However, this index had improved\nto the high average range by Time 3. The improvement at Time 3 compared to his predicted\nscore based on his Time 2 attainment was statistically significant, with the base rate of this\ndifference being at the <1st percentile.\nBA’s immediate memory score at Time 1 was in the average range but dropped to the\nlow average range at Time 2, with his Time 2 score being significantly lower than predicted.\nExamination of his subtest scores revealed that several of these were lower at Time 2 than\nTime 1. The immediate recall conditions of the auditory memory subtests were both signif-\nicantly less at Time 2 than predicted by his Time 1 scores. At Time 3, the Immediate Memory\nIndex had returned to the average range and was significantly higher than predicted by his\nTime 2 index, the base rate of difference being at the 1st percentile. BA scored higher on all\nof the immediate recall subtests at Time 3 compared to Time 2; however, the Designs I subtest\nTable 2. serial assessment of memory functioning.\nInitial assess-\nment (Time 1) Follow up (Time 2) Follow up (Time 3)\nObtained Predicted Obtained Predicted Obtained Base rate\nIndex/test score score score Base rate (%) score score (%)\naMi 88 100 84* 2–5 97 100 –\nVMi 92 91 86 – 86 113* <1\nVWMi 80 89 83 – 91 88 –\niMi 94 96 84* –10 89 107* 1\nDMi 82 89 81 – 88 108* 1\nscaled score\nlM i 9 11 7* 5 10 10 –\nlM ii 6 9 7 – 10 10 –\nVpa i 9 12 7* –1 10 10 –\nVpa ii 8 9 8 – 9 10 –\nDe i 9 10 8 – 9 13* 5\nDe ii 9 8 7 – 7 10 –\nVr i 10 10 9 – 9 11 –\nVr ii 7 9 7* 25 9 15* 1\nsa 5 7 6 – 8 5* 10\nssp 8 9 8 – 9 11 –\nnotes: index scores are provided for WMs-iV indexes (mean = 100, SD = 15). scaled scores are provided for WMs-iV subtests\n(mean = 10, SD = 3). predicted scores are based upon obtained test scores at the previous administration.\n*p ≤.05 compared to predicted score.\nTHE CLINICAL NEUROPSyCHOLOGIST 7\nwas the only immediate recall condition to significantly improve at Time 3 compared to\npredicted scores according to the ACS calculations.\nHis Delayed Memory Index scores did not demonstrate a significant improvement between\nTime 1 and 2. At Time 3, the Delayed Memory Index had improved to the average range and\nwas significantly higher than predicted by his Time 2 index, with the base rate of difference\nbeing at the 1st percentile. BA scored higher on all the delayed recall subtests at Time 3 com-\npared to Time 2; however, visual Reproduction II was the only delayed recall condition to show\nsignificant improvement compared to the predicted scores given by the ACS calculations.\nHis scores for visual Working Memory remained largely unchanged at all three time points,\nremaining in the low average range. However, his index scores showed steady increases,\nwith the exception of his Spatial Addition score at Time 3 which was significantly lower than\npredicted and adversely affected his index score.\nExecutive functioning\nTwo subtests of the D-KEFS were completed at Time 1 and 3 (see Table 3 for an overview of\nadditional assessments). In the Trail Making test at Time 1, BA scored in the average range\nacross all 5 subtests (visual Scanning, Letter Sequencing, Number Sequencing, Letter-\nNumber Sequencing and Motor Speed). There was more variability in his scores at Time 3\nas he scored in the average range for visual Scanning and Number–Letter Sequencing, the\nborderline range for Number Sequencing, and the high average range for Letter Sequencing\nand Motor Speed. The number of errors made on the Number–Letter Sequencing task was\nin the average range. In summary, his performance on the Trail Making Test remained largely\nstatic and overall was not strongly suggestive of underlying executive dysfunction.\nThe verbal Fluency test was also performed at Time 1 and 3. Letter Fluency at Time 1 was\nin the low average range but showed improvement to the average range at Time 3. His\nCategory Fluency scores remained in the average range for both time points. However, he\nappeared to have more difficulty with the Category Switching task. At Time 1, he scored in\nTable 3. serial assessment of mood and executive functioning.\nTime 1 Time 3\nScaled score Percentile Scaled score Percentile\nD-KEFS Trail Making Test\nVisual scanning 9 37 9 37\nnumber sequencing 12 75 5 5\nletter sequencing 8 25 12 75\nnumber letter sequencing 10 50 10 50\nMotor speed 12 75 12 75\nD-KEFS Verbal Fluency Test\nletter fluency 6 9 8 25\nCategory fluency 7 16 8 25\nCategory switching 6 9 5 5\nCategory switching accuracy 7 16 6 9\nHospital Anxiety and Depression raw score interpretation raw score interpretation\nScale (HADS)\nanxiety 4 normal 3 normal\nDepression 1 normal 1 normal\nDelis–Kaplan executive Function system (D-KeFs).\nscaled scores are provided for D-KeFs subtests (mean = 10, SD = 3).\n8 K. MCIvOR AND P. MOORE\nthe low average range for number of responses and the average range for switching accuracy.\nAt Time 3, he scored in the borderline range for number of responses and the low average\nrange for switching accuracy. The number of errors made on the fluency tasks was in the\naverage range. This could indicate improvement in his verbal fluency scores and that his\ncategory fluency remained intact. However, his performance appeared confounded when\na switching element was introduced.\nMood\nBAs mood was assessed by the HADS at Time 1 and 3. His scores for anxiety and depression\nconsistently resided in the normal range.\nDiscussion\nWe report neuropsychological assessment and serial cognitive testing of memory function\nin an untreated case of Anti-NMDAR encephalitis. Our findings revealed mild memory prob-\nlems 6 months post-discharge with, at best, static and potentially declining memory func-\ntioning at follow-up assessment 12 months post-discharge. However, the results of testing\nat 30 months post-discharge revealed significant improvements in immediate and delayed\nmemory index performances on the WMS-Iv with a very low base rate of this degree of dif-\nference expected to occur in the general population. Therefore, testing over 2½ years\npost-discharge revealed evidence of spontaneous recovery in BA’s memory functioning.\nWe considered issues relevant to the assessment of change in test scores over time, spe-\ncifically the practice effects on the WMS-Iv and the regression calculations embodied within\nthe ACS package. A key aspect of determining reliable change is test stability, commonly\nreferred to as test–retest reliability. Practice effects have received substantial attention in\nterms of their influence on test–retest reliability, with effects lasting up to 7 years docu-\nmented (Salthouse, Schroeder, & Ferrer, 2004), while shorter retest intervals have been asso-\nciated with greater effect sizes and longer test–retest intervals associated with lower\ncorrelations (Duff et al., 2010). Test–retest data for the WMS-Iv used in the serial assessment\ncalculations in the ACS package are based on retest data obtained for an interval of 14–84 days\n(mean 23 days) (Pearson Clinical Assessment, 2009). For the purpose of a serial assessment\nsuch as ours, with intervals of 223 and 525 days, the regression-based change model still\nemploys the standard interval data as a basis for calculations. Subsequently, it is possible\nthat the test–retest correlations used in the ACS regression model may be optimistically\nfavorable when considering many of the typical repeat testing scenarios encountered in\nclinical practice, such as ours, where patient follow-ups are conducted many months and\neven years apart.\nAs the normative population on which the WMS-Iv test–retest data underpinning the\nACS serial assessment calculations comprised healthy examinee data, a further limitation\nexists in the ability to extrapolate practice effects from a healthy population to a clinical\nsample. Differences in the degree of practice effects between clinical and non-clinical sam-\nples have been observed, even in the absence of significant broader memory impairments\non cognitive tasks (Baker, Taylor, & Aldenkamp, 2011). This introduces the possibility that\nexpected practice effects derived from persons with normal memory functioning might\nover-estimate the degree of practice effect expected in an individual with underlying mem-\nory impairment.\nTHE CLINICAL NEUROPSyCHOLOGIST 9\nAnother issue of relevance to our serial assessment is that practice effects are typically\nreported to be largest between the first and second administrations, with small to negligible\nincreases on further administrations (Ivnik et al., 1999), that have also been demonstrated\nin clinical populations in the early stages of recovery (Rawlings & Crewe, 1992). As the regres-\nsion model in the ACS package does not account for changes in practice effects beyond the\nfirst and second administrations, it remains possible that the results obtained from our third\nassessment of BA underestimate the magnitude of the observed improvement.\nA clinical conundrum in our formulation resulted from the finding that, despite a 16 index\npoint increase in BA’s AMI between T2 and T3, this was not found to be a statistically signif-\nicant improvement in memory scores according to the ACS serial assessment calculation.\nThe observed AMI change between T1 and T3 was in fact very similar to the change in score\nthat was predicted from T1 to T2. In BA’s case, we might expect that the practice effect would\nnot be as substantial as the ACS package predicted between T2 and T3 as we would expect\nsmaller practice effects to be occurring by the third administration. From a clinical perspec-\ntive, we also considered it important to acknowledge the self-reported improvements in\nmemory being made at T3. As such, it appeared that looking only for the presence of statis-\ntical significance in the change scores for the T2–T3 comparison would seem to ignore the\nbroader improvements in memory test scores observed in this assessment and the patient’s\nperception of improvement. We believe that this example supports the view of Iverson and\nSchatz (2015), who have noted that rigid application of reliable change approaches is likely\nto result in a failure to identify change in some people and that reliable change estimates\nshould supplement, and not replace, clinical judgment.\nIt is interesting to consider the mechanism behind BA’s recovery. There were clinical fea-\ntures that indicated the condition did not reach a critical stage for him including the fact he\ndid not require intubating and imaging did not reveal any obvious atrophy. Other researchers\nhave questioned why some people recover well from the condition. Iizuka et al. (2010) con-\ncluded that the condition results in functional rather than structural neuronal damage and\ntherefore recovery is possible. They further suggest that recovery could be related to phar-\nmacological effects, synaptic plasticity, or brain remodeling. A number of researchers have\nalso indicated that brain atrophy after anti-NMDAR encephalitis can be reversible (Iizuka\net al., 2010; Taguchi, Takashima, Nukui, & Tanaka, 2011). Taguchi et al. (2011) proposed that\ntemporal brain shrinkage could be caused by long-term anesthetic agents and the immune\nresponses of the anti-NMDAR encephalitis. Given that abnormal antibodies tend to decrease\nover time it may be that the immune response is not maintained.\nAB’s cerebral spinal fluid was monitored post-illness and although the antibodies reduced,\nit was still not considered to be in the normal range. However, this could indicate a trend\ntowards normal antibody composition which might be relevant in explaining his gradual\nrecovery. Given that no tumor was found, he may be at greater risk of relapse, which stands\nat about 25% (Dalmau et al., 2008). It has been suggested that patients receive immunosup-\npression treatment for 12 months to reduce the risk of relapse (young et al., 2013).\nAdditionally, his initial episode should mean that the condition would be identified and\ntreated quickly if it re-occurred in the future.\nOne potential limitation to this case study is that no formal assessment of effort was used\nto evaluate performance validity. However, there was no indication of secondary gain and\nmost of BA’s scores were in the average range, which was not suggestive of widespread\nunderperformance. He additionally scored above suggested cut-offs for suboptimal effort\n10 K. MCIvOR AND P. MOORE\non the Spatial Addition and Symbol Span task (Bouman, Hendriksm, Schmand, Kessels, &\nAldenkamp, 2016; young, Caron, Baughman, & Sawyer, 2012). A further limitation is the\nsmaller number of cognitive assessments completed at Time 1 and 2. This occurred due to\nthe demands of the clinical setting and due to memory function being the focus of the\nassessment.\nIn summary, our data supports a view that cognitive recovery from anti-NMDAR enceph-\nalitis is possible but may occur over an extended period. Therefore, long-term monitoring,\nrehabilitation, and cautious hope are recommended in these cases. From an assessment\nmethodology perspective, the use of reliable change calculations in serial cognitive assess-\nment can provide useful empirical validation of perceived differences in test scores over\ntime and inform neuropsychological formulations. In our view, the ACS package provided\na relatively sophisticated approach to reliable change assessment fronted by a user-friendly\ninterface. Use of the ACS package may be limited in clinical practice, when assessments take\nplace over more than two occasions and when follow-up cognitive testing spans larger\ntest–retest intervals than those from which the regression model of the ACS is derived. These\nadditional considerations highlight a need for the collation of test–retest data over more\nclinically relevant timescales and assessment scenarios involving larger numbers of follow-up\nadministrations. We also consider that the scale of first to second administration practice\neffects on some tests highlights the need for alternative test stimuli on memory tests to be\nconsidered alongside the continued development of clinically useful reliable change assess-\nment tools.\nDisclosure statement\nNo potential conflict of interest was reported by the authors.\nReferences\nAcién, P., Acién, M., Ruiz-Maciá, E., & Martín-Estefanía, C. (2014). Ovarian teratoma-associated anti-\nNMDAR encephalitis: A systematic review of reported cases. Orphanet Journal of Rare Diseases,\n9, 157–166.\nBaker, G. A., Taylor, J., & Aldenkamp, A. P. (2011). Newly diagnosed epilepsy: Cognitive outcome after\n12 months. Epilepsia, 52, 1084–1091.\nBouman, Z., Hendriksm, M. P. H., Schmand, B. A., Kessels, R. P. C., & Aldenkamp, A. P. (2016). Indicators\nof suboptimal performance embedded in the Wechsler memory scale-fourth edition (WMS–Iv).\nJournal of Clinical and Experimental Neuropsychology, 38, 455–466.\nChapman, M., & vause, H. (2011). Anti-NMDA receptor encephalitis: Diagnosis, psychiatric presentation,\nand treatment. American Journal of Psychiatry, 168, 245–251.\nChelune, G. J., Naugle, R. I., Luders, H., Sedlak, J., & Awad, I. A. (1993). Individual change after epilepsy\nsurgery: Practice effects and base-rate information. Neuropsychology, 7, 41–52.\nDalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., … Lynch, D. R. (2008). Anti-NMDA-\nreceptor encephalitis: Case series and analysis of the effects of antibodies. The Lancet Neurology,\n7, 1091–1098.\nDalmau, J., Lancaster, E., Martinez-Hernandez, E., Rosenfeld, M. R., & Balice-Gordon, R. (2011). Clinical\nexperience and laboratory investigations in patients with anti-NMDAR encephalitis. The Lancet\nNeurology, 10, 63–74.\nDalmau, J., Tüzün, E., Wu, H. y., Masjuan, J., Rossi, J. E., voloschin, A., … Lynch, D. R. (2007). Paraneoplastic\nanti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Annals of\nNeurology, 61, 25–36.\nTHE CLINICAL NEUROPSyCHOLOGIST 11\nDay, G. S., High, S. C., Cot, B., & Tang-Wai, D. F. (2011). Anti-NMDA-receptor encephalitis: Case report and\nliterature review of an under-recognised condition. Journal of General Internal Medicine, 26, 811–816.\nDelis, D. C., Kaplan, E., & Kramer, J. (2001). Delis kaplan executive function system. San Antonio, TX: The\nPsychological Corporation.\nDuff, K., Beglinger, L. J., Moser, D. J., Paulsen, J. S., Schultz, S. K., & Arndt, S. (2010). Predicting\ncognitive change in older adults: The relative contribution of practice effects. Archives of Clinical\nNeuropsychology, 25, 81–88.\nEker, A., Saka, E., Dalmau, J., Kurne, A., Bilen, C., Ozen, H., … Elibol, B. (2008). Testicular teratoma and\nanti-N-methyl-D-aspartate receptor-associated encephalitis. Journal of Neurology, Neurosurgery and\nPsychiatry, 79, 1082–1083.\nEvoli, A., Spinelli, P., Frisullo, G., Alboini, P. E., Servidei, S., & Marra, C. (2012). Spontaneous recovery from\nanti-NMDAR encephalitis. Journal of Neurology, 259, 1964–1966.\nFinke, C., Kopp, U. A., Prüss, H., Dalmau, J., Wandinger, K. P., & Ploner, C. J. (2012). Cognitive deficits\nfollowing anti-NMDA receptor encephalitis. Journal of Neurology Neurosurgery and Psychiatry, 83,\n195–198.\nHeilbronner, R. L., Sweet, J. J., Attix, D. K., Krull, K. R., Henry, G. K., & Hart, R. P. (2010). Official position of\nthe American academy of clinical neuropsychology on serial neuropsychological assessments: The\nutility and challenges of repeat test administrations in clinical and forensic contexts. The Clinical\nNeuropsychologist, 24, 1267–1278.\nHinkle, C. D., Porter, J. N., Waldron, E. J., Klein, H., Tranel, D., & Heffelfinger, A. (2016). Neuropsychological\ncharacterization of three adolescent females with anti-NMDA receptor encephalitis in the acute,\npost-acute, and chronic phases: An inter-institutional case series. The Clinical Neuropsychologist, 13,\n1–21. doi:10.1080/13854046.2016.1191676\nIizuka, T., Sakai, F., Ide, T., Monsen, T., yoshii, S., Iigaya, M., … Dalmau, J. (2008). Anti-NMDA receptor\nencephalitis in Japan: Long-term outcome without tumour removal. Neurology, 70, 504–511.\nIizuka, T., yoshii, S., Kan, S., Hamada, J., Dalmau, J., Sakai, F., & Mochizuki, H. (2010). Reversible brain\natrophy in anti-NMDA receptor encephalitis: A long-term observational study. Journal of Neurology,\n257, 1686–1691.\nIverson, G. L. (2001). Interpreting change on the WAIS-III/WMS-III in clinical samples. Archives of Clinical\nNeuropsychology, 16, 183–191.\nIverson, G. L., & Schatz, P. (2015). Advanced topics in neuropsychological assessment following sport-\nrelated concussion. Brain Injury, 29, 263–275.\nIvnik, R. J., Smith, G. E., Lucas, J. A., Petersen, R. C., Boeve, B. F., Kokmen, E., & Tangalos, E. G. (1999).\nTesting normal older people three or four times at 1 to 2 year intervals: Defining normal variance.\nNeuropsychology, 13, 121–127.\nJacobson, N. S., & Truax, P. (1991). Clinical significance: A statistical approach to defining meaningful\nchange in psychotherapy research. Journal of Consulting and Clinical Psychology, 59, 12–19.\nKruse, J. L., Jeffrey, J. K., Davis, M. C., Deralove, J., IsHak, W. W., & Brooks, J. O. (2014). Anti-N-methyl-D-\naspartate receptor encephalitis: A targeted review of clinical presentation, diagnosis, and approaches\nto psychopharmacologic management. Annals of Clinical Psychiatry, 26, 111–119.\nLebon, S., Mayor-Dubois, C., Popea, I., Poloni, C., Selvadoray, N., Gumy, A., & Roulet-Perez, E. (2012).\nAnti-N-methyl-D-aspartate (NMDA) receptor encephalitis mimicking a primary psychiatric disorder\nin an adolescent. Journal of Child Neurology, 27, 1607–1610.\nLo, J., Leung, E., Ng, B., Fu, M. H., yip, K. K., Chan, R., & Chang, C. M. (2010). Anti-N-methyl-D-aspartate\nreceptor encephalitis in a young woman with an ovarian tumour. Hong Kong Medical Journal, 16,\n313–316.\nMarcos-Arribas, L., Almonacid, J. J., & Dolado, A. M. (2013). Neuropsychological profile of anti-NMDA\nreceptor encephalitis. Psychology, 4, 776–781.\nMartin-Mozon, I., Trujillo-Pozo, I., & Romero, R. R. (2012). Functional recovery after neuropsychological\nrehabilitation in a case of Anti-N-methyl-D-apartate receptor encephalitis: Successful results suggest\nneural plasticity. Advanced Research in Scientific Areas Virtual Conference. Retrieved from http://\narsaconf.com/archive/?vid=1&aid=1&kid=60101\nPearson Clinical Assessment. (2009). Advanced clinical solutions for WAIS-IV and WMS-IV. Bloomington,\nMN: Pearson Clinical Assessment.\n12 K. MCIvOR AND P. MOORE\nRawlings, D. B., & Crewe, N. M. (1992). Test–retest practice effects and test score changes of the WAIS-R\nin recovering traumatically brain-injured survivors. The Clinical Neuropsychologist, 6, 415–430.\nSalthouse, T. A., Schroeder, D. H., & Ferrer, E. (2004). Estimating retest effects in longitudinal assessments\nof cognitive functioning in adults between 18 and 60 years of age. Developmental Psychology, 40,\n813–822.\nTaguchi, y., Takashima, S., Nukui, T., & Tanaka, K. (2011). Reversible “brain atrophy” in anti-NMDA receptor\nencephalitis. Internal Medicine, 50, 2697.\nUchino, A., Iizuka, T., Urano, y., Arai, M., Hara, A., Hamada, J., … Mochizuki, H. (2011). Pseudo-piano\nplaying motions and nocturnal hypoventilation in anti-NMDA receptor encephalitis: Response to\nprompt tumour removal and immunotherapy. Internal Medicine, 50, 627–630.\nvahter, L., Kannel, K., Sorro, U., Jaakmees, H., Talvik, T., & Gross-Paju, K. (2014). Cognitive dysfunction\nduring anti-NMDA-receptor encephalitis is present in early phase of the disease. Oxford Medical\nCase Reports, 12, 74–76.\nWechsler, D. (2008). Wechsler adult intelligence scale–fourth edition. San Antonio, TX: Pearson.\nWechsler, D. (2009). Wechsler memory scale–fourth edition (WMS-IV) technical and interpretive manual.\nSan Antonia, TX: Pearson.\nWechsler, D. (2011). Test of pre-morbid functioning (ToPF) manual. San Antonio, TX: The Psychological\nCorporation.\nyoung, P. J., Baker, S., Cavazzoni, E., Erickson, S., Krishnan, A., Kruger, P., … Wibrow, B. A. (2013). A case\nseries of critically ill patients with anti-N-methyl-D-aspartate receptor encephalitis. Critical care and\nResuscitation, 15, 8–14.\nyoung, J. C., Caron, J. E., Baughman, B. C., & Sawyer, R. J. (2012). Detection of suboptimal effort with\nsymbol span: Development of a new embedded index. Archives of Clinical Neuropsychology, 27,\n159–164.\nZigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica\nScandinavica, 67, 361–370.",
  "Takeda - Miki, 2014": "MultipleSclerosisandRelatedDisorders(2014)3,391–397\nAvailable online at www.sciencedirect.com\njournal homepage: www.elsevier.com/locate/msard\nCASE REPORT\nN\nA case of anti- -methyl- -aspartate receptor\nD\nencephalitis with multiple sclerosis-like\ndemyelinated lesions\nAkitoshi Takedaa,n , Hiroyuki Shimadaa, Akiko Tamuraa,\nMasaaki Yasuia, Kei-ichi Yamamotoa, Kazuhiro Itoha,\nSuzuka Atakaa, Sayaka Tanakab, Masahiko Ohsawab,\nHiroyuki Hatsutac, Makito Hiranod, Hikaru Sakamotod,\nShuichi Uenod, Yusaku Nakamurad, Tsuyoshi Tsutadaa,\nTakami Mikia\naDepartment of Geriatric Medicine and Neurology, Osaka City University, Graduate School of Medicine,\nOsaka, Japan\nbDepartment of Diagnostic Pathology, Osaka City University, Graduate School of Medicine, Osaka, Japan\ncDepartment of Neuropathology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan\ndDepartment of Neurology, Sakai Hospital, Kinki University Faculty of Medicine, Osaka, Japan\nReceived 21May2013;receivedinrevised form27August2013;accepted 6September2013\nKEYWORDS Abstract\nAnti-N-methyl-D- Objective: To describe an unusual case of a male patient with anti-N-methyl-D-aspartate\naspartate receptor receptor(NMDAR)encephalitiswhopresentedwithmultiplewhitematterlesions.Brainbiopsy\nencephalitis; ofthepatientwasperformed,andfollow-upevaluationofthecerebrospinalfluid(CSF)NMDAR\nMultiple sclerosis;\nantibody titerwasimplemented.\nNeuromyelitis optica;\nDesign: Casereport.\nBrain biopsy;\nSetting: University hospital.\nDemyelination;\nPatient: A 35-year-old man with anti-NMDAR encephalitis initially presented with fever and\nCSFantibody titer\npsychiatric symptoms. After an initial attack of anti-NMDAR encephalitis, 2 atypical relapses\noccurred,whichpresentedwithmyelitisandmultifocalwhitematterlesions;thelesionswere\nopen-ring-shaped andpartially enhanced.\nIntervention: Analysisofthebrainbiopsyspecimenrevealedthepresenceofdemyelinatedlesions\nwithdiscreteborders.Subsequentintravenousmethylprednisolonetherapyresultedinimprovement\ninthebrainlesions.Prednisoloneandcyclophosphamidewereorallyadministeredthereafter.Clinical\nprogressionofthediseaseparalleledobservedchangesintheCSFNMDARantibodytiter.\nnCorrespondenceto:1-4-3AsahimachiAbeno-ku,Osaka545-8585,Japan.Tel./fax:+81666453889.\nE-mailaddress:a-taked@med.osaka-cu.ac.jp(A.Takeda).\n2211-0348/$-seefrontmatter&2014ElsevierB.V.Allrightsreserved.\nhttp://dx.doi.org/10.1016/j.msard.2013.09.005\n392 A. Takeda et al.\nConclusion: Thedemyelinatedlesionsobservedinthiscaseweresimilartolesionsfoundinmultiple\nsclerosis.Onthebasisofourfindingthattheclinicalprogressionofthediseaseandtheassociated\nsymptomsparalleledchangesintheCSFNMDARantibodytiter,wespeculatethatthelesionsformed\nasaresultofanti-NMDARencephalitis.\n&2014ElsevierB.V.Allrightsreserved.\n1. Introduction (titer=1:64). Plasmapheresis (7 times in 2 weeks) com-\nmenced on day 40, followed by oral administration of\nAnti-N-methyl-D-aspartatereceptor(anti-NMDAR)encephalitis steroids, and the patient's consciousness level improved.\nThe patient was ambulant on day 61. Two months after\nis a rare, autoimmune clinical entity that can present with\nsymptom onset, the level of anti-NMDAR antibodies in the\npsychiatric symptoms, dyskinesia, decreased consciousness,\nandhypoventilation(Dalmauetal.,2011).Itisassociatedwith CSF (day 81) remained weakly positive (1:4); however,\nfollow-up MRI revealed that the right cerebral peduncle\nantibodies against functional NMDARs and predominantly\naffects young women. The first published report of anti- lesion had almost disappeared. On day 81, he developed\nNMDAR encephalitis described 4 young women with ovarian sudden diplopia with abnormal movement of the right eye.\nMRIonthisdaydidnotshowthepresenceofanynewlesion.\nteratomas (Vitaliani et al., 2005). Recently, unusual clinical\nThe CSF contained white blood cells (2.3cells/μL [normal\ncoursesoffemalepatientswithanti-NMDARencephalitishave\nrange:0–5])andprotein(86mg/dL[normalrange:10–52.6]).\nbeen reported (Johnston et al., 2010; Kruer et al., 2010;\nLekoubou et al., 2012; Motoyama et al., 2010; Pennington Becauseofhispersistentrequest,hewasdischargedfromour\nhospital on day 85. Thoracic, abdominal, or pelvic contrast-\netal.,2012;Yamamotoetal.,2013).Herein,wedescribethe\nenhanced computed tomography revealed no evidence of\nunusual case of a male patient with anti-NMDAR encephalitis\nwhopresentedwithmultipledemyelinatedlesions. tumors,andwholebodyMRIrevealednoevidenceoftumors.\nFurthermore, the results of serum tumor marker examina-\ntions were negative. Urologic evaluations did not detect\n2. Case report testiculartumors(fordetailsontheclinicalcourseofthefirst\nattack, see Sakamotoet al., 2013, patient 4).\nWe obtained the patient's consent by using a consent form Four months after his initial hospitalization, the patient\nprovided by Osaka City University Hospital. A previously developed paraparesis and hypoesthesia of the lower extre-\nhealthy 35-year-old man experienced headaches and fever. mities and had to be readmitted to Sakai Hospital, Kinki\nHevisitedalocalhospital.Abnormalcerebrospinalfluid(CSF) University Faculty of Medicine on day 141. At the time of\nfindings (white blood cells, 164/μL [normal range: 0–5], admission, CSF examination revealed the following: white\nprimary mononuclear cells; total protein, 90mg/dL [normal\nbloodcells,16cells/μL(normalrange:0–5),mononuclearcells\nrange: 10–52.6]; glucose, 56mg/dL [normal range: 50–80]) dominance; total protein, 85mg/dL (normal range 10–52.6);\nindicated meningitis. He refused hospital admittance. Six and MBP, 1200pg/mL (normal range: 0–102). Moreover, the\ndays later, he became delirious and violent (day 1). He was anti-NMDARantibodytiterintheCSF(day141)hadincreased\nthen admitted to an emergency hospital, where he was (1:8). The immunoglobulin-G index was within normal limits\ndiagnosed with encephalitis (day 4). Because of severe andanti-aquaporin4(AQP4)antibodieswerenotdetected.A\ndelusion, the patient was sedated and put under artificial T 2 -weighted sagittal MRI of the thoracic spine revealed a\nventilation after intubation; however, hypoventilation lesion with a long vertical axis that was centered on T7\nbecause of encephalitis was not apparent. He was trans- (Fig.1A).AxialMRIshowedlesionsinthecenterofthespinal\nferredtoSakaiHospital,KinkiUniversityFacultyofMedicine cord(Fig.1B),whileT 2 -weightedaxialMRIindicatedlesionsin\n(day 7). Two courses of steroid pulse therapy (3 days(cid:1)1000 the rightcerebellar hemisphere(Fig. 1D and F),the leftside\nmg methylpredonisolone/day) and intravenous acyclovir (14 ofthepons(Fig.1F),andaroundthelateralventricles(Fig.1C\ndays(cid:1)2250mg/day) were administered as herpes encepha- and E). MRI of the brain fulfilled the McDonald imaging\nlitiswassuspected,afterwhichhisconsciousnessmarginally criteria. The patient underwent 3 courses of steroid pulse\nimproved.CSFexaminationrevealedpleocytosis(whiteblood therapy.Hesubsequentlyrecoveredfromtheparaparesisand\ncells, 61cells/μL [normal range: 0–5], primary mononuclear hypoesthesiaandwasdischarged.\ncells; total protein, 36mg/dL [normal range: 10–52.6]; Follow-up MRI, performed 4 months after the second\nmyelin basic protein (MBP),o40pg/mL [normal range: 0– hospitalization, revealed multiple contrast-enhanced lesions\n102]; and no oligoclonal band). Blood tests revealed no inthecerebrumonday265.Duringthisfollow-upperiod,the\nautoantibodies associated with vasculitides (anti-nuclear patientdevelopeddiplopiaandptosisofthelefteyeandwas\nantibody, antibodies to MPO-ANCA, PR3-ANCA, SSA, or SSB) admittedtoOsakaCityUniversityHospitalonday293.During\nor glutamic acid decarboxylase (GAD). He was weaned from this period of hospitalization, the patient developed fever\nmechanicalventilationonday11.However,hisconsciousness (37.5–39.01C). Neurologic examination revealed disorienta-\nremainedmildlydisturbed.Magneticresonanceimaging(MRI) tion and left oculomotor nerve paralysis, but no motor\non day 14 revealed a lesion in the right cerebral peduncle. paralysis. Deep tendon reflexes increased in all 4 limbs, but\nAntiviral medications were discontinued because the poly- no pathologic reflexes were elicited. No abnormality in\nmerasechainreaction(PCR)(day9)resultforherpessimplex sensory or motor coordination was detected, except for a\nvirus was negative. An additional examination of the CSF mild right limp during normal gait. T -weighted axial MRI\n2\n(day 4) revealed the presence of anti-NMDAR antibodies showedmultiplelesionsinthecerebellum,middlecerebellar\nA case of anti-N-methyl-D-aspartate receptor encephalitis with multiple sclerosis-like demyelinated lesions 393\nFig.1 MRIduringthethirdhospitalizationperiod.(A)SpinalMRT2WI(TR/TE=4200/89)showedaT2high-signallesionaroundthe\nlevelofTh6-7(arrow).(B)Thislesionwaslocatedinthecenterofthespinalcord(arrow).(CandE)AT2-highsignallesionwaspresent\naroundthelateralventricles(arrow).(DandF)Lesionsintherightcerebellarhemisphereandtheleftsideofthepons(arrow).\npeduncle (Fig. 2A), and cerebral white matter (Fig. 2B An open-brain biopsy was performed. Tissue samples\nand C), which were worse than those observed on day 265. were collected from the contrast-enhanced lesion in the\nPost-contrast T -weighted images demonstrated contrast- right frontal lobe (Fig. 2F). A demyelinated lesion with\n1\nenhanced lesions at the same sites (Fig. 2D and E) as well discrete borders was observed (Fig. 3A–C). Bodian histo-\nas an open-ring-shaped and partially enhanced lesion chemical stain and immunostaining for phosphorylated\n(Fig.2E).MRIofthespinalcordrevealedthatthepreviously neurofilaments demonstrated that axons were relatively\nobserved lesions in this area had resolved and that no new preserved in the myelin-deficient lesion (Fig. 3B and C),\nlesions had formed. Blood tests revealed no increase in the and immunohistochemistry for MBP was negative (Fig. 3D).\ninflammatory response and no autoantibodies associated Scattered axonal swellings were found in the lesion\nwith vasculitides (anti-nuclear antibody, anti-DNA antibody, (Fig. 3C). Numerous foamy macrophages and glial fibrillary\nantibodies to MPO-ANCA, PR3-ANCA, SSA, or SSB). CSF acidic protein-positive (+) reactive astrocytes were\nexamination at this stage presented the following: no observedinthelesion(Fig.3AandE).Macrophagescontain-\npleocytosis (normal range: 0–5), no oligoclonal bands, ingLuxolfastblue-positiveparticlesofmyelinwerepresent\nincreased protein level (74mg/dL (normal range: 10–52.6), (Fig. 3G). Numerous inflammatory cells were observed in\nand an immunoglobulin-G index within normal limits. Cyto- the perivascular space (Figs. A.1–A.5). CD68+ activated\nlogical examinations revealed no evidence of malignancy or microgliaandmacrophageswerepresentintheperivascular\nother notable abnormalities. The anti-NMDAR antibody titer space and parenchyma (Fig. A.4). Immunohistochemistry\nin the CSF (day 294) increased (1:40). However, the test revealed diffuse presence of AQP4 in the white matter,\nresults for anti-HIV antibodies, anti-AQP4 antibodies, and including in the demyelinated lesion (Fig. 3F).\nparaneoplastic syndrome-related autoantibodies (Ma2, Ma1, Afterthebiopsy,intravenousmethylprednisolonetherapy\namphiphysin, CV2, Ri, Yo, and Hu) were negative, and PCR wasstarted,whichimprovedthesymptomsoffeverandleft\nanalysis of the CSF for John Cunningham (JC) virus also oculomotornerveparalysis.BrainMRIrevealedshrinkageof\nrevealed negative results. Follow-up evaluation showed no the lesions and attenuation of the contrast enhancement.\nevidence of tumors. We decided to perform an open brain After 3 additional courses of intravenous methylpredni\nbiopsy because the patient presented with impaired con- solone therapy, treatment with oral prednisolone (30mg/day)\nsciousness (disorientation), and the brain lesions had wor- and cyclophosphamide (100mg/day) was initiated; the anti-\nsened in a few weeks. NMDARantibodytiterintheCSFsubsequentlydecreased(1:20)\n394 A. Takeda et al.\nFig. 2 MRI during the fourth hospitalization period. (A–C) T2WI (TR/TE=4000/79) multiple cerebral and middle cerebellar peduncle\nlesions.(D–F)AT1contrast-enhancedimage(TR/TE=5.82/2.63)showedcontrastenhancementinmostofthecerebrumlesions(arrow).\nFig. 3 Histology of brain biopsy. (A and G) Hematoxylin and eosin/Luxol fast blue (HE/LFB) staining, (B) Bodian staining,\n(C)immunostainingforanti-phosphorylatedneurofilament,(D)myelinbasicprotein(MBP),(E)glialfibrillaryacidicprotein(GFAP),\nand(F)aquaporin-4 (AQP4). Scalebar=100mm(A–F);20mm(G).\nTable1 Theclinical characteristicsof anti-NMDARencephalitis withmultiple sclerosis-like demyelinated lesions.\nKrueretal.(2010) Motoyamaetal. Johnstonetal.(2010) Lekoubouetal.(2012) Penningtonetal. Yamamotoetal. Presentcase\n(2010) (2012) (2013)\nAge/sex 15/Fa 10/F 32/F 34/F 31/F 27/F 35/Mf\nOnset Headache ON Seizure Agitation Myelitis Hemiparesis Headache\nPartialseizure Fluctuatingconsciousness Delusion Sensorydisturbance Impairedconsciousness\nImpairedconsciousness Oraldyskinesia Hemiparesis Abnormalbehavior\nOrofacialdykinesia Catatonia Cerebellarataxia Hypoventilation\nMutism\nTreatment Plasmapheresis Steroid Antibiotics IVIg Plasmapheresis Acyclovir Plasmapheresis\nSteroid Acyclovir Steroid Steroid\nCyclophosphamide Steroid Rituximab Azathioprine Steroid Cyclophosphamide\nRituximab\nRelapse Myelitis, Seizure ON ((cid:3)) Seizure Abnormalbehavior Myelitis\nONb Trigeminalnervesensory Personalitychange Impaired Impairedconsciousness\ndisturbance consciousness\nImpairedmemory Orofacialdyskinesia Oculomotorpalsy\nTumor ((cid:3)) ((cid:3)) ((cid:3)) ((cid:3)) ((cid:3)) ((cid:3)) ((cid:3))\nMRIfindings Multifocalwhitematter Multifocalwhite CompatiblewithMSe(Fulfilled Multifocalwhite Multifocalspinalcord Brainstem Brainstem,\nlesions matterlesions Barkhofcriteria) matterlesions lesions\nContrastenhancement Leptomeningeal Contrast Multifocalwhite Cerebellarwhitematterlesions\nLETMc enhancement enhancement,LETM Multifocalwhite matterlesions Multifocalwhitematterlesions\nmatterlesions\nAnti-NMDA CSF CSF NA CSF CSF CSFandSerum CSF\nantibodies\nPathology Perivascularinfiltration NAd NA NA NA NA Demyelinatedlesionwithdiscrete\nbordersAQP4g(+)\nSelectivedemyelination MBPh((cid:3))\n((cid:3))\naF:female.\nbON:opticneuritis.\ncLETM:longitudinallyextensivetransversemyelitis.\ndNA:notavailable.\neMS:mulitiplesclerosis.\nfM:male.\ngAQP4:aquaporin4.\nhMBP:myelinbasicprotein.\nA\ncase\nof\nanti-N-methyl-D-aspartate\nreceptor\nencephalitis\nwith\nmultiple\nsclerosis-like\ndemyelinated\nlesions\n395\n396 A. Takeda et al.\nFig. 4 Time course of the clinical severities and CSF NMDAR antibody titers. The Modified Rankin Scale scores (mRS, red line)\nparalleled changes observed in the CSF NMDAR antibody titers (blue line). Arrow: mPSL pulse (SP), plasmapheresis (PE). (For\ninterpretation ofthereferences tocolorinthis figure legend,thereader isreferred tothewebversionof thisarticle.)\non day 340. The patient was discharged after his symptoms caused by anti-NMDAR encephalitis. Kruer et al. (2010)\nsignificantlyimprovedonday349. speculated that an epitope spread, which occurs after\nanti-NMDAR encephalitis, causes seronegative NMO. While\nthe present case was pathologically negative for NMO, the\n3. Comment patternofdemyelinationwasmoresimilartothatobserved\ninMS.Theclinicalprogressionandtheassociatedsymptoms\nWe describe the unusual case of a male patient with anti- of our case paralleled changes observed in CSF NMDAR\nNMDAR encephalitis who presented with multiple sclerosis antibody titers (Fig. 4; (Martinez-Hernandez et al., 2011).\n(MS)-like demyelinated lesions. To the best of our knowl- We could not determine whether the patient had MS after\nedge, a similar case, supported by immunohistochemical anti-NMDAR encephalitis, because he responded well to\nresults, has not been previously reported. Six female steroid therapy—a therapy usually insufficient to treat\npatientswithmultipledemyelinatinglesionsofthecerebral anti-NMDAR encephalitis. However, absence of an oligoclo-\nand spinal cord due to anti-NMDAR encephalitis have been nalbandaswellasfeverandimpairedconsciousnessinour\nreportedthusfar(Table1);however,ourpatientisonlythe patient during his third admission to hospital were atypical\nsecond case showing pathological findings. In addition, this of MS. Additionally, since the CSF titers of anti-NMDAR\nis the first patient in whom the anti-NMDAR antibody titers antibodies decreased after steroid therapy, which subse-\nintheCSFandtheclinicalseveritywereseriallydetermined quently reduced the severity of the disease, we speculate\nduring the recurrent disease course. In 3 of the 6 reported that the patient had an atypical form of recurrent anti-\nfemale cases, the presence of optic neuritis complicated NMDAR encephalitis.\nthe differentiation of an NMDAR-related condition from MS\nand neuromyelitis optica (NMO) (Johnston et al., 2010; Conflict of interest\nKruer et al., 2010; Motoyama et al., 2010). MRI analysis\ndetected multiple lesions of acute disseminated encepha-\nThe authors declare no potential conflicts of interest\nlomyelitis(ADEM)atthetimeofonsetinoneofthesecases\nrelated to the research, authorship, and/or publication of\n(Lekoubou et al., 2012), whereas MS or myelitis occurred\nthis article.\nbefore the onset of encephalitis in the other cases\n(Pennington et al., 2012;Yamamoto et al., 2013).Common\ncharacteristics in these cases, except the case with ADEM-like Funding source\npresentation (Lekoubou et al., 2012), included polyphasic\nprogressionthatwasresponsivetoimmunosuppressivetherapy\nNone.\nandtheabsenceoftumors.\nAnalysis of the brain biopsy in our case revealed clear\ndemyelinating borders of the myelin sheath. In addition, a Acknowledgments\nlowintensityofMBPantibodystaininginthesameareawas\nfurther indicative of demyelination. A low level of AQP4 We thank Drs. Josep Dalmau and Lindsey McCracken of the\nantibodystaining,suggestiveofNMO(Misuetal.,2007),was Hospital of the University of Pennsylvania for providing\nnot observed. Pathologically, the findings of this case were helpfulcommentsandformeasuringanti-NMDARantibodies;\nmore indicative of MS than of NMO. In a case of NMO Dr. Kazuo Nakamichi of the National Institute of Infectious\nreported by Kruer et al. (2010), no marked demyelination Diseasesforconductingthepolymerasechainreactionofthe\nwas observed, which suggests that the pathological char- JC virus; Dr. Toshiyuki Takahashi of Tohoku University for\nacteristics of their patient and that of our patient were measuring the anti-AQP4 antibodies; Dr. Ayumu Uchibori\ndifferent. Many unknown aspects of the polyphasic clinical and Dr. Atsuro Chiba of Kyorin University for measuring the\ncourseaswellaslesionsinthebrainandthespinalcordare paraneoplastic neurological syndrome-related antibodies;\nA case of anti-N-methyl-D-aspartate receptor encephalitis with multiple sclerosis-like demyelinated lesions 397\nandDr.MasakiTakaoofTokyoMetropolitanGeriatricHospital Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N,\nfor assistanceinthe pathologicalexaminations. Martinez-LageM,DalmauJ.Analysisofcomplementandplasma\ncells in the brain of patients with anti-NMDAR encephalitis.\nAppendix A. Supporting information\nNeurology2011;77:589–93.\nMotoyama R, Shiraishi K, Tanaka K, Kinoshita M, Tanaka M. Anti-\nNMDA receptor antibody encephalitis with recurrent optic\nSupplementary data associated with this article can be neuritisand epilepsy.[ArticleinJapanese].RinshoShinkeigaku\nfound in the online version at http://dx.doi.org/10.1016/ 2010;50:585–8.\nj.msard.2013.09.005. Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S,\net al. Loss of aquaporin 4 in lesions of neuromyelitis optica:\ndistinctionfrommultiplesclerosis.Brain2007;130:1224–34.\nReferences\nPennington C, Livingstone S, Santosh C, Razvi S. N-methyl-D-\naspartate receptor antibody encephalitis associated with mye-\nlitis.JournaloftheNeurologicalSciences2012;317:151–3.\nDalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, SakamotoH,HiranoM,SamukawaM,UenoS,MaekuraS,Fujimura\nBalice-Gordon R. Clinical experience and laboratory investiga- H, et al. Details of treatment-related difficulties in men with\ntionsinpatientswithanti-NMDARencephalitis.LancetNeurology anti-N-methyl-D-aspartatereceptorencephalitis.EuropeanNeu-\n2011;10:63–74. rology2013;69:21–6.\nJohnston J, Ali K, Pearson OR, Rickards C, Vincent A. Multiple Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J.\nsclerosis:apotentialassociationwithanti-N-methyl-D-aspartate Paraneoplastic encephalitis, psychiatric symptoms, and hypo-\nreceptor encephalitis [abstract]. Journal of Neurology, Neuro- ventilation in ovarian teratoma. Annals of Neurology\nsurgery,andPsychiatry2010;81:e56. 2005;58:594–604.\nKruerMC,KochTK,BourdetteDN,ChabasD,WaubantE,MuellerS, Yamamoto M, Kokubun N, Watanabe Y, Okabe R, Nakamura T,\net al. NMDA receptor encephalitis mimicking seronegative HirataK.NMDAreceptorencephalitisinthecourseofrecurrent\nneuromyelitisoptica.Neurology2010;74:1473–5. CNS demyelinating disorders: a case report. [Article in Japa-\nLekoubouA,ViaccozA,DidelotA,AnastasiA,MarignierR,DucrayF, nese].RinshoShinkeigaku2013;53:345–50.\net al. Anti-N-methyl-D-aspartate receptor encephalitis with\nacute disseminated encephalomyelitis-like MRI features. Eur-\nopeanJournalofNeurology2012;19:e16–7.",
  "Rosenbloom - Tran-Lim, 2018": "Neurology® Clinical Practice Case\nNMDA receptor antibody\nencephalitis presenting with\nenhancing lesion and seizures\nMichael H.Rosenbloom, MD;MelissaK.Samuelsson,MD;Michael E.Brogan,MD;Teresa A.Tran-Lim, MD\nW\ne report an adult man presenting with sudden-onset epilepsy syndrome with\nevolution to refractory status epilepticus and an enhancing left frontal MRI\nPractical\nlesion. The atypical nature of his presentation resulted in emergent epilepsy\nImplications\nsurgery. He was eventually diagnosed with NMDA receptor antibody\n(NMDAR AB) encephalitis based on positive CSF antibodies. Inrareinstances,NMDA\nreceptorantibodyencephalitis\nCASE REPORT maypresentclinicallywith\nA 19-year-oldAfrican American manpresented with a new-onset generalized seizure after refractoryseizuresandradio-\nwatchingafilmfollowedbyanotherevent3dayslater.BrainMRIperformedafterthepa- logicallyasafocalenhancing\ntient recovered revealed an 8-mm focus of increased fluid-attenuated inversion recovery lesiononbrainMRI.\nsignal intensity with gadolinium enhancement of the left middle frontal gyrus, suggestive\nof neoplasm (figure, A and B). Despite initiation of levetiracetam 500 mg bid, he\ncontinued to have breakthrough seizures that resulted in a hospitalization 2.5 weeks\nfrom symptom onset.\nOnexamination,thepatienthadexpressiveaphasiawithoutanyotherfocalfindings.Initial\nEEGshowedcontinuouslateralizedperiodicdischargesovertheleftfrontalregion,culminating\nin frequent left frontal seizures and 1 generalized convulsion (figure, C). Repeat brain MRI\nshowed a stable left frontal lesion. Initial CSF analysis revealed a leukocyte count of 63 with\n99% lymphocytosis, protein 52, and glucose 57, and no oligoclonal bands or immunoglob-\nulinG(IgG)indexelevation.SerumstudiesforHIV,Lymeantibodies,Bartonellaantibodies,\nAnaplasma antibodies, and an autoimmune epilepsy panel were negative. He was treated\nempirically with methylprednisolone 1 g IV 3 3 days without clinical response. A repeat\nlumbar puncture performed 1 week after the initial study showed 6 leukocytes and normal\nprotein (37) and glucose (83). Again, there was no evidence for oligoclonal bands or elevated\nIgG index. CSF studies were normal or negative for herpes simplex virus 1, cryptococcus,\nvaricella-zoster virus, viral/bacterial cultures, West Nile virus, enterovirus, Lyme, Whipple\nPCR, pyruvate/lactate, and venereal disease research laboratory. CSF for an autoimmune\nepilepsy panel was sent to the Mayo Clinic.\nThroughouthishospitalization,thepatientcontinuedtohavepersistentseizuresrefractory\nto phenytoin 200 mg Q8, levetiracetam 2,500 mg Q12, phenobarbital 150 mg Q12, lacosa-\nmide 250 mg Q12,topiramate 150 mg Q12,and felbamate 600mg TID. Herequired intu-\nbationandtherapeuticcomatoattempttocontrolrefractorystatus.Seizuresinitiallyresponded\ntopropofol,butrelapsedontaper.Hecontinuedtohavebreakthroughseizuresduringasecond\ntrial of propofol 120 mg/kg/min and midazolam 2.0 mg/kg/h. He was treated empirically\nwithout improved seizure control.\nHealthPartners(MHR,MKS,MEB),St.Paul;andPark-Nicollet(TAT-L),SaintLouisPark,MN.\nFundinginformation anddisclosures areprovidedattheendofthearticle. Fulldisclosure forminformation\nprovided bytheauthorsisavailablewiththefulltextofthisarticle atNeurology.org/cp.\nCorrespondence to:Michael.H.Rosenbloom@HealthPartners.com\nNeurology:ClinicalPractice |||||||||||| October2017 Neurology.org/cp 433\nª 2017AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.\nMichaelH.Rosenbloometal.\nFigure ClinicalstudiesinapatientpresentingwithfocalseizuresandpositiveCSFNMDA\nreceptorantibodies\n(A)BrainMRIrevealsafocalleftmiddlefrontalgyrushyperintensityonfluid-attenuatedinversionrecoverysequen-\ncescorrespondingtothelocationofictaldischarges(redarrow).(B)T1-weightedMRIsequencedemonstratestrace\nenhancementoftheleftmiddlefrontalgyruslesion(arrowhead).(C)InitialEEGshowscontinuouslateralizedperiodic\ndischargesovertheleftfrontalregionthatdevelopedintofocalleftfrontalseizures.(D)Pathology(hematoxylin&\neosin,originalmagnification3400)revealschronicinflammationofthecerebralcortexwithoutevidenceforcor-\nticaldysplasiaorneoplasm(redarrow).\nDue to the patient’s refractory seizures, focal lesion on structural MRI, and seizures on\ncontinuous EEG, the patient underwent resection of the left middle frontal gyrus. The\nelectrographic seizures persisted postoperatively. Pathology revealed chronic perivascular/pa-\nrenchymal inflammation and reactive astrocytosis without evidence for cortical dysplasia or\nneoplasm (figure, D).\nACSFautoimmuneepilepsypaneleventuallyrevealedpositiveNMDARAB.BodyCTscan\nandtesticularultrasoundwerenegativeformalignancy.Thepatientwasstartedonmethylpred-\nnisolone1gIVandplasmaexchange35days,immediatelyfollowedbyIVimmunoglobulin3\n5 days due to initial minimal response. Furthermore, he received rituximab 3 2 doses, sepa-\nratedby 1 week. With immunosuppression, the patient’s refractory statusresolved, and he was\ndischarged from the hospital with a normal neurologic examination 6 weeks from admission.\nDISCUSSION\nNMDAR encephalitis is the most common cause of autoimmune encephalitis after acute de-\nmyelinatingencephalomyelitisandischaracterizedbypsychiatricsymptoms,seizures,extrapy-\nramidalsigns,decreasedlevelofconsciousness,andautonomicinstability.Thedisorderaffects\nindividualsofallages,withahighpredilectionforyoungwomenwithorwithoutteratomas.1,2\nThe most common presenting symptom in our patient’s age group is behavior changes\nfollowed by seizures,3 which may be focal, but are most commonly generalized.2 In addition,\nroutine structural brain MRI is often normal in this patient population.4\n434 ©2017AmericanAcademyofNeurology\nª 2017AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.\nNMDAreceptorantibodyencephalitispresentingwithenhancinglesionandseizures\nAlthough our patient’s CSF autoantibodies and neuropathology were consistent with\nNMDAR AB encephalitis, this case was unusual based on (1) symptoms confined to a focal\nepilepsy syndrome and (2) enhancing focal lesion suggesting CNS neoplasm. A case series\ndescribed focal seizures in 8 patients with NMDAR antibodies, but all the patients presented\nwith accompanying cognitive, behavioral, or motor symptoms.5 Furthermore, none of the\ndescribed patients were found to have a focal, enhancing brain MRI lesion. Thus, NMDAR\nAB encephalitis presenting with isolated seizures and a clinical syndrome mimicking a focal\nCNS neoplasm is relatively rare.\nDiagnosiswasdelayedduetotheuniqueclinicalpresentationaswellasthefactthatthese-\nrumstudieswerenegativeforNMDARAB.Ourpatientemphasizestheimportanceofinves-\ntigatingNMDARantibodiesinCSF6asrecentlysuggestedbymostinvestigatorsinthefieldof\nautoimmune encephalitis.7\nREFERENCES\n1. DalmauJ,GleichmanAJ,HughesEG,etal.Anti-NMDA-receptorencephalitis:caseseriesandanalysis\nof the effects of antibodies. Lancet Neurol 2008;7:1091–1098.\n2. Viaccoz A, Desestret V, Ducray F, et al. Clinical specificities of adult male patients with NMDA\nreceptor antibodies encephalitis. Neurology 2014;82:556–563.\n3. Kayser MS, Titulaer MJ, Gresa-Arribas N, Dalmau J. Frequency and characteristics of isolated\npsychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol 2013;70:\n1133–1139.\n4. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term out-\ncomeinpatientswithanti-NMDAreceptorencephalitis:anobservationalcohortstudy.LancetNeurol\n2013;12:157–165.\n5. SandsTT,NashK,TongS,SullivanJ.Focalseizuresinchildrenwithanti-NMDAreceptorantibody\nencephalitis. Epilepsy Res 2015;112:31–36.\n6. Gresa-Arribas N, Titulaer MJ, Torrents A, etal. Antibody titres at diagnosis and during follow-up of\nanti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 2014;13:167–177.\n7. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis.\nLancet Neurol 2016;15:391–404.\nReceivedSeptember26,2016.AcceptedinfinalformMarch1,2017.\nAUTHOR CONTRIBUTIONS\nM.Rosenbloom:manuscriptpreparationandfiguredesign.M.Samuelsson:manuscriptreviewandfig-\nure design. M. Brogan: manuscript review and editing. T. Tran-Lim: manuscript review, editing, and\nfiguredesign.\nSTUDY FUNDING\nNotargetedfundingreported.\nDISCLOSURES\nM. Rosenbloom serves on a scientific advisory board for Struthers Parkinson’s Center and receives\nresearch support from HealthPartners Institute for Education & Research and Regions Hospital\nFoundation.M.Samuelsson, M. Brogan,andT.Tran-Lim reportnodisclosures.Fulldisclosure form\ninformationprovidedbytheauthorsisavailablewiththefulltextofthisarticleatNeurology.org/cp.\nNeurology:ClinicalPractice |||||||||||| October2017 Neurology.org/cp 435\nª 2017AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.",
  "Zubkov - Kothare, 2015": "RESIDENT\n&FELLOW Teaching NeuroImages:\nSECTION\nNMDA encephalomyelitis with MRI\nSection Editor\nJohn J.Millichap,MD abnormalities isolated to ventral spinal\ncord gray matter\nSarahZubkov,MD\nFigure MRIspinalcordwithoutcontrast\nPujaAggarwalJoshi,MD\nTimothyM.Shepherd,\nMD,PhD\nSanjeevV.Kothare,MD\nCorrespondenceto\nDr.Zubkov:\nsarah.zubkov@gmail.com\nThebrainappearednormalonMRI(A)whereassagittalcervicalMRI(B)demonstratedsubtleT2hyperintensityintheventral\nC4-C7spinalcordthatcorrelatedaxiallywithsymmetricT2hyperintensitiesintheventralgraymatter(C).Therewasno\ncorrespondingcontrastenhancement.RepeatMRIafterresolutionofmyelopathyappearednormal(D).\nA17-year-oldgirlpresentedwithamonthofanxiety spinal cord gray matter involvement has not been\nfollowedbyacutepsychosis,catatonia,choreoatheto- reportedpreviously.\nsis, seizures, autonomic instability, lower extremity\nspasticity, and hyperreflexia. CSF was positive for AUTHORCONTRIBUTIONS\nthe NMDA antibody; additional antibodies and Sarah Zubkov: drafting and revision of manuscript, clinical care of\npatient.PujaAggarwalJoshi:clinicalcareofpatient,revisionofmanu-\ninfectious etiologies tested negative. MRI brain was\nscript.TimothyM.Shepherd:interpretationandpreparationofimages,\nnormal. MRI spine revealed symmetric T2 hyperin-\nrevisionofmanuscript.SanjeevV.Kothare:clinicalcareofpatient,revi-\ntensitiesinventralgraymatter(figure).EEGshowed sionofmanuscript.\nextreme delta brush. She received the following\nSTUDYFUNDING\nsequentially: IV gammaglobulin, methylpredniso-\nNotargetedfundingreported.\nlone,ovarianteratomaresection,andplasmapheresis,\nonlyimprovingafterrituximab.At3months,repeat\nDISCLOSURE\nMRIspineandmotorexaminationresultswerenor-\nThe authors report no disclosures relevant to the manuscript. Go to\nmal.NMDAencephalitiswithmyelopathy is rare1,2; Neurology.orgforfulldisclosures.\nDownloadteachingslides:\nNeurology.org\nFromNYULangoneMedicalCenter,NewYork,NY.\n©2015AmericanAcademyofNeurology e55\nª 2015AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.\n5202\ntsuguA\n5\nno\n942.321.151.5\nyb\ngro.ygoloruen.www//:sptth\nmorf\ndedaolnwoD\nREFERENCES 2. Pennington C, Livingstone S, Santosh C, et al.\n1. KruerMC,KochTK,BourdetteDN,etal.NMDArecep- N-methyl d-aspartate receptor antibody encephalitis\ntorencephalitismimickingseronegativeneuromyelitisopti- associated with myelitis. J Neurol Sci 2012;317:\nca.Neurology2010;74:1473–1475. 151–153.\ne56 Neurology85 August11,2015\nª 2015AmericanAcademyofNeurology.Unauthorizedreproductionofthisarticleisprohibited.\n5202\ntsuguA\n5\nno\n942.321.151.5\nyb\ngro.ygoloruen.www//:sptth\nmorf\ndedaolnwoD",
  "Lesher": "JournalofPediatricSurgery(2010)45,1550–1553\nwww.elsevier.com/locate/jpedsurg\n–N\nAnti -methyl- -aspartate receptor encephalitis associated\nD\n☆\nwith an ovarian teratoma in an adolescent female\n⁎\nAaron P. Leshera, Thomas J. Myersa, Fred Tecklenburgb, Christian J. Strecka,\naDivision of Pediatric Surgery, Department of Surgery, Medical University of South Carolina, Charleston, SC 29425, USA\nbDepartment of Pediatrics-Critical Care, Medical University of South Carolina, Charleston, SC 29425, USA\nReceived 11February 2010; revised 1 April 2010; accepted 5 April 2010\nKey words:\nAbstract Anti–N-methyl-D-aspartate (NMDA) receptor encephalitis is a recently described para-\nEncephalitis;\nneoplasticsyndromewithprominentneuropsychiatricsymptoms.WereportacaseofNMDAreceptor\nNMDA receptor\nencephalitis in a 15-year-old female related to the development of NMDA receptor autoantibodies\nantibodies;\ntriggered by an ovarian teratoma. Removal of the mature teratoma proved curative with eventual\nOvarian teratoma;\nresolution of the paraneoplastic disease process and associated psychiatric symptoms. Increasingly,\nChildren;\nreports of anti-NMDAreceptor encephalitis associated with ovarianteratomasin pediatric patients, as\nParaneoplastic syndrome\nwellasanovelassaytomeasuretheseantibodies,suggestanetiologyforthisdiseaseprocessthatmay\nbeamenabletopromptsurgicalexcision.Theclinicalpresentation,diagnosis,andsurgicalmanagement\nof the disease, aswell as areview of the literature, areincluded.\n© 2010Elsevier Inc. All rightsreserved.\n1. Case report Hospital for further evaluation and treatment when her\nsymptomsprogressed,includingworseningemotionallabil-\nity, increasing disorientation, and a progressive dyskinetic\nA 15-year-old previously healthy Hispanic female pre-\nmovement disorder. Inpatient consultations with neurology,\nsented to a local referring hospital with transient loss of\npsychiatry,andinfectiousdiseasewereobtained.Workupof\nconsciousness and seizure-like activity. Initial evaluation,\nher delirium, including repeat electroencephalogram and\nincludingroutinelaboratorytestsandcomputedtomographic\nhead CT, revealed no underlying pathologic condition.\n(CT) imaging of the head, was unremarkable. She was\nMagnetic resonance imaging of the brain demonstrated a\ndischarged home with outpatient neurology follow-up. The\nsubtle hyper-T2 signal of the mesial temporal lobes\nfollowing day, she began having visual hallucinations and\nbilaterally. Lumbar puncture; blood cultures; serum viral\nbizarrepsychoticbehavior.Shewasfurtherevaluatedbyan\nstudies, including herpes simplex virus, cytomegalovirus,\nelectroencephalogram that demonstrated bitemporal sharp\nEpstein-Barr virus, and Varicella-Zoster Virus; toxicology;\nspikes,startedonantiseizuremedication,andreadmittedfor\nand metabolic evaluation did not reveal an etiology. The\ninpatient observation. Shewas transferred to ourChildren's\npatient became increasingly agitated with little response to\nintravenous benzodiazepines, sedatives, and antipsychotics\n☆ Nofinancialconflictsofinteresttodisclose. and required antihypertensive medication for new-onset\n⁎ hypertension.Onhospitalday6,thepatientdevelopedacute\nCorrespondingauthor.Tel.:+18437923853;fax:+18437923858.\nE-mailaddress:streck@musc.edu(C.J.Streck). nonoliguricrenalfailure.Evaluationofherhypertensionand\n0022-3468/$–seefrontmatter©2010ElsevierInc.Allrightsreserved.\ndoi:10.1016/j.jpedsurg.2010.04.002\nAnti-NMDAR encephalitis and ovarian teratoma 1551\nacuterenalfailureincludedarenalultrasoundandbiopsythat fetoprotein were measured and were normal. A diagnostic\nwereunremarkable.Despiteempiricantiviraltherapy,broad- laparoscopy revealed a solid left ovarian mass. The\nspectrum antibiotics, and stress-dose steroids for suspected contralateral ovary was normal appearing. Pelvic fluid\nautoimmuneencephalitis,thepatient'smentalstatuscontin- sampling and a laparoscopic left oophorectomy were\nuedtodeteriorate requiring intensive care unitobservation. performed given the extensive tumor involvement of the\nWhileintheintensivecareunit,areviewofthepatient's ovary.Pathologicexaminationconfirmedthediagnosisofa\nextensiveevaluationrevealedanincidentalfindingofa6.0× mature ovarian teratoma. The results of the anti-NMDA\n4.0×4.3-cmleftovarianmassonherrenalultrasound(Fig. receptorantibodyassaylaterrevealedhighantibodytitersin\n1). The Pediatric Surgery Service was consulted, and an cerebrospinal fluid and serum. Three doses of intravenous\nabdominal CT scan demonstrated a solid left adnexal mass immunoglobulin were given in the first postoperative week\nwith evidence of calcification consistent with an ovarian with minimal improvement in her agitation. The patient\nteratoma (Fig. 2). Because of concern for a paraneoplastic remainedconfusedanddisorientedwithperiodsofimprove-\nsyndrome,serumand cerebrospinal fluidsampleswere sent ment and decline for approximately 2 weeks, at which time\nforanalysisofanti–N-methyl-D-aspartate(NMDA)receptor she had a rapid improvement in her mental status and\nantibodies. Serum β-human chorionic gonadotropin and α progressedtoherprediseasestateoverthenextfewdays.An\nFig.1 Transabdominalultrasonographydemonstratesa6.2×4.0×4.3-cmcysticmassintheleftovary(panelA)comparedtoanormal-\nappearingrightovary(panelB).\n1552 A.P. Lesher et al.\nsubunit of the NMDA receptor are detectable in serum and\ncerebrospinal fluid. The NMDA receptors are ligand-gated\ncationchannelsprimarilyexpressedinthehippocampusand\nforebrain and are implicated in memory and learning [3].\nDrugs interacting with the NMDA receptor, including\nketamine and phencyclidine, induce paranoia, dissociative\nsymptoms,andhallucinations,whicharecommonsymptoms\ninanti-NMDA receptor encephalitis.\nThe incidence of paraneoplastic anti-NMDA receptor\nencephalitis is not known. The first substantial case series\ndescribed 12 patients with 3 similarities: all were young\nfemales(14-44yearsofage)withprominentneuropsychiatric\nsymptoms,ovarian(n=11)ormediastinal(n=1)teratomas,\nwith detectable quantities of serum or cerebrospinal fluid\nantibodies that interacted with the cell membrane of rat\nhippocampal neurons in vitro [2]. In this report, initial\npresenting symptoms ranged from short-term memory loss\nand confusion to acute psychiatric syndrome with paranoia\nand behavioral changes. Eleven patients had partial or\ngeneralized seizures, and 10 patients required mechanical\nventilationbecauseofcentralhypoventilation.Ninepatients\nunderwentteratoma resection with 8patients demonstrating\nneurologicimprovement.Onepatientdiedwithoutimprove-\nment of neurologic symptoms. Clinical improvement in\npatientscorrelatedwithfallingserumandcerebrospinalfluid\nanti-NMDA receptor antibody levels. A subsequent larger\nseriesof100patientswithanti-NMDAreceptorencephalitis\ndocumented 58 cases associated with tumors, 49 of which\nwere ovarian teratomas [4]. Patients in this series who\nunderwent tumor excision within 4 months of the onset of\nneurologicsymptomshadasignificantlybetteroutcomethan\npatientswithouttumororthosewithlateornotumorremoval.\nFig. 2 A coronal reconstruction of a CT scan of the patient's A recent report of 81 patients with anti-NMDA receptor\nabdomen and pelvis reveals a cystic left adnexal mass with an encephalitis revealed that 40%were younger than 18 years,\ninternal focus of fat and high attenuation material suggesting an\nwithamedianageof14years[5].Olderfemalepatientshada\novarianteratoma(blackarrow).\nhigherfrequencyofovarianteratomasthanyoungerpatients,\nwith31%ofgirlsyoungerthan18yearsoldhavingteratomas\ncomparedwith56%offemalesolderthan18years.Only9%\nof females younger than 14 years had associated teratomas.\noutpatient follow-up appointment revealed an active, alert\nMost patients presented with behavioral or personality\nteenager withoutresidual neurologic deficit.\nchanges with progression to seizures in 77%, 84% with\nstereotypedmovements,86%withautonomicinstability,and\n23%withcentralhypoventilation.Patientsweretreatedwith\n2. Discussion\nimmunotherapy with teratoma removal if applicable. Full\nrecoverywasmorecommoninpatientswithimmunotherapy\nWe present a case of an adolescent female with and teratoma excision than those without teratoma [5].\nparaneoplastic anti-NMDA receptor encephalitis. Paraneo- Although not all patients presenting with NMDA receptor\nplastic syndromes in children are uncommon and are encephalitisarefemalewithovarianteratomas,thefrequency\ntraditionallyassociatedwithWilm'stumorandneuroblasto- of these patients mandates screening of these patients with\nma [1]. Recent work by Dalmau and colleagues [2] has ultrasound,CTscans,ormagneticresonanceimagingtorule\nuncovered an autoimmune paraneoplastic process that outacausativetumor.\naccounts for a severe form of encephalitis previously The common presenting symptoms of patients with\nundescribed. Patients present with a recognizable syndrome NMDA receptor encephalitis include neuropsychiatric\npredominantlycharacterizedbyescalatingconfusion,amne- symptoms, seizures, dyskinesias, loss of consciousness,\nsia, agitation, and paranoid or delusional thoughts. In this amnesia, and autonomic dysfunction. Our patient exhibited\ndisease process, autoantibodies to the NMDA Receptor 1 all of these symptoms over her disease course. However,\nAnti-NMDAR encephalitis and ovarian teratoma 1553\nunlike the patients described in other series, our patient did evaluation and treatment of suspicious ovarian masses\nnotexhibitcentralhypoventilation.Onereasonforthiscould while inthecare ofa multidisciplinary team.\nbeidentificationandremovalofthetumorrelativelyearlyin Awareness and recognition of anti-NMDA receptor\nherclinicalcourse,comparedtopatientsintheliterature.Our encephalitis is of utmost importance to pediatric specialists\npatient's ovarian teratoma was removed approximately 3 because complete recovery after surgical resection is\nweeksaftertheonsetofsymptoms.Inonereport,neurologic possible despite the severity of symptoms. Increasing\nsymptoms were present for 3 weeks to 4 months before the numbers of case reports in the neurology [2,6,9] and\ndiagnosis of teratoma, with time to initial improvement gynecology [10] literature, as well as coverage in the lay\nrangingfrom3daysto16weeks[2].Inaddition,ourpatient press[11],arehighlightingtheseverityofthediseaseaswell\ndemonstratedneurologicimprovementonpostoperativeday as the potential for surgical cure. Adolescents presenting\none with subsequent waxing and waning. Steady, gradual withseverepsychoticsymptomsorseizuresanddyskinesias\nimprovementinhercognitiveabilities beganapproximately may have previously been misdiagnosed with psychiatric\n14 days after excision of the teratoma with full return to illness or viral encephalitis. With the development of a\nfunction by postoperative day 20. Slow improvement with reliableassaytomeasureautoantibodytiters,andtheclinical\nperiodsofrelapseseemstobeacharacteristicofanti-NMDA awarenesstoruleoutanovarianmass,otherwisedifficult-to-\nencephalitis, likely because of the failure of common treat neuropsychiatric patients may benefit from prompt\nimmunomodulatory therapies to provide sustained control diagnosisand treatment ofthis novelclinical entity.\nof the immune response [4]. Removal of the NMDA-\nexpressing tumor has been associated with a decrease in\nserum and cerebrospinal fluid levels of the pathologic\nReferences\nautoantibody [6]. For benign-appearing ovarian masses,\ncystectomyshouldbeattemptedifaplanecanbedeveloped\nbetween the cystic tumor and normal ovarian tissue. [1] ReesJH.Paraneoplasticsyndromes:whentosuspect,howtoconfirm,\nCystectomy preserves gonadal tissue in the patient of andhowtomanage.JNeurolNeurosurgPsychiatry2004;75(SupplII):\nii43-50.\nchildbearing age with an otherwise benign tumor. In our\n[2] Dalmau J, Tuzun E, Wu H, et al. Paraneoplastic anti–N-methyl-D-\ncase, oophorectomy was performed because there was no\naspartatereceptorencephalitisassociatedwithovarianteratoma.Ann\nnormal-appearing ovarian tissue. In addition, some authors Neurol2007;61:25-36.\nsuggest that symptomatic ovarian masses, as in the case of [3] Waxman EA, Lynch DR. N-methyl-D-aspartate receptor subtypes:\npatientswithprecociouspuberty,warrantoophorectomy[7]. multiplerolesinexcitotoxicityandneurologicaldisease.Neuroscien-\ntist2005;11:37-49.\nOutcomesofNMDAreceptorencephalitisvaryfromfull\n[4] Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor\nrecovery, to 24-hour institutional care, to death after\nencephalitis: case series and analysis of the effects of antibodies.\nprolonged hospitalization [2,6,8]. In addition to surgical LancetNeurol2008;7:1091-8.\nexcision of the teratoma, immunotherapy, including corti- [5] Florance NR, Davis RL, Lam C, et al. Anti–N-methyl-D-aspartate\ncosteroids, intravenous immunoglobulin, and plasmaphere- receptor (NMDAR) encephalitis in children and adolescents. Ann\nNeurol2009;66:11-8.\nsis, has been widely used in patients to date [5]. Given the\n[6] Seki M, Suzuki S, Lizuka T, et al. Neurological response to early\nrelative novelty of this disease process, there are no\nremoval ofovarian teratoma inanti-NMDAR encephalitis. JNeurol\nrandomized, controlled data to support or condemn the use NeurosurgPsychiatry2008;79:324-6.\nofimmunotherapyinthispatientpopulation.Ourpatientdid [7] Hayes-JordanA.Surgicalmanagementoftheincidentallyidentified\nreceive 3 doses of intravenous immunoglobulin in the early ovarianmass.SeminPediatrSurg2005;14:106-10.\n[8] Ishiura H, Matsuda S, Higashihara M, et al. Response of the anti-\npostoperative period, although no immediate neurologic\nNMDA receptor encephalitis without tumor to immunotherapy\nimprovement was noted. However, reports of patients with\nincludingrituximab.Neurol2008;71:1921-6.\nanti-NMDA receptor encephalitis with and without a [9] Sansing LH, Tuzun E, Ko MW, et al. A patient with encephalitis\nteratoma have demonstrated clinical responses to immuno- associated with NMDA receptor antibodies. Nat Clin Pract Neurol\nmodulatory regimens, including steroids, intravenous im- 2007;3:291-6.\n[10] Kort DH, Vallerie AM, DeMarco EF, et al. Paraneoplastic anti–N-\nmunoglobulin, and plasmapheresis in patients [5,8].\nmethyl-D-aspartatereceptorencephalitisfrommaturecysticteratoma.\nAlthough the reasons for our patient's successful outcome\nObstetGynecol2009;114:373-6.\nare unknown, treatment should clearly include prompt [11] SandersL.Diagnosis:braindrain.NewYorkTimesMag2008:MM22.",
  "Naeije": "ClinicalNeurologyandNeurosurgery112 (2010) 509–511\nContentslistsavailableatScienceDirect\nClinical Neurology and Neurosurgery\njournal homepage: www.elsevier.com/locate/clineuro\nCasereport\nAcute behavioural change in a young woman evolving towards cerebellar\nsyndrome\nG.Naeije∗,Q.deHemptinne,C.Depondt,M.Pandolfo,B.Legros\nDepartmentofNeurology,ErasmeHospital,UniversitéLibredeBruxelles,Brussels,Belgium\na r t i c l e i n f o a b s t r a c t\nArticlehistory: Symptomaticparaneoplasticneurologicalsyndromesareraremanifestationsofcancers.Recently,anew\nReceived30January2009 type of encephalitis associated with antibodies against NMDA-glutamate receptors (A-NMDAR) was\nReceivedinrevisedform24February2010 defined.Thepatients,usuallyyoungwomen,presentwithacuteonsetofpsychiatricsymptomsand\nAccepted2March2010\ndecreasedconsciousness.Wedescribethecaseofapatientwhopresentedwithacuteonsetofdelir-\nAvailable online 29 March 2010\niumalternatingwithsub-comatosestate.Bloodanalyseswerewithinnormalrange.Lumbarpuncture\nshowedlymphocyticpleiocytosis.BraingadoliniuminjectedMRI,brainandfullbodyPETscanswerenor-\nKeywords:\nmal.InvestigationsledtosuspectaparaneoplasticsyndromeandarightovarianteratomaandA-NMDAR\nEncephalitisassociatedwithantibodies\nwerefoundandtheteratomaremoved.Theremainingsequellaeincludedacerebellarsyndromeseldom\nagainstNMDA-glutamatereceptors\nPsychiatricsymptoms describedbefore.AscerebellarandcorticalneuronssharethesameexcitatorypathwaythroughNMDA-\nCerebellarsyndrome glutamatereceptors,thecerebellarfunctionimpairmentobservedinourpatientcouldbeexplainedby\nParaneoplasticsyndrome adisablingactiononglutamateNMDARbytheA-NMDAR.\n© 2010 Elsevier B.V. All rights reserved.\n1. Introduction a lethargic, unreactive state and extreme agitation. She had no\npast medical history, took no medication and had not travelled\nSymptomatic paraneoplastic neurological syndromes are rare recently. Family and friends reported she had never used drugs.\nmanifestations of cancers. Recently, a new type of encephalitis Physicalexaminationwastheredescribedasnormal.TheERblood\nassociatedwithantibodiesagainstNMDA-glutamatereceptors(A- analyses were within normal range, including a complete blood\nNMDAR)wasdefined.Thepatients,usuallyyoungwomen,present count,electrolytes,kidney,liverandinflammatoryparametersand\nwithacuteonsetofpsychiatricsymptomsanddecreasedconscious- urinarytoxicologyscreening.Abraincomputedtomography(CT)\nness. Abnormal movement and seizures are often found but a scanwasnormal.Thecerebrospinalfluid(CSF)analysisrevealed24\ncerebellarsyndromehasbeenexceptionallydescribed.Wereport whitebloodcells(90percentlymphocytes)permilliliter(normal\na case of a young woman with A-NMDAR encephalitis evolving range<5/mL), with normal chemistries. The patient was empiri-\ntowardscerebellarsyndrome. callytreatedwithceftriaxone,ampicillinandacyclovir.Asthedirect\nexaminationandthecultureoftheCSFresultednegative,ceftri-\naxone and ampicillin were stopped. Her condition continued to\n2. Casereport\nworsenand4daysaftertheonsetofthedelirium,thepatientwas\ntransferredtoourinstitution.\nWereportthecaseofa29-year-oldwomanwhopresentedwith\nOn admission, we were confronted with a deeply agitated\nacuteonsetofdeliriumalternatingwithsub-comatosestate.Ten\nwomanwhosephysicalexaminationwasunremarkable.Shewas\ndays before her admission, the patient went nightclubbing and\nafebrile.Theneurologicalexaminationwaslimitedduetolackof\nreturned at dawn. She was then reported as “out of character”\ncollaboration.Sheseldomansweredsimplequestions,butsome-\nand behaving like drunk, although she was sober. The following\ntimesutteredanadequatesentenceandthenresumedtoshouting\nweek,behaviouralalterationsexacerbated.Atwork,shecouldnot\nincoherent sounds. There was no sign of meningeal irritation,\nconcentrate.Concerned,sheaskedtobedriventotheemergency\nthe pupils were symmetric and reactive to light, there was no\nroom(ER)ofanotherhospital.Inthecar,shebegantoshoutand\napparent oculomotor or facial palsy. She moved her four limbs\nhaveuncontrolledmovements.Afterwards,shealternatedbetween\nagainst resistance. Deep tendon reflexes were present and sym-\nmetric. The only positive neurological sign was a right plantar\nreflex in extension. Since there had been no improvement with\n∗\nCorrespondingauthorat:DepartmentofNeurology,ErasmeHospital,808Route\nantiviralandantibiotictreatment,atrialwith1000mgofmethyl-\ndeLennik,1070Brussels,Belgium.Tel.:+32477542862;fax:+3225553942.\nprednisolone per day during 5 days was undertaken. There was\nE-mailaddress:gillesnaeije@yahoo.com(G.Naeije).\n0303-8467/$–seefrontmatter© 2010 Elsevier B.V. All rights reserved.\ndoi:10.1016/j.clineuro.2010.03.002\n510 G.Naeijeetal./ClinicalNeurologyandNeurosurgery112 (2010) 509–511\nTable1\nToxicologic\nPhenylcycline,LSD,cocaine,amphetamines,cannabis,...\nMetabolic\nAcuteporphyria\nUreacycledisorder\nEndocrinepsychosis\nElectrolyteimbalance\nInfectious\nViral:HIV,JCvirus,HSV1,HSV2,VZV,HHV6,CMV,EBV,rabies,...\nBacterial:tuberculosis,Listeria\nVectortransmitted:borreliosis,arbovirosis,trypanosomiasis,malaria\nFungalandparasitic:cryptoccocosis,toxoplasmosis\nSystemicautoimmuneorvasculitic\nSLE,Sjögren’ssyndrome\nPrimaryangiitisofthecentralnervoussystem\nEpileptic\nTemporallobeepilepsy\nNeoplastic\nCNSlymphoma\nPrimarybraintumour\nMetastaticdisease\nFig.1. T2weightedpelvicMRIrevealinga5cm×3cm×2cmheterogenousmass Paraneoplastic\nintherightovary(whitearrow).Anatomopathologicexaminationdisclosedater- Limbicencephalitis\natoma. Encephalitiswithovarianteratomaandanti-NMDAR\nEncephalitiswithVGKC-A\nabsolutelynochangeinherclinicalstate.Bloodanalysisshowed HIV=humanimmunodeficiencyvirus,HSV=herpessimplexvirus,VZV=varicella\nno inflammatory syndrome: white blood cells were masured zostervirus,HHV=humanherpesvirus,CMV=cytomegalovirus,EBV=EpsteinBarr\nat 8000/mm3 (normal range<10,000/mm3),C reactive protein virus,SLE=systemiclupuserythematous,VGKC-A=voltage-gatedpotassiumchan-\nnelantibodies.\nat 9.4mg/L (normal range<10mg/L), erythrocyte sedimentation\nrateat4mm/h(normalrange<20mm/h),anti-nuclearantibodies\nwerenegative,anti-neutrophiliccytoplasmicantibodieswerepos- 3. Discussion\nitive at 1:40 dilution without specificity against proteinase 3 or\nmyeloperoxydase.Alumbarpuncturewasreiteratedandshowed Thedifferentialdiagnosisoforganicpsychosisiswideandsum-\n10 lymphocytes per milliliter. Proteins and lactate were normal marized in Table 1. In this case, systematic exclusion of each\nand no oligoclonal bands were detected. We performed a broad diagnosticentitymadeussuspectaparaneoplasticsyndrome.The\nserological screening including Borrelia burgdorferi, toxoplasma, clinical pattern of our patient and the absence of specific anti-\nsyphilis,arboviruses,rabies,enteroviruses,herpessimplex,herpes bodies (anti-Hu, anti-Ma2, ...) rules out paraneoplastic limbic\nzoster: all were negative. Human immunodeficiency virus (HIV) encephalitis[1].Hallucinatorybehaviourandcognitiveimpairment\nserology and polymerase chain reaction (PCR) were negative on hinttowardsencephalitiswithanti-voltage-gatedpotassiumchan-\nbothbloodandCSF.Analysisofhaememetabolitesandaminoacids nel antibodies but the other features associated: hyponatremia,\non urine ruled out porphyria and urea metabolism disorders. A autonomic hyperactivation and antibodies against voltage-gated\n24h video-electroencephalogram showed rare sharp waves over potassiumchannelsweremissing[2].Prominentpsychiatricsymp-\nthelefttemporalregion.AbrainMRIwithgadoliniuminjection,a tomsarealsothehallmarkoftherecentlydescribedencephalitis\ntrans-cranialDopplerandafundoscopicexaminationwerenormal. associated with A-NMDAR and ovarian teratoma. Further imag-\nAparaneoplasticsyndromewasthensuspected.Hu,riandantigan- ingledustodiscoveranovarianteratomaandthediagnosticwas\ngliosideantibodieswerenegative.Awholebodypositron-emission confirmedbythediscoveryofA-NMDARintheserum.\ntomographyscan(PET)wasnormal.BrainPETdisclosedabilateral EncephalitisassociatedwithA-NMDARwasrecentlydefinedin\nposteriorhypometabolism.Thispatient’sclinicalcourseresembled aseriesof100adultpatientsandinasmallerseriesof32children.\nseveralcasesofencephalitisassociatedwithovarianteratomaand In adults, the median age is 23 years, 90 percent of patients are\nA-NMDAR, prompting us to perform a pelvic MRI that revealed women,allpresentwithpsychiatricsymptomsand88percentwith\na 5cm×2cm×3cm ovarian teratoma (Fig. 1). We subsequently decreasedconsciousness.Dysautonomia,seizures,dyskinesiasand\ntestedforthepresenceofA-NMDARwhichwerepositive. hypoventilationoccurinmorethantwo-thirdthecases.Onlyone\nFive weeks after the onset of symptoms, the patient started caseassociatingataxiawithopsoclonus-myoclonusandthepresent\ntowakeupandcommunicateforincreasingperiodsoftime.The case report had cerebellar features [4]. CSF shows inflammatory\novarianteratomawassurgicallyremovedandthepatientcontin- alterations,flairorT2weightedbrainMRIsignalshowshyperin-\nuedtoimprove.Fourteenweeksaftertheonsetofsymptoms,the tensitiesinthetemporallobesandPETshowshypermetabolismin\nremainingsequelaeweresevereorthostatichypotensionwithout oneorbothtemporallobes.PETanomaliescanprecedethesignal\nany increase of heart rate, disinhibition and a cerebellar syn- anomaliesonMRIandabouthalfthepatientshavenormalimag-\ndrome.Neurologicalexaminationdisclosedcerebellar,pyramidal ing[4,6].Anovarianteratomaisfoundin60percentofthecases.\nand frontal abnormalities. There was mental slowing, scanning Inwomen,ovarianteratomamustbelookedfor,sincetheremoval\nspeech,square-wavesjerksonocularpursuit,bilateralhyperme- oftheteratomainducesafallinA-NMDARtitre[5]andisassoci-\ntriaonthefinger-to-nosetestandimpairedheel-to-shintest.Rapid atedwithabetteroutcomeandlessrelapses.17monthsafterthe\nalternatingmovementswereimpossible.Theplantarresponsewas onset,halfthepatientsremainwithfrontallobedysfunctionlike\ninextensionontherightside.Gaitwasataxicandtandemgaitwas behaviouraldysinhibition,attentionandplanificationdisorders.In\nimpossible.Thetonus,musclestrength,andsensationwerenormal. children,atumourislesslikelytobefoundandautonomicdistur-\nG.Naeijeetal./ClinicalNeurologyandNeurosurgery112 (2010) 509–511 511\nbances are less severe but more frequent than in adults [7]. The tractussolitari,corticalandcerebellarneuronspotentialtargetsfor\nsequelsareseverein25percentofadultcases.Inourcase,after alterationbyA-NMDAR.\n3months,therewasnoobviousimprovementbutrecoverieshave\nbeenknowntohappenevenafterseveralmonths. Conflictofinterest\nNMDAreceptors(NMDAR)playakeyroleinneuronalexcitatory\npathways and plasticity throughout the central nervous system. Theauthorshavenoconflictofinterest.\nPharmacological antagonists of the glutamate NMDAR can cause\nsymptoms of psychotic behaviour in human [8]. The prominent References\nbehaviouraldisordersinpatientssufferingfromencephalitisasso-\nciatedwithA-NMDARledtosuspectapathogenicandantagonistic [1] FarrugiaME,ConwayR,SimpsonDJ,KurianKM.Paraneoplasticlimbicencephali-\neffectoftheantibodiesontheNMDAreceptors.Thishypothesisis tis.ClinNeurolNeurosurg2005;107(2):128–31.\n[2] TanKM,LennonVA,KleinCJ,BoeveBF,PittockSJ.Clinicalspectrumofvoltage-\nsupportedbystudiesshowingthatA-NMDARbindstheNR1sub- gatedpotassiumchannelautoimmunity.Neurology2008;70(20):1883–90.\nunit of the NMDAR and that application of A-NMDAR to culture [4] KurianKM,LalivePH,DalmauJ,HorvathJ.Opsoclonus-myoclonusinanti-N-\nof hippocampal neurons decreased postsynaptic NMDA clusters.\nmethyl-d-aspartatereceptorencephalitis.ArchNeurol2010;67:118–21.\n[5] DalmauJ,TüzünE,WuHY,Masjuan,RossiJE,VoloschinA,etal.Paraneoplastic\nFurthermore, clinical neurological improvement correlates with anti-N-methyl-d-aspartatereceptorencephalitisassociatedwithovarianter-\ndecreasingantibodiestitre[6].SimilarimpairementoftheNMDAR atoma.AnnNeurol2007;61(1):25–36.\nin the nucleus tractus solitari could explain autonomic features [6] DalmauJ,GleichmanAJ,HughesEG,RossiJE,PengX,LaiM,etal.Anti-NMDA-\nreceptorencephalitis:caseseriesandanalysisoftheeffectsofantibodies.Lancet\nlike orthostatic hypotension [9]. As cerebellar and cortical neu-\nNeurol2008;7(12):1091–8.\nronssharethesameexcitatorypathwaythroughNMDA-glutamate [7] FloranceNR,DavisRL,LamC,SzperkaC,ZhouL,AhmadS,etal.Anti-N-methyl-\nreceptors an alteration of cerebellar function by A-NMDAR is d-aspartatereceptor(NMDAR)encephalitisinchildrenandadolescents.Ann\nNeurol2009;66(1):11–8.\nexpected[10].ThecerebellumcouldbelesssensitivetoA-NMDAR\n[8] KaliaLV,KaliaSK,SalterMW.NMDAreceptorsinclinicalneurology:excitatory\nthan other brain structures making its impairment an atypical timesahead.LancetNeurol2008;7(8):742–55.\nmanifestationofthisautoimmunedisorder.Encephalitisassociated [9] MachadoBH.Neurotransmissionofthecardiovascularreflexesinthenucleus\ntractussolitariiofawakerats.AnnNYAcadSci2001;940:179–96.\nwithA-NMDARisarecentlydescribeddiseaseinwhichA-NMDAR\n[10]LlansolaM,Sanchez-PerezA,CauliO,FelipoV.ModulationofNMDAreceptorsin\nhavebeendemonstratedtohaveafunctionaleffect.TheNMDAR thecerebellum.1.PropertiesoftheNMDAreceptorthatmodulateitsfunction.\narewidelyexpressedinthecentralnervoussystemmakingnucleus Cerebellum2005;4(3):154–61.",
  "Reyna-Villasmil – Herrera-Moya, 2017 ": "Cómo citar este artículo: Reyna-Villasmil E, et al. Encefalitis por anticuerpos antirreceptores de N-metil-aspartato debida a teratoma\nquístico ovárico. Med Clin (Barc). 2017.\nG Model\nARTICLE IN PRESS\nMEDCLI-4196;\nhttp://dx.doi.org/10.1016/j.medcli.2017.06.049\nNo. of Pages 2\nMed Clin (Barc). 2017;xxx(xx):xxx–xxx\nwww.elsevier.es/medicinaclinica\nCarta al Editor\nEncefalitis por anticuerpos antirreceptores de\nN-metil-aspartato debida a teratoma quístico\novárico\nAnti-N-methyl-D-aspartate-receptor encephalitis due ovarian\nteratoma\nSr. Editor:\nLa encefalitis por anticuerpos contra el receptor N-metil-\nD-aspartato (anti-NMDAR) se ha relacionado con tumores que\nexpresan tejido nervioso1. La presentación clínica es variable,\nsiendo los síntomas psiquiátricos, convulsiones y trastornos del\nmovimiento sus manifestaciones iniciales. A pesar de la gravedad y\ncurso clínico prolongado, la mayoría de los pacientes se recuperan\ncuando es diagnosticada y tratada tempranamente2. Se presenta\nel caso de la primera paciente con síntomas neurológicos que fue\ndiagnosticada y tratada por encefalitis anti-NMDAR asociada a tera-\ntoma ovárico en el hospital y demuestra la necesidad de considerar\nesta posibilidad diagnóstica en mujeres jóvenes con encefalitis.\nSe trata de una paciente de 23 an˜os, sin antecedentes de impor-\ntancia, llevada a la urgencia con alteraciones del comportamiento\nde 3 días de evolución, episodios de rigidez generalizada y movi-\nmientos tónico-clónicos que se transformó en encefalopatía con\nestatus epiléptico. Previamente había presentado fiebre, cefalea,\nastenia, afectación del estado general y episodios autolimitados de\nalteración del lenguaje, desorientación en tiempo-espacio y agita-\nción psicomotriz.\nAl examen físico estaba consciente, agitada, pensamiento y\nlenguaje desorganizados con constantes vitales normales. La explo-\nración abdominogenital estaba dentro de límites normales. La\nanalítica general, radiografía de tórax, tomografía y angiotomo-\ngrafía de cráneo fueron normales. En la resonancia magnética\nse observó afectación inflamatoria meníngea-aracnoidea. El elec-\ntroencefalograma mostró enlentecimiento difuso. La punción\nlumbar reveló 101 leucocitos (97% mononucleares) en el líquido\ncefalorraquídeo, siendo negativo para Gram y varios virus.\nTras el ingreso se estableció un diagnóstico de sospecha de\nencefalitis autoinmune, siendo tratada con esteroides e inmuno-\nglobulina intravenosa y se solicitó tomografía abdominopélvica que\nreportó teratoma de ovario izquierdo de 5 cm de diámetro con valo-\nres elevados de CA-125 y alfafetoproteína. Se realizó ooforectomía\nizquierda laparoscópica. El estudio anatomopatológico demostró\nhallazgos compatibles con teratoma quístico maduro. Se consideró\nsolicitar anticuerpos anti-NMDAR en sangre y líquido cefalorraquí-\ndeo (LCR) que resultaron positivos, confirmando el diagnóstico. La\npaciente continuó siendo tratada con corticoides e inmunoglobuli-\nnas intravenosas. A los 7 días presentó desorientación y\npsicomotriz\nagitación\ny movimientos tónico-clónicos generalizados, indicán-\ndose tratamiento con rituximab semanal por 4 semanas, mejorando\nclínicamente. La paciente recuperó el estado de conciencia y ritmo\nvigilia-suen˜o normal, persistiendo ligera bradipsiquia y bradilalia.\nFue dada de alta luego de lograr estabilidad clínica con seguimiento\npor neurología.\nLa encefalitis anti-NMDAR es un síndrome neuropsiquiátrico\nde origen autoinmune. Se describe en mujeres de 18-30 an˜os\ncon cambios de personalidad-conducta, paranoia y trastornos de\nla memoria. La relación hombre-mujer de esta enfermedad es\n9:911. Durante el cuadro clínico se producen múltiples déficits\nneurológicos, discinesias, convulsiones, inestabilidad autonómica\ny alteraciones de la conciencia. La discinesia orofacial y protrusión\nde la lengua son características del síndrome2.\nAlrededor del 60% de los pacientes presentan tumores subya-\ncentes y el 95% son teratomas ováricos3, pero también se han\ndescrito en teratomas testiculares y cáncer de pulmón de célu-\nlas pequen˜as2. Todos estos tumores que contienen tejido nervioso,\nque actúa como antígeno, conducen eventualmente al síndrome. La\npatogénesis está posiblemente relacionada con respuestas inmunes\nde células B y células plasmáticas. Los anticuerpos en el suero y LCR\nse combinan con el NMDAR en forma preferente al hipocampo3.\nEl diagnóstico se realiza con los siguientes criterios4: comienzo\nrápido (menos de 3 meses) de al menos 4 de los siguientes: com-\nportamiento anormal o disfunción cognitiva, disfunción del habla,\nconvulsiones, trastornos del movimiento, discinesias o rigidez,\ndisminución del nivel de conciencia y disfunción autonómica o\nhipoventilación central. Y al menos uno de los siguientes resul-\ntados de estudios paraclínicos: EEG anormal (actividad focal o\ndifusa, lenta o desorganizada, actividad epiléptica o pincel delta\nextremo), LCR con pleocitosis o bandas oligoclonales. Además, se\ndeben excluir otros posibles trastornos.\nEl tratamiento temprano es fundamental para lograr resultados\nfavorables e incluye esteroides, inmunoglobulinas y, ocasio-\nnalmente, plasmaféresis2. Algunos pacientes presentan mejoría\ntransitoria, son dados de alta sin diagnóstico y posteriormente pre-\nsentan nuevamente la sintomatología si la causa no es eliminada1,3.\nNo se debe esperar el resultado de los anticuerpos, que puede tomar\nsemanas para ser procesado. El tratamiento quirúrgico consiste en\nla extirpación del tumor. La recuperación postoperatoria es gene-\nralmente lenta. El rituximab se puede utilizar cuando el tratamiento\ninicial falla. Los pacientes que no responden al tratamiento y que\nreciben el fármaco muestran mejores resultados clínicos y menor\ntasa de recurrencia comparado con los que no los recibieron. Este\nsuprime selectivamente la función de las células B, contribuyendo\na restablecer la respuesta inmune, al inhibir la función de presen-\ntación de antígenos y secreción de citocinas, por lo cual impide la\nestimulación de las células T5.\nhttp://dx.doi.org/10.1016/j.medcli.2017.06.049\n0025-7753/© 2017 Elsevier Espan˜a, S.L.U. Todos los derechos reservados.\nCómo citar este artículo: Reyna-Villasmil E, et al. Encefalitis por anticuerpos antirreceptores de N-metil-aspartato debida a teratoma\nquístico ovárico. Med Clin (Barc). 2017.\nG Model\nARTICLE IN PRESS\nMEDCLI-4196;\nhttp://dx.doi.org/10.1016/j.medcli.2017.06.049\nNo. of Pages 2\n2 Carta al Editor / Med Clin (Barc). 2017;xxx(xx):xxx–xxx\nBibliografía\n1. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-\nreceptor encephalitis: Case series and analysis of the effects of antibodies. Lancet\nNeurol. 2008;7:1091–8.\n2. Nakamoto R, Nakamoto Y, Ishimori T, Fushimi Y, Togashi K. 18F-\nfluorodeoxyglucose uptake in anti-N-methyl-D-aspartate-receptor encephalitis\nassociated with an immature teratoma. Clin Nucl Med. 2017;42:157–60.\n3. Henry C, Husson H, de Broucker T. Autoimmune limbic encephalitis with\nanti-NMDA receptor antibodies and ovarian teratoma: A treatable form of para-\nneoplastic limbic encephalitis. Rev Neurol (Paris). 2009;165:70–5.\n4. Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach\nto diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.\n5. Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, et al. Rituximab treat-\nment for autoimmune limbic encephalitis in an institutional cohort.\nEduardo\nNeurology.\n2016;86:1683–91.\nReyna-Villasmila,∗, Gabriel Mayner-Tresolb\ny Pedro Herrera-Moyac\naHospital Central Dr. Urquinaona., Maracaibo, Venezuela\nbUniversidad Católica de Santiago de Guayaquil, Guayaquil, Ecuador\ncUniversidad Nacional Estatal de Milagro, Milagro, Ecuador\n∗Autor para correspondencia.\nCorreo electrónico: sippenbauch@gmail.com (E. Reyna-Villasmil).",
  "Mutti -Caffarra, 2017": "NeurolSci(2017)38:2231–2236\nDOI10.1007/s10072-017-3105-4\nNEWSANDVIEWS\nA case of reversible anti-NMDA-receptor encephalitis:\nneuropsychological and neuroradiological features\nCarlottaMutti1&FedericaBarocco2&LuciaZinno3&AnnaNegrotti3&MarcoSpallazzi4&\nGiovanniPavesi1&SimonaGardini5&PaoloCaffarra1\nReceived:4May2017/Accepted:30August2017/Publishedonline:13September2017\n#Springer-VerlagItaliaS.r.l.2017\nAbstract Anti-N-methyl-D-aspartate receptor (anti- Keywords Amnesticsyndrome .Anti-NMDA-receptor.\nNMDAR)encephalitisisanautoimmuneencephalitismainly Encephalitis .Hippocampus .Ovarianteratoma\naffecting young women. We report a case of a mild\nparaneoplasticanti-NMDARencephalitisina31-year-oldfe-\nmalewithanovarianimmatureteratoma.Thepatientexhibit-\nIntroduction\nedasevereshort-termepisodicmemoryimpairmentandpsy-\nchiatric symptoms. A detailed diagnostic work-up including\nAnti-N-methyl-D-aspartatereceptor(anti-NMDAR)encepha-\ncompleteclinicalandlaboratoryexaminations,neuropsycho-\nlitisisanautoimmunelife-threateningneurologicalsyndrome\nlogicalassessments,andneuroradiologicalinvestigationshas\nfrequently associated with an ovarian teratoma. Clinical fea-\nbeen done at the onset and during follow-up. The amnestic\ntures include cognitive impairment, behavioral, autonomic,\nsyndrome and MRI medial-temporal abnormalities reversed\nand consciousness changes, and epileptic seizures [1, 2].\naftermedicalandsurgicaltreatment.Thepresentreportindi-\nPatients firstly present with memory deficits, probably due\ncates that the disease can be rapidly reversible if promptly\nto NMDAR role in learning [3], that could be reversible or\ndiagnosed and treated. While the disease has already been\npersist after recovery from illness. There are few reports\ndescribedelsewhere,thecourseofneurospychologicaldeficits\nconcerningdetailedneuropsychologicalprofileduringthedis-\ninadultsisnotasmuchknown.Usually,whenthediagnosis\nease and long-term cognitive outcome [3–10]. We report a\nofanti-NMDARencephalitisismade,theseverityofthedis-\ncase of a woman with anti-NMDAR encephalitis associated\nease makes the assessment of the neuropsycological profile\nwith a low-grade immature ovarian teratoma with a rapid\nparticulary challenging. The present report is of interest be-\ncompleteclinical,neuropsychological,andneuroradiological\ncauseitdescribesthecompleteneuropsychologicalprofileof\nrecoveryaftermedicalandsurgicaltreatments.\namildformofanti-NMDARencephalitis.\nCasereport\nA 31-year-oldMexican women,livinginParma and profes-\n* PaoloCaffarra sional teacher of dances, with history of cocaine abuse and\npaolo.caffarra@unipr.it\nroutinelyuseofcannabisandalcohol,twovoluntarypregnan-\ncyinterruptions,familiarityforepilepsy(mother),andarecent\n1 DepartmentofMedicineandSurgery,SectionofNeurology,\ndiscovery of an asymptomatic left abdominal-pelvic mass\nUniversityofParma,ViaGramsci14,43126Parma(PR),Italy\nsuspected for malignant tumor elected for surgery, had first-\n2 AlzheimerCenter,BrioliniHospital,Gazzaniga,Bergamo,Italy\nevergeneralizedtonic-clonicseizureandwasadmittedtothe\n3 DepartmentofEmergencycare,GeneralandSpecialistMedical EmergencyDepartmentofaperipheralhospital.Shewasori-\nArea,AOU,Parma,Italy\nentedintimeandspace,confused,andhadshort-termmem-\n4 DepartmentofEmergency,NeurologyUnit,Piacenza,Italy orydeficits.TheCTbrainscanwasnegative.Theelectroen-\n5 GrupposostegnoAlzheimer,Fidenza,Parma,Italy cephalogram(EEG)showedslowwavesintheposteriorbrain\n2232 NeurolSci(2017)38:2231–2236\nFig.1 BrainMRIFLAIR a\nb\nsequences(transverseandcoronal\nsections).Performedbefore\nsurgery(a,c),show\nhyperintensityinthemedial\nregionofthetemporallobeswith\nleftpredominance,which\ndisappeared10daysaftersurgical\ntreatment(b,d)\nd\nc\nregions without epileptiform discharges. Toxicological cells/mm3). The cytological examination excluded the pres-\nscreeningwaspositiveforcannabinoids. ence of neoplastic elements. Microscopic examination and\nDuetothepersistenceofmemorydeficitsandverbalrep- PCRs for neurotropic virus (herpes simplex virus 1 and 2,\netition during spontaneous speech, she was admitted to our human herpesvirus 6, cytomegalovirus, Ebstein Barr Virus,\nUnit in Parma. From the recollection of friends of her, the VaricellaZosterVirus,enterovirus)werenegative.Weinclud-\nepisodic memory deficits were present since a week before ed a quote of CSF for the research of paraneoplastic\ntheacuteworseningofsymptoms. onconeural antibodies directed against intracellular or cell\nAttheadmissionvitalsigns,electrocardiogram(ECG)and membrane antigens but meanwhile, suspecting a\nroutinelaboratoryinvestigationswereinthenormalrange.On paraneoplasticlimbicencephalitis,intravenoussteroidtherapy\nneurological examination, she was alert and collaborating, (methylprednisolone1gQD)wasstarted.\npartially oriented in time and space, without focal deficits Sheunderwentacompleteneuropsychologicalassessment\nbutwithasevereshort-termmemoryimpairment.TheMini- (Table1).\nMentalStateExamination(MMSE)scorewas24/30,sugges- The battery was designed to cover a wide range of\ntive of a mild cognitive impairment. The EEG showed the cognitive functions. General cognitive functions were\npresence of generalized spike-and-wave activity suggesting assessed using the Italian version of MMSE [11]. Most\ntobeginanantiepileptictreatment.Thebrain3T-MRIshowed of the tests are reported in a book [12], and the scoring\nabnormal hyperintense signals on fluid-attenuated inversion procedure which generates the equivalent score (ES) is\nrecovery (FLAIR) sequences, asymmetrically involving the described in Capitani et al. [13]. This method provides\nmedialregionofthetemporallobes(hippocampusandamyg- cut-off scores, and adjusted scores are transformed into a\ndala),suggestiveforlimbicencephalitis(Fig.1). 5-point interval scale (from 0 to 4) that allows a compar-\nThecerebrospinalfluid(CSF)analysisshowednormalpro- ison of level of performance across tests. ES 0 means\nteinsandglucoselevelandamildlymphocyticpleocytosis(7 pathological performance. Assessment of memory\nNeurolSci(2017)38:2231–2236 2233\nTable1 Neuropsychologicalassessmentatbaselineandduringfollow- Features Target Cancelation Test, FCSRT Free and Cued Selective\nup.Valuesintheleftcolumnareexpressedinrawscore.Eachscorehad RemindingTest,IFRimmediatefreerecall,ITRimmediatetotalrecall,\nbeenthentransformedintoEquivalentScore(ES)onlyforthetestsfor DFR delayed free recall, DTR delayed total recall, ISC Index of\nwhichthisprocedureisavailable(seereferences13)(NVnormalvalue, Sensitivity of Cueing, FAB frontal assessment battery, NPI\nT0baseline before surgery, T1 7 daysaftersurgery, T2 4 weeks after Neuropsychiatric InventoryTest, ADL activities of daily living, IADL\nsurgery, ES equivalent score, MMSE mini-mental state examination, instrumentalactivitiesofdailyliving)\nRavenCPM 47Raven’s Colored Progressive Matrix, MFTC Multiple\nNV T0 ES T1 ES T2 ES\nScreeningtest\nMMSE[11] ≥23.8 24 29 29\nCognition\nRavenCPM47[18] ≥18.96 32 3 32 3 32 3\nAttention\nStroop[19]\nTimeinterferenceeffect ≤36.91 11.5 3 9.5 4 9.5 4\nErrorinterferenceeffect ≤4.23 0 4 0 4 0 4\nTrailMakingTest[20]\nPartA(sec) ≤93 19 4 25 4 27 4\nPartB(sec) ≤282 105 2 90 3 81 3\nB-A(sec) ≤186 86 2 65 2 54 3\nMFTC[21]\nTimeofexecution(sec) ≤135.73 59 97 96\nItemsdetected ≥8.53 12 13 13\nFalsealarms ≤2.77 0 0 0\nAccuracy ≥0.869 0.96 1 1\nMemory\nDigitspan[14]\nForward ≥4.26 5 1 5 1 5 1\nBackward ≥2.65 4 2 4 2 4 2\nRatio ≥0.48 0.8 0.8 0.8\nBabcockStoryRecall[15]\nImmediate 6 10 17\nDelayed 1 14 21\nAverage ≥15.76 3.5 0 12 1 19 4\nFCSRT[16]\nIFR ≥19.6 10 24 31\nITR ≥35 23 34 36\nDFR ≥6.32 0 7 0 12 4\nDTR ≥11 5 11 12\nISC ≥0.9 0.5 0.83 1\nIntrusions ≤0 18 9 0\nReyComplexFigureTest[17]\nDelayed ≥9.47 7 0 17.5 3 23 4\nConstructivepraxia\nReyComplexFigureTest[17]\nImmediate ≥28.88 36 4 35 4 36 4\nVisuo-spatialskills\nClockDrawingTest[22]\nNumbers 4 4 4\nPosition 3 3 3\nHands 3 3 3\nTotal ≥8 10 10 10\n2234 NeurolSci(2017)38:2231–2236\nTable1 (continued)\nNV T0 ES T1 ES T2 ES\nLanguage\nPhonemicfluency[23] ≥17.35 34 3 34 3 34 3\nSemanticfluency[23] ≥25 29 0 34 1 43 3\nBostonNamingTest[24] ≥16 14 0 18 20\nExecutivefunctions\nFAB[25] ≥13.5 15 1 18 4 18 4\nAffectiveandbehavioralassessment\nNPI[26]\nDelusions 0 0 0\nHallucinations 0 0 0\nAgitation/aggression 8 0 0\nDepression/dysphoria 0 4 4\nAnxiety 8 0 0\nElation/euphoria 4 0 0\nApathy/indifference 4 0 0\nDisinhibition 4 0 0\nIrritability/lability 0 0 0\nAberrantmotorbehavior 0 0 0\nSleepandnighttimebehaviordisorders 0 0 0\nAppetiteandeatingdisorders 0 0 0\nTotal 28 4 4\nFunctionalassessment\nADL[27] 6 6 6\nIADL[27] 8 8 8\nincluded Digit Span, Babcock Story Recall, Free and fluency, and executive functions were in the normal range\nCued Selective Reminding Test (FCSRT), and Rey (Table 1). Functional abilities were not involved while\nOsterrieth Complex Figure (ROCF) [14–17]. Raven’s neuropsychiatric symptoms were present with agitation,\nProgressive Matrices test (CPM 47) was employed for anxiety and mild depression, and apathy. During the neu-\nnonverbal logical functions [18]. Further assessments in- ropsychological assessment, she had several crying epi-\ncluded attention (Stroop Test, Trail Making Test, Multiple sodes with guilty feelings referring to the relationship\nFeatures Target Cancelation Test (MFTC), constructive with her boyfriend, and worries about the lack of perfor-\npraxia (Copy Rey Complex Figure Test), visuo-spatial mance due to the severe short-term memory deficits. She\nskills (Clock Drawing Test), language (phonemic verbal was partially collaborative, appearing suspicious, and\nfluency, semantic verbal fluency, Boston Naming Test), reporting conflictual behavior about personal ideas and\nand executive functions (FAB) [17, 19–25]. The beliefs, such as religiosity. She reported to have a\nNeuropsychiatric Inventory (NPI) was employed to mon- premorbid personality with mild euphoria and boredom\nitor the affective and behavioral profile, while function that induced her to drug abuse.\ndisability was assessed according to activities of daily During the hospitalization, the patient had no further\nliving (ADL) and instrumental activities of daily living seizures but she developed disinhibition, hypersexuality,\n(IADL) [26, 27]. Neuropsychological assessment revealed and persecutory delusions. Plasmapheresis was started\na global mild cognitive impairment (MMSE 24/30), with and stopped immediately due to severe symptomatic hy-\na severe deficit in immediate and delayed verbal memory potension. Waiting for surgical ovarian neoplasm remov-\n(FCSRT and prose memory), visuo-spatial memory al, a treatment with intravenous immunoglobulin (IVIG\n(ROCF delayed recall), visual naming (Boston Naming), 0.4 g/kg daily) was started and administered for 5 days\nand semantic verbal fluency. Verbal working memory re- without remarkable recovery.\nsulted in the lowest normal value limit. Nonverbal intelli- Fifteen days after hospitalization, the patient underwent\ngence, attention, visuoconstructive abilities, phonemic gynecological laparotomy surgery (left annessiectomy and\nNeurolSci(2017)38:2231–2236 2235\nperitoneal washing). The definitive histological examination onset with inability to recognize the examiner after few mi-\nrevealed a low-grade immature ovarian teratoma. Two days nutes. Inordertoachieve more information onthe natureof\nafterthesurgery,thepatientcompletelyrecovered. the memory deficit,the FCSRT test clearly demonstrated an\nSeven daysafter the surgery, MMSE normalized (29/30), inabilitytocodeandstorageverbalmaterialwhichistypical\nand neuropsychological evaluation resulted within normal ofmemorydeficitofthehippocampaltype[33]associatedtoa\nlimits with exception for immediate verbal recall and index deficitonvisuo-spatialmemory.Evidenceshavedemonstrat-\nof cueing sensitivity during recall (FCSRT). The working ed that NMDARs play a central role in several neurological\nmemory performance was in normal range (Table 1). On functions suchaslearningand memoryacquisitionand con-\nNPItest,onlymilddepressionwasdetected.BrainMRIper- solidation; they seem to be necessary for the induction of\nformed10daysafterthesurgerywasnormal(Fig.1). long-term potentiation (LTP) and long-term depression\nEEGshowedasignificantreductionofcriticaldischarges. (LTD), thought to be the molecular correlates of memory\nAfter the discharge, we received the positivity for anti- consolidation.\nNMDAR antibodies, thus confirming the diagnosis of After treatment, a clear improvement in cognitive, emo-\nparaneoplasticlimbicencephalitis. tional, and behavioral profile was observed, withnormaliza-\nThe neuropsychological re-assessment performed at tion of neuropsychological functions atfollow-up. Although\n8 weeks after the onset of the disease and 4 weeks after the cases of anti-NMDAR encephalitis with complete remission\nteratoma removal remained stable. Affective and emotional havebeenreportedbefore,ourreportshowsforthefirsttime\nbehaviors recovered lasting only mild depression related to theneuropsychologicalprofileacrosstheclinicalcourseofthe\nworriesforherjobandhealthycondition. disease, demonstrating the complete recovery after surgery.\nTheneuropsychologicalevaluationwasnotdoneat60days According to literature, the clinical evolution of our patient\nintervalafterthediseaseonsetasmostofthetaskswereina is probably related to early and aggressive immunotherapy\nnormalrangesjust4weeksaftersurgery.Shereturnedtowork andrapidresectionofunderlyingtumor[3,34].\nandtoherusualsociallife,withoutanyneurologicaldisability. Limiteddataareavailableinliteraturetoquantifycognitive\neffects in cases of anti-NMDA encephalitis, and when diag-\nnosis is made, the severity of other neurological symptoms\nDiscussion usually interfere with neuropsychological assessment. The\npresent observation adds interest to properly approach these\nEpidemiological studies suggested that anti-NMDAR en- aspects in the early onset of the disease as well as in the\ncephalitis is the most common cause of autoimmune en- follow-up.\ncephalitis after acute disseminated encephalomyelitis In conclusion, the disorder is potentially fatal but despite\n(ADEM),typicallyaffectingyoungwomen.Itisclassically the severity of the symptoms, it has a better prognosis than\nassociated to ovarian teratoma but it can occur also in ex- mostotherparaneoplasticencephalitisifearlyrecognizedand\ntragonadal teratoma (such as mediastinal tumors), other treated[35,36].\nneoplasm (small cell lung cancer, Hodgkin’s lymphoma,\nneuroblastoma, breast cancer, and testicular germ-cell tu-\nCompliancewithethicalstandards\nmor), or in the absence of neoplasia [28].\nClinical features could include acute-subacute psychiatric\nConflictofinterest Theauthorsdeclarethattheyhavenoconflictsof\nsymptoms,seizures,decreasedlevelofconsciousness,severe interest.\nmemorydeficits,involuntarymovements,autonomicinstabil-\nity,andrespiratoryfailure[1,29].Mostpatientshavemildto\nmoderateCSFlymphocyticpleocytosisandmoderateincrease References\nof protein concentration and oligoclonal bands (60%) [30].\nBrain MRI demonstrates abnormalities in almost half of pa- 1. Dalmau J, Tüzün E, Wu H, Masjuan J, Rossi JE et al (2007)\ntients,mainlyfluid-attenuatedinversionrecovery(FLAIR)or Paraneoplasticanti-N-methyl-D-aspartatereceptorencephalitisas-\nT2sequences-increasedsignalsinthemedialtemporallobes.\nsociatedwithovarianteratoma.AnnNeurol61(1):25–36\n2. GrausF,TitulaerMJ,BaluR,BenselerS,BienCGetal(2016)A\nThe diagnosis is confirmed by the detection of antibodies\nclinicalapproachtodiagnosisofautoimmuneencephalitis.Lancet\nagainstNMDARinserumorCSF. Neurol15:391–404\nTothebestofourknowledge,therearefewstudiesfocus- 3. Marcos-Arribas L, Almonacid JJ, Dolado AM (2013)\ning on neuropsychological profile during the acute phase of Neuropsychologicalprofileofanti-NMDA receptor encephalitis.\nthediseaseand1monthaftertherecovery[31,32].\nPsychology4(10):776–781\n4. Han DY, Koehl LM, Patel A, Zhou Z, Phillips S et al (2017)\nOur report describes a patient with psychiatric symptoms\nChronic neuropsychological sequelae in a patient with\nandcognitivedeclinedespitegoodgeneralclinicalcondition.\nnontumorousanti-NMDA-receptorencephalitis.CaseRepNeurol\nSheexhibitedasevereshort-termmemoryimpairmentatthe Med2017:5675732Epub2017Apr19\n2236 NeurolSci(2017)38:2231–2236\n5. McIvor K et Moore P (2017) Spontaneous recovery of memory 20. Giovagnoli AR, Mascheroni S, Simoncelli M, Laiacona M,\nfunctions in an untreated case of anti NMDAR encephalitis—a Capitani E(1996) Trail makingtest: normativevalues from287\nreason to maintain hope. Clin Neuropsychol. Jan;31(1):289-300. normaladultcontrols.NeurolSci17(4):305–309\nEpub2016 21. MarraC,GainottiG,ScaricamazzaE,PiccininniC,FerraccioliM\n6. BeisJMetRenardM.(2016)Adultanti-NMDAreceptorenceph- etal(2013)Themultiplefeaturestargetcancellation(MFTC):an\nalitis:which physicalandrehabilitationmedicineprogram?Case attentionalvisualconjunctionsearchtest.Normativevaluesforthe\nreports and literature review. Ann Phys Rehabil Med. Sep;59S: Italianpopulation.NeurolSci34(2):173–180\ne153-e154 22. Mondini S, Mapelli D, Vestri A, Bisiacchi PS (2003) Esame\n7. McKeonGL,ScottJG,SpoonerDM,RyanAE,BlumSetal(2016) neuropsicologicobreve(ENB).Unabatteriaditestperloscreening\nCognitive and social functioning deficits after anti-N-methyl-D- neuropsicologico.Milano,RaffaelloCortinaEditore\naspartate receptor encephalitis: an exploratory case series. J Int 23. Novelli G, Papagno C, Capitani E, Laiacona M, Vallar G et al\nNeurops Neuropsychol Soc Sep;22(8):828–38 Epub 2016 Au (1986b)Tretest clinicidiricercaeproduzionelessicale.taratura\n(2016Aug22) susoggettinormali.ArchiviodiPsicologiaNeurologiaaPsichiatria\n8. HinkleCD,PorterJN,WaldronEJ,KleinH,TranelD,etal(2017)\n4(47):477–506\nNeuropsychological characterization of three adolescent females 24. KaplanE,GoodglassH,WeintraubS(1983)BostonNamingTest.\nwith anti-NMDA receptor encephalitis in the acute, post-acute, Lea&Febiger,Philadelphia\nand chronic phases: an inter-institutional case series. Clin 25. AppollonioI,LeoneM,IsellaV,PiamartaF,ConsoliTetal(2005)\nNeuropsychol.Jan;31(1):268–288.Epub2016Jun13.Review The frontal assessment battery (FAB): normative values in an\n9. Loughan AR, Allen A, Perna R, Malkin MG (2016) Anti-N-\nItalianpopulationsample.NeurolSci26(2):108–116\nmethyl-D-aspartatereceptorencephalitis:areviewandneuropsy- 26. CummingsJL,MegaM,GrayK,Rosenberg-ThompsonS,Carusi\nchological casestudy. Clin Neuro Neuropsychol 30(1):150–163. DA,GornbeinJ(1994)Theneuropsychiatricinventory:compre-\nEpub2016Jan14Review hensive assessment of psychopathology in dementia. Neurology\n44:2308–2314\n10. Morris NA, Kaplan TB, Linnoila J, Cho T (2016) HSV\n27. LawtonMP,Brody EM (1969)Assessment ofolder people: self\nencephalitis-induced anti-NMDAR encephalitisin a 67-year-old\nmaintaining and instrumental activities of daily living.\nwoman:reportofacaseandreviewoftheliterature.JNeurovirol\nFeb22(1):33–37\nGerontologist:179–186\n28. Titulaer MJ, McCracken L, GabilondoI,Armangué T, Glaser C\n11. MagniE,BinettiG,BianchettiA,RozziniR,TrabucchiM(1996)\net al (2013) Treatment and prognostic factors for long-term out-\nMini-mentalstateexamination:anormativestudyinItalianelderly\npopulation.EurJNeuro3:1–5 comeinpatientswithanti-N-methyl-D-aspartate(NMDA)receptor\nencephalitis:acohortstudy.LancetNeurol12(2):157–165\n12. Barletta-Rodolfi C, Ghidoni E, Gasparini F (2011) KIT del\n29. Panzer JA, Gleichman AJ, Lynch DR (2014) Glutamatergic\nNeuropsicologo Italiano. Società Italiana di Neuro-Psicologia,\nautoencephalitides: an emerging field. J Neural Transm 121(8):\nBologna\n957–968\n13. Capitani E (1997) Normative values and neuropsychological as-\n30. VitalianiR,MasonW,AncesB,ZwerdlingT,JiangZetal(2005)\nsessment. Common problems in clinical practice and research.\nParaneoplastic encephalitis, psychiatric symptoms, and\nNeuropsychologicalRehabilitation7:295–309\nhypoventilationinovarianteratoma.AnnNeurol58(4):594–604\n14. MonacoM,CostaA,CaltagironeC,CarlesimoGA(2013)Forward\n31. BakTH,AntounN,BalanKK,HodgesJR(2001)Memorylost,\nandbackwardspanforverbalandvisuo-spatialdata:standardiza-\nmemoryregained:neuropsychologicalfindingsandneuroimaging\ntionandnormativedatafromanItalianadultpopulation.NeurolSci\nin two cases of paraneoplastic limbic encephalitis with radically\n34(5):749–754\ndifferentoutcomes.J.NeurolNeurosurgPsychiatry71:40–47\n15. Novelli G,PapagnoC, Capitani E, LaiaconaM,Cappa SFetal 32. FinkeC,KoppUA,PrüssH,DalmauJ,WandingerKP,etal(2012)\n(1986a) Tre test clinici di memoria verbale a lungo termine. Cognitive deficits following anti-NMDAreceptor encephalitis. J\nTaraturasusoggettinormali.ArchiviodiPsicologiaNeurologiaa NeurolNeurosurgPsychiatry.February;83(2):195–198\nPsichiatria2(47):278–296\n33. DuboisB,FeldmanHH,JacovaC,HampelH,MolinuevoJLetal\n16. FrassonP,GhirettiR,CatricalàE,PomatiS,MarconeAetal(2011) (2014)AdvancingresearchdiagnosticcriteriaforAlzheimer’sdis-\nFreeandcuedselectiveremindingtest:anItaliannormativestudy. ease:theIWG-2criteria.LancetNeurol13(6):614–629\nNeurolSci32(6):1057–1062\n34. FinkeC,KoppUA,PajkertA,BehrensJR,LeypoldtFetal(2015)\n17. CaffarraP,VezzadiniG,DieciF,ZonatoF,VenneriA(2002a)Rey- Structural hippocampal damage following anti-N-methyl-D-\nOsterriethcomplexfigure:normativevaluesinanItalianpopulation aspartatereceptorencephalitis.BiolPsychiatry(Feb26)\nsample.NeurolSci22(6):443–447\n35. Acién P, Acién M, Ruiz-Macià E, Martin-Estephanià C (2014)\n18. CarlesimoG,CaltagironeC,GainottiG,NocentiniU,FaddaLetal Ovarianteratoma-associatedantiNMDARencephalitis:asystemat-\n(1995)Batteriaperlavalutazionedeldeterioramentomentale(parte icreviewofreportedcases.OrphanetJournalofRarediseases9:\nII):standardizzazioneeaffidabilitàdiagnosticanell’identificazione 157\ndi pazienti affetti da sindrome demenziale. Arch Psicol Neurol 36. ImaiK,FukudaT,WadaT,KawanishiM,YamauchiMetal(2015)\nPsichiatr56(4):471–488 Completerecoveryfromparaneoplasticanti-NMDARencephalitis\n19. CaffarraP,VezzadiniG,DieciF,ZonatoA,VenneriA(2002b)Una associatedwithasmallovarianteratomafollowingalaparoscopic\nVersione Abbreviata Del Test di Stroop: Dati Normativi Nella salpingo-oophorectomy:acasereport.Experimentalandtherapeu-\nPopolazioneItaliana.NuovaRivistadiNeurologia12(4):111–115 ticmedicine9:1723–1726",
  "Herrero-Velázquez -Dalmau-Obrador, 2010": "NOTA CLÍNICA\nEncefalitis por anticuerpos contra el receptor NMDA.\nDescripción de una paciente sin tumor asociado y revisión\nde la bibliografía\nSonia Herrero-Velázquez, Ángel Luis Guerrero-Peral, Gonzalo Gámez-Leyva, M. Nieves Fernández-Buey,\nAna Conde, Margarita Rodríguez, Esther Rojo-Martínez, Julio Pascual, M. Rosario Fernández-Herranz,\nJosep Dalmau-Obrador\nIntroducción. Recientemente se ha descrito una forma grave de encefalitis aguda asociada a anticuerpos contra el recep- Servicio de Neurología\ntor N-metil-D-aspartato (NMDA). Este cuadro ocurre en jóvenes, no siempre con un tumor subyacente y, pese a la gra- (S. Herrero-Velázquez, A.L.\nGuerrero-Peral, M.N. Fernández-\nvedad inicial, su identificación y tratamiento precoz pueden llevar a recuperaciones sin secuelas. Presentamos un nuevo\nBuey, E. Rojo-Martínez, M.R.\ncaso y revisamos los conocimientos disponibles acerca de esta nueva entidad. Fernández-Herranz); Servicio\nde Radiología (M. Rodríguez);\nCaso clínico. Mujer de 22 años de edad que acudió a nuestro centro como consecuencia de un trastorno progresivo del Hospital Clínico Universitario\ncomportamiento. Durante los días siguientes, un deterioro del nivel de conciencia hizo necesario el soporte respiratorio. de Valladolid. Servicio de\nNeurología; Complejo\nUna resonancia magnética craneal mostró lesiones hiperintensas principalmente en regiones temporales profundas. El Hospitalario de Salamanca\nestudio de líquido cefalorraquídeo reveló pleocitosis con predominio linfocitario y anticuerpos contra el receptor NMDA. (G. Gámez-Leyva, A. Conde).\nServicio de Neurología;\nEn el estudio complementario no se apreció tumor subyacente. El tratamiento con corticoesteroides e inmunoglobulinas\nHospital Universitario Marqués\ndio lugar a una lenta pero continua mejoría. Al cabo de un año de seguimiento no ha presentado recidivas, no ha apa- de Valdecilla; Santander,\nCantabria, España (J. Pascual).\nrecido tumor alguno y la paciente se ha reintegrado a sus actividades habituales. Incluso una atrofia temporal llamativa\nDepartamento de Neurología;\ndesarrollada al inicio del cuadro se ha ido resolviendo en estudios de neuroimagen de control. Universidad de Pennsylvania;\nPhiladelphia, Estados Unidos\nConclusión. La encefalitis por anticuerpos anti-NMDA es una enfermedad recientemente caracterizada, pero, de acuerdo (J. Dalmau-Obrador).\ncon los datos disponibles hasta la fecha, relativamente frecuente. Clínicamente bien definida, la sospecha de esta entidad\nCorrespondencia:\nhará posible un diagnóstico definitivo y la instauración de un tratamiento precoz.\nDr. Ángel L. Guerrero Peral.\nPalabras clave. Anticuerpos anti-NMDA. Antígenos de la membrana neuronal. Antígenos del neurópilo del hipocampo. Servicio de Neurología.\nHospital Clínico Universitario.\nEncefalitis asociada a anticuerpos NMDA. Inmunodiagnóstico. Síndrome paraneoplásico. Avda. Ramón y Cajal, 3.\nE-47005 Valladolid.\nE-mail:\ngueneurol@gmail.com\nIntroducción genos de superficie del neurópilo del hipocampo, Agradecimientos:\nA los Dres. Graus y Saiz, del\nconcretamente los receptores N-metil-D-aspartato Servicio de Neurología del\nLa encefalitis límbica ha sido, hasta ahora, una en- (NMDA), constituye una entidad que debe tenerse Hospital Clínic de Barcelona, por\nsu revisión de este manuscrito.\ntidad poco conocida y aún menos identificada en la en cuenta, con características clínicas bien delimi-\npráctica clínica. Fue definida como tal en la segun- tadas, con posibilidades terapéuticas reales y donde Presentado parcialmente como\npóster en el XIX Congreso de la\nda mitad del siglo pasado [1]. En la mayoría de los el pronóstico, pese a la gravedad de la presentación\nSociedad Europea de Neurología.\ncasos aportados inicialmente se describió la asocia- inicial, puede ser bueno. Milán, junio de 2009.\nción a un proceso tumoral subyacente, en su mayo- La notificación de un nuevo caso de encefalitis\nAceptado tras revisión externa:\nría cáncer de pulmón de células pequeñas. límbica con anticuerpos frente al receptor NMDA y 07.04.10.\nEl hallazgo en estos pacientes de anticuerpos sin tumor subyacente nos permite revisar el estado\nCómo citar este artículo:\nfrente a antígenos intracelulares y, más reciente- de la cuestión en esta entidad. Herrero-Velázquez S, Guerrero-\nmente, frente a antígenos extracelulares, ha permi- Peral AL, Gámez-Leyva G,\nFernández-Buey MN, Conde A,\ntido ampliar la correlación clínico-inmunológica,\nRodríguez M, et al. Encefalitis por\nque ha supuesto no sólo el aumento de casos diag- Caso clínico anticuerpos contra el receptor\nNMDA. Descripción de una\nnosticados, sino también la descripción de presen-\npaciente sin tumor asociado\ntaciones fuera del contexto de un síndrome para- Mujer de 22 años de edad con antecedentes fami- y revisión de la bibliografía.\nneoplásico. liares de neoplasia de colon (su padre), que apare- Rev Neurol 2010; 50: 661-6.\nEn este nuevo escenario definido por los avances ció en la quinta década de la vida. Antecedentes © 2010 Revista de Neurología\nde las técnicas de inmunodiagnóstico, la encefalitis personales de pólipo de colon extirpado cinco años\nlímbica relacionada con anticuerpos frente a antí- antes y poliquistosis ovárica.\nwww.neurologia.com Rev Neurol 2010; 50 (11): 661-666 661\nS. Herrero-Velázquez, et al\nSin síntomas prodrómicos aparentes, comenzó\nFigura 1. Resonancia magnética cerebral potenciada en FLAIR: hiperin-\ncon apatía, astenia, actitud regresiva y alucinacio-\ntensidad de señal en ambos lóbulos temporales mediales, núcleo cau-\nnes auditivas con contenido musical. El inicio del\ndado derecho, puente y pedúnculos cerebrales medios.\nproceso se relacionó temporalmente con una rup-\ntura sentimental. Durante un mes, estos síntomas\naumentaron en intensidad y la paciente ingresó en\nla planta de hospitalización de psiquiatría con el\ndiagnóstico clínico de cuadro psicótico-disociativo;\ninició tratamiento con neurolépticos y benzodiace-\npinas. El cuadro continuó progresando y apa reció\nhipotonía generalizada, disminución del nivel de\nconciencia, incontinencia urinaria, fiebre sin foco\naparente, nistagmo y paresia del VI par izquierdo.\nAsimismo, se apreció rigidez ocasional con parato-\nnía y protrusión lingual. Al sexto día de su ingreso\nen Psiquiatría, la paciente presentó un deterioro\nprogresivo del nivel de conciencia que hizo necesa-\nrio soporte respiratorio con intubación orotra-\nqueal. En la Unidad de Cuidados Intensivos presen-\ntó crisis epilépticas en forma de estado convulsivo\ngeneralizado.\nEl estudio bioquímico general así como la deter-\nminación de hormonas tiroideas, perfil autoinmu-\nne, marcadores tumorales y anticuerpos onconeu-\nronales, además de los anticanales de potasio volta- vir. Ante la negatividad del estudio microbiológico\nje-dependientes (VGKC), no aportó alteraciones fue retirado posteriormente. De un modo paralelo,\nsignificativas salvo unos anticuerpos antinucleares se añadieron al tratamiento pulsos venosos de me-\n(ANA) positivos a 1/160. Se realizó un estudio de tilprednisolona ante la duda razonable de un pro-\nresonancia magnética (RM) craneal que mostró le- ceso de origen autoinmune, como otra posibilidad\nsiones hiperintensas en secuencias de TR largo e diagnóstica. Posteriormente, se llevó a cabo infu-\nhipointensas en secuencia T , sin restricción en la sión de inmunoglobulinas en dosis de 2 g/kg de peso\n1\ndifusión ni efecto masa, localizadas en regiones repartida en cinco sesiones en días consecutivos. El\ntemporales profundas bilaterales, así como en tála- tratamiento dio lugar a una mejoría progresiva de la\nmos, núcleo caudado derecho, corteza insular dere- situación neurológica y sistémica en las semanas si-\ncha, y periferia de la protuberancia y de ambos pe- guientes, pero persistía una alteración de la memo-\ndúnculos cerebelosos medios (Fig. 1). En la punción ria anterógrada importante que se correlacionaba\nlumbar se obtuvo un líquido cefalorraquídeo (LCR) con una atrofia temporal mesial en el estudio de RM\ncon 30 leucocitos/mm3 (90% linfocitos) con pro- cerebral, en el que el volumen lesional disminuyó\nteinorraquia y glucorraquia normales. Los resulta- en secuencias de TR largo (Fig. 2). Estudios elec-\ndos de los estudios microbiológicos y serológicos, troencefalográficos (EEG) seriados evolucionaron\nincluyendo la reacción en cadena de la polimerasa de una lentificación difusa con brotes generalizados\npara el grupo herpes, fueron negativos y las ban- con frecuencia pseudoperiódica a una progresiva\ndas oligoclonales aparecieron ligeramente positi- normalización posterior. La paciente permaneció\nvas con un índice de IgG de 0,75. Los anticuerpos ingresada un total de 85 días y fue dada de alta cons-\nanti-NMDA fueron positivos en el LCR. Se com- ciente, con marcha autónoma, sin crisis comiciales y\npletó el estudio con una tomografía computari- con la mencionada amnesia anterógrada, así como\nzada (TC) toracoabdominopélvica, colonoscopia y alteraciones conductuales de grado moderado. Un\necografía transvaginal, y se descartó la presencia de mes después se había normalizado la conducta y se\nuna neoplasia. apreciaba franca recuperación de la memoria. A los\nPrevio a su ingreso en la unidad de cuidados tres meses del alta, la paciente reanudó sus estudios.\nintensivos, ante la tórpida evolución clínica y el Al año de seguimiento, ha normalizado con éxito su\nresultado del estudio radiológico, se considera la actividad académica y social sin evidencia de recidi-\nencefalitis herpética como posibilidad diagnóstica, va clínica. Tiene revisiones periódicas en el depar-\nmotivo por el que se inició tratamiento con aciclo- tamento de ginecología, y ni las exploraciones clíni-\n662 www.neurologia.com Rev Neurol 2010; 50 (11): 661-666\nEncefalitis por anticuerpos contra el receptor NMDA. Descripción de una paciente sin tumor asociado\nFigura 2. Resonancia magnética cerebral potenciada en FLAIR: atrofia Figura 3. Resonancia magnética cerebral de control potenciada en FLAIR:\nen los lóbulos temporales mediales. disminución de la atrofia en los lóbulos temporales mediales.\ncas ni las ecografías transvaginales muestran lesión lulares neuronales en pacientes afectos de este sín-\ntumoral alguna. Estudios de RM craneal de control drome, no sólo apoyó la patogenia inmune del pro-\nhan revelado una progresiva desaparición de la atro- ceso sino que posibilitó el ensayo terapéutico con\nfia temporal descrita (Fig. 3). inmunosupresores. Otros anticuerpos (anti-Ma2,\nanfifisina, CV2/CRMP5) con similar mecanismo de\nacción fueron identificados, todos ellos en pacientes\nDiscusión con cuadros clínicos de encefalitis límbica y tumor\nsubyacente. En la mayoría de los casos, la respuesta\nEl sistema límbico está constituido por un conjunto obtenida con la terapia inmunosupresora no es muy\nde estructuras nucleares y de tractos situados al- alentadora, probablemente por tratarse patogénica-\nrededor del tálamo de un modo anular, que actúa mente de respuestas citotóxicas [4] mediadas por\ncomo principal regulador del control emocional y linfocitos T. Por ello, se consideró que estos anti-\nde la codificación de la memoria. A mediados del cuerpos aunque podían ser buenos marcadores no\nsiglo pasado se describió por primera vez un cua- eran patógenos [5]. Únicamente casos aislados de\ndro de encefalitis subaguda con afectación predo- encefalitis en varones menores de 40 años de edad\nminante en regiones límbicas, que se correlacionó asociadas a tumores testiculares con anticuerpos\nconforme se repetían las descripciones clínicas, anti-Ma2 presentaron una respuesta favorable a la\ncon síntomas como irritabilidad, depresión, tras- resección tumoral o a la inmunosupresión.\ntornos del sueño, alucinaciones, crisis convulsivas En estos últimos años, los avances en las técni-\ny afectación de la memoria a corto plazo. La pos- cas de inmunodiagnóstico han permitido seguir\nterior asociación de este cuadro con una neopla- describiendo anticuerpos frente a estructuras intra-\nsia subyacente le dio la consideración de síndrome celulares neuronales, y han dado lugar al hallazgo\nparaneoplásico. El carcinoma pulmonar de células de nuevos anticuerpos que reaccionan frente a antí-\npequeñas (CPCP) fue el primero en el que se des- genos de superficie [4,6-8].\ncribió, con la suma después otros tumores como el Así, la encefalitis asociada con anticuerpos que\nlinfoma de Hodgkin, timomas, leucemia mieloide reaccionan frente a los receptores NMDA del neuró-\ncrónica, cáncer de testículo, ovario o mama, o te- pilo del hipocampo constituye uno de los subgrupos\nratomas de ovario [2,3]. La identificación de un pri- de encefalitis límbicas por anticuerpos extracelula-\nmer anticuerpo, el anti-Hu, que reaccionaba frente res recientemente descritos. Supone alrededor del\na células tumorales del CPCP y estructuras intrace- 70-75% de las encefalitis límbicas autoinmunes me-\nwww.neurologia.com Rev Neurol 2010; 50 (11): 661-666 663\nS. Herrero-Velázquez, et al\ndiadas por anticuerpos extracelulares [4]. El recep- principalmente de teratomas de ovario y ocasional-\ntor NMDA está formado por heterómeros de NR1 mente de mediastino [6,11-16]. Un estudio reciente\ny NR2, con afinidad por la glicina y al glutamato mostró que mientras el 56% de mujeres mayores de\nrespectivamente, y la unidad funcional del receptor 18 años de edad tenía un teratoma de ovario, la fre-\nes la formada conjuntamente por NR1/NR2B [4]. cuencia de teratomas en niñas menores de 14 años\nLas primeras descripciones, compatibles con esta de edad era del 9% [16]. En los varones, la identifica-\nentidad, sin la sospecha de que el proceso era au- ción de tumores es muy infrecuente [16]. El cuadro\ntoimmune, aparecen en la literatura a partir de 1981 neurológico puede preceder al diagnóstico del tu-\n[3,9,10]. Pese a no estar determinado el marcador in- mor entre tres semanas y cuatro meses [13,16]. En la\nmunológico, en 2005 se publica una serie de cuatro literatura también se describen casos de encefalitis\ncasos [11] en los que se sugiere el perfil sindrómico límbica sin tumor subyacente con hasta seis años de\ny en cuyas muestras biológicas se identifican poste- seguimiento posterior sin aparición de tumor [17].\nriormente anticuerpos de membrana contra el neu- En cuanto a las alteraciones en las exploraciones\nrópilo del hipocampo. Desde entonces, la asociación complementarias realizadas en estos pacientes [3-\nde clínica y perfil inmunológico se han repetido en 5,14,16,18], se detectan frecuentemente pleocito-\nnuevos casos [12-14], ocasionalmente sin identifica- sis linfocitaria e hiperproteinorraquia en LCR, así\nción de neoplasia subyacente asociada [5,6,15]. como síntesis intratecal de anticuerpos. Los estu-\nRespecto al fenotipo de la encefalitis con an- dios EEG muestran de forma casi constante en la\nticuerpos anti-NMDA [13,14], recientemente se fase aguda del cuadro de anomalías, principalmen-\nha publicado un estudio de 100 pacientes afectos te lentificación focal o generalizada.\nde esta patología [17]. El cuadro es clínicamente Más variables son los resultados en los estudios\nbastante homogéneo y tiene unas características de RM; hay hallazgos patológicos en algo más de la\nque se repiten en la mayoría de los casos. Afecta mitad de los pacientes, generalmente aumento de\nprincipalmente a mujeres jóvenes (edad media: 23 la intensidad de la señal en secuencias de TR lar-\naños; intervalo: 5-76 años). En cuanto a su inicio, go, con mayor frecuencia localizada en los lóbulos\nen el 85% de los pacientes en los que se dispone de temporales mediales, pero también es posible la\nese dato, existen síntomas prodrómicos, como ce- afectación de la corteza, cerebelo, tronco, ganglios\nfalea, febrícula o viriasis inespecífica. Pese a este basales, cuerpo calloso, hipotálamo, región peri-\npródromo pseudogripal [12,14,16], la negatividad ventricular, e incluso médula y cordones espinales.\nen la búsqueda de virus en estudios microbiológi- Está descrita la desaparición de estas lesiones en los\ncos en LCR, suero, biopsias cerebrales o incluso en casos con buena respuesta a la inmunoterapia o la\nlas escasas autopsias realizadas es constante, por lo resección tumoral.\nque se cree que forma parte de la activación inmu- La detección y extirpación precoz del tumor\nnológica temprana [16]. Posteriormente aparecen cuando está presente, y el tratamiento con cortico-\nsíntomas psiquiátricos como ansiedad, agitación, esteroides, inmunoglobulinas o plasmaféresis con-\npensamientos paranoides, o alucinaciones visuales fieren un mejor pronóstico y menor posibilidad de\no auditivas, y, en ocasiones, el primer síntoma es recidivas principalmente cuando se lleva a cabo de\nla alteración de la memoria a corto plazo [16]. No forma precoz [16]. Recientemente se ha propuesto\nes infrecuente, como en nuestro caso, que los pa- la utilidad del rituximab [19].\ncientes sean inicialmente hospitalizados en el ser- A pesar de la gravedad de la presentación inicial,\nvicio de psiquiatría. Posteriormente, hasta el 76% el 75% de los pacientes se recupera por completo o\nde los pacientes sufre crisis epilépticas, con más presentan un déficit residual leve, y el 25% fallece\nfrecuencia generalizadas y en el 88% de los casos, o tiene secuelas graves [16]. El 85% de los pacientes\ndis minución del nivel de conciencia con hipoventi- dados de alta con déficit ligeros presenta, como en\nlación central que puede requerir soporte respira- nuestro caso, signos de disfunción del lóbulo tem-\ntorio durante un tiempo medio de ocho semanas poral. La recuperación puede durar meses [16].\n[16]. Hasta el 86% presenta discinesias, la mayoría En cuanto a las recurrencias, se han registrado\nde las veces oculofaciales. También se han descrito en el 15% de los casos, a veces, hasta en tres ocasio-\ncuadros de inestabilidad autonómica con labilidad nes [16]. Cuando la encefalitis se asocia a un tumor,\ntensional, alteraciones del ritmo cardíaco, diafore- la recurrencia clínica y la recidiva tumoral aconte-\nsis o disritmias cardíacas, que en ocasiones requie- cen simultáneamente [12,14]. La recuperación de la\nren la implantación de un marcapasos [16]. recurrencia puede ser completa.\nLa asociación con algún tipo de tumor varía en Llama la atención, además del buen pronóstico\nfunción de la edad y el sexo. En mujeres se trata clínico descrito en un porcentaje significativo de ca-\n664 www.neurologia.com Rev Neurol 2010; 50 (11): 661-666\nEncefalitis por anticuerpos contra el receptor NMDA. Descripción de una paciente sin tumor asociado\nsos, que la atrofia, en ocasiones importante, detec- Clinical-immunologic associations. Neurology 2008; 71:\ntada en la RM frontal o temporal puede ser reversi- 930-6.\n7. Graus F, Saiz A. Encefalitis límbica: un síndrome probable-\nble, como también se observa en el seguimiento del\nmente infradiagnosticado. Neurología 2005; 20: 24-30.\ncaso que presentamos [20]. Esto contrasta con las 8. Cervantes-Arriaga A, Vargas-Cañas S, Rodríguez-Violante\nencefalitis paraneoplásicas clásicas asociadas a an- M. Uso clínico de autoanticuerpos en neurología. Rev Neurol\n2008; 47: 89-98.\nticuerpos intracelulares en las que las alteraciones 9. Delong GR, Bean SC, Brown FR III. Acquired reversible\nradiológicas son, por lo general, irreversibles. autistic syndrome in acute encephalopathic illness in children.\nArch Neurol 1981; 38: 191.\n10. Sebire G, Devictor D, Huault G, Aicardi J, Landrieu P,\nEn conclusión, las encefalitis autoinmunes, para- Tardieu M. Coma associated with intense bursts of abnormal\nneoplásicas o no, representan un proceso clínico de movements and long-lasting cognitive disturbances: an acute\nencephalopathy of obscure origin. J Pediatr 1992; 121: 845.\ndifícil diagnóstico [21], aunque su sospecha diag-\n11. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau\nnóstica y tratamiento precoz pueden modificar fa- J. Paraneoplastic encephalitis, psychiatric symptoms, and\nvorablemente el pronóstico del paciente. En el mo- hypoventilation in ovarian teratoma. Ann Neurol 2005; 58:\n594-604.\nmento actual disponemos de una batería de pruebas\n12. Dalmau J, Tüzün E, Wu HY, Masjuán J, Rossi JE, Voloschin\ninmunológicas que nos permitirán filiar muchos de A, et al. Paraneoplastic Anti-N-methyl-D-aspartate receptor\nestos procesos, dentro de los cuales las encefalitis encephalitis associated with ovarian teratoma. Ann Neurol\n2007; 61: 25-36.\nasociadas a anticuerpos anti-NMDA tienen una\n13. Kataoka H, Dalmau J, Ueno S. Paraneoplastic encephalitis\npresentación clínica muy bien definida. Pero ante associated with ovarian teratoma and N-methyl-D-aspartate\nuna clara sospecha, la espera de la confirmación de receptor antibodies. Eur J Neurol 2008; 15: e5-6.\n14. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al.\nestas pruebas no debería demorar el inicio del tra-\nAnti-NMDA receptor encephalitis in Japan: long-term outcome\ntamiento inmunomodulador o inmunosupresor. without tumor removal. Neurology 2008; 70: 504-11.\n15. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad\nS, et al. Anti-NMDA receptor encephalitis in children and\nadolescents. Ann Neurol 2009; 66: 11-8.\n16. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai\nBibliografía\nM, et al. Anti-NMDA-receptor encephalitis: case series and\n1. Corsellis J, Golderg GJ, Norton AR. ‘Limbic encephalitis’ analysis of the effects of antibodies. Lancet Neurol 2008; 7:\nand its association with carcinoma. Brain 1968; 91: 481-96. 1091-8.\n2. Graus F, Delattre J, Antoine J, Dalmau J, Giometto B, 17. Prats-Viñas JM, Gaztañaga-Expósito R, Palacio-Pina M.\nGrisold W, et al. Recommended diagnostic criteria for Encefalitis límbica no paraneoplásica. Rev Neurol 2003; 36:\nparaneoplastic neurological syndromes. J Neurol Neurosurg 335-7.\nPsychiatry 2004; 75: 1135-40. 18. Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin\n3. Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, A, Houghton DJ, et al. Treatment-responsive limbic\nDalmau J. Paraneoplastic limbic encephalitis: neurological encephalitis identified by neuropil antibodies: MRI and PET\nsymptoms, inmunological finding and tumor association in correlates. Brain 2005; 128: 1764-77.\n50 patients. Brain 2000; 123: 1481-94. 19. Darnell RD, Posner JB. Autoimmune encephalopathy: the\n4. Dalmau J, Bataller L. Encefalitis límbica: los nuevos antígenos spectrum widens. Ann Neurol 2009; 66:1-2.\nde membrana y propuesta de una clasificación clinico- 20. Iizuka T, Yoshii S, Ide T, Hamada J, Sakai F, Kan S, et al.\ninmunológica con implicaciones terapéuticas. Neurología Reversible brain atrophy in anti-NMDA receptor encephalitis:\n2007; 22: 526-37. A long-term observational study. Neurology 2009 (Suppl 3); 72:\n5. Vincent A, Bien CG. Anti-NMDA-receptor encephalitis: A27-28.\na cause of psychiatric, seizure, and movement disorders 21. Ramos-Rivas M, Rojas-Velasco G, Acuña-Hidalgo R,\nin young adults. Lancet Neurol 2008; 7: 1074-5. Márquez-Valero OA, Arellano-Bernal RH, Castro-Martínez\n6. Graus F, Saiz A, Lai M, Bruna J, López F, Sabater L, et al. E. Encefalitis límbica paraneoplásica: una entidad de difícil\nNeuronal surface antigen antibodies in limbic encephalitis. diagnóstico. Rev Neurol 2009; 48: 311-6.\nEncephalitis due to antibodies against the NMDA receptor. A case report of a female patient with no associated\ntumour and a literature review\nIntroduction. A severe form of acute encephalitis associated to antibodies against the N-methyl D-aspartate (NMDA) re-\nceptor has recently been reported. This clinical picture occurs in young people, not always with an underlying tumour and,\ndespite the initial severity, if identified and treated at an early stage, complete recovery without any kind of sequelae can\nbe achieved. We report on a new case and review the body of knowledge currently available on this recently identified\ncondition.\nCase report. A 22-year-old female who visited our centre due to a progressive conduct disorder. Over the days that fol-\nlowed, deterioration in the level of consciousness made it necessary to put her on assisted respiration. Magnetic reso-\nnance imaging of the head showed hyperintense lesions mainly in deep temporal regions. A study of the cerebrospinal\nfluid revealed pleocytosis with a predominance of lymphocytes and antibodies against the NMDA receptor. In the comple-\nmentary study no underlying tumour was observed. Treatment with corticosteroids and immunoglobulins brought about\nwww.neurologia.com Rev Neurol 2010; 50 (11): 661-666 665\nS. Herrero-Velázquez, et al\na slow but steady improvement. After a one-year follow-up there have been no recurrences, no tumours have appeared\nand the patient has gone back to her usual day-to-day activities. Even a significant temporal atrophy that developed at the\nbeginning of the clinical picture has gradually been seen to resolve itself in neuroimaging studies performed as a control\nmeasure.\nConclusion. Encephalitis due to anti-NMDA antibodies is a disease that has only recently been characterised, but which,\naccording to currently available data, is relatively frequent. Clinically well defined, suspicion of this condition will make it\npossible to reach a definitive diagnosis and to establish early treatment.\nKey words. Antigens of the hippocampal neuropil. Anti-NMDA antibodies. Encephalitis associated to NMDA antibodies.\nImmunodiagnosis. Neuronal membrane antigens. Paraneoplastic syndrome.\n666 www.neurologia.com Rev Neurol 2010; 50 (11): 661-666",
  "Casanova-Gracia - Cortina-Lacambra, 2012": "NOTA CLÍNICA\nEncefalitis asociada a anticuerpos antirreceptor de NMDA:\ndescripción de dos casos en población infantojuvenil\nNatalia Casanova-Gracia, Cristina Banzo-Arguis, Pedro Sanz-Asín, Maite Zapata-Usabel,\nNuria Jordana-Vilanova, M. Teresa Cortina-Lacambra\nIntroducción. El diagnóstico clínico de encefalitis por anticuerpos antirreceptor de N-metil-D-aspartato (NMDA) del gluta- Servicio de Psiquiatría.\nmato (encefalitis anti-NMDA) es complejo debido a que al inicio suele predominar la clínica psiquiátrica. Esto puede conllevar Hospital Clínico Universitario\nLozano Blesa. Zaragoza, España.\nun retraso en el diagnóstico, tratamiento y pronóstico de la enfermedad.\nCorrespondencia:\nCasos clínicos. Presentamos dos casos clínicos atendidos por la Sección de Psiquiatría Infanto-Juvenil de nuestro hospital,\nDra. Natalia Casanova Gracia.\nen colaboración con los servicios de Pediatría y Neurología. Caso 1: varón de 4 años remitido por alteración de conducta Paseo de Sagasta, 13, 4.º B.\nE-50008 Zaragoza.\ny regresión de habilidades previamente adquiridas. Caso 2: mujer de 13 años ingresada por alteración de la conducta\nen un contexto de posible primer episodio psicótico. En ambos casos se hacen las pruebas complementarias oportunas, Fax:\nincluyendo punción lumbar y anticuerpos anti-NMDA, que son positivos. Una vez realizado el diagnóstico de encefalitis +34 976 765 788.\nanti-NMDA, se inicia el tratamiento: en el primer caso, con perfusión intravenosa de corticoides e inmunoglobulinas y, en E-mail:\nel segundo, es necesario asociar rituximab. La evolución de ambos fue hacia la mejoría clínica. natcasanova185@hotmail.com\nConclusiones. Se observa un aumento del diagnóstico de encefalitis anti-NMDA en población infantojuvenil en los dos últi- Agradecimientos:\nmos años. Se trata de un cuadro neuropsiquiátrico y autoinmune, que puede corresponder a un síndrome paraneoplásico. Dra. Sonia Santos, Dra. África\nJiménez, Dr. Pedro Ruiz y Dr.\nSe recomienda seguimiento y la realización de una ecografía transvaginal y tomografía computarizada toracoabdominal Mariano Velilla, del Hospital\ndurante al menos dos años tras el diagnóstico. Es importante realizar un diagnóstico y tratamiento precoces, por lo que Clínico Universitario Lozano Blesa.\nresulta necesario un abordaje multi e interdisciplinar. Aceptado tras revisión externa:\n21.12.11.\nPalabras clave. Anticuerpos antineuronales. Encefalitis anti-NMDA. Síndromes neuropsiquiátricos en la infancia. Síndro-\nmes paraneoplásicos. Cómo citar este artículo:\nCasanova-Gracia N, Banzo-Arguis C,\nSanz-Asín P, Zapata-Usabel M,\nJordana-Vilanova N, Cortina-\nIntroducción La evolución del cuadro comienza con clínica pro- Lacambra MT. Encefalitis asociada\na anticuerpos antirreceptor de\ndrómica, que con frecuencia pasa desapercibida, NMDA: descripción de dos casos\nen población infantojuvenil.\nLa encefalitis generalmente se describe de forma consistente en cefalea, febrícula y afectación leve\nRev Neurol 2012; 54: 475-8.\nbreve en los tratados de neuropsiquiatría y psiquia- gástrica o respiratoria. Posteriormente, de manera\ntría, a pesar de que con frecuencia presenta una clí- súbita, predomina la clínica psiquiátrica, que habi- © 2012 Revista de Neurología\nnica caracterizada por alteración del estado mental. tualmente es intensa y precede a los signos neuro-\nPor ello, resulta importante considerarla dentro del lógicos, por lo que la primera asistencia suele ser\ndiagnóstico diferencial de pacientes con sintomato- por parte de psiquiatría. Las pruebas son poco es-\nlogía psiquiátrica, especialmente si ésta es de inicio pecíficas y, dada la presentación clínica inicial, se\nagudo. puede dificultar y retrasar el diagnóstico definitivo.\nEn 1960 Brierley et al [1] describieron en un artí- Este dato resulta relevante, ya que, a pesar de la gra-\nculo tres casos similares de encefalitis que afectan vedad clínica, es potencialmente reversible.\nal área límbica, y en 1968 Corsellis et al [2] utiliza- En este artículo exponemos la dificultad en el\nron por primera vez el término ‘encefalitis límbica’, diagnóstico diferencial de síndromes neuropsiquiá-\nal presentar otros tres pacientes. Se relacionaban tricos, con la presentación de dos casos de encefali-\ncon diferentes tipos de cáncer, de modo que se con- tis anti-NMDA.\nsideraba un síndrome paraneoplásico. En las déca-\ndas de los ochenta y noventa comenzaron a recono-\ncerse los mecanismos fisiopatológicos de estas enti- Casos clínicos\ndades, y se sugirió que probablemente estaban in-\nfradiagnosticadas [3]. En 2007 Dalmau et al [4,5] Caso 1\ndescubrieron un tipo de encefalitis relacionada con\nanticuerpos antirreceptor de N-metil-D-aspartato Niño de 4 años remitido por alteración del compor-\n(NMDA), la encefalitis anti-NMDA. tamiento de dos semanas de evolución. Desarrollo\nwww.neurologia.com Rev Neurol 2012; 54 (8): 475-478 475\nN. Casanova-Gracia, et al\npsicológico previo normal. Antecedentes médicos cedentes de asma y, a los 11 años, tras nacer su her-\npersonales de bronquitis de repetición y episodio mana, cambio conductual con repercusión en la di-\nde faringoamigdalitis aguda en los días previos. námica familiar, que mejoró tras seis meses de tra-\nLa historia actual se circunscribe a las dos últi- tamiento psicológico.\nmas semanas. Coincidiendo con la ausencia de su La historia actual comienza tres semanas antes\nmadre por un motivo laboral, el niño comienza a de la visita a urgencias, en las que la paciente pre-\nmostrar alteraciones conductuales de corte regresi- senta de forma progresiva alteración del comporta-\nvo, expresando su malestar y enfado hacia la madre, miento con irritabilidad intensa, conductas extra-\nalternando episodios de agresividad con otros de ñas sin finalidad e insomnio mixto. En el momento\ntristeza e inhibición. La clínica empeora progresi- del examen mental está consciente y orientada, con\nvamente a pesar del regreso de la madre, por lo que una actitud suspicaz, perpleja, hipomimia facial,\nel niño ingresa para su estudio. conducta regresiva y desorganizada, estereotipias\nEn el examen inicial se objetivan erosiones por motoras y verbales. Presenta bradipsiquia y discur-\nrascado, heridas por mordedura y hematomas de- so desorganizado con bloqueos del pensamiento.\nbidos a autolesiones. Asimismo, aparece bruxismo, Angustia intensa y embotamiento afectivo. Verbali-\nchupeteo, distonías y movimientos de tipo coreico, za ideación sobrevalorada/deliroide, depresiva, so-\ncon rigidez en las extremidades y fluctuaciones del mática y autorreferencial, no estructurada ni siste-\nnivel de conciencia con desconexión con el medio. matizada. Fenómenos de despersonalización y des-\nJunto con ello, se observa una ausencia práctica- realización. Juicio de realidad alterado. No se apre-\nmente total del lenguaje, pérdida del control de es- cia focalidad neurológica.\nfínteres y dificultad para la ingesta de líquidos, has- En el estudio inicial sólo se objetiva megacister-\nta llegar a perder la capacidad de deglución. Se ob- na magna en la tomografía computarizada (TC) ce-\njetiva febrícula ocasional, incremento del cociente rebral; el resto de pruebas (analíticas, tóxicos, sero-\nCD4/CD8 y electroencefalograma (EEG) modera- logías y EEG) son normales. Se pauta tratamiento\ndamente lento, sin signos claros de focalidad. En la con antipsicóticos (risperidona y posteriormente\npunción lumbar se observa una pleocitosis linfoci- olanzapina), ante los que la paciente presenta reac-\ntaria. En un posterior estudio de anticuerpos anti- ciones extrapiramidales y escasa respuesta. En la\nNMDA, por sospecha de encefalitis letárgica auto- evolución, se da una disminución del nivel de con-\ninmune, éstos resultan positivos, por lo que, final- ciencia, fiebre y movimientos tonicoclónicos suges-\nmente, se diagnostica encefalitis anti-NMDA. El res- tivos de trastorno mental orgánico, por lo que se la\nto de pruebas realizadas –resonancia magnética (RM), traslada al Servicio de Pediatría para filiar la etiolo-\nfunción tiroidea, ecografías abdominal, tiroidea y gía. La clínica empeora, pues muestra síndrome\ntesticular– son normales. confusional agudo con agitación psicomotriz, habla\nAnte la gravedad de la clínica, con disminución escandida e incoherente, tics oculares, trismo, chu-\nprogresiva del nivel de conciencia, se traslada al pa- peteo, alteración de la coordinación motora, pérdi-\nciente a la Unidad de Cuidados Intensivos Pediátri- da del control de esfínteres, cianosis y taquicardia.\nca y se inicia el tratamiento con metilprednisolona Se inicia un tratamiento empírico con corticoides y\nintravenosa y perfusión intravenosa de inmunoglo- cefotaxima. En la RM cerebral se aprecia una leve\nbulinas. dilatación de la cisterna magna con probable comu-\nMejoró la evolución y se objetivó la recuperación nicación con el IV ventrículo y una leve atrofia ver-\ncompleta de su estado premórbido en el seguimiento miana inferior, con asimetría ventricular lateral sin\nambulatorio por parte de Neuropediatría. En la ac- causa aparente. En la punción lumbar se evidencia\ntualidad, más de un año después del diagnóstico, el una ligera pleocitosis linfocitaria y una reacción en\npaciente permanece estable y no se ha encontrado cadena de la polimerasa positiva (PCR) al virus her-\npatología tumoral asociada hasta el momento. pes tipo 6, por lo que se pauta tratamiento con gan-\nciclovir. A pesar de ello, la paciente entra en un es-\nCaso 2 tado comatoso; en el EEG se objetiva un trazado\nlento generalizado. A posteriori, en la inmunorreac-\nMujer de 13 años que acude a Urgencias por angus- tividad-líquido cefalorraquídeo (LCR) se detectan\ntia y alteración conductual. Se sospecha un primer anticuerpos anti-NMDA positivos. A la paciente se\nepisodio psicótico y se deriva a Psiquiatría para su le diagnostica una encefalitis anti-NMDA y se ini-\ningreso. cia el tratamiento con inmunoglobulinas intraveno-\nEn su historia de desarrollo se documenta parto sas. En la evolución, recupera el nivel de conciencia\npor cesárea y desarrollo psicomotor precoz. Ante- y la marcha, con abasia inicial. Persiste la inquietud\n476 www.neurologia.com Rev Neurol 2012; 54 (8): 475-478\nEncefalitis asociada a anticuerpos antirreceptor de NMDA\npsicomotriz, alteración de funciones superiores y Los anticuerpos anti-NMDA causan una dismi-\nestereotipias, y su actitud es regresiva, con una im- nución reversible de receptores de glutamato tipo\nportante labilidad emocional y crisis de angustia. Se NMDA, que son ligandos de canales con mayor sig-\ncompleta el estudio con ecografía y TC abdominal. nificación. La etiopatogenia del trastorno es desco-\nSe observa que la paciente tiene los ovarios leve- nocida, pero parece estar mediada por una predis-\nmente aumentados de tamaño e hipodensos. La RM posición a la autoinmunidad en un contexto tumo-\ntorácica es normal y en la RM pélvica se aprecia una ral o tras el aumento de la actividad por una infec-\nnodulación quística en el ovario derecho, que tras la ción viral (coincide con el período prodrómico en\nooforectomía se comprueba que se trata de un quis- el 48% casos) [5,7,10,18].\nte folicular. La PCR-LCR positiva para virus herpes Se documentan diferencias clínicas entre adultos\ntipo 6 se considera un falso positivo. y niños [7]; los adultos tienen presentación psiquiá-\nDebido a la evolución tórpida, se repite la tanda trica en el 85% de los casos, mientras que en pobla-\nde inmunoglobulinas y corticoides y se inicia el tra- ción infantil la clínica neurológica suele aparecer\ntamiento con rituximab. En la punción lumbar de primero y síntomas como irritabilidad en niños o\ncontrol los títulos de anticuerpos disminuyen. La alteraciones de conducta en adolescentes a menudo\nmejoría clínica es parcial, ya que persiste una alte- pasan desapercibidos [5]. En los niños son frecuentes\nración en las funciones ejecutivas y el trastorno del trastornos del movimiento, lenguaje, sueño y presen-\nhabla, lo que requiere rehabilitación neurocogniti- cia de convulsiones. La inestabilidad autonómica es\nva ambulatoria, con una evolución favorable al año menos frecuente y grave que en adultos [5,7,10].\nde seguimiento. No aparecen signos específicos en la RM ni en el\nLCR [10-13]. El diagnóstico requiere en todos los\ncasos la existencia de anticuerpos circulantes [8,9,\nDiscusión 11,13,14].\nEn el 97% de los casos el tratamiento ensayado\nLa encefalitis asociada a anticuerpos contra los re- es con corticoides, inmunoglobulinas intravenosas\nceptores NMDA (anti-NMDA) en población infan- o plasmaféresis; también se usan rituximab y ciclo-\ntojuvenil es una entidad clínica documentada de for- fosfamida. Seis semanas es la media de tiempo para\nma creciente en los últimos dos años [5-8], incluso la mejoría clínica [12,17,19,20]. Existen series de\nen edades tempranas (2-3 años) [5,7,9]. Previamente casos en los que ha sido efectiva la terapia electro-\nse planteaba este cuadro como una forma para- convulsiva [21].\nneoplásica exclusivamente, si bien hasta en un 63% Más del 75% de los pacientes tiene una recupe-\nde los casos no se documenta el tumor [10]. Hay es- ración sustancial [22] que se produce en el orden\ntudios [5] que refieren que, de los casos con encefali- inverso de aparición de los síntomas y se asocia con\ntis anti-NMDA, en edad pediátrica sólo se asocian a una disminución de los títulos de anticuerpos [13,\ntumor el 40%, en adolescentes el 25% y en prepúbe- 18]. La recaída se produce en el 25% de los casos,\nres el porcentaje es aún menor [10]. En otros estu- sobre todo si no se extirpó el tumor o se hizo tarde\ndios se documenta asociación hasta en el 59%, en [5,9,19,23].\nmujeres de 18 años o menos en el 31% y en niños de\n14 años o menos en el 9% [11-14]. En la cohorte pe- En conclusión, la encefalitis anti-NMDA es un sín-\ndiátrica, el 30% de los tumores son teratomas ovári- drome neuropsiquiátrico, autoinmune, en el que es\ncos [15,16]; también hay neuroblastomas, carcino- importante realizar un diagnóstico y tratamiento\nmas microcíticos de pulmón y teratomas testicula- precoces, y para ello es necesario un abordaje multi\nres, entre otros [10,12,13]. Hace falta un seguimiento e interdisciplinar, incluyendo psiquiatría, neurolo-\nlongitudinal de los pacientes con encefalitis anti- gía, inmunología, radiología, oncología, medicina ge-\nNMDA debido a que la menor tasa de detección del neral y cirugía [24-26].\ntumor pudiera estar relacionada con dificultades de\ndiagnóstico según la edad, y a que muchos casos se\nBibliografía\nhan detectado recientemente y la aparición tumoral\npuede ser posterior. Se recomienda ecografía trans- 1. Brierley JB, Corsellis JAN, Hierons R, Nevin S. Subacute\nencephalitis of later adult life. Mainly affecting the limbic areas.\nvaginal y TC toracoabdominal al menos durante los\nBrain 1960; 83: 357-68.\ndos años siguientes al diagnóstico clínico [8]; este 2. Corsellis JAN, Goldberg GJ, Norton AR. ‘Limbic encephalitis’\nperíodo podría ser mayor, ya que en una cohorte pe- and its association with carcinoma. Brain 1968; 91: 481-96.\n3. Graus F, Saiz A. Limbic encephalitis: a probably under-\ndiátrica en Japón se describe detección tumoral has-\nrecognized syndrome. Neurologia 2005; 20: 24-30.\nta 4-7 años tras el diagnóstico de encefalitis [17]. 4. Dalmau J, Tüzün E, Wu HY, Masjuán J, Rossi JE, Voloschin A,\nwww.neurologia.com Rev Neurol 2012; 54 (8): 475-478 477\nN. Casanova-Gracia, et al\net al. Paraneoplastic anti-N-methyl-D-aspartate receptor 16. Gómez-Esteban JC, Agundez M, Ciordia R, Zarranz JJ,\nencephalitis associated with ovarian teratoma. Ann Neurol Llorens V. Teratoma en un caso de encefalitis por anticuerpos\n2007; 61: 25-36. contra el receptor de NMDA. Rev Neurol 2011; 53: 574.\n5. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, 17. Sakuma H, Sugai K, Sasaki M. Acute nonparaneoplastic limbic\net al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis encephalitis in childhood: a case series in Japan. Pediatr Neurol\nin children and adolescents. Ann Neurol 2009; 66: 11-18. 2010; 43: 167-72.\n6. Schimmel M, Blen CG, Vincent A, Schenk W, Penzien J. 18. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M,\nSuccessful treatment of anti-N-methyl-D-aspartate receptor et al. Anti-NMDA-receptor encephalitis: case series and\nencephalitis presenting with catatonia. Arch Dis Child 2009; analysis of the effects of antibodies. Lancet Neurol 2008;\n94: 314-6. 7: 1091-8.\n7. Biancheri R, Pessagno A, Baglietto MG, Irani SR, Rossi A, 19. Haberlandt E, Bast T, Ebner A, Holthausen H, Kluger G,\nGiribaldi G, et al. Anti-N-methyl-D-aspartate-receptor Kravljanac R, et al. Limbic encephalitis in children and\nencephalitis in a four-year-old girl. J Pediatr 2010; 156: 332-4. adolescents. Arch Dis Child 2011; 96: 186-91.\n8. Tardieu M. Anti-N-methyl-D-aspartate receptor encephalitis: 20. McCoy B, Akiyama T, Widjaja E, Go C. Autoimmune limbic\na new entity? Dev Med Child Neurol 2010; 52: 407-12. encephalitis as an emerging pediatric condition: case report\n9. Wandinger KP, Saschenbrecker S, Stoecker W, Dalmau J. and review of the literature. J Child Neurol 2011; 26: 218-22.\nAnti-NMDA-receptor encephalitis: a severe, multistage, 21. Lee A, Glick DB, Dinwiddie SH. Electroconvulsive therapy in\ntreatable disorder presenting with psychosis. J Neuroimmunol a pediatric patient with malignant catatonia and paraneoplastic\n2011; 231: 86-91. limbic encephalitis. J ECT 2006; 22: 267-70.\n10. Greiner H, Leach JL, Lee KH, Krueger DA. Anti-NMDA 22. González-Soltero ME, Gámez-Leyva G, Gavilán-Iglesias T,\nreceptor encephalitis presenting with imaging findings and Portilla-Cuenca JC, Casado-Naranjo I. Nuevo caso de encefalitis\nclinical features mimicking Rasmussen syndrome. Seizure antirreceptor de NMDA sin tumor asociado. Rev Neurol\n2011; 20: 266-70. 2011; 52: 250.\n11. Chan S, Wong V, Fung C, Dale R, Vincent A. Anti-NMDA 23. Wells EM, Dalmau J. Paraneoplasic neurologic disorders\nreceptor encephalitis with atypical brain changes on MRI. in children. Curr Neurol Neurosci Rep 2011; 11: 187-94.\nPediatr Neurol 2010; 43: 274-8. 24. Revilla FJ, McMasters MD, Kobet CA, Espay AJ. Encefalitis\n12. Breese E, Dalmau J, Lennon V, Apiwattanakul M, Sokol D. asociada a anticuerpos contra receptores NMDA: reconocimiento\nAnti-N-methyl-D-aspartate receptor encephalitis: early de un nuevo síndrome neuropsiquiátrico. Rev Neuropsiquiatr\ntreatment is beneficial. Pediatr Neurol 2010; 42: 213-4. 2010; 73: 20-5.\n13. Dalmau J, Lancaster E, Martínez-Hernández E, Rosenfeld 25. Odriozola-Grijalba M, Galé-Ansó I, López-Pisón J, Monge-\nMR, Balice-Gordon R. Clinical experience and laboratory Galindo L, García-Íñiguez JP, Madurga-Revilla P, et al.\ninvestigations in patients with anti-NMDAR encephalitis. Encefalitis antirreceptor de NMDA en un niño de cuatro\nLancet Neurol 2011; 10: 63-74. años. Rev Neurol 2011; 53: 58-60.\n14. Dale RC, Church AJ, Surtees R, Lees AJ, Adcock J, Harding B, 26. Herrero-Velázquez S, Guerrero-Peral AL, Gámez-Leyva G,\net al. Encephalitis lethargica syndrome: 20 new cases and Fernández-Buey MN, Conde A, Rodríguez M, et al. Encefalitis\nevidence of basal ganglia autoimmunity. Brain 2004; 127: 21-33. por anticuerpos contra el receptor NMDA. Descripción de\n15. Reyes-Botero G, Uribe CS, Hernández-Ortiz OE, Ciro J, una paciente sin tumor asociado y revisión de la bibliografía.\nGuerra A, Dalmau-Obrador J. Encefalitis paraneoplásica por Rev Neurol 2010; 50: 661-6.\nanticuerpos contra el receptor de NMDA. Remisión completa\ndespués de la resección de un teratoma ovárico. Rev Neurol\n2011; 52: 536-40.\nEncephalitis associated to anti-NMDA receptor antibodies: a description of two cases in the child/youth\npopulation\nIntroduction. The clinical diagnosis of encephalitis due to anti-glutamate receptor N-methyl D-aspartate (NMDA) antibodies\n(anti-NMDA encephalitis) is made more complex by the fact that psychiatric clinical features are usually predominant in\nthe early stages. This can lead to a delay in the diagnosis, treatment and prognosis of the disease.\nCase reports. We report on two clinical cases attended by the Child/Youth Psychiatry Section of our hospital, in collaboration\nwith the Paediatric and Neurology services. Case 1: a 4-year-old male who was referred owing to behavioural alterations and\nthe regression of previously acquired skills. Case 2: a 13-year-old female who was admitted due to a behavioural disorder\nwithin the context of a possible initial psychotic episode. In both cases appropriate complementary tests were performed,\nincluding lumbar puncture and anti-NMDA antibodies, which were positive. Once the diagnosis of anti-NMDA encephalitis\nhad been reached, treatment was started: in the first case, with intravenous perfusion of corticoids and immunoglobulins,\nwhile in the second rituximab had to be associated. Both patients progressed towards clinical improvement.\nConclusions. Over the last two years there has been an increase in the number of cases of anti-NMDA encephalitis diagnosed\nin the child/youth population. It is a neuropsychiatric, autoimmune condition, which can correspond to a paraneoplastic\nsyndrome. Follow-up and transvaginal ultrasonography as well as thoracoabdominal computerised axial tomography\nscans are recommended for at least two years after diagnosis. Early diagnosis and treatment are important, which means\nthat a multi- and interdisciplinary approach is required.\nKey words. Antineuronal antibodies. Anti-NMDA encephalitis. Neuropsychiatric syndromes in childhood. Paraneoplastic\nsyndromes.\n478 www.neurologia.com Rev Neurol 2012; 54 (8): 475-478",
  "Kitada, 2011": "Rinsho Shinkeigaku. 2011 Sep;51(9):683-7.\n[Dramatic improvement in two cases of anti-NMDA receptor encephalitis after immunomodulating therapy].\n[Article in Japanese]\nKitada M1, Suzuki H, Ichihashi J, Mitsui Y, Tanaka K, Kusunoki S.\n\nAbstract\nWe report two patients with encephalitis associated with antibodies against NR1-NR2 heteromers of the NMDA receptor that showed dramatic improvement after immunomodulating therapies. A 38-year old woman (case 1) suddenly developed seizures and short term memory loss. Brain MRI appeared almost normal except for a small number of high intensity spots of white matter on T(2) weighted images. Cerebrospinal fluid examination (CFS) disclosed lymphocytic pleocytosis (61/µl) and Qualitative analysis of NR1-NR2 antibodies in both CFS and serum were positive. Although an initial treatment with high-dose methylprednisolone was not beneficial for clinical improvement, intravenous immunoglobulin (IVIg) therapy led to complete recovery from her neurological problems. Repeated general surveys showed no evidence of tumors including ovarian teratoma. A 71-year old man (case 2) suddenly developed seizures and short-term memory loss three days after receiving an influenza vaccination. Brain MRI appeared normal. CSF analysis revealed no pleocytosis and a slight elevation of protein value accompanying oligoclonal IgG band. Qualitative analysis of NR1-NR2 antibodies in both CFS and serum were positive. Intravenous high-dose methylprednisolone caused dramatic improvement and his neurological problems immediately disappeared. Repeated general surveys showed no evidence of tumors, as in case 1. These two cases showed relatively benign clinical courses with no evidence of tumors and were quite different from the well-known encephalitis associated with antibodies against NR1-NR2 heteromers of the NMDA receptor. Our clinical experience in these two cases suggests that the disease spectrum of anti-NMDA-receptor associated encephalitis might be broader than was once considered.",
  "Beaudonnet, 2012": "L’encéphalite à anticorps\nantirécepteur au NMDA : une\ncause sous estimée de psychose\naiguë chez l’enfant et l’adulte\njeune\nAnti-NMDA receptor encephalitis: An\nunderestimated cause of acute psychiatric\nsyndrome in children and young adults\nL’encéphalite à anticorps antirécepteur au N-Methyl-D-Aspar-\ntate (NMDA-R) est une entité récemment décrite, associée à la\nprésence d’anticorps dirigés contre les hétéromères NR1 et\nNR2 des récepteurs au NMDA et dont le tableau clinique est\nessentiellement neuropsychiatrique. Initialement rapportée en\nassociation à des tératomes matures de l’ovaire, plusieurs cas\n(notamment pédiatriques) ont ensuite été décrits de façon\nisolée. Nous rapportons ici deux cas survenus la même année\ndans le centre hospitalier de Lagny-Marne-la-Vallée (Seine et\nMarne).\nObservations\nCas no1\nUne adolescente de 14 ans était admise en janvier 2010 pour\ndes troubles du sommeil et du comportement avec hallucina-\ntions. Issue de parents d’origine marocaine non consanguins,\nl’adolescente n’avait pas d’antécédent médical et menait une\nscolarité normale. L’histoire débutait en novembre 2009 par\ndes troubles du sommeil et une attitude de la jeune fille décrite\ncomme « renfermée ». Fin décembre, elle avait une crise\nconvulsive tonicoclonique généralisée sans fièvre suivie\n24 heures après d’hallucinations visuelles et auditives. La jeune\nfille était hospitalisée en psychiatrie pendant deux semaines,\navec persistance d’hallucinations et de troubles du comporte-\nment (jusqu’à ingestion de ses matières fécales et refus ali-\nmentaire avec perte de 6 kg en trois semaines) malgré un\ntraitement neuroleptique. Après récidive d’une seconde crise\nconvulsive généralisée, un traitement par valproate de sodium\nétait débuté et la jeune fille était transférée en pédiatrie. Elle\navait un tableau de confusion avec une alternance de phases\ncalmes et agitées, une insomnie avec inversion du rythme\nnycthéméral, une écholalie. Du point de vue cognitif, un tableau\nde régression avec perte de la lecture et de l’écriture.\nclinique\nL’examen\ntrouvait des dyskinésies orofaciales sans autre ano-\nmalie. Il n’y avait pas de syndrome inflammatoire biologique.\nL’analyse du liquide céphalorachidien (LCR) était strictement\nnormale. La recherche d’infection virale et de maladie méta-\nbolique était infructueuse. On retrouvait des anticorps antinu-\ncléaires faiblement positifs à 1/160, sans spécificité. La\nrecherche d’anticorps antirécepteurs au NMDA s’avérait po-\nsitive dans le LCR et le sang (taux non quantifié). L’IRM\ncérébrale était normale et l’EEG trouvait une activité lente\ndelta diffuse, prédominant à droite, sans anomalie paroxys-\ntique. La recherche de tumeur primitive par échographie et\ntomodensitométrie thoracoabdomino-pelviennes était néga-\ntive. Un traitement par anticorps anti-CD20 (rituximab) était\ndébuté après huit semaines d’évolution (deux injections à\n14 jours d’intervalle, à la dose de 375 mg/m2). Les dyskinésies\norofaciales avaient disparu lors de la seconde injection. Les\nhallucinations commençaient à régresser 15 jours après la\nseconde injection pour disparaître complètement par la suite.\nElle recommençait à écrire quelques phrases simples après\ntrois semaines et pouvait reprendre sa scolarité après cinq\nsemaines. Il persistait à un an d’évolution une amnésie\nlacunaire. L’EEG contrôlé deux mois après la fin du traitement\nétait normal ainsi que l’IRM à quatre mois. À six mois\nd’évolution, aucune tumeur n’avait pu être identifiée. À un\nan de l’épisode, elle avait repris une scolarité normale. À\n18 mois, la recherche d’anticorps anti-NMDAR était toujours\npositive dans le sang, sans avoir pu être contrôlée dans le LCR\n(refus de la patiente).\nCas no2\nUne jeune femme de 24 ans sans antécédents, était hospita-\nlisée en janvier 2010 pour un tableau psychiatrique évoluant\ndepuis cinq jours et associant : insomnie, anxiété, désorienta-\ntion temporospatiale, troubles mnésiques et syndrome délirant\nenrichi d’hallucinations auditives. Après une semaine, devant la\nsurvenue, en contexte fébrile d’une hémiparésie droite et d’un\nsyndrome méningé avec altération de la conscience (score de\nGlasgow à 7), la jeune femme était admise en réanimation.\nL’analyse du LCR retrouvait 54 éléments/mm3 (90 % de\nlymphocytes). La recherche d’HSV 1 et 2 était négative.\nL’EEG montrait de grandes ondes lentes diffuses, prédominant\ndans la région temporale gauche. Le scanner cérébral avec\ninjection était normal. Son évolution en réanimation était\nmarquée par une aggravation rapide des troubles de la\nconscience et une nécessité d’assistance respiratoire, puis la\nsurvenue de troubles hémodynamiques avec\nen\nhypotension\nligne sur / on line on Presse\nwww.em-consulte.com/revue/lpm\nwww.sciencedirect.com\nMed. 2012; 41: 318–325\nnoitcadér\nal\nà\nsertteL\n813\ntome 41 > n83 > mars 2012\nartérielle et bradycardie (BAV III). Le diagnostic d’encéphalite\nlimbique était évoqué après un mois d’évolution. Un tératome\nmature de l’ovaire gauche était trouvé sur une TDM abdomino-\npelvienne, puis retiré chirurgicalement. Les anticorps anti-\nNMDAR étaient positifs dans le sang et le LCR (taux non\nquantifié).\nLors du début du traitement, elle avait toujours un état de mal\nconvulsif à l’EEG. Le traitement étiologique a consisté en deux\ninjections d’immunoglobulines (Ig) et deux injections d’antic-\norps anti-CD20 (rituximab). L’évolution après traitement était\nmarquée par la reprise d’une communication par le regard dix\njours après la seconde injection d’Ig, une autonomie respira-\ntoire et reprise de la marche après six semaines. Il persistait à\ndeux mois du traitement une aphasie, des dyskinésies faciales\net un ralentissement psychomoteur. À quatre mois persistaient\ndes troubles de l’attention, des troubles mnésiques et un déficit\nmoteur proximal du membre supérieur droit. À dix mois d’évo-\nlution, l’examen clinique était normal et elle pouvait reprendre\nson activité professionnelle. Les anticorps anti-NMDAR étaient\nnégatifs dans le sang et n’ont pas pu être contrôlés dans le LCR\n(refus de la patiente).\nDiscussion\nEn 1994, ont été décrits quatre cas d’« encéphalite limbique\nnon herpétique », entité ainsi nommée en raison de sa re-\nssemblance (clinique et radiologique) avec l’encéphalite herpé-\ntique malgré un pronostic plus favorable que cette dernière [1].\nEn 1997, son association à un tératome mature de l’ovaire et sa\nrégression après exérèse tumorale ont été rapportées chez\ndeux patientes jeunes [2]. La prévalence de l’encéphalite\nlimbique à anticorps anti-NMDAR est faible mais en augmenta-\ntion, et vraisemblablement sous estimée, certains auteurs\nayant en effet trouvé ces anticorps chez de jeunes patientes\nprésentant une épilepsie sévère isolée [1,3]. Elle touche es-\nsentiellement le sujet jeune avec une nette prédominance\nféminine (80 %) [4–6]. Identifiés pour la première fois en\n2007 [7], les anti-NMDAR sont dirigés contre des canaux\nioniques ayant un rôle dans la transmission synaptique et la\nplasticité cérébrale. Ces canaux sont particulièrement abon-\ndants dans la partie interne des lobes temporaux, l’hippo-\ncampe, l’hypothalamus et sont parfois retrouvés au sein du\ncontingent de tissu nerveux des tératomes matures. Reconnus\nalors comme étrangers, ils induisent la synthèse d’anticorps par\nles lymphocytes B. Le passage de la barrière hématoméningée\npar ces anticorps aurait lieu au décours d’une infection virale\n(on retrouve parfois un syndrome pseudogrippal dans les\n15 jours précédents, ce qui n’était pas trouvé dans les deux\nobservations présentées) [5,6,8]. Le mode de révélation de\nl’encéphalite est psychiatrique dans 77 % des cas (troubles de\nl’humeur, troubles mnésiques, hallucinations visuelles et audi-\ntives, délire paranoïde) et neurologique dans 23 % des cas\n(convulsions) [5]. Les deux observations rapportées ici\nbien\nillustrent\nces deux aspects initiaux différents. À la phase d’état, la\nprésence de dyskinésies orofaciales est très évocatrice du\ndiagnostic et celles-ci étaient trouvées chez les deux patientes.\nOn trouve souvent une écholalie et une dysarthrie, des mouve-\nments choréo-athétosiques, des anomalies des paires\ncrâniennes, une ataxie [6,9]. Les convulsions sont présentes\ndans 75 % des cas. Une atteinte du système nerveux autonome\nest plus fréquente chez l’adulte (66 %) que chez l’enfant\n(23 %). Chez l’adulte, une évolution vers un état catatonique,\nalternant avec des phases d’agitation a été rapportée jusque\ndans 88 % des cas [5,6], avec parfois l’existence d’un état\n« dissociatif » caractérisé par des réactions paradoxales à\ncertains stimuli [6]. Les manifestations cliniques sont le reflet\nd’une encéphalopathie diffuse et dans les cas les plus sévères\n(décès ou épilepsie réfractaire), on retrouve une atrophie\ncérébrale marquée [6]. Les deux observations rapportées ici\nétaient donc très évocatrices du diagnostic. Elles illustrent bien\npar ailleurs les différences de présentation entre enfants et\nadultes (évolution plus sévère vers un état catatonique avec\ndysautonomie chez la patiente de 24 ans). L’analyse du LCR est\nanormale dans 80 à 95 % des cas avec surtout une pléïocytose,\nparfois une hyperprotéinorachie modérée et présence de\nbandes oligoclonales [5,6]. Des deux cas rapportés ici, seule\nla patiente adulte avait ces anomalies. Les IRM des deux\npatientes étaient restées normales, ce qui est rapporté dans\n50 à 60 % des cas [6,9]. Sur les enregistrements EEG on retrouve\ndans trois quart des cas un ralentissement delta diffus, prédo-\nminant dans les régions frontotemporales [5,6], avec des\nanomalies focales dans seulement 10 % des cas [2,9] malgré\ndes convulsions cliniques. Nos deux patientes avaient des\nanomalies similaires. La patiente adulte avait néanmoins un\ntableau plus sévère d’état de mal, moins souvent rapporté dans\nla littérature. Une tumeur primitive est retrouvée dans environ\ndeux tiers des cas chez l’adulte, mais chez moins de 10 % des\nenfants avant 14 ans [4,5]. Des deux observations rapportées,\nseule la patiente adulte avait une tumeur. Il s’agit le plus\nsouvent d’un tératome mature de l’ovaire, d’autres tumeurs\nétant rapportées de façon exceptionnelle [10]. Dalmau et al. [6]\nrecommandent de chercher en priorité un tératome de l’ovaire\npar IRM, TDM et échographie endovaginale. Chez les patients\navec tératome, le traitement consiste en une résection tumo-\nrale et l’administration intraveineuse d’immunoglobulines. Les\npatients sans tumeur retrouvée nécessitent souvent un traite-\nment immunosuppresseur de seconde ligne (rituximab ou\ncyclophosphamide) [6]. Les deux patientes avaient reçu un\ndouble traitement par Ig et anticorps anti-CD20 avec une bonne\nefficacité. Le taux de décès est de 4 à 7 % [5,6]. Une guérison\ncomplète est obtenue dans 30 à 47 % des cas selon les séries\n[4,5], ce qui est le cas des deux patientes. Vingt-cinq pour\ncent des patients ont de lourdes séquelles [6]. L’amélioration\nest généralement attendue dans les six semaines suivant le\ndébut du traitement et est corrélée à la diminution des\nnoitcadér\nal\nà\nsertteL\n913\ntome 41 > n83 > mars 2012\nanticorps [5]. L’observation rapportée ici de la jeune fille de\n14 ans est en contradiction avec cette notion car malgré\nune guérison clinique complète, les anticorps sériques étaient\ntoujours présents. Nous n’avons malheureusement pas eu la\npossibilité de doser ces anticorps dans le LCR pour aucune des\ndeux patientes. L’amnésie lacunaire est constante dans la lit-\ntérature, ce qui est le cas des deux patientes. Les séquelles les\nplus souvent rapportées sont un syndrome frontal modéré et des\ntroubles du sommeil. Le risque de rechute est compris entre 20 et\n25 % des cas dans les deux ans [6]. Une évolution favorable est\ncorrélée à la précocité de mise en route du traitement. En\nl’absence de tumeur trouvée initialement, une surveillance\npar imagerie abdomino-pelvienne est nécessaire pendant deux\nans [6].\nConclusion\nL’encéphalite à anticorps anti-NMDAR est une entité rare mais\ndont la prévalence est probablement sous estimée. Sa présen-\ntation initiale est essentiellement psychiatrique ou comitiale.\nSon évolution est favorable dans la majorité des cas après\ntraitement. Le diagnostic devrait être évoqué devant tout\npatient jeune ayant des troubles du comportement d’apparition\nbrutale associés à des mouvements anormaux, des convul-\nsions, ou des symptômes dysautonomiques.\nDéclaration d’intérêts : les auteurs déclarent ne pas avoir de conflits\nd’intérêts en relation avec cet article.\nRemerciements : remerciements particuliers au Pr M. Tardieu, CHU de\nBicêtre.\nRéférences\n[1] Asaoka K, Shoji H, Nishizaka S et al. Non-herpetic acute limbic\nencephalitis: cerebrospinal fluid cytokines and magnetic resonance\nimaging findings. Intern Med 2004;43(1):42-8.\n[2] Iisuka T, Sakai F. Anti-NMDA receptor encephalitis, clinical manifesta-\ntions and pathophysiology. Brain Nerve 2008;60(9):1047-60.\n[3] Niehusmann P, Dalmau J, Rudlowski C et al. Diagnostic value of NMDA\nreceptor antibodies in women with new onset epilepsy. Arch Neurol\n2009;66(4):458-64.\n[4] Florance NR, Davis RL, Lam C et al. Anti-NMDAR encephalitis in children\nand adolescents. Ann Neurol 2009;66:11-8.\n[5] Dalmau J, Gleichman AJ, Hughes EG et al. Anti-NMDA receptor\nencephalitis: case series and analysis of the effects of antibodies. Lancet\nNeurol 2008;7(12):1091-8.\n[6] Dalmau J, Lancaster E, Martinez-Hernandez E et al. Clinical experience\nand laboratory investigations in patients with anti-NMDAR encephalitis.\nLancet Neurol 2011;10:63-74.\n[7] Tüzün E, Dalmau J. Limbic encephalitisand variants: classification,\ndiagnosis and treatment. Neurologist 2007;13:261-71.\n[8] Takahashi Y, Yamazaki E, Nishimura S et al. Acute limbic encephalitis and\nNMDA type-glutamate receptor. Rinsho Shinkeigaku 2008;48(11):926-9.\n[9] Gable MS, Gavali S, Radner A et al. Anti-NMDA receptor encephalitis:\nreport of 10 cases and comparison with viral encephalitis. Eur J Clin\nMicrobiol Infect Dis 2009;28:1421-9.\n[10] Lebas A, Husson B, Didelot A et al. Expanding spectrum of encephalitis\nwith NMDA receptor antibodies in young children. J Child Neurol\nFrédérique\n2010;\n25(6):742-5.\nBeaudonnet1, Nathalie Garrec1, Annie Sfez1,\nVéronique Epain2, Isabelle Secret2, François Angenard3,\nEstelle Wafo4, Kumaran Deiva5, Arnaud Chalvon-Demersay1\n1Centre hospitalier de Lagny-Marne-La-Vallée, service de\npédiatrie, 77400 Lagny-sur-Marne, France\n2Centre hospitalier de Lagny-Marne-La-Vallée, service\nde psychiatrie, 77400 Lagny-sur-Marne, France\n3Centre hospitalier de Lagny-Marne-La-Vallée, service\nde réanimation, 77400 Lagny-sur-Marne, France\n4Centre hospitalier de Lagny-Marne-La-Vallée, service de\ngynécologie-obstétrique, 77400 Lagny-sur-Marne, France\n5CHU Bicêtre, service de neurologie pédiatrique,\n94270 Le-Kremlin-Bicêtre, France\nCorrespondance : Frédérique Beaudonnet,\ncentre hospitalier de Lagny-Marne-La-Vallée,\n77400 Lagny-sur-Marne, France.\nfbeaudonnet@ch-lagny77.fr\nReçu le 30 mars 2011\nAccepté le 29 juillet 2011\nDisponible sur internet le 17 octobre 2011\n(cid:2) 2011 Publié par Elsevier Masson SAS.\ndoi: 10.1016/j.lpm.2011.07.014\nOstéoarthropathie syphilitique : à\npropos d’un cas avec PCR positive\nSyphilitic arthroparthy: A case report with\npositive PCR\nL’infection syphilitique avait quasiment disparu au cours des\nannées 1990 en partie grâce à l’amélioration de la prévention\ndes maladies sexuellement transmissibles. Depuis quelques\nannées, les cas de syphilis se multiplient touchant principale-\nment les homosexuels masculins. L’aspect clinique de cette\ninfection, « grande simulatrice », est polymorphe et les phases\nprimaires et secondaires peuvent régresser spontanément ou\npasser inaperçues. Cela explique le retard diagnostique\nfréquent et le risque de contamination de nouveaux parte-\nnaires. La plupart des grandes villes ont ainsi vu réémerger la\nmaladie y compris sous ses formes tertiaires historiques [1].\nC’est dans ce contexte que nous rapportons l’observation d’une\nostéoarthropathie syphilitique survenue chez un patient de\n57 ans sans co-infection par le VIH. Cette observation illustre\nles difficultés diagnostiques et thérapeutiques de ces syphilis\ntardives.\nObservation\nUn patient de 57 ans, d’origine marocaine, consultait en\njanvier 2006 pour une monoarthropathie du genou gauche\névoluant depuis 2004. Il s’agissait d’un patient sans facteur de\n023\nLettres a` la re´daction\ntome 41 > n83 > mars 2012",
  "Çoban - Gürvit, 2016": "TJ Tumori 2016; 102(Suppl 2): S3-S4\nDOI: 10.5301/tj.5000447\nISSN 0300-8916 Case report\nNMDA receptor encephalitis with cancer of unknown\nprimary origin\nArzu Çoban1, Gökçen Gündoğdu2, Mürüvvet Poyraz3, Gülçin Yegen2, Aslı Demirtaş-Tatlıdede1, Başar Bilgiç1,\nHasmet A. Hanagasi1, Erdem Tüzün1, Hakan Gürvit1\n1 Department of Neurology, Istanbul Faculty of Medicine, Istanbul University, Istanbul - Turkey\n2 Department of Pathology, Istanbul Faculty of Medicine, Istanbul University, Istanbul - Turkey\n3 Department of Neurology, Istanbul Medipol University Medical Research Center, Istanbul - Turkey\nabstraCt\nPurpose: N-methyl-D-aspartate receptor (NMDAR) encephalitis may present as a paraneoplastic syndrome in\nyoung women and is often associated with ovarian teratoma.\nMethods: We report 2 male cases of NMDAR encephalitis presenting with metastatic cancer of unknown primary\norigin.\nResults: Both patients showed cognitive dysfunction as well as other neurological symptoms, slow waves on\nEEG, and NMDAR antibodies in sera and CSF. Symptoms were effectively treated by pulse steroid and intra-\nvenous immunoglobulin treatment. The patients developed metastatic small cell neuroendocrine carcinoma\nof the parotid gland and inguinal metastatic squamous cell cancer shortly after their neurological episodes.\nFollow-up PET studies showed small cell lung cancer in the first patient while no primary origin could be found\nin the second patient.\nConlusions: Our cases imply that NMDAR encephalitis may present with metastatic cancers that display slow\nprogression rates and occur after encephalitis attacks.\nKeywords: Autoimmune encephalitis, Ion channel antibody, Metastatic tumor, NMDA receptor\nIntroduction Case presentations\nParaneoplastic neurological syndromes (PNS) constitute Case 1\na rare group of disorders caused by the remote effects of\ncancer (1). In adults, PNS are mostly associated with small A 62-year-old man presented with a 2-month history of\ncell lung cancer (SCLC), lymphoma, thymoma and gyneco- amnesia, complex partial seizures and hallucinations. Neuro-\nlogical tumors (1). Antibodies to ion channel and synapse logical and psychiatric examinations were normal and neu-\nproteins have recently been recognized as important con- ropsychological examination showed impaired verbal-visual\ntributors to PNS pathogenesis. Among the various known memory and visual-spatial function. Routine blood tests, an\nPNS, N-methyl-D-aspartate receptor (NMDAR) encephalitis extensive screen for rheumatological, vasculitic and viral dis-\nis most commonly associated with ovarian teratoma. Tumors orders, and cranial magnetic resonance imaging (MRI) were\nrelated to NMDAR encephalitis generally have a relatively normal, whereas EEG showed widespread slow waves. Cere-\nbenign nature, although neuroendocrine tumors and lung brospinal fluid (CSF) examination showed 1 lymphocyte/mm3,\ncancers with a high risk of metastasis have been encoun- normal protein (38 mg/dL) and glucose (55 mg/dL) concentra-\ntered in rare cases (2, 3). tions, and no oligoclonal bands. NMDAR antibody was found\npositive in serum and CSF. Whole-body computed tomogra-\nphy (CT) and positron emission tomography (PET) scans were\nAccepted: September 21, 2015 normal. The patient’s symptoms promptly regressed with\nPublished online: October 19, 2015 intravenous administration of steroids (1,000 mg for 5 days)\nand immunoglobulin (IVIG) (total dose 30 g). Following sub-\nCorresponding author: sequent monthly steroid and IVIG treatment, the symptoms\nArzu Çoban completely disappeared in 4 months. Three months later, the\nDepartment of Neurology patient developed a right parotid gland mass that was surgi-\nIstanbul Faculty of Medicine\ncally removed. Pathological examination demonstrated small\nIstanbul University\ncell neuroendocrine carcinoma of the parotid gland (Fig. 1).\nMillet cad. Capa\n34390 Istanbul, Turkey Although his PET examination at the time did not reveal any\narzucoban2002@yahoo.com additional lesions, 6 months after surgery a repeat PET scan\n© 2015 Wichtig Publishing\nS4 NMDAR encephalitis and metastatic cancer\nCSF. Following treatment with intravenous steroids (1,000 mg\nfor 5 days), IVIG (total dose 28 g) and plasma exchange, the\nneurological symptoms completely regressed in 2 months.\nOne month later, PET revealed a left inguinal mass, which on\npathological examination was found to be a metastatic squa-\nmous cell carcinoma. PET studies failed to reveal the under-\nlying primary tumor. After chemotherapy and radiotherapy\nthe inguinal mass was reduced in size. In a 5-year follow-up\nperiod, the inguinal mass did not recur, the primary tumor\ncould not be detected despite several repeat PET studies, and\nno neurological relapses were observed.\nDiscussion\nNMDAR encephalitis occurs most commonly in young\nwomen and is associated with an underlying ovarian tera-\ntoma in approximately half of the patients. Aggressive and\npotentially metastatic tumors are observed very rarely in\npatients with NMDAR encephalitis. Therefore, the outcome\nis expected to be good, especially when tumor resection is\nperformed at an early stage (2, 3). By contrast, both of our\nNMDAR encephalitis cases presented with metastatic lesions\nshortly after the encephalitis episodes. Also, in 1 patient no\nprimary tumor could be detected despite an extensive inves-\ntigation. To our knowledge, cancer of unknown origin has\nnever been reported in NMDAR encephalitis. Moreover, pa-\nrotid gland metastasis of SCLC (4) was reported for the first\ntime in association with NMDAR encephalitis.\nOur study implies that NMDAR encephalitis may occur\nwith metastatic cancer and metastasis might even be the\ninitial presentation of the cancer. Moreover, the underlying\ncancer in NMDAR encephalitis may show a very insidious\ncourse and may potentially affect the lifetime survival rate\nand prognosis of the patient. Therefore, so-called tumor-\nfree NMDAR encephalitis patients should be closely followed\nFig. 1 - Histopathological image of small-cell carcinoma of the pa- with regular examinations for underlying undetected prima-\nrotid gland. (a) Tumor cells forming solid nests with hyperchromatic\nry tumors over a long follow-up time.\nnuclei, inconspicuous nucleoli and scanty cytoplasm. Mitotic figures\nare frequent and the stroma is vascular (hematoxylin and eosin stain,\nmagnification ×400). (b) The tumor cells are immunoreactive for Disclosures\nsynaptophysin, confirming the neuroendocrine origin of the tumor\nFinancial support: None.\n(magnification ×400).\nConflict of interest: The authors declare that they have no conflict of\ninterest related to this article.\nshowed a lung mass, which was diagnosed as SCLC. He did not\ndevelop any neurological symptoms after immunotherapy.\nReferences\nCase 2\n1. Gromadzka G, Karlińska AG, Łysiak Z, Błażejewska-Hyżorek B,\nLitwin T, Członkowska A. Positivity of serum “classical” onco-\nA 64-year-old man was admitted with a 2-month histo- neural antibodies in a series of 2063 consecutive patients with\nry of generalized weakness, ataxia, confusion and excessive suspicion of paraneoplastic neurological syndrome. J Neuroim-\ndaytime sleepiness, which progressed to coma and respira- munol. 2013;259(1-2):75-80.\ntory failure requiring mechanical ventilation. The patient and 2. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR,\nhis relatives did not report any psychiatric symptoms. EEG Balice-Gordon R. Clinical experience and laboratory investiga-\nshowed widespread slow waves and brain MRI revealed hy- tions in patients with anti-NMDAR encephalitis. Lancet Neurol.\n2011;10(1):63-74.\nperintensity in both medial temporal lobes with no contrast\n3. Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and\nenhancement. CSF examination showed 2 lymphocytes/mm3,\nprognostic factors for long-term outcome in patients with anti-\nnormal protein (42 mg/dL) and glucose (61 mg/dL) concen-\nNMDA receptor encephalitis: an observational cohort study.\ntrations. Oligoclonal IgG bands were found in CSF but not in\nLancet Neurol. 2013;12(2):157-165.\nserum (pattern 2). While routine blood tests and an extensive 4. Ulubas B, Ozcan C, Polat A. Small cell lung cancer diagnosed\nscreen for rheumatological, vasculitic and viral disorders were with metastasis in parotid gland. J Craniofac Surg. 2010;21(3):\nnormal, NMDAR antibody was found positive in serum and 781-783.\n© 2015 Wichtig Publishing",
  "Liu - Liu, 2015": "Original Paper\nEur Neurol 2015;74:73–78 Received: February 16, 2015\nDOI: 10.1159/000435953 Accepted: June 14, 2015\nPublished online: August 8, 2015\nAnti-NMDAR Encephalitis of 11 Cases in\nChina – Detailed Clinical, Laboratory and\nImagiological Description\nJunfeng Liu Deren Wang Yao Xiong Bian Liu Ming Liu\nDepartment of Neurology, West China Hospital, Sichuan University, C hengdu , China\nKey Words Introduction\nAnti-N-methyl-D-aspartate receptor encephalitis ·\nAutoimmune encephalitis · China · Teratoma Anti-N-methyl-D-aspartate receptor (NMDAR) en-\ncephalitis belongs to a new category of immune-mediated\ndisorders that can be fatal but it is also treatable; it can be\nAbstract diagnosed serologically [1] . The presence of NMDAR,\nBackground and Purpose: Anti-N-methyl-D-aspartate re- which is the target antigen of anti-NMDAR encephalitis,\nceptor (NMDAR) encephalitis is a synaptic autoimmune dis- was originally confirmed in 2007 [ 2] . Along with the\norder in which the auto-antibodies target NMDARs were first progress of the anti-NMDAR antibody assay and the\nreported in 2007. Now, anti-NMDAR encephalitis is a widely growing attention paid to the disease, researches about\nrecognized disease in the world. Our purpose was to analyze the disease began to develop rapidly. Anti-NMDAR en-\nthe clinical characteristics of anti-NMDAR encephalitis pa- cephalitis is a described disorder with clinical features; it\ntients in West China Hospital in China and report the progno- is predominantly seen in young adults and children with\nsis of the patients after accepting immunotherapy. Methods: or without teratomas [1, 3]. The patients of anti-NMDAR\nPatients admitted to the West China Hospital who were diag- encephalitis usually have prominent psychiatric manifes-\nnosed with anti-NMDAR encephalitis from 2013 to 2014 were tations, followed by severe neurological features like sei-\nretrospectively collected and their clinical features were ana- zures, movement abnormalities, autonomic instability, or\nlyzed. Results: We ultimately included 11 anti- NMDAR en- hypoventilation, often requiring ICU-level care [1, 4] .\ncephalitis patients. The median age of the 11 patients was 25 Despite the serious disorder, patients often improve with\nyears, 46% patients were females, 27% patients were 15–18 immunotherapy in autoimmune anti-NMDAR encepha-\nyears, and 73% patients were over 18 years. One of them was litis, or through the removal of the teratoma in paraneo-\ndiagnosed with teratoma after discharging from hospital. plastic anti-N MDAR encephalitis [ 5] .\nThe application of immunotherapy produced favorable out- A quick and accurate diagnosis of anti-NMDAR en-\ncomes in 67% patients included in our study. Conclusions: cephalitis is critical for the implementation of treatment\nAnti-NMDAR encephalitis should be suspected in patients strategies. However, the recovery process is slow, taking\nwho developed a rapid change in behavior or psychosis, sei- nearly 18 months, and the disease can relapse during this\nzures, dyskinesia, and hypoventilation. Anti-NMDAR enceph- time [ 5, 6] . There were a few reports about patients with\nalitis is a kind of fatal but treatable disease. Timely diagnosis anti-NMDAR encephalitis in China [7, 8], but the char-\nand treatment may yield favorable prognosis. acteristics of the disease in Chinese people have not been\n© 2015 S. Karger AG, Basel\n© 2015 S. Karger AG, Basel Prof. Ming Liu\n0014–3022/15/0742–0073$39.50/0 Stroke Clinical Research Unit, Department of Neurology\nWest China Hospital, Sichuan University, No. 37\nE-Mail karger@karger.com\nGuoXue Xiang, Chengdu 610041, Sichuan Province (PR China)\nwww.karger.com/ene\nE-Mail wyplmh @ hotmail.com\nDownloaded\nfrom\nhttp://karger.com/ene/article-pdf/74/1-2/73/2725398/000435953.pdf\nby\nUniversity\nCollege\nLondon\nuser\non\n05\nAugust\n2025\ndescribed uniformly. The aim of this study was to charac- sea before admission to the hospital were viewed in 8 (73%)\nterize the clinical presentation, laboratory findings, re- of the 11 patients. Ten patients (91%) had psychiatric\nsponses to immunotherapy, and prognosis of the patients symptoms, with mood, behavioral, or personality changes:\nwith anti-NMDAR encephalitis. agitation, mood lability, and bizarre behavior, and 6 (55%)\npatients had visual or auditory hallucinations. Seizures\nwere observed in 10 (91%) patients, and a fall in conscious-\nSubjects and Methods ness was developed in 10 (91%) patients as well. Seven\n(64%) patients had obvious speech problems including\nPatients\nspeech reduction, aphasia, or mutism. During the process\nPatients diagnosed with anti-NMDAR encephalitis were retro-\nof the disease, 5 (46%) patients developed movement ab-\nspectively included after being admitted to the West China Hospi-\ntal, Sichuan University, Chengdu, China, from January 1, 2013 to normality with orofacial dyskinesia, and the percentage of\nNovember 30, 2014. We used human embryonic kidney 293 cells patients with dystonic postures was 36 (4/11). Further-\nexpressing the NR1 subunit of NMDARs to test for the presence of more, 8 (73%) patients also had autonomic dysfunction\nNMDAR antibodies in serum and/or cerebrospinal fluid samples.\nwith mild fever, cardiac dysrhythmias and unstable blood\npressure, and 5 (46%) patients had central hypoventilation.\nBaseline Data Collection and Categorization\nFour patients required assistant respiration because of cen-\nWe analyzed symptoms, laboratory examinations, CSF exami-\nnations, and imageological examinations of the patients included. tral hypoventilation. No differences in clinical manifesta-\nSymptoms were categorized into 8 groups: psychiatric symptoms, tions were observed between male and female patients.\nmemory deficits, speech disturbances, seizures, movement disor-\nders, loss of consciousness, autonomic instability, and central hy-\nAuxiliary Examinations\npoventilation [5, 9] . The immune therapy (corticosteroids, intra-\nAntibodies against NMDAR were tested both in serum\nvenous immunoglobulins, plasmapheresis or rituximab, and cy-\nclophosphamide) and the prognosis of the patients were also and CSF of these 11 patients. All of the 11 patients were\nobserved and analyzed. The treatment effect and outcome were tested positive in CSF: 9 patients were positive and 2 pa-\nassessed by the modified Rankin scale (mRS). Favorable and poor\ntients were strongly positive. The proportion of testing\nfunctional outcomes were defined as mRS scores of 0–2 and 3–6,\nnegative in serum was 28% (3/11). Ten patients received\nrespectively.\nbrain MRI, and 2 patients (cases 4 and 11) had general-\nStatistical Analysis ized or focal meningitis changes. The others did not show\nWe described the characteristics of the clinical manifestations, any changes of encephalitis in brain MRI. Seven patients\nand the frequencies of the clinical manifestations were described\nreceived electroencephalography. Only 1 patient’s elec-\nas percentages respectively. Fisher exact test for categorical vari-\ntroencephalography result (case 10) was normal, and the\nables was used to compare groups. Two-sided values of p < 0.05\nwere considered statistically significant, but we acknowledge the EEG results of others were abnormal. All the patients re-\nunlikelihood of positive p values with a small sample size. All sta- ceived cerebrospinal fluid examinations. Cerebrospinal\ntistical analyses were performed using SPSS version 20.0. fluid studies revealed leukocyte counts of 10–220 × 106 /l,\nglucose levels of 2.47–4.7 mmol/l, and total protein levels\nof 0.56–0.79 g/l (t able 2 ).\nResults All of the patients had negative results of viral assay in\nCSF. Four patients (cases 3, 5, 6 and 11) were positive in\nFrom January 1, 2013 to November 30, 2014, 11 pa- serological viral assay, all of whom were found with CMV,\ntients were tested positive of antibodies against NMDAR, rubella virus, and single blister type I/II virus antibody\nand were eventually diagnosed as anti-NMDAR encepha- IgG in serum. In addition, case 6 was found to have a\nlitis. Five of the 11 patients were female (46%), with ages single blister type I/II virus antibody IgM as well.\nranging from 15 to 39 years (median 25 years). The clini- All the 11 patients had no tumors identified during\ncal features of these 11 patients are summarized in table 1 . hospitalization. Only 1 patient (case 3) was examined by\nThree patients (27%) were 15–18 years and 8 (73%) pa- abdominal computed tomography, and the others were\ntients were over 18 years. examined using ultrasonography during hospitalization.\nWhen the patients were discharged from the hospital, all\nClinical Features of them had a whole body examination done including\nThe characteristics of the clinical features are shown in abdominal CT or MRI. Teratoma was identified in 1 fe-\ntable 1 . The prodromal symptoms including fever, head- male patient (case 1), aged 15 years, and the tumor was\nache, upper respiratory symptoms, vomiting, and/or nau- immediately removed.\n74 Eur Neurol 2015;74:73–78 Liu/Wang/Xiong/Liu/Liu\nDOI: 10.1159/000435953\nDownloaded\nfrom\nhttp://karger.com/ene/article-pdf/74/1-2/73/2725398/000435953.pdf\nby\nUniversity\nCollege\nLondon\nuser\non\n05\nAugust\n2025\nTable 1. Clinical features of the 11 patients with anti-NMDAR encephalitis in China\nCase, Sex/age, Tumor Prodromal Neuropsychiatric symptoms Movement Autonomic dysfunction and\nn years symptoms abnormalities hypoventilation\n1 F/15 Yes Fever Mood lability, hallucination, Orofacial Hyperthermia, tachycardia,\nagitation, seizure dyskinesia hypoventilation\n2 M/34 No Memory deficit, bizarre b ehavior Hypoventilation\nseizure\n3 F/39 No Sleep disorder, hallucination Hyperthermia, hypoventilation\n4 M/25 No Dizziness, Hallucination, bizarre behavior Orofacial, Hyperthermia, hypoventilation\nheadache talkative, seizure dyskinesia and\ndyskinesia\n5 F/28 No Fever, headache, Hallucination, bizarre behavior Hyperthermia, hypoventilation\nvomiting talkative, seizure\n6 F/32 No Dizziness, Hallucination, seizure Orofcial,\nheadache dyskinesia and\ndyskinesia\n7 M/16 No Headache upper, Hallucination, seizure, talkative Orofacial, Hyperthermia, tachycardia\nrespiratory dyskinesia and\nsymptoms dyskinesia\n8 M/27 No Fever, headache Hyperthermia\n9 F/21 No Fever Talkative, agitation seizure Hyperthermia\n10 M/25 No Talkative, agitation seizure Orofacial, Hyperthermia\ndyskinesia and\ndyskinesia\n11 M/18 No Fever Talkative, agitation, mood\nlability, seizure\nTreatment and Outcomes ment following the doctor’s advice, while 4 patients did\nOf the 11 patients, 2 patients (cases 2 and 8) refused to not receive any treatment during the follow-up.\naccept any immunotherapy. The others received first-line None of the patients were lost to follow-up. The follow-\nimmunotherapy consisting of corticosteroids and immu- up period ranged from 8 to 16 months ( table 2 ). The pa-\nnoglobulins, or cyclophosphamide as second-line immu- tients (cases 2 and 8) who refused to accept immunother-\nnotherapy for acute treatment during hospitalization. apy had different outcomes. Case 2 had a poor outcome\nNine patients accepted immunotherapy, and the time (mRS 3) at 9 months follow-up, while case 8 had a good\nfrom onset to start immunotherapy ( table 2 ) ranged from outcome (mRS 0) at 1 year follow-up. Of the 9 patients\n1 to 28 days (median 13.1 days) after being admitted to who received immunotherapy, 6 patients (67%) had a sub-\nhospital. Seven patients received combination therapy stantial recovery after immunotherapy. One patient (case\nconsisting of corticosteroids and immunoglobulins, and 3) died because of multiple organ dysfunction syndrome\n2 patients (cases 4 and 10) received immunoglobulins (MODS) during hospitalization, case 5 committed suicide\nonly. One patient (case 9) accepted cyclophosphamide at 11 months follow-up, and the score of case 6 was 3 at\n800 mg after failing first-line immunotherapy (combina- 1 year follow-up. In addition, case 1 who was diagnosed\ntion of corticosteroids and immunoglobulins). with teratoma and had the teratoma removed immedi-\nAfter getting discharged from the hospital, 4 patients ately, finally had a neurological improvement (mRS 0) at\n(cases 1, 4, 6 and 7) accepted antiepileptic treatment, 2 follow-up of 9 months. Lastly, none of the 11 patients had\npatients (cases 9 and 10) received antipsychiatric treat- a neurological relapse during follow-up.\nAnti-NMDAR Encephalitis of 11 Cases in Eur Neurol 2015;74:73–78 75\nChina DOI: 10.1159/000435953\nDownloaded\nfrom\nhttp://karger.com/ene/article-pdf/74/1-2/73/2725398/000435953.pdf\nby\nUniversity\nCollege\nLondon\nuser\non\n05\nAugust\n2025\n76 Eur Neurol 2015;74:73–78 Liu/Wang/Xiong/Liu/Liu\nDOI: 10.1159/000435953\nanihC\nni\nsitilahpecne\nRADMN-itna\nhtiw\nstneitap\n11\neht\nfo\nsemoctuo\ndna\n,tnemtaert\n,snoitanimaxe\nyrailixuA\n.2 elbaT\n11 esaC\n01\nesaC\n9 esaC\n8\nesaC\n7 esaC\n6 esaC\n5 esaC\n4 esaC\n3 esaC\n2\nesaC\n1\nesaC\nn ,esaC FSC\nlamroN\nlamroN\n↓\nlamroN\nlamroN\n↑\n↑\n↑\nlamroN\nlamroN\nlamroN\n,esoculG l/lomm\nlamroN\nlamroN\n↑\n↑\nlamroN\n↑\nlamroN\nlamroN\n↑\nlamroN\nlamroN\nl/lomm\n,lC\nlamroN\nlamroN\n↑\n↑\nlamroN\nlamroN\n↑\nlamroN\nlamroN\n↑\nlamroN\nl/g ,nietorP\n↑\n↑\n↑\n↑\nlamroN\n↑\nlamroN\n↑\n↑\n↑\n↑\n,setycokueL l/601×\nlamroN\nlamroN\n↑\nlamroN\nlamroN\nlamroN\nlamroN\n↑\n↑\nlamroN\n,sisehtnys\nGgI yad/gm\n,VMC\n–\n–\n–\n,VMC\n,VMC\n–\n,suriv\nallebur\n,VMC\n–\nmureS\n,suriv\nallebur\nsuriv\nallebur\n,suriv\nallebur\nepyt\nretsilb\nelgnis\ndna\nygoloriv\nretsilb\nelgnis\nepyt\nretsilb\nelgnis\nretsilb\nelgnis\nydobitna\nsuriv\nII/I\nsuriv\nII/I epyt\nsuriv II/I\nsuriv\nII/I epyt\n↑\nGgI\nGgI\nydobitna\n,↑\nGgI\nydobitna\n↑\nGgI\nydobitna\nepyt\nretsilb\nelgnis suriv II/I\n↑\nMgI\nydobitna\n–\n–\n–\n–\n–\n–\n–\n–\n–\n–\n–\nyg\noloriv FSC\n++\n+\n++\n++\n++\n–\n–\n–\n++\n++\n++\nRADMN seidobitna )mures(\n++\n++\n++\n++\n++\n++\n++\n+++\n++\n++\n+++\nRADMN seidobitna )FSC(\ndliM\nlamroN\ndekraM\ndekraM\netaredoM\ndliM\ndekraM\nGEE\nlamronba\nlamronba\nlamronba\nlamronba\nlamronba\nlamronba\ndeziareneG\nlamroN\nlamroN\n–\n–\nlamroN\nlamroN\nlacoF\n–\nlamroN\nIRM\nsitigninem\nsitigninem\negnahc\negnahc\n31\n52\n11\n82\n5\n1\n8\n02\n7\nmorf emiT ot esno ,sisongaid syad\n,sdioretS\nGIVI\n,sdioretS\n,sdioretS\n,sdioretS\n,sdioretS\nGIVI\n,sdioretS\n,sdioretS\ntnemtaerT\nGIVI\nXTC\n,GIVI\nGIVI\nGIVI\nGIVI\nGIVI\nGIVI\n)shtnom\n8(\n2\n)shtnom\n61(\n1\n)shtnom\n41(\n1\n)raey\n1(\n0\n)raey\n1(\n1\n)raey 1(\n3\nediciuS\n)shtnom\n01(\n2\ngnirud(\ndaeD\n)shtnom\n9(\n3\n)shtnom\n9(\n0\nSRm\n)shtnom11(\n)noitazilatipoh\npu-wollof( )emit\nDownloaded\nfrom\nhttp://karger.com/ene/article-pdf/74/1-2/73/2725398/000435953.pdf\nby\nUniversity\nCollege\nLondon\nuser\non\n05\nAugust\n2025\nDiscussion and West Nile virus. In this study, none of the patients\nfound positive results in CSF viral assay, except that 4\nAnti-NMDAR encephalitis, which was once consid- patients were identified positive for CMV, rubella virus,\nered fatal-encephalitis, is now clinically recognizable, di- and single blister type I/II virus antibody in serum. This\nagnosable by the presence of antibodies in CSF or serum, can be explained by the possibility that some patients\nand treatable with the immunotherapy. Little informa- may have had viral infection before or during the dis-\ntion about clinical features of anti-NMDAR encephalitis ease.\nin China is currently available. There were a few cases that None of the 11 patients was found to have tumors dur-\nreported about anti-NMDAR encephalitis in China [ 7, 8, ing hospitalization. Not all of them had enough examina-\n10–12] , which have many limitations like a small number tions during hospitalization. One female patient (case 1),\nof cases, and lacking long time follow-up. Our research aged 15 years, was diagnosed with teratoma through a\nreported clinical symptoms, laboratory examinations, whole body examination, 1 month after getting dis-\nCSF examinations, imageological examinations, the re- charged from the hospital. In a case series of 400 patients,\nsponse to the immune therapy and the long time progno- an underlying teratoma was detected more often in fe-\nsis of the 11 patients diagnosed with anti-NMDAR en- male patients over 18 years [22] . Therefore, we suggest\ncephalitis. that female patients with anti-NMDAR encephalitis be\nAccording to previous studies [ 13–16] , approximate- screened for ovarian tumors. Periodic screening for ovar-\nly 80% of patients with anti-NMDAR encephalitis ian teratomas for at least 2 years has been recommended\nwere female. In addition, it predominantly affected even if the patients have recovered from encephalitis\nyoung adults and children. However, the median age [ 17] .\nin the present study was higher than the one mentioned Management of anti-NMDAR encephalitis should ini-\nin previous reports [ 1–4, 13–16] . Furthermore, there tially focus on immunotherapy and the detection and re-\nwas no predominance of female patients in the pres- moval of ovarian tumors [1–5] . In the Titulaer et al. [ 5] ,\nent study. This might be affected by a small number of 81% of the patients with anti-NMDAR encephalitis who\ncases. received immunotherapy and removal of tumors had\nIn our research, 9 patients (81.9%) had the typical 5 good outcomes after a median follow-up of 24 months. In\nstages [6] : prodromal phase, psychotic and/or seizure the research, 1 patient with tumors underwent tumor re-\nphase, unresponsive phase, hyperkinetic phase, and grad- section, and 9 patients received immunotherapy. At the\nual recovery phase, except cases 8 and 11, and this finding end of follow-up ranging from 8 to 16 months, 67% pa-\nis similar to that of the other earlier studies [6, 17] . There- tients had achieved a neurological recovery after immu-\nfore, our study indicates that testing of antibodies against notherapy or removal of tumors. In this study, the prog-\nNMDAR in serum and CSF should be performed in nosis of the patients with immunotherapy tended to be\nyoung females, or children with any step of the typical 5 favorable, in accordance with the results of the previous\nstages. study [ 16] .\nIn the study, antibodies against NMDAR of the 11 pa- In this study, 2 patients (18%) died during the follow-\ntients were found positive in CSF. According to previous up. Case 3 died of MODS during hospitalization, though\nstudies [ 18, 19] , antibodies against NMDAR were intra- she had received immunotherapy. It may be associated\nthecal synthesis antibody. When we found antibodies with the time of starting immunotherapy (20 days) de-\nagainst NMDAR in CSF, patients can certainly be diag- layed. Case 5 committed suicide because of serious psy-\nnosed with anti-NMDAR encephalitis. chiatric disease at 11 months after anti-NMDAR enceph-\nApproximately, 37–50% of encephalitis have un- alitis. Therefore, it is also important to assess the mental\nknown etiologies according to the previous studies [ 20, condition of these patients with anti-N MDAR encepha-\n21] . Since the development of systematic laboratory litis after discharging them from the hospital.\ntesting included PCR and antibody assays, some cases\nof unknown cause have been able to be reclassified as\nthe infectious encephalitis, or as an autoimmune pro- Conclusions\ncess. Previous studies [ 22, 23] indicated that approxi-\nmately 4.4% of encephalitis with uncertain etiology In our clinical work, anti-NMDAR encephalitis should\nwere anti-NMDAR encephalitis, followed by enterovi- be suspected in patients who developed a rapid change in\nrus, herpes simplex virus type 1, varicella zoster virus, behavior or psychosis, seizures, dyskinesia, and hypoven-\nAnti-NMDAR Encephalitis of 11 Cases in Eur Neurol 2015;74:73–78 77\nChina DOI: 10.1159/000435953\nDownloaded\nfrom\nhttp://karger.com/ene/article-pdf/74/1-2/73/2725398/000435953.pdf\nby\nUniversity\nCollege\nLondon\nuser\non\n05\nAugust\n2025\ntilation for unknown reasons. At the same time, patients Disclosure Statement\nshould be examined for the underlying tumor, especially\nThe authors have no conflicts of interest to declare.\nfor teratoma. As a neurologist, it is important to be famil-\niar with the clinical presentations of the disease, especial-\nly in children and young adults.\nReferences\n1 Dalmau J, Gleichman AJ, Hughes EG, Rossi 9 Lin JJ, Lin KL, Hsia SH, Chou ML, Hung PC, male patients with NMDA receptor antibodies\nJE, Peng X, Lai M, et al: Anti-NMDA-receptor Hsieh MY, Chou IJ, Wang HS; Children with encephalitis. Neurology 2014; 82: 556–563.\nencephalitis: case series and analysis of the ef- Encephalitis and/or Encephalopathy Related 17 Iizuka T, Sakai F, Ide T, et al: Anti-NMDA\nfects of antibodies. Lancet Neurol 2008; 7: Status Epilepticus and Epilepsy (CHEESE) receptor encephalitis in Japan: long-term out-\n1091–1098. Study Group: Anti-N-methyl-D-aspartate re- come without tumor removal. Neurology\n2 Dalmau J, Tüzün E, Wu HY, Masjuan J, Ros- ceptor encephalitis in Taiwan – a comparison 2008; 70: 504–511.\nsi JE, Voloschin A, et al: Paraneoplastic anti- between children and adults. Pediatr Neurol 18 Barry H, Hardiman O, Healy DG: Anti-\nN-methyl-D-aspartate receptor encephalitis 2014; 50: 574–580. NMDA receptor encephalitis: an important\nassociated with ovarian teratoma. Ann Neu- 10 Xiangshu HU, Ouyang M, et al: Anti-NMDA differential diagnosis in psychosis. Br J Psy-\nrol 2007; 61: 25–36. receptor encephalitis in 3 cases. Chin J Neu- chiatry 2011; 199: 508–509.\n3 Florance NR, Davis RL, Lam C, et al: Anti-N- roimmunol Neurol 2014; 1: 66–68. 19 Luca N, Daengsuwan T, Dalmau J: Anti-N-\nmethyl-D-aspartate receptor (NMDAR) en- 11 Jing X, Zhao H: Anti-NMDA-receptor en- methyl-D-aspartate receptor encephalitis: a\ncephalitis in children and adolescents. Ann cephalitis in one case. Shandong Med J 2014; newly recognized inflammatory brain disease\nNeurol 2009; 66: 11–18. 26: 107–108. in children. Arthritis Rheum 2011; 63: 2516–\n4 Vitaliani R, Mason W, Ances B, Zwerdling T, 12 Liu M, Xie Y, et al: Anti-NMDA-receptor en- 2522.\nJiang Z, Dalmau J: Paraneoplastic encephali- cephalitis. Chin J Neuroimmunol Neurol 20 Granerod J, Ambrose HE, Davies NW, et al:\ntis, psychiatric symptoms, and hypoventila- 2010; 6: 449–451. Causes of encephalitis and differences in their\ntion in ovarian teratoma. Ann Neurol 2005; 13 Vitaliani R, Mason W, Ances B, Zwerdling T, clinical presentations in England: a multicen-\n58: 594–604. Jiang Z, Dalmau J: Paraneoplastic encephali- tre, population-based prospective study. Lan-\n5 Titulaer MJ, McCracken L, Gabilondo I, Ar- tis, psychiatric symptoms, and hypoventila- cet Infect Dis 2010; 10: 835–844.\nmangué T, Glaser C, Iizuka T, et al: Treatment tion in ovarian teratoma. Ann Neurol 2005; 21 Vora NM, Holman RC, Mehal JM, Steiner\nand prognostic factors for long-term outcome 58: 594–604. CA, Blanton J, Sejvar J: Burden of encephali-\nin patients with anti-NMDA receptor en- 14 Titulaer MJ, McCracken L, Gabilondo I, Iizu- tis-associated hospitalizations in the United\ncephalitis: an observational cohort study. ka T, Kawachi I, Bataller L, et al: Late-onset States, 1998–2010. Neurology 2014; 82: 443–\nLancet Neurol 2013; 12: 157–165. anti-NMDA receptor encephalitis. Neurolo- 451.\n6 Dalmau J, Lancaster E, Martinez-Hernandez gy 2013; 81: 1058–1063. 22 Gable MS, Sheriff H, Dalmau J, Tilley DH, Gla-\nE, Rosenfeld MR, Balice-Gordon R: Clinical 15 Gresa-Arribas N, Titulaer MJ, Torrents A, ser CA: The frequency of autoimmune N-meth-\nexperience and laboratory investigations in Aguilar E, McCracken L, Leypoldt F, Gleich- yl-D-aspartate receptor encephalitis surpass-\npatients with anti-NMDAR encephalitis. man AJ, Balice-Gordon R, Rosenfeld MR, es that of individual viral etiologies in young\nLancet Neurol 2011; 10: 63–74. Lynch D, Graus F, Dalmau J: Antibody titres individuals enrolled in the California encepha-\n7 Song L, Liu AH: Anti-N-methyl-D-aspartic at diagnosis and during follow-up of anti- litis project. Clin Infect Dis 2012; 54: 899–904.\nacid receptor encephalitis: clinical analysis of NMDA receptor encephalitis: a retrospective 23 Kayser MS, Titulaer MJ, Gresa-Arribas N,\n7 cases. Natl Med J China 2013; 93: 2508–2510. study. Lancet Neurol 2014; 13: 167–177. Dalmau J: Frequency and characteristics of\n8 Chunling X, Weiqin Z, et al: Anti-NMDA- 16 Viaccoz A, Desestret V, Ducray F, Picard G, isolated psychiatric episodes in anti-N-meth-\nreceptor encephalitis in one case. Chin J Neu- Cavillon G, Rogemond V, Antoine JC, Delattre yl-D-aspartate receptor encephalitis. JAMA\nrol 2010; 43: 781–783. JY, Honnorat J: Clinical specificities of adult Neurol 2013; 70: 1133–1139.\n78 Eur Neurol 2015;74:73–78 Liu/Wang/Xiong/Liu/Liu\nDOI: 10.1159/000435953\nDownloaded\nfrom\nhttp://karger.com/ene/article-pdf/74/1-2/73/2725398/000435953.pdf\nby\nUniversity\nCollege\nLondon\nuser\non\n05\nAugust\n2025",
  "Baizabal-Carvallo -  Jankovic, 2013": "A N T I - N M D A R E N C E P H A L I T I S M O V E M E N T D I S O R D E R S\nwith a younger age at onset, and their outcomes can be The Spectrum of Movement\nfavorablewithmultidisciplinarytreatment. Disorders in Children With\nAnti-NMDA Receptor Encephalitis\nLegends to the Video\nVideo 1. Videoofawomanaged68yearswithsudden\nonset tremor (elderly group, case 7). The video demon- Jose(cid:2) FidelBaizabal-Carvallo, MD,MSc,1\nstrates entrainment and distractibility of a right hand AmberStocco, MD,2 EyalMuscal, MD2,3 and\njerky tremor with complete resolution on suggestion. JosephJankovic, MD1*\nThe patients has associated functional gait with fluctua-\ntionsofstanceandgaitandbucklingoftheknees.There 1Parkinson’sDiseaseCenterandMovementDisordersClinic,\nDepartmentofNeurology,BaylorCollegeofMedicine,Houston,\nisatendencytoholdontosurroundingobjects.\nTexas,USA2DivisionofPediatricNeurologyandDevelopmental\nVideo 2. Video of a man aged 78 years with abrupt\nNeuroscience,TexasChildren’sHospital,BaylorCollegeofMedicine,\nonset dystonia (elderly group, case 33). The video Houston,Texas,USA3DivisionofImmunology,AllergyandRheuma-\ndemonstrates the incongruous movements of face and tology,TexasChildren’sHospital,BaylorCollegeofMedicine,Hous-\nupper limbs with variability and distractibility. ton,Texas,USA\nVideo 3. This video demonstrates functional right\nhand and leg tremor accompanied by functional gait\nwith uneconomic postures (identity masked).\nABSTRACT\nReferences\nBackground: Movement disorders are frequent but dif-\n1. Edwards MJ, Bhatia KP. Functional (psychogenic) movement dis-\nficult to characterize in patients with anti-N-methyl-D-\norders:mergingmindandbrain.LancetNeurol2012;11:250–260. aspartate receptor(NMDAR)encephalitis.\n2. Williams DT, Ford B, Fahn S. Phenomenology and psychopathol- Methods: The phenomenology of movement disorders\nogy related to psychogenic movement disorders. Adv Neurol was characterized after a detailed examination of chil-\n1995;65:231–257.\ndrenwithanti-NMDAR-encephalitis.\n3. Miyasaki JM, Sa DS, Galvez-Jimenez N, Lang AE. Psychogenic Results: We studied 9 children (5 females), ages 3–14\nmovementdisorders.CanJNeurolSci2003;30(suppl1):S94–S100.\nyears, with confirmed anti-NMDAR-encephalitis. All\n4. Factor SA, Podskalny GD, Molho ES. Psychogenic movement dis-\npatients presented with at least 1 movement disorder,\norders: frequency, clinical profile, and characteristics. J Neurol\nNeurosurgPsychiatry1995;59:406–412. including chorea (n54), stereotypic movements (n54),\n5. FahnS,WilliamsDT.Psychogenic dystonia.AdvNeurol1988;50: ataxia (n53), limb dystonia (n52), limb myorhythmia\n431–455. (n52), oromandibular dystonia (n52), facial myorhyth-\n6. Thomas M, Vuong KD, Jankovic J. Long-term prognosis of mia, blepharospasm, opisthotonus, athetosis, and\npatientswithpsychogenicmovementdisorders.ParkinsonismRelat tremor (n51, each). More than a single movement dis-\nDisord2006;12:382–387.\norder was observed in 6 of these patients. Resolution\n7. FeinsteinA,StergiopoulosV,FineJ,LangAE.Psychiatricoutcomein of the abnormal movements was observed in all\npatientswithapsychogenicmovement disorder:aprospectivestudy.\nNeuropsychiatryNeuropsycholBehavNeurol2001;14:169–176. patients with immunotherapy; 1 patient improved with\ntetrabenazine.\n8. RanawayaR,RileyD,LangA.Psychogenicdyskinesiasinpatients\nwithorganicmovementdisorders.MovDisord1990;5:127–133. Conclusions: A wide variety of movement disorders,\n9. Marjama J, Troster AI, Koller WC. Psychogenic movement disor- often in combination, can be observed in children\nders.NeurolClin1995;13:283–297. with anti-NMDAR encephalitis. Patients commonly\n10. Kellinghaus C, Loddenkemper T, Dinner DS, Lachhwani D, Luders present with more than a single movement disorder.\nHO.Non-epilepticseizuresoftheelderly.JNeurol2004;251:704–709. VC 2013MovementDisorderSociety\n11. Lempert T, Brandt T, Dieterich M, Huppert D. How to identify Key Words: anti-NMDAR encephalitis; stereotypies;\npsychogenic disorders of stance and gait. A video study in 37\nchorea;dystonia; myorhythmia;autoimmune\npatients.JNeurol1991;238:140–146.\n12. Baik JS, Lang AE. Gait abnormalities in psychogenic movement\ndisorders.MovDisord2007;22:395–399.\n13. SchragA,TrimbleM,QuinnN,BhatiaK.Thesyndromeoffixed\n------------------------------------------------------------\ndystonia: an evaluation of 103 patients. Brain 2004;127(pt\n10):2360–2372. SupportingInformationmaybefoundintheonlineversionofthisarticle.\n14. McBride AE, Shih TT, Hirsch LJ. Video-EEG monitoring in the Correspondenceto:Dr.JosephJankovic,ProfessorofNeurology,\nelderly:areviewof94patients.Epilepsia2002;43:165–169. DistinguishedChairinMovementDisorders,Director,Parkinson’s\n15. KellinghausC,LoddenkemperT,DinnerDS,LachhwaniD,Luders DiseaseCenterandMovementDisordersClinic,BaylorCollegeof\nHO. Seizure semiology in the elderly: a video analysis. Epilepsia Medicine,DepartmentofNeurology,theSmithTower,Suite1801,6550\n2004;45:263–267. Fannin,Houston,Texas77030,USA;josephj@bcm.tmc.edu\n16. EspayAJ,GoldenharLM,VoonV,SchragA,BurtonN,LangAE. Relevantconflictsofinterest/financialdisclosures:Nothingtoreport.\nOpinionsandclinicalpracticesrelatedtodiagnosingandmanaging Fullfinancialdisclosuresandauthorrolesmaybefoundintheonline\npatients with psychogenic movement disorders: an international versionofthisarticle.\nsurvey of Movement Disorder Society members. Mov Disord\n2009;24:1366–1374. Received:8August2012;Revised:22November2012;Accepted:9\n17. Kranick S, Ekanayake V, Martinez V, Ameli R, Hallett M, Voon December2012\nV. Psychopathology and psychogenic movement disorders. Mov Publishedonline11February2013 inWileyOnlineLibrary\nDisord2011;26:1844–1850. (wileyonlinelibrary.com).DOI:10.1002/mds.25354\nMovementDisorders,Vol.28,No.4,2013 543\nB A I Z A B A L - C A R V A L L O E T A L\nTABLE 1.Movement disordersobservedin thiscaseseries\nMyorhythmia Myorhythmia Cranial Limb Stereotypic\nCase Sex/ageatonset (facial) (limb) Chorea Athetosis dystonia Opisthotonus dystonia movements Ataxia\n1 F/13yearsold 1 1 1b 1\n2 M/8yearsold 1\n3 M/3yearsold 1 1a 1 1 1\n4 F/8yearsold 1\n5 M/3yearsold 1 1\n6 M/11yearsold 1 1\n7 F/5yearsold 1 1\n8 F/14yearsold 1\n9 F/10yearsoldc 1 1\naBlepharospasms\nborolingualandhemifacialdystonia\ncfineupperlimbposturaltremor.\ntremor (n51, each). Orolingual dyskinesias frequently\nreported in this syndrome were observed in 2 patients\nAnti-N-methyl-D-aspartate receptor (anti-NMDAR)\nand corresponded to myorhythmia and oromandibular\nencephalitis has received much attention in the last 5\ndystonia. All patients had movement disorders involv-\nyears. The clinical syndrome usually follows a multi-\ning their limbs, and 5 also had cranial involvement.\nstage course, often starting with behavioral manifesta-\nOne patient had 5 types of movement disorders, 1\ntions and followed by an acute or subacute emergence\npatient had 4, 1 patient had 3, 3 patients had 2, and 3\nof movement disorders. Although well characterized in\npatients had a single type (Table 1). No patient had\nadults,1 the syndrome is more variable and atypical in\nan underlying tumor. We describe 6 representative\nchildren. Movement disorders typically appear after a\ncases.\nperiod of prodromal and psychiatric manifestations in\nadults, but they may be the initial manifestation in\nchildren with anti-NMDAR encephalitis.2,3 The phe- Case 1\nnomenology of these abnormal movements may be\nA previously healthy 13-year-old African American\ndifficult to characterize, and patients may manifest\nfemale presented to the emergency room after a recent\nmore than a single one.\nhistory of vague complaints of “heaviness” in the right\nleg, followed by unstable, ataxic gait. These manifes-\nPatients and Methods tations were rapidly followed by altered mental status\nwith perseverance, uncontrolled laughing, loud sing-\nWe aimed to characterize the movement disorders\ning, and delusional religious thoughts. The patient was\nobserved in a series of 9 children (4 males and 5\nadmitted to the intensive care unit because of hypo-\nfemales, between 3 and 14 years old) with confirmed\nventilation, generalized seizures, and autonomic dys-\nanti-NMDAR encephalitis referred to a tertiary-care\nfunction with tachypnea and tachycardia. During that\ncenter. All patients underwent extensive neurological\ntime she developed 1- to 2-Hz repetitive contractions\nevaluation and investigations searching for possible in-\nof the procerus, corrugator, orbicularis oculi, and oro-\nfectious, metabolic, and autoimmune causes of en-\nmandibular muscles with tongue protrusion, along\ncephalitis. Parents or legal custodians signed informed\nwith slow leg tremor, consistent with facial and limb\nconsent for videotaping; the study was approved by\nmyorhythmia (Video 1) and cranial dystonia. A brain\nthe Institutional Review Board. All patients satisfied\nMRI was unremarkable. Marked improvement was\nthe following inclusion criteria: positive anti-NMDAR\nobserved after treatment with corticosteroids and in-\nantibody titers (blood or cerebrospinal fluid [CSF]);\ntravenous immunoglobulins, followed by plasmaphere-\nand lack of evidence of other causes of encephalitis or\nsis and rituximab.\nmovement disorders.\nCase 2\nResults\nAn 8-year-old Hispanic boy presented with a 3-\nAll patients presented with at least 1 movement dis- month history of agitation, insomnia, hallucinations,\norder: chorea (n54), stereotypic movements (n54), and generalized seizures, followed by social withdrawal\nataxia (n53), limb dystonia (n52), limb myorhythmia and anorexia. He was found nonverbal and minimally\n(n52), oromandibular dystonia (n52), facial myor- interactive with the environment. Episodes of leftward\nhythmia, blepharospasm, opisthotonus, athetosis, and gaze deviation were observed as well as stereotypic\n544 MovementDisorders,Vol.28,No.4,2013\nA N T I - N M D A R E N C E P H A L I T I S M O V E M E N T D I S O R D E R S\nFIG.1.A:ProtondensityMRIshowsbilateralhyperintensitiesintheexternalandinternalcapsules—thelentiform“forksign.”B:Thesamehyperin-\ntensitiesweremoresubtleintheT2WsequenceandFLAIR(notshown).C:MRSshowsadecreaseinthepeakofN-acetylaspartatewithrespect\ntocholineandcreatinineandanincreaseinmyoinositolinthebasalganglia.D,E:AxialandcoronalFLAIRshowsaleftcerebellarhyperintensity.F:\nMRSshowsafallinthepeakofN-acetylaspartatesuggestingneuronaldamage.\nright and left arm flexion, elevation, and abduction corresponding to the episodes of arm elevation.\n(Video 2). When the right arm was restrained, he had Marked improvement was observed with pulses of\npurposeless left arm elevation. The electroencephalo- methylprednisolone and intravenous immunoglobulins;\ngram showed absence of an occipital dominant rhythm, seizures responded to phenytoin and levetiracetam.\nmultifocal sharp waves, most prominent in the left The movement disorders (dystonia, chorea, and stereo-\nfrontotemporal region, and diffuse slowing. A brain typies) improved with tetrabenazine 25 mg 3 times a\nMRI was unremarkable. A 5-day trial of intravenous day. He had a relapse 5 months into his course, with\nimmunoglobulins did not provide symptomatic benefit. further seizures and cognitive decline. Treatment with\nHowever, marked clinical improvement was observed monthly intravenous immunoglobulins and mofetil\nafter treatment with intravenous pulses of corticoste- mycophenolate 200 mg twice a day resulted in return\nroids and 6 cycles of plasmapheresis. Seizures were con- to normal baseline.\ntrolled with levetiracetam.\nCase 4\nCase 3\nAn 8-year-old Hispanic girl had sudden onset of\nA 3-year-old Hispanic male had subacute onset of generalized tonic-clonic seizures. During the hospitali-\nmyalgias, frontal headache, malaise, and vomiting, fol- zation, she had a transient episode of right-sided hemi-\nlowed by mental confusion, insomnia, hallucinations, paresis on awakening, dysautonomic symptoms with\ndysarthria, and motor aphasia. The patient was admit- episodic tachycardia, hypertension, fluctuating mental\nted to the hospital. During the hospitalization he status, and abnormal movements consisting of slow,\ndeveloped generalized seizures, dysautonomia with involuntary asynchronous (alternating flexion-exten-\nbrief episodes of apnea and complex abnormal move- sion) 1- to 2-Hz lower limb myorhythmia (Video 4).\nments with repetitive orofacial stereotypies, dystonic The electroencephalogram showed no occipital domi-\ncontractions of the left side of his face, blepharo- nant rhythm with a diffusely slow background. Brain\nspasm, dystonic flexion of the right wrist and hand, MRI was unremarkable. The CSF anti-NMDAR anti-\nopisthotonus, and chorea (Video 3). The electroence- body was positive. The patient was treated with\nphalogram indicated epileptiform activity monthly intravenous immunoglobulins and pulses of\nMovementDisorders,Vol.28,No.4,2013 545\nB A I Z A B A L - C A R V A L L O E T A L\ncorticosteroids with initial response. However, she had NMDAR encephalitis.3 Movement disorders have been\na relapse 3 months later with generalized tonic-clonic reported in 86% of adults and 84% of children and\nseizures and tactile hallucinations; this time she include orofacial dyskinesias; chorea; choreoathetosis;\nrequired treatment with plasmapheresis. Seizures facial, limb, and trunk dystonia; myoclonus; tremor;\nrequired treatment with multiple medications includ- opsoclonus-myoclonus; and ataxia.1–3 In a series of 32\ning zonisamide, fosphenytoin, levetiracetam, and lora- children and adolescents with anti-NMDAR encephali-\nzepam. Her serum NMDAR titers remained markedly tis, stereotyped movements and orofacial dyskinesias\nelevated and she was maintained on mycophenolate werethemostcommonmovementdisorders,with85%\nfor a year following this. and45%,respectively.2Inadditiontochorea,dystonia,\nandathetosis,theothertypeofhyperkineticmovements\nCase 5 observed in cases 1 and 4 was myorhythmia. The term\nmyorhythmia was coined by Hertz4 to describe a rest\nThis is a 3-year-old Hispanic boy who was brought\ntremor usually associated with brain stem lesions and\nto the hospital for evaluation of a 10-day history of\ndistinguishablefromparkinsoniantremorbyslower(1–\nprogressive generalized movements. This presentation\n3 Hz) and more irregular frequency. The movement is\nwas followed by a wide-based, unsteady ataxic gait,\ntypically seen in patients with Whipple’s disease and\nlimb ataxia with inability to feed himself, and dysarth-\nothertypes ofencephalitis.5–7Myorhythmiacanbedif-\nria. The examination showed random, purposeless,\nferentiated from parkinsonian tremor by its lower fre-\ninvoluntary, nonsuppressible movements correspond-\nquency,lackofparkinsoniansigns,andabsentresponse\ning to chorea (Video 5). The movements disappeared\nto levodopa and can be distinguished from stereotypies\nwith sleep and worsened with excitement. Mild motor\nby the characteristic features it is lacking, most impor-\nimpersistence was also noticed. No seizures were\ntantly,patterned,repetitive,coordinatedmovement.8\nobserved. A brain MRI showed symmetric hyperinten-\nCases 3, 5, 6, and 7 (the 4 youngest children)\nsitiesintheexternalandinternalcapsuleresemblingthe\nshowed features of chorea. Chorea is particularly\n“fork sign” (Fig. 1A,B). Magnetic resonance spectros-\ndominant in younger children and anti-NMDAR cho-\ncopy (MRS) showed a reduced peak of N-acetyl aspar-\nrea should be considered in the differential diagnosis\ntate with increased levels of myoinositol in the basal\nof all childhood choreas, including Sydenham’s cho-\nganglia(Fig.1C).Thepatientshowedmarkedimprove-\nrea. Case 5 showed decreased levels of N-acetyl aspar-\nment after intravenous pulses of methylprednisolone\ntate in the MRS, suggesting neuronal damage of the\nfollowed by oral corticosteroids. He had recurrence of\nbasal ganglia, with hyperintensities in the external and\nhis chorea 2 months later. Intravenous immunoglobu-\ninternal capsule resembling the lentiform “fork sign”\nlins followed by oral prednisone were reinitiated, with\ndescribed in patients with renal impairment and meta-\nimprovementinhismovementdisorder.\nbolic acidosis.9 Nevertheless, our patient did not have\nevidence of any of these conditions.\nCase 6\nOrofacial dystonia was observed in case 3. Different\nAn 11-year-old Hispanic male presented for evalua-\ntypes of oromandibular-lingual “dyskinesias” have\ntion of acutely altered mental status, irritability, agita-\nbeen described in patients with anti-NMDAR and in-\ntion, restlessness, hallucinations, vomiting, and fectious encephalitis,10 but careful observation usually\nfrequent crying, followed by generalized seizures. Ex-\nallows differentiation of these dyskinesias into orofa-\namination showed generalized chorea and distal limb\ncial stereotypy, dystonia, or myorhythmia.\nathetosis.ThebrainMRIshowedafocalhyperintensity\nIn conclusion, the phenomenology of movement dis-\nin the left cerebellar cortex without contrast enhance-\norders in children affected with anti-NMDAR enceph-\nment (Fig. 1D,E) with reduction of the N-acetyl aspar- alitis may be difficult to characterize,11 and patients\ntate peak (Fig. 1F). The electroencephalogram showed\noften present with more than a single abnormal move-\nslow occipital rhythm and delta activity in the frontal\nment, further complicating the classification of the\nand occipital leads without epileptic discharges. Anti-\nmovement disorders. These hyperkinetic movements\nNMDAR antibodies were negative in serum but posi-\nusually improve with immunosuppressive therapy or\ntive in the CSF. Treatment with prednisone 3 mg/kg\ntetrabenazine, a monoamine depleter of the central\nresulted in prominent neurological improvement. nervous system.12\nOxcarbazepine was used to mitigate seizures. At fol-\nlow-up he had no further seizures or abnormal move-\nLegends to the Videos\nments but exhibited academic difficulties and anxiety.\nFurtherimmunotherapywasdiscussedbutnotpursued. Video 1. This is a 13-year-old female with repetitive\nfacial, tongue protrusion, and lower limb movements\nDiscussion\ncorresponding to myorhythmia.\nOur patients illustrated the broad spectrum of hyper- Video 2. This is an 8-year-old male with repetitive\nkinetic movement disorders associated with anti- stereotypic left arm flexion, elevation, and abduction.\n546 MovementDisorders,Vol.28,No.4,2013\nP A R K I N S O N I A N M E T A B O L I C B R A I N P A T T E R N S\nVideo 3. This is a 3-year-old male with orolingual\nstereotypic movements, blepharospasm, dystonic left\nfacial contractions, and stereotypic movements of the\nABSTRACT\nleft arm.\nVideo 4. This is an 8-year-old female with slow Background: The objective of this study was to vali-\nalternating movement of the lower limbs correspond- date disease-related metabolic brain patterns for Par-\nkinson’s disease, multiple system atrophy, and\ning to myorhythmia.\nprogressivesupranuclearpalsy.\nVideo 5. This is a 3-year-old male with generalized\nMethods: The study included 20 patients with Parkin-\nchorea and motor impersistence.\nson’s disease, 21 with multiple system atrophy, and 17\nwith progressive supranuclear palsy, all of whom had\nundergone a clinically motivated [18F]-fluoro-deoxyglu-\ncose positron emission tomography scan at an early\nReferences\nstageoftheirdisease.Atafollow-uptimeafterthescan\n1. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, of 2–4 years, a clinical diagnosis was made according\nBalice-GordonR.Clinicalexperienceandlaboratoryinvestigations to established clinical research criteria. Patient groups\nin patients with anti-NMDAR encephalitis. Lancet Neurol.\nwere compared with 18 healthy controls using a multi-\n2011;10:63–74.\nvariate covariance image analysis technique called\n2. Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate\nreceptor (NMDAR) encephalitis in children and adolescents. Ann scaledsubprofilemodel/principalcomponentanalysis.\nNeurol.2009;66:11–18. Results: Disease-related metabolic brain patterns for\n3. Baizabal-Carvallo JF, Jankovic J. Movement disorders in autoim- these parkinsonian disorders were identified. Validation\nmunediseases.MovDisord.2012;27:935–946.\nshowed that these patterns were highly discriminative\n4. Hertz E. Die amyostatischen Unruheerscheinungen. Klinisch kine- of the 3 disorders.\nmatographische Analyse ihrer Kennzeichen und Beleiterscheinun-\ngen.JPsycholNeurol.1931;43:146–163. Conclusions: Early diagnosis of parkinsonian disorders\nis feasible whenthe expressionof disease-related met-\n5. MasucciEF,KurtzkeJF,SainiN.Myorhythmia:awidespreadmove-\nmentdisorder.Clinicopathologicalcorrelations.Brain.1984;107:53–79. abolic brain patterns is quantified at a single-subject\n6. Park KI, Chung JM, Lee SH, Lee HK. Myorhythmia associated level.VC 2013MovementDisorderSociety\nwithlisterialrhombencephalitis.MovDisord.2010;25:950–952. Key Words: Parkinson’s disease; FDG-PET imaging;\n7. Tan EK, Chan LL, Lo YL. Isolated facial myorhythmia. J Neurol disease-specific metabolic brain patterns; differential\nSci.2007;252:36–38.\ndiagnosis; multivariate statistical analysis technique\n8. EdwardsMJ,LangAE,BhatiaKP.Stereotypies:acriticalappraisal\nand suggestion of a clinically useful definition. Mov Disord.\n2012;27:179–185.\n9. KumarG,GoyalMK.LentiformForksign:auniqueMRIpicture.\nIs metabolic acidosis responsible? Clin Neurol Neurosurg.\n2010;112:805–812.\n10. Kalita J, Misra UK, Pradhan PK. Oromandibular dystonia in en- Visual examination of [18F]-fluoro-deoxyglucose posi-\ncephalitis.JNeurolSci.2011;304:107–110. tron emission tomography (FDG-PET) scans may guide\n11. Kleinig TJ, Thompson PD, Matar W, et al. The distinctive move- the differential diagnosis of parkinsonian syndromes.\nment disorder of ovarian teratoma-associated encephalitis. Mov\nDisord.2008;23:1256–1261. Nevertheless, interpretation of both clinical symptoms\n12. Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of andFDG-PETscanscanbedifficult.Previously, univari-\nchorea and other hyperkinetic movement disorders. Expert Rev ate methods such as statistical parametric mapping\nNeurother.2011;11:1509–1523.\n(SPM) have been used to identify group differences\nbetween parkinsonian patients and controls.1–3 How-\nValidation of Parkinsonian ever, scaled subprofile modeling/principal component\nanalysis (SSM/PCA), a multivariate method, not only\nDisease-Related Metabolic Brain\nidentifies group differences, but also shows relationships\nPatterns in metabolic activity between different brain regions in\ncombined samples of patients and control scans.4,5 A\nParkinson’s disease–related metabolic pattern was\nLauraK. Teune,MD,1 RemcoJ. Renken,PhD,2 ------------------------------------------------------------\nDeborah Mudali,MSc,3BaukeM. De Jong,MD, PhD,1 Correspondenceto:KlausL.Leenders,DepartmentofNeurology,\nUniversityMedicalCenterGroningen,Hanzeplein1,Postbus30.001,\nRudiA.Dierckx, MD,PhD,4 JosB.T.M. Roerdink,PhD3 and\n9700RBGroningen,TheNetherlands;k.l.leenders@umcg.nl\nKlausL.Leenders, MD, PhD1*\nFundingagencies:Thisresearchwasfundedwithagrantfromthe\nInternationalParkinsonDiseaseFoundation(IPF).\n1DepartmentofNeurology,UniversityMedicalCenterGroningen,\nRelevantconflictsofinterest/financialdisclosures:Nothingtoreport.\nGroningen,TheNetherlands2NeuroImagingCenter,UniversityMedi-\nFullfinancialdisclosuresandauthorrolesmaybefoundintheonlinever-\ncalCenterGroningen,Groningen,TheNetherlands3JohannBernoulli sionofthisarticle.\nInstituteforMathematicsandComputerScience,Universityof\nReceived:6July2012;Revised:13December2012;Accepted:19\nGroningen,Groningen,TheNetherlands4DepartmentofNuclear\nDecember2012\nMedicineandMolecularImaging,UniversityMedicalCenter\nPublishedonline11March2013 inWileyOnlineLibrary\nGroningen,Groningen,TheNetherlands (wileyonlinelibrary.com).DOI:10.1002/mds.25361\nMovementDisorders,Vol.28,No.4,2013 547",
  "Armangue, Titulaer - Dalmau, 2013": "NIH Public Access\nAuthor Manuscript\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nPublished in final edited form as:\nJ Pediatr. 2013 April ; 162(4): 850–856.e2. doi:10.1016/j.jpeds.2012.10.011.\nPediatric Anti-NMDAR encephalitis-Clinical analysis and novel\nfindings in a series of 20 patients\nThaís Armangue, MD2,4, Maarten J. Titulaer, MD, PhD2, Ignacio Málaga, MD, PhD5, Luis\nBataller, MD, PhD6, Iñigo Gabilondo, MD2, Francesc Graus, MD, PhD2, and Josep Dalmau,\nMD, PhD1,2,3,* on behalf of the Spanish anti-NMDAR Encephalitis Work Group\n1Institució Catalana de Recerca i Estudis Avançats (ICREA), Service of Neurology, Hospital\nClínic, University of Barcelona, Barcelona (Spain)\n2Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Service of Neurology, Hospital\nClínic, University of Barcelona, Barcelona (Spain)\n3Department of Neurology, University of Pennsylvania, Philadelphia, PA (USA)\n4Service of Pediatric Neurology, Hospital Materno-Infantil Vall d’Hebron, Universitat Autònoma de\nBarcelona, Barcelona (Spain)\n5Child Neurology Unit, Pediatrics Department, Hospital Universitario Central de Asturias. Oviedo\n(Spain)\n6Service of Neurology, Hospital Universitari Politècnic La Fe, Valencia (Spain)\nAbstract\nObjective—To report the clinical features of 20 pediatric patients with anti-N-methyl-D-\naspartate receptor (NMDAR) encephalitis.\nStudy design—Review of clinical data, long-term follow-up, and immunological studies\nperformed in a single center in Spain in the last 4 years.\nResults—The median age of the patients was 13 years (range, 8 months-18 years), 70% were\nfemale. In 12 patients (60%) the initial symptoms were neurologic, usually dyskinesias or\nseizures, and in the other 40% psychiatric. One month into the disease, all patients had involuntary\nmovements and alterations of behavior and speech. All patients received steroids, intravenous\nimmunoglobulin (IVIG) or plasma exchange, and 7 rituximab or cyclophosphamide. With a\nmedian follow up of 17.5 months, 85% had substantial recovery, 10% moderate or severe deficits,\nand 1 died. Three patients had previous episodes compatible with anti-NMDAR encephalitis, 2 of\nthem with additional relapses after the diagnosis of the disorder. Ovarian teratoma was identified\nin two patients, one at onset of encephalitis and the other one year later. Two novel observations\n(one patient each) include, the identification of an electroencephalographic pattern (“extreme delta\nbrush”) considered characteristic of this disorder, and the development of anti-NMDAR\nencephalitis after herpes simplex encephalitis (HSE).\n© 2012 Mosby, Inc. All rights reserved.\nAddress correspondence to: Josep Dalmau, MD, PhD, Service of Neurology, IDIBAPS-Hospital Clínic, University of Barcelona,\nCasanova, 143; Floor 5, Lab 503, Department 2 Barcelona 08036 (Spain), [Josep.dalmau@uphs.upenn.edu] Phone: +34 932 271 738.\n*A list of members of the Spanish anti-NMDAR Encephalitis Work Group is available at www.jpeds.com (Appendix 1).\nPublisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our\ncustomers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of\nthe resulting proof before it is published in its final citable form. Please note that during the production process errors may be\ndiscovered which could affect the content, and all legal disclaimers that apply to the journal pertain.\nThe authors declare no conflicts of interest.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 2\nConclusions—The initial symptoms of pediatric anti-NMDAR encephalitis vary from those of\nthe adults (more neurologic and less psychiatric in children), the development of a mono-\nsymptomatic illness is extremely rare (except in relapses), and most patients respond to treatment.\nOur study suggests a link between post-HSE choreoathetosis and anti-NMDAR encephalitis.\nKeywords\nAutoimmune encephalitis; Choreoathetosis; Herpes simplex encephalitis; Child; Extreme delta\nbrush\nSince its initial description in 20071, anti-N-methyl-D-aspartate receptor (NMDAR)\nencephalitis has been recognized as the most frequent autoimmune encephalitis in children\nafter acute demyelinating encephalomyelitis (ADEM).2 In a center focused on the etiology\nand epidemiology of encephalitis (California Encephalitis Project) the frequency of anti-\nNMDAR encephalitis surpassed that of any viral encephalitis.3 Patients develop serum and\ncerebrospinal fluid (CSF) antibodies to a restricted epitope region of the NR1 subunit of the\nNMDAR.4 In cultures of hippocampal neurons, patients’ IgG or CSF produce a substantial\ndecrease of the levels of NMDAR and NMDAR-mediated currents that it is reversible upon\nremoval of patients’ antibodies. A similar effect was obtained when antibodies were injected\nin vivo into the hippocampus of rats.5,6 In pediatrics, increased awareness of this disorder is\nlargely due to single case reports or small series7,8, with the largest experience being an\nAmerican series of 32 patients, 8 from a single Institution.9 This and subsequent studies\nsuggested that the younger the patient, the less likely a tumor would be found, and that the\ndisease onset in children may be different from that of adults.9,10 However, in those studies\nthe retrospective diagnosis of some patients and conservative treatment approach due to the\nnovelty of the disease limited the information on symptom onset, treatment, and outcome.\nTo address these issues, we report our experience with 20 pediatric patients with anti-\nNMDAR encephalitis focusing on disease presentation, spectrum of symptoms, treatment,\nand relapses. Moreover, the identification of a patient who developed the disorder one\nmonth after onset of herpes simplex encephalitis (HSE) provides an explanation for a rare\nand poorly understood complication of HSE11–13 that often presents with choreoathetosis\nand occurs without viral reactivation.\nMethods\nFrom January 2008 until February 2012 we identified 61 patients (median 22 years; 8\nmonths-76 years) with anti-NMDAR encephalitis whose serum and CSF were referred for\nantibody testing to Hospital Clinic, University of Barcelona. All patients were suspected to\nhave autoimmune encephalitis after being extensively studied by their physicians. Twenty\npatients (33%) were younger than 19 years and are the focus of this study. Analysis of serum\nand CSF for NMDAR antibodies was performed using two different tests,\nimmunohistochemistry with rodent brain tissue and a highly specific cell-based assay,\nfollowing reported criteria.14 None of the patients had antibodies to other cell surface or\nsynaptic proteins using cell-base assays for the following proteins: AMPA receptor,\nGABA(B) receptor, mGluR1, mGluR5, LGI1, Caspr2, Glycine receptor (GlyR) and\ndopamine receptor (D2). All patients were seen by the authors. Disease severity and residual\ndeficits were determined with the \"Pediatric Cerebral Performance Category Scale\" (PCPC;\nTable I; available at www.jpeds.com).15 There was not standardized protocol for ancillary\ntests; all patients underwent electroencephalography (EEG), magnetic resonance imaging\n(MRI), CSF analysis and extensive bacterial and viral studies, including in all instances\nherpes simplex virus (HSV) among others. Treatment decisions were based on the\nphysician’s discretion. Three patients have been previously reported as part of a series of\npatients with relapses of encephalitis.16\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 3\nThe study was approved by the Ethics Committee of the Hospital Clinic. Samples are\ndeposited in a collection of biological samples registered in the Biobank of Institut d’\nInvestigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona.\nResults\nThe median age of the patients was 13 years (8 months-18 years); 14 were Caucasian, 5\nHispanic, and 1 Asian. NMDAR antibodies were identified in the CSF of all patients and\nserum of 9; the serum of two patients was negative and was not available from the other\nnine. Seventy percent of the patients were female. The ratio female/ male varied according\nto age, so that 33% of patients younger than 12 years and all above this age were female.\nInitial symptom\nEleven patients (55%) developed prodromal symptoms a few days before the onset of the\ndisease, including fever (n=7), headache (6), and vomiting (4). A two year-old girl\ndeveloped anti-NMDAR encephalitis 1 week after completing treatment with acyclovir for\nHSE (Appendix 2 and Videos 1–3; available at www.jpeds.com).\nIn 12 patients (60%) the first symptom was neurologic, usually abnormal movements or\nseizures, and in the other 8 patients (40%) the first symptom was psychiatric or cognitive\ndysfunction. Neurologic presentations were more frequent in patients younger than 12 years\n(67% versus 55%) (Figure 1, A). Three patients were admitted to Psychiatric Units.\nSymptoms and diagnostic studies during the first four weeks of disease\nFigure 1, B shows the predominant symptoms that occurred within the first month of the\ndisease grouped in 9 categories. The median number of symptoms was 5.5 (range 4–8), and\nall patients developed psychiatric dysfunction, impaired speech, and abnormal movements,\nusually orofacial dyskinesias and choreoathetosis.\nThe EEG was abnormal in 18 patients (90%) and the brain MRI in 9 (45%). A list of these\nfindings is shown in Table II. One of the patients had an EEG pattern named “extreme delta\nbrush” (Figure 2; available at www.jpeds.com).17 Extreme delta brush consists of a nearly\ncontinuous combination of delta activity with superimposed fast activity, usually in the beta\nrange, in patients who are not under effects of sedation or anesthetics. This pattern\nresembles the delta brushes described in premature infants but extreme delta brush is more\nsymmetric and synchronous involving predominantly frontal regions.17 We have not been\nable to review all EEG studies performed in other patients.\nIn one patient, the MRI obtained when the patient developed HSE showed increased T2/\nFLAIR signal in opercular regions, medial temporal lobes, and posterior aspect of the basal\nganglia (Figure 3, A–D). In contrast to these rapid and irreversible viral-induced\nabnormalities, the subsequent development of anti-NMDAR encephalitis did not result in\nadditional changes to the MRI (Figure 3, E–H).\nThe initial CSF study showed lymphocytic pleocytosis in 14 (70%) patients (median 30\ncells/µL; range 5–140). Only one patient had elevated CSF protein concentration. CSF\nspecific oligoclonal bands were identified in 3 of 6 (50%) patients. One patient underwent a\nbrain biopsy that was normal.\nIn all patients the CSF polymerase chain reaction (PCR) for HSV-1 was negative. Four\npatients had specific viral or bacteriological findings including, a throat swab positive for H.\ninfluenza; a CSF PCR positive for Human Herpesvirus 6; serum IgM and IgG antibodies to\nmumps virus, and a nasopharyngeal aspirate positive for Enterovirus.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 4\nAll patients had tumor screening with MRI of the abdomen and pelvis, or abdominal or\ntesticular ultrasound. An ovarian mass suggesting a teratoma was identified in 2 patients,\nleading to unilateral oophorectomy; in one of the patients (17 year-old) pathological studies\ndemonstrated a mature teratoma, and in the other (13 year-old) a benign follicular cyst.\nTreatment\nDuring the first episode of encephalitis, 19 (95%) patients received first-line\nimmunotherapies (one patient was only treated at third relapse). All patients received at least\na short course of high-dose steroids (median 1, range 1–3 courses), followed in 13 patients\nby oral steroid tapering for a median of 12 weeks (range 3–47). In addition, 14 patients\nreceived intravenous immunoglobulin (IVIG; median 2 cycles, range 1–12) and one patient\nhad plasmapheresis. In one patient, steroids were stopped because of worsening symptoms\nof psychosis; no side effects of first line therapies occurred in the other patients.\nAt last follow up all patients had received immunotherapy: 20 had first-line therapies\n(steroids, IVIG and/or plasma exchange), and 7 (35 %) second-line therapies (rituximab\nalone or combined with cyclophosphamide) (Table II). The reasons for using second-line\ntherapies included unsatisfactory response to first-line drugs in six patients and multiple\nrelapses in one. The median number of treatments with rituximab was 4 weekly doses (range\n4–6) and the median number of cycles of cyclophosphamide was 5.5 monthly doses (range 4\n–7). Although 18 patients (90%) were treated with antiepileptic drugs, none of them\ndeveloped chronic or recurrent seizures and at the last follow-up only one continued with\nantiepileptic medication. Abnormal movements were symptomatically treated with a variety\nof medications (tetrabenazine, piracetam), none of them clearly effective.\nDisease severity and outcome\nAt the peak of the disease the median degree of disability was 4 in the PCPC scale (all\npatients had ≥ 4, and 1 died [PCPC=6]). Nine patients were admitted to Pediatric Intensive\nCare Units, two of them requiring mechanical ventilation. The median time of\nhospitalization was 56 days (13–336).\nAfter a median follow up of 17.5 months (4–149), 17 (85%) patients had substantial\nimprovement (PCPC of 1 or 2: 60% complete recovery and 25% minimal residual deficits),\n2 (10%) moderate or severe disability (PCPC of 3 or 4) and 1 died. The two patients with\nmoderate or severe disabilities (follow-up of 4 and 9 months) are still improving at the time\nof writing this manuscript.\nThe median time from symptom onset until the first sign of improvement was 40 days (7–\n276), and from the start of immunotherapy until the first sign of improvement 11.5 days (2–\n176). Full recovery was achieved in 12 patients; this occurred between 8 and 12 months\nafter symptom onset in 8 patients, and 3 and 5 months in 4 patients. For the 17 patients with\nsubstantial improvement, the last symptoms to improve in 16 patients (94%) were related to\nexecutive functions; in one patient the last symptom to improve was gait ataxia.\nThe patient who died was a 15 years old girl who presented with psychiatric symptoms\n(auditory hallucinations, memory disturbance, and anxiety) and subsequently developed\nabnormal movements, episodes of bradycardia and hypertension, and coma requiring\nmechanical ventilation and vasoactive drugs. She developed multiple organ failure and\nintestinal perforation; during surgery multiple areas of ischemia were noted in the liver and\nintestine. No tumor was identified; she was treated with intravenous steroids and IVIG\nwithout effect, and died 8 weeks after onset of encephalitis.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 5\nBefore the diagnosis of anti-NMDAR encephalitis, three patients (15%) had at least one\nepisode of encephalitis that had been classified as “encephalitis lethargica” (Table III). In\nretrospect, these episodes were likely prior episodes of anti-NMDAR encephalitis; in all\ninstances symptoms included dyskinesias, language dysfunction, and psychiatric\nmanifestations. Since the diagnosis of anti-NMDAR encephalitis, one of these three patients\nhas developed a new relapse, and another patient three relapses. In the latter patient the two\nepisodes preceding the diagnosis of anti-NMDAR encephalitis were not treated with\nimmunotherapy, episode #3 (when the diagnosis of anti-NMDAR encephalitis was made)\nand episodes # 4 and 5 were treated with first-line immunotherapy, and episode #6 with\nrituximab and cyclophosphamide followed by mycophenolate mofetil. At last follow-up, 8\nmonths after rituximab, the patient had substantial neurologic improvement without further\nrelapses (Table III).\nA 14 year old girl whose neurologic symptoms of anti-NMDAR encephalitis resolved in 8\nmonths, developed 4 months later (1 year from the diagnosis of encephalitis) acute\nabdominal pain without neurologic symptoms. A large ovarian mass was identified and\nremoved, with pathological studies demonstrating an inmature teratoma. Review of the\ntumor screening performed 1 year earlier with computed tomography, MRI, and ultrasound\nof abdomen and pelvis confirmed that no tumor was visible at the time she developed\nencephalitis.\nDiscussion\nOur study suggests that the presentation of anti-NMDAR encephalitis in children can be\ndifferent from that reported in adults. Although 60% of children presented with seizures,\nabnormal movements, and focal neurologic deficits, previous experience with large series of\npredominantly young adults demonstrated that 70% presented with psychosis and other\npsychiatric symptoms.14 In the current study, patients older than 18 years were excluded, but\na similar trend was noted comparing the symptom presentation of patients older and younger\nthan 12 years: those older than 12 presented more often with psychiatric symptoms (45%\nversus 33%). Subsequently, during the first month of the disease all patients developed\nabnormal movements, psychiatric symptoms, and language dysfunction. Similar features\nwere recently described by Titulaer et al in a series of 568 patients of all ages in which\n95.6% developed at least 3 of the groups of symptoms shown in Figure 1, and only 0.7%\nhad a monosymptomatic illness.10 In patients who develop the full syndrome, there is\nusually a gradual progression of symptoms from those mentioned above towards decrease\nlevel of consciousness, autonomic instability, and hypoventilation. Overall, these findings\nsuggest caution in accepting the diagnosis of anti-NMDAR encephalitis in\nmonosymptomatic cases or when symptoms do not fit with the expected syndrome. A\nprudent approach to these cases is re-assessment of CSF and serum for antibodies. However,\nclinical relapses can be monosymptomatic and less severe than the initial presentation16, as\noccurred in one of our patients who over a period of 3 years developed 4 episodes of isolated\nbehavioral and language dysfunction.\nThe frequency of CSF alterations in this study appears lower than in prior series (70%\nversus 91% in adults.14 This may be due to an earlier recognition of the disease resulting in\nprompt diagnosis and reduction of repeat spinal taps that may have shown alterations. The\nMRI and EEG findings are in most respects similar to those reported in adults, including in\none of the patients a unique EEG pattern (“extreme delta brush”) recently described in 30%\nof adults with anti-NMDAR encephalitis.17\nEighty-five percent of the patients had remarkable clinical improvement or full recovery.\nThe delay between treatment and first sign of improvement was 11.5 days, but in most cases\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 6\nthe recovery was achieved 8–12 months after symptom onset. It has been postulated that the\nprolonged duration of the disease and slow response to immunotherapy are due in part, to\nthe production of antibodies within the CNS as well as systemically. This is supported by\nthe almost constant detection of intrathecal synthesis of antibodies14,18,19 (identified in all 9\npatients studied here), and the demonstration of parenchymal and meningeal infiltratres of\nplasma cells, which are long-lived and difficult to eliminate.20 By abrogating systemic B-\ncells, rituximab would prevent the entry of these cells in the CNS and subsequent\ndevelopment into antibody-producing plasma cells.21 Cyclophosphamide, which can\npenetrate the blood-brain-barrier, affects T and B cells, and increases anti-inflammatory\ncytokines contributing to immunosuppression.22 In the current study, all 7 patients that\nreceived rituximab (2 with cyclophosphamide) responded to treatment without further\nrelapses, including one patient who had had 5 previous episodes. None of the patients had\nsignificant side effects of the treatment.\nAs noted in previous series and case reports7,9, most children with anti-NMDAR\nencephalitis do not have an underlying tumor. However, some patients (usually older than\n12 years) do have a teratoma, and as occur in young adults, the tumor may be detectable\nafter the patient has recovered from encephalitis, similar to one of our patients.23 The\nfrequency and duration of tumor surveillance in children is a question that needs to be\nanswered in future studies.\nA 2 year-old girl developed anti-NMDAR encephalitis four weeks after HSE. Her symptoms\nwere remarkably similar to the choreoathetosis and orofacial dyskinesias that occur in some\npatients during the first month of onset of HSE. This complication has an unclear\netiology.11–13 In these cases viral reactivation seems unlikely because CSF and brain viral\nstudies are negative, the MRI studies do not show new necrotic-hemorrhagic lesions, and\nsymptoms are refractory to acyclovir. The abnormal movements may last several months or\nyears and are refractory to antiepileptics and dopamine receptor antagonists.11 These\nobservations have suggested a post-infectious immune-mediated etiology.11–13 Taken\ntogether, the biphasic course of symptoms of our patient, along with the CSF findings\n(negative PCR HSV, positive NMDAR antibodies), no additional changes in the brain MRI,\nand lack of response to acyclovir but improvement after rituximab and cyclophosphamide,\nsuggest that some patients with “post-HSE choreoathetosis” may in fact have anti-NMDAR\nencephalitis. This link between both disorders is supported by a recent study showing IgG\nNMDAR antibodies in serum or CSF of 11% of patients with past history of HSE.24\nOur study was not prospective and did not have a uniform systematic treatment approach\n(e.g., same criteria and timing to change from first line immunotherapy to second line\nimmunotherapy, and duration of treatments). Future studies should address these issues in\nthe context of a clinical trial. In addition, studies with larger number of patients will provide\npredictor factors of the response to treatment and relapses.\nFindings from this study suggest that in children the first symptom of anti-NMDAR\nencephalitis may be different from that of the adults (more neurologic in children, more\npsychiatric in adults); the development of a monosymptomatic illness is extremely rare\n(except in relapses), and although the disease is potentially lethal, most patients respond to\nimmunotherapy. Moreover, second line immunotherapy, mostly including rituximab is often\neffective and well tolerated. A notable feature not previously reported in children is the EEG\npattern named extreme delta brush. Further studies are needed to determine the frequency of\nNMDAR antibodies in patients with “post-HSE choreoathetosis” and whether this disorder\nis in fact anti-NMDAR encephalitis.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 7\nSupplementary Material\nRefer to Web version on PubMed Central for supplementary material.\nAcknowledgments\nSupported by the National Institutes of Health (RO1NS077851 and RO1MH094741to J.D.), the National Cancer\nInstitute (RO1CA89054 to J.D.), Fundació la Marató de TV3 (to J.D.), Fondo de Investigaciones Sanitarias\n(PI11/01780 to J.D. and PS09/0193 to F.G.), a fellowship from the Dutch Cancer Society (KWF 2009-4451), and a\nMcKnight Neuroscience of Brain Disorders award (to J.D.). J.D. has received a research grant from Euroimmun,\nand receives royalties from the Editorial Board of Up-To-Date and from patents for the use of Ma2 and NMDA\nreceptor as autoantibody tests.\nWe thank physicians and family members of patients who provided clinical information. We also thank Myrna R.\nRosenfeld for the critical review of the manuscript and Bart M. Titulaer for designing and developing Figure 1.\nAbbreviations\nCSF cerebrospinal fluid\nEEG electroencephalography\nHSE herpes simplex encephalitis\nHSV herpes simplex virus\nIVIG intravenous immunoglobulin\nMRI magnetic resonance imaging\nNMDAR N-methyl-D-aspartate receptor\nPCPC Pediatric Cerebral Performance Category\nPCR polymerase chain reaction\nReference List\n1. Dalmau J, Tuzun E, Wu HY, Masjuan J, Rossi JE, Voloschin A, et al. Paraneoplastic anti-N-methyl-\nD-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007; 61:25–36.\n[PubMed: 17262855]\n2. Granerod J, Ambrose HE, Davies NW, Clewley JP, Walsh AL, Morgan D, et al. Causes of\nencephalitis and differences in their clinical presentations in England: a multicentre, population-\nbased prospective study. Lancet Infect Dis. 2010; 10:835–844. [PubMed: 20952256]\n3. Gable MS, Sheriff H, Dalmau J, Tilley DH, Glaser CA. The Frequency of Autoimmune N-Methyl-\nD-Aspartate Receptor Encephalitis Surpasses That of Individual Viral Etiologies in Young\nIndividuals Enrolled in the California Encephalitis Project. Clin Infect Dis. 2012; 54:899–904.\n[PubMed: 22281844]\n4. Gleichman AJ, Spruce LA, Dalmau J, Seeholzer SH, Lynch DR. Anti-NMDA Receptor Encephalitis\nAntibody Binding Is Dependent on Amino Acid Identity of a Small Region within the GluN1\nAmino Terminal Domain. J Neurosci. 2012; 32:11082–11094. [PubMed: 22875940]\n5. Hughes EG, Peng X, Gleichman AJ, Lai M, Zhou L, Tsou R, et al. Cellular and synaptic\nmechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010; 30:5866–5875. [PubMed:\n20427647]\n6. Mikasova L, De Rossi P, Bouchet D, Georges F, Rogemond V, Didelot A, et al. Disrupted surface\ncross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;\n135:1606–1621. [PubMed: 22544902]\n7. Luca N, Daengsuwan T, Dalmau J, Jones K, deVeber G, Kobayashi J, et al. Anti-N-methyl-D-\naspartate receptor encephalitis: a newly recognized inflammatory brain disease in children. Arthritis\nRheum. 2011; 63:2516–2522. [PubMed: 21547896]\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 8\n8. Bseikri MR, Barton JR, Kulhanjian JA, Dalmau J, Cohen RA, Glaser CA, et al. Anti-N-methyl D-\naspartate receptor encephalitis mimics viral encephalitis. Pediatr Infect Dis J. 2012; 31:202–204.\n[PubMed: 22094630]\n9. Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, et al. Anti-N-methyl-D-aspartate\nreceptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009; 66:11–18.\n[PubMed: 19670433]\n10. Titulaer MJ, McCracken L, Gabilondo I, Martinez-Hernandez E, Graus F, Balice-Gordon R, et al.\nClinical features, treatment and outcome of 500 patients with anti-NMDA receptor encephalitis\n[Meeting Abstracts 1]. Neurology. 2012; 78:PL01.001.\n11. Hargrave DR, Webb DW. Movement disorders in association with herpes simplex virus\nencephalitis in children: a review. Dev Med Child Neurol. 1998; 40:640–642. [PubMed: 9766743]\n12. De Tiège X, Rozenberg F, Des Portes V, Lobut JB, Lebon P, Ponsot G, et al. Herpes simplex\nencephalitis relapses in children: differentiation of two neurologic entities. Neurology. 2003;\n61:241–243. [PubMed: 12874408]\n13. De Tiège X, De Laet C, Mazoin N, Christophe C, Mewasingh LD, Wetzburger C, et al.\nPostinfectious immune-mediated encephalitis after pediatric herpes simplex encephalitis. Brain\nDev. 2005; 27:304–307. [PubMed: 15862196]\n14. Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, et al. Anti-NMDA-receptor\nencephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008; 7:1091–\n1098. [PubMed: 18851928]\n15. Fiser DH, Long N, Roberson PK, Hefley G, Zolten K, Brodie-Fowler M. Relationship of pediatric\noverall performance category and pediatric cerebral performance category scores at pediatric\nintensive care unit discharge with outcome measures collected at hospital discharge and 1- and 6-\nmonth follow-up assessments. Crit Care Med. 2000; 28:2616–2620. [PubMed: 10921604]\n16. Gabilondo I, Saiz A, Galan L, Gonzalez V, Jadraque R, Sabater L, et al. Analysis of relapses in\nanti-NMDAR encephalitis. Neurology. 2011; 77:996–999. [PubMed: 21865579]\n17. Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D. \"Extreme delta brush\": a\nunique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012; 79:1094–\n1100. [PubMed: 22933737]\n18. Pruss H, Dalmau J, Harms L, Holtje M, Ahnert-Hilger G, Borowski K, et al. Retrospective analysis\nof NMDA receptor antibodies in encephalitis of unknown origin. Neurology. 2010; 75:1735–1739.\n[PubMed: 21060097]\n19. Irani SR, Bera K, Waters P, Zuliani L, Maxwell S, Zandi MS, et al. N-methyl-D-aspartate antibody\nencephalitis: temporal progression of clinical and paraclinical observations in a predominantly\nnon-paraneoplastic disorder of both sexes. Brain. 2010; 133:1655–1667. [PubMed: 20511282]\n20. Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, Sangha N, Martinez-Lage M, Dalmau J.\nAnalysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis.\nNeurology. 2011; 77:589–593. [PubMed: 21795662]\n21. Martin MP, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al. Depletion of B\nlymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol. 2009; 66:1016–1020.\n[PubMed: 19667224]\n22. Elkhalifa A, Weiner H. Cyclophosphamide Treatment of MS: Current Therapeutic Approaches and\nTreatment Regimens. Int MS J. 2010; 17:12–18. [PubMed: 20663416]\n23. Iizuka T, Sakai F, Ide T, Monzen T, Yoshii S, Iigaya M, et al. Anti-NMDA receptor encephalitis in\nJapan: long-term outcome without tumor removal. Neurology. 2008; 70:504–511. [PubMed:\n17898324]\n24. Pruss H, Finke C, Holtje M, Hofmann J, Klingbeil C, Probst C, et al. NMDA receptor antibodies in\nherpes simplex encephalitis. Ann Neurol. 2012 Jul 16.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 9\nFigure 1.\nSymptoms at presentation and during the first month of the disease. A, The initial symptoms\nof each patient are shown in panel; every radial segment represents one patient. The\npercentages assist to determine the percentage of patients with a specific symptom or\ncombination of symptoms, each symptom coded with a different color. Patients > 12 years-\nold are shown in the section with white background, and those ≤ 12 in the section with grey\nbackground. Behavioral dysfunction included agitation and aggression (4 patients),\npsychosis, delusional thoughts, and hallucinations (3), nonspecific behavioral disturbance\n(3), anxiety (2), stereotyped behavior and obsessions (1), and negativism and autolytic\nthoughts (1). B, The symptoms during the first month of the disease; patients are represented\nin the same order as in A.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 10\nFigure 3.\nMRI findings in a patient who developed herpes simplex encephalitis (HSE) followed by\nanti-NMDAR encephalitis. A–D, The MRI findings during the first week of HSE. A-C,\nIncreased T2-FLAIR signal was demonstrated in the right medial temporal lobe, right insula,\nposterior basal ganglia, and bilateral opercular regions, and D, increased signal in diffusion\nweighted images (DWI) . E–H, The MRI obtained during admission for anti-NMDAR\nencephalitis, one month after HSE onset, showed no additional changes other than the\ninterval evolution of areas of encephalomalacia in opercular regions and hippocampal\natrophy.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 11\nTable II\nClinical features, diagnostic tests, treatment, and outcome\nPatient’s age <12 years 12–18 years All patients\nNumber of patients 9 11 20\nFemale 3 (33%) 11 (100%) 14 (70%)\nMedian age (range), years 3 (0,7–11) 15 (13–18) 13 (0,7–18)\nAssociated Tumor 0 2 (18%), both ovarian 2 (10%)\nteratoma\nProdomal symptoms 6 (67%) 5 (45%) 11 (55%)\nSymptom presentation* 3 (33%) 5 (45%) 8 (40%)\n- Psychiatric features 6 (67%) 6 (55%) 12 (60%)\n- Neurological\nAbnormal EEG** 8 (89%) 10 (90%) 18 (90%)\nAbnormal MRI*** 5 (55%) 4 (36%) 9 (45%)\nCSF pleocytosis 4 (44%) 10 (91%) 14 (70%)\nHospitalization, median (range) days 56 (13–90) 56 (17–336) 56 (13–336)\nPCPC maximum, median (range) 4 (4–5) 4 (4–6) 4 (4–6)\nTreatment 9 (100%) 11 (100%) 20 (100%)\n- Steroids 6 (67%) 9 (82%) 15 (75%)\n- IVIg 1 (11%) 0 1 (5%)\n- Plasma exchange 2 (22%) 3 (27%) 5 (25%)\n- Rituximab alone 1 (11%) 1 (9%) 2 (10%)\n- Rituximab combined with 2 (22%) 1 (9%) 3 (15%)\nCyclophosphamide\n- Other∞\nFollow up, median (range), months 18 (9–149) 15 (4–103) 17,5 (4–149)\nDelay of treatment from disease onset 3 (33%) 4 (36%) 7 (35%)\n>1 month 0 2 (18%) 2 (10%)\n>2 months\nFirst sign of improvement since disease onset, 20 (7–180) 46 (25–276) 40 (7–276)\nmedian (range), days\nFirst sign of improvement since 7 (2–176) 15 (2–90) 11,5 (2–176)\nimmunotherapy, median (range), days\nOutcome (PCPC score) 5 7 12 (60%)\n1: Full recovery 3 2 5 (25%)\n2: Mild disability 0 0 0\n3: Moderate disability 1 1 2 (10%)\n4: Severe disability 0 0 0\n5: Coma 0 1 1 (5%)\n6: Death\nFor patients with relapses, the information used in the table corresponds to the first episode, except treatment that includes all episodes.\n*\nSee Figure 1A for detailed information about symptom presentation.\n**\nAbnormal EEG findings included: 7 patients with generalized slowing, 6 with generalized slowing and focal epileptic activity, 3 with\nasymmetrical or focal slowing, 1 with generalized epileptiform activity, and 1 with \"extreme delta brush\"19(Figure 2, online).\n***\nBrain MRI abnormalities included: 6 patients with T2/fluid-attenuated inversion recovery (FLAIR) abnormalities in the temporal lobes (one\nwith contrast enhancement, and two with abnormal diffusion weighted images), 1 patient with minimal changes in arterial spin labeled perfusion in\ninsular regions, 1 patient with cystic lesions in the left temporal lobe with perilesional gliosis, and 1 patient with transient brain atrophy attributed\nto steroids.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 12\n∞\nOne patient received tacrolimus before the diagnosis of anti-NMDAR encephalitis for suspected Rasmussen Encephalitis. Two other patients\nreceived oral mycophenolate mofetil after completing second-line immunotherapies.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nNIH-PA\nAuthor\nManuscript\nArmangue et al. Page 13\nTable III\nClinical features of episodes of relapses\nPatient 1 Patient 2 Patient 3\nTotal number of episodes of 2 3 6\nencephalitis\nTime between episodes (months) 31 108 and 36 13, 49, 16, 5 and 12\nNumber of episodes before the 1 1 2\ndiagnosis of 13 8 18 and 19\nanti-NMDAR encephalitis Leg dystonia dyskinesias behavior/ speech disorder\n- Age (years) Full syndrome Full syndrome Full syndrome / Full syndrome\n- First symptom 4 4 4 / 4\n- Course Steroids, IVIg Steroids No treatment / No treatment\n- PCPC maximum Full recovery (PCPC Full recovery (PCPC Partial recovery; slow improvement in both\n- Immunotherapy 1) in 8 months 1) in 6 months episodes (PCPC 2)\n- Outcome\nEpisode that led to the diagnosis of 15 17 23\nanti- Speech disorder Behavior behavior and speech disorder\nNMDAR encephalitis Only speech Full syndrome behavior and speech symptoms\n- Age (years) dysfunction 4 3\n- First symptom 3 CSF 1:20, serum NA CSF 1:160, serum 1:1600\n- Course CSF 1:80, serum NA Steroids Steroids, monthly IVIg for long period of time\n- PCPC maximum Steroids Full recovery (PCPC Recovered to previous baseline,(PCPC 2, in\n- Anti-NMDAR antibodies Full recovery (PCPC 1) in 6 months less than 1 month\n- Immunotherapy 1) in 1 month\n- Response\nNumber of episodes after the 0 1 3\ndiagnosis of - 20 24; 25; 26\nanti-NMDAR encephalitis - aphasia All 3 episodes: behavioral and speech deficits\n- Age (years) - only aphasia (more\n- First symptom - 3 severe psychiatric symptoms in last episode)\n- Course - CSF 1:80, serum 3 / 3 / 4\n- PCPC maximum - 1:400 Between relapses (CSF NA, serum 1:1600)\n- Anti-NMDAR antibodies - Steroids Last episode (CSF 1:80, serum 1:3200),\n- Immunotherapy Still improving (1 After second-line drugs (CSF 1:20, serum\n- Response month of follow up) 1:1600)\nSteroids, IVIg. Last episode also: rituximab,\ncyclophosphamide and myophenolate mofetil.\nRecovery to previous baseline (PCPC, 2),\nepisodes #4 and 5 in 1 month, episode #6 in 3\nmonths.\nFollow up since first episode/ since 62/ 31 149 / 1 103 / 8\nlast\nrelapse (months)\nNA: not available.\nJ Pediatr. Author manuscript; available in PMC 2014 April 01.",
  "Pinho, 2012": "Psychiatry and Clinical Neurosciences 2012; 66: 153–156 doi:10.1111/j.1440-1819.2011.02308.x\nShort Communication\nDiversity in anti-N-methyl-D-aspartate receptor encephalitis:\nCase-based evidence\npcn_2308153..156\nJoão Pinho, MD, João Rocha, MD, Margarida Rodrigues, MD, João Pereira, MD,\nRicardo Maré, MD, Carla Ferreira, MD, Esmeralda Lourenço, MD and Pedro Beleza, MD*\nNeurology Department, Hospital de Braga, Braga, Portugal\nAntibodies against N-methyl-D-aspartate receptor presentedwithacutepsychosisfollowedaweeklater\n(NMDAR) are identified in the form of immune- by seizures, dystonia, rigidity, oromandibular dyski-\nmediated encephalitis in which typical manifesta- nesias and dysautonomia. Possible mechanisms\ntions include neuropsychiatric symptoms, seizures, responsible for the clinical manifestations of this\nabnormal movements, dysautonomia and hypoven- disease are discussed in light of recently described\ntilation.Theauthorsreporttwocasesofanti-NMDAR additional clinical and laboratory findings.\nencephalitiswithdifferentpresentationsandpatterns\nofprogression.Thefirstpatientpresentedwithstatus Key words: encephalitis, immune-mediated, N-\nepilepticusandlaterdevelopedpsychosis,pyramidal methyl-D-aspartate receptor.\nsignsanddiffuseencephalopathy.Thesecondpatient\nENCEPHALITIS WITH ANTIBODIES against arefrequent.5Patternofprogressionandspectrumof\nN-methyl-D-aspartatereceptors(anti-NMDAR)is manifestationsledtothehypothesisofimmunologi-\nanimmune-mediatedencephalitisinwhichantibod- cal response spreading against other central nervous\nies against neuronal surface antigens are found.1 In system antigens.6,7 We report two patients with anti-\n2005, patients with paraneoplastic encephalitis pre- NMDAR encephalitis and discuss underlying patho-\nsenting with psychiatric manifestations, short-term physiologic mechanisms.\nmemory loss, hypoventilation and autoantibodies\nagainstunknownneuropilantigensweredescribed.2,3\nCASE REPORTS\nSubsequently, antibodies against NMDAR-NR1/NR2\nheteromerswereidentified,andNR1wasconsidered\nCase 1\nthe crucial epitope.4,5 Patients were young adult\nwomen with typical manifestations: initial psychiat- A63-year-oldCaucasianmalewithamedicalhistory\nric symptoms followed by seizures, dyskinesias, of febrile seizures was admitted for left facial motor\nchorea, autonomic instability and central hypo- status epilepticus. Despite treatment with phenytoin\nventilation. Psychiatric manifestations are variable, andvalproate,hedevelopedconvulsivestatusepilep-\nincluding anxiety, bizarre behavior, mania, halluci- ticus, requiring intensive care unit admission. CSF\nnations,delusions,andposediagnosticdifficultiesat revealedhighprotein(0.78g/L),positiveunmatched\nonset.Lymphocyticpleocytosis,highproteinorposi- oligoclonalbands,butwasotherwisenormal,includ-\ntive oligoclonal bands in cerebrospinal fluid (CSF) ing herpes simplex virus polymerase chain reaction\n(HSV-PCR). IV acyclovir was administered for\n14days. Brain magnetic resonance imaging (day 1)\n*Correspondence:PedroBeleza,MD,NeurologyDepartment,Hospital showed multiple cortical lesions (Fig.1). On day 4,\ndeBraga,SeteFontes,SãoVictor,4701-243Braga,Portugal.\nhe had decreased consciousness, severe dysarthria\nEmail:beleza.76@gmail.com\nand dysphagia, left hemiparesis and electroencepha-\nReceived23December2010;revised12October2011;accepted4\nNovember2011. lography (EEG) showed a right temporal status\n©2012TheAuthors 153\nPsychiatryandClinicalNeurosciences©2012JapaneseSocietyofPsychiatryandNeurology\n154 J. Pinho etal. Psychiatry and Clinical Neurosciences 2012; 66: 153–156\nFigure1. Brain magnetic resonance\nimaging, fluid attenuated inversion\nrecovery – hyperintense lesions in\nright fronto-opercular, (a) right\ninsular and (b) bilateral temporal\ncortex. Absent diffusion-weighted\nimaging abnormality or contrast\nenhancement.\nepilepticus. Subsequently he developed persecutory Department,treatedwithrisperidone,diazepamand\ndelusions, and visual and auditory hallucinations aweeklaterhadageneralizedseizure.Atfirstneuro-\nwhich improved with olanzapine. During psychosis, logical evaluation she was drowsy, with no verbal\nEEG revealed moderate encephalopathy and no response, had generalized right-side predominant\nepileptiform activity. Extensive blood testing was rigidity, with catatonia cerea, dystonia of the upper\nnormal.Betweendays20and58hebecameprogres- limbs, oromandibular dyskinesias and episodes of\nsively stuporous with bilateral extensor plantars. sinustachycardiaandperipheraldesaturation.Exten-\nHigh-dose IV methylprednisolone, followed by a sivebloodtestingandurinetoxicologicalscreenwere\n5-day course of IV immunoglobulins (IgIV), led to normal. CSF showed lymphocytic pleocytosis (10\nsignificant clinical improvement. Investigation for cells/uL, 95% lymphocytes) and was otherwise\noccult tumor was negative. Recurrence of psychosis normal including HSV-PCR and oligoclonal bands.\noccurred 1month later, and examination revealed Brain magnetic resonance imaging was normal\ndysarthria, multifocal myoclonus and ataxic gait. (including T2, diffusion-weighted imaging and\nPhenytoin intoxication was found, it was replaced contrast-T1). EEG revealed left frontotemporal\nby levetiracetam and after a 5-day course of IgIV, statusepilepticus.Statusepilepticuspersisteddespite\nhe recovered rapidly and has been asymptomatic phenytoin, levetiracetam and clonazepam. Brain\nfor 3years. Anti-NMDAR NR2B analysis was per- positron emission tomography (PET) scan revealed\nformed using a Western blot technique:8 antibodies left frontotemporal and left basal ganglia hyperme-\nin serum were IgG-positive and IgM-negative; in tabolism (Fig.2). Treatment with IgIV during 5days\nCSF both IgG and IgM were negative (samples and, later, a 5-day course of IV methylprednisolone\ncollected several weeks after presentation and IV ledtoprogressiveclinicalimprovement.Atdischarge\nmethylprednisolone). shehadattentionandarithmeticdeficits,globaldys-\nphasia and normal motor exam. She scored 17 in a\nMini Mental State Examination. Investigation for\nCase 2\noccult tumor was negative, slow cognitive and lan-\nA 21-year-old previously healthy Caucasian woman guage improvement was documented as the patient\nwas admitted for acute onset of delusions, ideas of gradually recovered functional independence, with\ngrandeur, and visual and auditory hallucinations. morethan18monthsoffollowup.Immunofluores-\nRecent hallucinogenic drug ingestion was suspected. cent cell-based assay was used to determine anti-\nShe had received a booster vaccination against NMDAR NR1/NR2:6 serum and CSF collected\ntetanus 3days earlier and since then had flu-like 3weeks after admission were positive for anti-\nsymptoms. She was admitted to the Psychiatry NMDAR NR1/NR2.\n©2012TheAuthors\nPsychiatryandClinicalNeurosciences©2012JapaneseSocietyofPsychiatryandNeurology\nPsychiatry and Clinical Neurosciences 2012; 66: 153–156 Anti-NMDA receptor encephalitis 155\nof NR1 subunits (neurons, oligodendrocytes, astro-\ncytes14,15) could explain the spectrum of manifesta-\ntions, but fails to explain the temporal pattern\npreviously described. Myelin basic protein autoanti-\nbodieswereidentifiedinapatientwithanti-NMDAR\nencephalitiswholaterdevelopedtransversemyelitis,\noptic neuritis and white matter lesions.7 Evidence of\nunmatched CSF oligoclonal bands in a later stage of\nanti-NMDAR encephalitis suggests the possibility\nof spreading of immunological response to other\nepitopes,leadingtoextra-corticalmanifestations.6An\nimportantlimitationofthecurrentreportconsistsof\nthe low specificity of anti-NMDAR-NR2B technique\ndevelopedbyTakahashiandcollaborators,andpaired\nanalysis of serum and CSF from the same patients\nusingbothtechniquescouldfurtherclarifythispoint.\nACKNOWLEDGMENTS\nWe would like to thank Professor Yukitoshi Taka-\nhashi at the Shizuoka Institute of Epilepsy and Neu-\nrologicalDisorders,ProfessorAngelaVincentandDr\nIsabel Leite at the University of Oxford. The authors\nFigure2. Brain positron emission tomography scan – left have no conflicts of interests.\nfrontotemporalandleftbasalgangliahypermetabolism.\nREFERENCES\nDISCUSSION\n1. Graus F, Saiz A, Dalmau J. Antibodies and neuronal\nEarlyclinicalmanifestationsinbothpatients(convul- autoimmune disorders of the CNS. J. Neurol. 2010; 257:\nsivestatusepilepticusandpsychiatricmanifestations) 509–517.\nwere likely secondary to cortical dysfunction. Sug- 2. Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z,\ngested underlying mechanisms include direct Dalmau J. Paraneoplastic encephalitis, psychiatric symp-\ntoms, and hypoventilation in ovarian teratoma. Ann.\nneuronal damage of anti-NMDAR antibodies, cell\nNeurol.2005;58:594–604.\ndeposition of membrane attack complex, antibody-\n3. Ances BM, Vitaliani R, Dalmau J etal. Treatment-\nmediated NMDAR internalization and decreased\nresponsive limbic encephalitis identified by neuropil\nsynaptic NMDAR-mediated postsynaptic currents.9\nantibodies: MRI and PET correlates. Brain 2005; 128:\nAdditional manifestations developed in a time-\n1764–1777.\ndependentpattern:acutepsychosisandotherdeficits 4. Dalmau J, Tüzün E, Lynch DR etal. Paraneoplastic\nin the first patient were possibly secondary to wide- N-methyl-D-aspartate receptor encephalitis associated\nspreadcorticaldysfunction,whilethesecondpatient withovarianteratoma.Ann.Neurol.2007;61:25–36.\ndevelopedbasalgangliaandbrainstemsigns.Findings 5. Dalmau J, Gleichman AJ, Lynch DR etal. Anti-NMDA-\nmustbeinterpretedwithcaution.Antibodiesagainst receptorencephalitis:caseseriesandanalysisoftheeffects\nNMDAR-NR2B determined by Takahashi and col- ofantibodies.LancetNeurol.2008;7:1091–1098.\n6. Irani SR, Bera K, Waters P etal. N-methyl-D-aspartate\nlaborators’techniquewerefoundinaheterogeneous\nantibody encephalitis: temporal progression of clinical\npopulation of patients.10–12 NMDAR are transmem-\nand paraclinical observations in a predominantly non-\nbrane proteins consisting of a combination of NR1,\nparaneoplastic disorder of both sexes. Brain 2010; 133:\nNR2 (A-D) and NR3 (A-B) subunits.13 Since NR2B\n1655–1667.\nsubunits have neocortical and hippocampal expres-\n7. KruerMC,KochTK,BourdetteDNetal.NMDAreceptor\nsion,thismayexplaintheearlycorticaldysfunctionof encephalitismimickingseronegativeneuromyelitisoptica.\nanti-NMDAR encephalitis. Widespread expression Neurology2010;74:1473–1475.\n©2012TheAuthors\nPsychiatryandClinicalNeurosciences©2012JapaneseSocietyofPsychiatryandNeurology\n156 J. Pinho etal. Psychiatry and Clinical Neurosciences 2012; 66: 153–156\n8. TakahashiY,SakaguchiN,KondoNetal.Epitopeanalysis 12. Takahashi Y, Mori H, Kondo N etal. Autoanti-\nof auto-antibodies against GluR e2 in patients with bodiestoNMDAreceptorinpatientswithchronicforms\nchronic progressive epilepsia partialis continua of child- of epilepsia partialis continua. Neurology 2003; 61: 891–\nhood.Epilepsia2002;43(Suppl.9):74. 896.\n9. HughesEG,PengX,GleichmanAJetal.Cellularandsyn- 13. Cull-Candy S, Brickley S, Farrant M. NMDA receptor\naptic mechanisms of anti-NMDA receptor encephalitis. subunits:diversity,developmentanddisease.Curr.Opin.\nJ.Neurosci.2010;30:5866–5875. Neurobiol.2001;11:327–335.\n10. Takahashi Y. Epitope of autoantibodies to N-methyl-N- 14. SalterMG,FernR.NMDAreceptorsareexpressedindevel-\naspartate receptor heteromers in paraneoplastic limbic oping oligodendrocytes processes and mediate injury.\nencephalitis.Ann.Neurol.2008;64:110–111. Nature2005;438:1167–1171.\n11. TakahashiY,MoriH,FujiwaraTetal.Autoantibodiesand 15. LaloU,PankratovY,KirchhoffF,NorthRA,VerkhrastkyA.\ncell-mediated autoimmunity to NMDA-type GluRe2 in NMDA receptors mediate neuron-to-glia signaling in\npatients with Rasmussen’s encephalitis and chronic pro- mouse cortical astrocytes. J. Neurosci. 2006; 26: 2673–\ngressive epilepsia partialis continua. Epilepsia 2005; 46 2683.\n(Suppl.5):152–158.\n©2012TheAuthors\nPsychiatryandClinicalNeurosciences©2012JapaneseSocietyofPsychiatryandNeurology",
  "Wright - Vincent, 2016": "FULL-LENGTH ORIGINAL RESEARCH\nNeuronal antibodies in pediatric epilepsy: Clinical features\nand long-term outcomes of a historical cohort not treated\nwith immunotherapy\n*SukhvirWright,†AdaT.Geerts,‡CorneliaMariaJol-vanderZijde,*LeslieJacobson,\n*BethanLang,*PatrickWaters,‡MaartenJ.D.vanTol,§HansStroink,†RinzeF.Neuteboom,\n¶OebeleF.Brouwer,and*AngelaVincent\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\nSUMMARY\nObjective:Inautoimmuneencephalitistheetiologicroleofneuronalcell-surfaceanti-\nbodiesisclear;patientsdiagnosedandtreatedearlyhavebetteroutcomes.Neuronal\nantibodies have also been described in patients with pediatric epilepsy without\nencephalitis.Theaimwastoassesswhetherantibodypresencehadanyeffectonlong-\ntermoutcomesinthesepatients.\nMethods:Patients (n = 178) were recruited between 1988 and 1992 as part of the\nprospective Dutch Study of Epilepsy in Childhood; none received immunotherapy.\nHealthyage-matchedbone-marrowdonorsservedascontrols(n = 112).Allserawere\ntestedforserumN-methyl-D-aspartatereceptor(NMDAR),alphaamino-3-hydroxy-5-\nmethyl-4-isoxazolepropionicacidreceptor,leucinerichgliomainactivated1,contac-\ntinassociatedproteinlike2(CASPR2),contactin-2,glutamicaciddecarboxylase,and\nvoltagegatedpotassiumchannel(VGKC)-complexantibodiesbystandardtechniques.\nNo cerebrospinal fluid (CSF) samples were available. Results were correlated with\nclinicaldatacollectedover15 years.\nResults:Seventeenpatients(9.5%)werepositiveforVGKCcomplex(n = 3),NMDAR\n(n = 7), CASPR2 (n = 4), and contactin-2 (n = 3), compared to three (3/112; 2.6%)\nhealthy controls (VGKC complex [n = 1], NMDAR [n = 2]; p = 0.03; Fisher’s exact\nDr. Sukhvir Wright is test).Titerswererelativelylow(≤1:100forcell-surfaceantibodies),but8(47%)ofthe\napediatric neurology 17positivesamplesboundtothesurfaceoflivehippocampalneuronsconsistentwitha\nspecialist registrar potentialpathogenicantibody.Preexistingcognitiveimpairmentwasmorefrequent\nresearching in antibody-positive patients (9/17 vs. 33/161; p = 0.01). Fourteen antibody-positive\nautoimmuneepileptic patientsweretreatedwithstandardantiepilepticdrugs(AEDs);three(17%)became\nencephalopathy. intractable but this was not different from the 16 (10%) of 161 antibody-negative\npatients.In96patientswithavailablefollow-upsamplesat6and/or12 months,6of7\npositiveantibodieshaddisappearedand,conversely,antibodieshadappearedforthe\nfirsttimeinafurther7patients.\nSignificance:Neuronal antibodies were found at low levels in 9.5% of patients with\nnew-onsetpediatricepilepsybutdidnotnecessarilypersistovertime,andthedevelop-\nmentofantibodiesdenovoinlatersamplessuggeststheycouldbeduetoasecondary\nresponsetoneuronaldamageorinflammation.Moreover,astheresponsetostandard\nAcceptedFebruary17,2016;EarlyViewpublication21March2016.\n*NuffieldDepartmentofClinicalNeurosciences,JohnRadcliffeUniversityHospital,UniversityofOxford,Oxford,UnitedKingdom; †Departmentof\nPediatricNeurology,ErasmusMedicalCenter,Rotterdam,TheNetherlands; ‡DepartmentofPediatrics,LeidenUniversityMedicalCenter,Leiden,The\nNetherlands; §Departmentsof PediatricNeurologyandNeurology,CanisiusHospital,Nijmegen,The Netherlands;and ¶Departmentof Neurology,\nUniversityMedicalCenterGroningen,UniversityofGroningen,Groningen,TheNetherlands\nAddresscorrespondencetoAngelaVincent,NuffieldDepartmentofClinicalNeurosciences,JohnRadcliffeHospital,Level5/6WestWing,Oxford\nOX39DU,U.K.E-mail:angela.vincent@ndcn.ox.ac.ukand OebeleF.Brouwer,DepartmentofNeurology,AB51,UniversityMedicalCenterGroningen,\nHanzeplein1,9700RBGroningen,TheNetherlands.E-mail:o.f.brouwer@umcg.nl\n©2016TheAuthors.EpilepsiapublishedbyWileyPeriodicals,Inc.onbehalfofInternationalLeagueAgainstEpilepsy.\nThisisanopenaccessarticleunderthetermsoftheCreativeCommonsAttributionLicense,whichpermitsuse,distributionandreproductioninany\nmedium,providedtheoriginalworkisproperlycited.\n823\n824\nS.Wrightet al.\nAEDs and the long-term outcome did not differ from those of antibody-negative\npediatric patients, these findings suggest that routine neuronal antibody testing is\nunlikelytobehelpfulinpediatricepilepsy.However,thehigherincidenceofpreexist-\ning cognitive problems in the antibody-positive group, the CASPR2 and contactin-2\nantibodiesin7of17patients,andthebindingof8of17ofserumsamplestolivehip-\npocampal neurons suggest that neuronal antibodies, even if secondary, could con-\ntributetothecomorbiditiesofpediatricepilepsy.\nKEY WORDS: Autoantibodies, Pediatric epilepsy, Voltage-gated potassium channel\ncomplex,NMDAreceptor.\ntreatment improves outcome in autoimmune encephalitis,\nit is important for the clinician to be able to make\nKey Points\ninformed decisions regarding which patients to test and\nwhether the results will affect patient management and\n(cid:129)\nLowlevelsofneuronalantibodiesarepresentin~10% epilepsy outcome.13,14\nofpatientswithpediatricepilepsyatonsetbutarenot\nHerewestudiedarchivedsamplesfrompatientswhohad\nassociatedwithpoorlong-termoutcomesortreatment\nbeensampledwithinamedian69 daysfromtheirfirstpre-\nintractability\nsentationtotheneurologistandfollowedupformanyyears.\n(cid:129)\nAntibodiescan developduring thecourseofepilepsy\nNoneofthepatientsweregivenimmunotherapiesandsome\nand are not likely to be the sole cause of epilepsy in\nwere resampled at 6 and 12 months. The results were\npediatricpatients\ncomparedwithage-andsex-matchedhealthycontrols.\n(cid:129)\nHowever, if associated with clinical features sugges-\ntive of autoimmune encephalitis, this “secondary\nMethods\ninflammation” may be immunotherapy responsive as\nseeninotherantibody-mediateddiseases\nPatientcohort\nChildren (aged 1 month to 16 years) were enrolled into\nIn adults, autoantibodies to essential neuronal proteins the Dutch Study of Epilepsy in Childhood (DSEC) from\nsuch as the N-methyl-D-aspartate receptor (NMDAR) and fourparticipatingcentersinTheNetherlandsbetween1988\nthe voltage gated potassium channel (VGKC)-complex and 1992. Details of exclusion and inclusion criteria have\nantigen, leucine rich glioma inactivated 1 (leucine rich been published previously.15,16 Children with a presumed\nglioma inactivated 1 (LGI1), are now widely recognized “acutesymptomatic”etiologyfortheirepilepsy(definedas\nas an important treatable cause of encephalitis.1,2 Patients seizuresoccurringonlyduringthefirstweekaftertheonset\npresent with memory loss, confusion, and seizures in lim- of acute neurologic insult, for example, stroke, head\nbic encephalitis with predominantly LGI1 antibodies3,4 trauma,orcentralnervoussysteminfection,orconcurrently\nand neuropsychiatric features, movement, and autonomic withanacutesystemicmetabolicdisturbance,forexample,\nsymptoms in NMDAR-Ab (antibody) encephalitis.5,6 uremia, hyponatremia, or hypoglycemia, or both.17) were\nHowever, the recent characterization of faciobrachial dys- excluded.\ntonic seizures (FBDS) in patients with LGI1 antibodies Sufficient volumes of serum were available only in 178\nhas widened the phenotype to include patients presenting childrenatenrollment(outofthetotalcohortof881patients\nwith seizure predominance.7,8 Recognition of each of who were enrolled and discussed). The median period\nthese diseases is important, as they are responsive to between the first seizure and first blood sampling was\nimmunotherapies. 69 days(range0 daysto6.4 years).Alloftheserumsam-\nIn adult and pediatric patients with epilepsy or seizures pleswerestoredat(cid:1)20°Cfromcollection.Apreviousstudy\nwithout encephalitis, autoantibodies are present in approx- bytheDSECfoundnosignificantdifferencesinsex,etiol-\nimately\n9–13%.9–12\nThese patients are more likely to have ogy, or epilepsy syndrome between those children with\nbeen classified as “focal epilepsy of unknown cause” and available samples and those without.18 Follow-up serum\nshow a tendency toward standard antiepileptic drug samples from 96 patients taken at 6 months (n = 30),\n(AED) resistance.11,12 However, in these studies, follow- 12 months (n = 34), and 6 and 12 months (n = 32) after\nup was short, and immunologic treatments have been tried intake were also available for testing. In addition, 112 age\non an empirical basis at a time when the presence of an and sex-matched control samples came from age-matched\nantibody was unknown. With increasing interest in the sibling donors of bone marrow transplantations (BMTs),\npossible etiologic role of autoantibodies in epilepsy, and collectedbetween1985and1995andstoredunderthesame\nthe recognition that early diagnosis and immunotherapy conditionasthepatients’sera.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\n825\nCNSAntibodiesinPediatricEpilepsy\nEthics Statisticalanalysis\nTheDSECwasapprovedbytheethicscommitteesofall Descriptive statistics were used to summarize patient\ninvolved hospitals, and informed consent was obtained in data. Fisher’s exact test was used to compare categorical\nallcasesbeforeenrollment.15,19 data.DatawereanalyzedusingGraphPadPrism6.0.\nEpilepsyclassificationanddefinitions Results\nAt enrollment, classification of the seizures and epi-\nlepsy syndromes was made after discussion by three par- Autoantibodytesting\nticipating pediatric neurologists according to the 1989 Seventeen patients (17/178;9.5%)were positive forone\nInternational League Against Epilepsy (ILAE) criteria. antibody (VGKC complex [n = 3]; NMDAR [n = 7],\nThis was revised after 2 years and at the end of the most CASPR2 [n = 4], and contactin-2 [n = 3], compared to 3\nrecent intractability study,20 as some children proved to [2.6%] of the 112 healthy controls (VGKC complex\nhave neurologic brain-related morbidities. In view of the [n = 1],NMDAR[n = 2];p = 0.03;Fisher’sexacttest;see\nnew terminology published in the most recent reorganiza- Fig. 1, Table 2). Antibodies to LGI1, AMPAR, or GAD\ntion of the ILAE seizure and epilepsy classification, and were not identified in any patients or controls. Although\nto facilitate interpretation of the new serologic data with antibodiesbindingtothecell-surfaceantigenswerenothigh\nthe preexisting clinical data, we have provided definitions (scoring 1 at dilution 1:20 in 5 and at dilution 1:100 in 9),\nofthe terms used in Table 1. eight of these samples bound to the surface of live hip-\npocampal neurons (see Table 2), which suggests potential\nAntibodytestingofserumsamples clinicalrelevance.\nAntibodiestotheVGKCcomplexandtotheintracellular\nenzymeglutamicaciddecarboxylase(GAD)weremeasured Clinicalfeaturesofantibodypositivepatients\nby radioimmunoassays. To avoid reporting results of low The clinical and paraclinical features, treatment\nspecificity,21,22VGKC-complexantibodypositivitywasset responses, and outcomes of the antibody-positive patients\nat >400 pM and GAD positivity at >100 units/ml.11 Cell- are listed in Table 2. All three patients with VGKC com-\nbased assays (CBAs) were used to detect antibodies to the plex Abs had cognitive impairment/learning difficulties\nNMDAR, alpha amino-3-hydroxy-5-methyl-4-isoxazole- (thiswasnotpresentintheVGKCcomplexantibody-posi-\npropionic acid receptor (AMPAR), LGI1, CASPR2, and tive healthy control). The two patients (cases 1 and 2;\ncontactin-2.Thesetestswerescoredonavisualscale:0,no Table 2) with the highest titers (712, 480 pM) had focal\nbinding;1,lowbutspecificbinding;to4,strongbindingto epilepsy that was difficult to treat, needing at least three\nalltransfectedcellsbytwoindependentobserversasprevi- AEDs for seizure control initially. Although there were no\nously described3,5 and in use for routine diagnostics. All antibodies detected to the VGKC-complex-associated pro-\npositive samples were confirmed, and then tested blind by teins, LGI1 and CASPR2 in these samples, both bound to\nLW as part of a routine antibody service, with dilutions to the surface of hippocampal neurons suggesting potential\nassess the titer; the positives samples were also tested for clinicalrelevance.\nbinding to the surface of live hippocampal neurons in cul- Three of the seven NMDAR-Ab-positive patients had\nture, prepared from P0 Sprague-Dawley rat pups as learning difficulties before the onset of epilepsy (cases 6–\ndescribedpreviously.23,24 8), including one severely affected (case 7), and required\nTable 1. DefinitionsofterminologyusedfromthepreexistinghistoricalclinicaldatabaseoftheDutchStudyof\nEpilepsyinChildhood\nTerminology Definition\nIdiopathicepilepsy(IE) EpilepticsyndromeswithparticularclinicalcharacteristicsandspecificEEGfindings.Unknownoriginbutpresumed\ngeneticetiology\nRemotesymptomatic Epilepsiesconsideredtheconsequenceofaknownorsuspecteddisorderofthecentralnervoussystemresultingina\nepilepsy(RSE) staticencephalopathy.Allchildrenwithmentalretardation(MR)withepilepsyofunknowncausewereclassifiedasRSE\nCryptogenicepilepsy(CE) EpilepsiesofunknownoriginthatdonotconformtothecriteriaforIEorRSE\nTerminalremission Intervalbetweentheverylastseizureandtheendoffollow-up\nFastresponseto 6Monthsofremissionstartingwithin2monthsafterinitiationofAED\nmedication\nIntractability Noremissionexceeding3months(atleastoneseizureper3months)duringaminimumperiodof1yearofobservation\ndespiteadequatetreatment.16 (Artsetal).Earlyonsetintractability:onsetofintractabilitywithinthefirst5yearsof\nfollow-up.Lateonsetintractability:onsetafterthefirst5yearsoffollow-up\nEEG,electroencephalogram;AED,antiepilepticdrug.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\n826\nS.Wrightet al.\nD F H\nA\nB\nE G I\nC\nFigure 1.\nAutoantibodytestingresultsoftheepilepsyandhealthycontrolcohorts.ThetransfectedCASPR2-EGFPtaggedtransfectedHEKcells\n(green)areshown(A).Serumfrompatient16bindstothesurfaceoftheCASPR2transfectedcells,seenwithanti-humanIgGlabelling\n(red,B).Thetransfectedcells(A)andanti-humanimmunoglobulin(IgG)–labelledcells(B)colocalizeindicatingapositiveresultforthis\npatient(C).ThescatterdiagramsshowthetitersandCBAscoresofpositivetestsforeachantigentestedattheonsetofepilepsycom-\nparedwithhealthycontrols;VGKCcomplex(D),NMDAR(E),CASPR2(F),andcontactin-2(G).Thereddashedlineindicatestheposi-\ntivecut-offusedforeachassay.Theserumsampleshighlightedbygreendotswerepositiveonsurfacehippocampalstaininginvitro.\nWhenavailable,follow-upsamplesweretested;fouroffiveNMDAR-AbpositivepatientsandbothVGKC-complexantibody-positive\npatientswerenegativeateither6or12 monthsafterintake(H,I).Patient4showedaninitialreductioninantibodylevelsthenincrease\novertime.Thesefluctuatingantibodylevelsdidnotcorrelatewithdevelopmentalregressionorseizureactivity.\nEpilepsia ILAE\nAEDs until the end of follow-up. Three others (cases 4, 5, patients with structural brain abnormalities, mild autism,\nand 9) had childhood absence epilepsy with 3-Hz general- and severe global development delay.\nized spike-wave discharge on electroencephalography At5-yearfollow-up,65%(11/17)ofpatientsintheanti-\n(EEG).Threepatientswerepositiveforcontactin-2antibod- body-positive and 78% (125/161) in the antibody negative\nies (cases 11–13); two were known to be on the autistic group had been seizure-free for >12 months (not signifi-\nspectrum and one had pharmacoresistant benign epilepsy cant).Atfinalcontact,57%(8/14)oftheantibody-positive\nwithcentrotemporalspikes(BECTS)requiringthreeAEDs patients were taking AEDs compared to 31% (44/140) of\nforseizurecontrol.FourpatientswerepositiveforCASPR2 antibody-negativepatients(p = 0.07,Table 3),buttherate\nantibodies;two(cases16,17)hadfocalepilepsywithperi- of intractability was not different between the two groups\nodsofresistancetoAEDs. (p = 0.18,Fisher’sexacttest).\nComparisonofclinicalfeaturesandlong-termoutcomes Testingoffollow-upsamples\nbetweenantibody-positiveandantibody-negative Ofthe 17patients whowereantibody positiveatintake,\npatients furthersamplesat6and12 monthswereavailableforanti-\nThere were no differences in the sex distribution or age body testing in 7 (Fig. 1H,I). Changes in these short-term\nat onset of epilepsy between antibody-positive and anti- antibodylevels(Fig. 1H,I)didnotcorrelatewithchangesin\nbody-negative patients. Seizure semiology and frequency seizure frequency or cognitive development (Table 2).\nalso showed no long-term difference, and computed Moreover,7(7.7%)of89serafrompatientswhohadbeen\ntomography (CT) and EEG findings were comparable antibody negative (n = 161) were found to be positive at\n(Table 3). Overall, however, there was a significantly follow-up (NMDAR-Abs [n = 3], CASPR2-Abs [n = 2],\nhigher rate of cognitive impairment/developmental delay CASPR2- and NMDAR-Abs [n = 1], and contactin-2-Abs\nin the antibody-positive patient group (9/17 vs. 33/161; [n = 1]). Two of these patients became intractable in the\np = 0.01). These featureswere all present before the onset long-term(cases27and64).Theantibodiesandclinicalfea-\nof epilepsy (and hence antibody testing), and included turesofthesepatientsarelistedinTable S1.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\nstneitapyspelipeevitisop-ydobitnafosemoctuomret-gnoldna,serutaeflacinilcarapdna,lacinilc,cihpargomeD\n.2\nelbaT\neruzies/esruocyspelipE\ngnimit/.onesaC\nraey5fodnetaepyt\ntsrfiyrotsihtnemtaerT\nmorf(elpmasfo\nytivitisopbA\nemoctuo/pu-wollof\nta/sraey5\ndetaicossA\n/yspelipefoepyT\neruzieS\n,yspelipefotesno\n)sretit/Mp(\n)sraey,RT(\n)sraey,UF(pu-wolloffodne\nserutaeflacinilc\nygoloite\ntesnotaepyt\nxesdnaegA\n)syad\na)Mp217(CKGV\n,SPSesruocgnivorpmI\nffo/esnopsertsafon:SDEA4\naigelpimehthgiR\ndetalernoitazilacoL\nSPC\nF4\n)33(1\nshtnom21taMp252\nseruziesraelcnu,ES\n)6.41(UFlanfitaDEA\nseitlucfifidgninraeL\netomer/citamotpmys\n2.01=RT\ncitamotpmys\na)Mp084(CKGV\nesruocrooP\nno/esnopsertsafon:sDEA3\n,noitadraterlatneM\ndetaler-noitazilacoL\nCT\nM7.1\n)0(2\nshtnom21taMp52\nraelcnu,SPC,SPS,CT\n)7.41(tcatnoclanfitaDEA\nevissergorpton\ncinegotpyrc/citamotpmys\n,raey1<RTseruzies\nelbatcartni\n)Mp414(CKGV\n,CTesruocgnivorpmI\nDEAnoton;sDEAoN\nlatnempoleveddliM\n/cihtapoididezilareneG\nCT\nF4.7\n)333,2(3\nseruziesraelcnu\n)3.51(tcatnoclanfita\nyaled\ncihtapoidi\n5.1=RT\n)001ni1(RADMN\nsecnesbaesruocdooG\nffo/esnopsertsaf:sDEA2\n–\ncihtapoididezilareneG\nsecnesbA\nM4.7\n)563(4\nshtnom21ta02ni1\n6.51=RT\n)7.51(tcatnoclanfitaDEA\necnesbadoohdlihc cihtapoidi/yspelipe\n)001ni1(RADMN\nesruocgnivorpmI\ndab(esnopseron:sDEA2\n–\ncihtapoididezilareneG\nrotomroniM\nF5.1\n)601(5\ntaevitageN\nsecnesbadnarotomroniM\nDEAno/)ecnailpmoc\necnesbadoohdlihc\nsecnesbadna\nshtnom21\n7.1=RT\n)5.31(tcatnoclanfita\ncihtapoidi/yspelipe\n)02ni1(RADMN\nesruocdooG\nno/esnopsertsaf:DEA1\n)DL(seitlucfifidgninraeldliM\ncihtapoididezilareneG\nCT\nF6.21\n)4(6\ntaevitageN\nCT\n)1.31(tcatnoclanfitaDEA\nloohcsralugerdednetta–\n/ytivitisnesotohphtiw\nshtnom21\n1.31=RT\ncitamotpmysetomer\na)02ni1(RADMN\nseruziesllamsraelcnu,ES\nno/esnopsertsafon:sDEA2\n05<QI,seitlucfifidgninraeL\ndetalernoitazilacoL\nES\nM21\n)0(7\n1=RT\nsraey4.1deid(htaedtaDEA\nsiseraparteT\netomer/citamotpmys\n)tnemllorneretfa\ncitamotpmys\na)02ni1(RADMN\nesruocgnitaroireteD\nno/esnopsertsafon:sDEA2\nyaledlabolgdliM\n-xonneLdezilareneG\nseruziescinotA\nF6.3\n)11(8\ntaevitageN\nCT,seruziescinotA\n)7.21(UFlanfitaDEA\n/emordnystuatsaG\nshtnom6\n5.0=RT\ncitamotpmysetomer\na)02ni1(RADMN\nsecnesbAesruocdooG\nffo/esnopsertsaf:DEA1\n–\ncihtapoidi/EAC\nsecnesbA\nF6.6\n)98(9\ntaevitageN\n8.41=RT\n)8.41(UFlanfitaDEA\nshtnom21\n)02ni1(RADMN\npu-wollofottsoL\n)2(UFlanfitaDEAffo/DEAoN\n–\ncihtapoidi/EGI\nCT\nF5.51\n)0(01\nsraey2retfa\nCT\n2=RT\n2-nitcatnoC\nesruocdooG\nffo/esnopsertsaf:DEA1\n,seitlucfifidgninraeldliM\ndetalernoitazilacoL\nES\nM1.4\n)64(11\na)001ni1(\nES\n)9.51(UFlanfitaDEA\nsredrosidmurtcepsmsitua\nSR/citamotpmys\n1.21RT\nRMgnidulcni\n2-nitcatnoC\nesruocgnivorpmI\nno/esnopsertsaf:DEA1\n,noitadraterlatnemlabolG\ncitamotpmysetomeR\nseruziesraelcnU\nM2.4\n)421(21\n)001ni1(\ntesnolacofhtiwCT\n)5(UFlanfitaDEA\nsmelborplausiv,yticitsaps\nRMgnidulcni\n2>RT\n2-nitcatnoC\nffo/esnopsertsafon:DEA3\n–\ncihtapoidi/STCEB\ncitatsa,cinotA\nF8.8\n)172(31\n)001ni1(\n)5(UFlanfitaDEA\ndeunitnoC\n827\nCNSAntibodiesinPediatricEpilepsy\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\n.deunitnoC\n.2\nelbaT\neruzies/esruocyspelipE\ngnimit/.onesaC\nraey5fodnetaepyt\ntsrfiyrotsihtnemtaerT\nmorf(elpmasfo\nytivitisopbA\nemoctuo/pu-wollof\nta/sraey5\ndetaicossA\n/yspelipefoepyT\neruzieS\n,yspelipefotesno\n)sretit/Mp(\n)sraey,RT(\n)sraey,UF(pu-wolloffodne\nserutaeflacinilc\nygoloite\ntesnotaepyt\nxesdnaegA\n)syad\nesruocgnivorpmI\nnoitazilareneghtiwSPS\n2>RT\na)001ni1(2RPSAC\nesruocdooG\nDEAdesureveN\n–\nlaitrapngineB\nSPS\nM5.21\n)13(41\nnoitazilareneghtiwSPS\ncihtapoidi/yspelipe\n5>RT\na)001ni1(2RPSAC\nesruocdooG\non/esnopsertsaf:DEA1\n–\ncihtapoidi/EGI\nSCT\nM9.8\n)94(51\nSCT\n)41(UFlanfitaDEA\n5>RT\n)001ni1(2RPSAC\nelbatcartni,esruocrooP\n,esnopsertsafon:DEA3\n–\ndetalernoitazilacoL\nyradnoceshtiwSP\nM5.01\n)1(61\nneghtiwSPderetsulC\ntaDEAno/yparehtylop\ncinegotpyrc/cinegotpyrc\nnoitazilareneg\nnoitazilatipsohotgnidael\n)3.31(UFlanfi\n1.0<RT\n)001ni1>(2RPSAC\n.esruocgnivorpmI\nno/esnopsertsafon:DEA4\nnoitadraterlatnemereveS\ndezilarenegyradnoceS\n,cinolcoym,SPC\nM6.0\n)031(71\n–sraey5taelbatcartnI\n)5.61(UFlanfitaDEA\nUFgnirudseruzieselirbeF\ncinotahtiwlacofitlum\ncinota\nSCT.ecnailpmocdab\nlacipytadna\n5>RT\n/seruziesecnesba\nRMgnidulcniSR\n-wollof,UF;yhpargolahpecneortcele,GEE;yhpargomotdetupmoc,TC;seruzieslaitrapxelpmoc,SPC;yspelipeecnesbadoohdlihc,EAC;sekipslaropmetortnechtiwyspelipengineb,STCEB;gurdcitpelipeitna,DEA -imret,RT;eruziescinolc–cinot,SCT;cinolc–cinot,CT;egrahcsidevaw-ekips,DWS;seruzieslaitrapelpmis,SPS;citamotpmysetomer,SR;eruzieslaitrap,SP;skrejcinolcoym,JM;yspelipedezilarenegcihtapoidi,EGI;pu\n.citpelipesutats,ES;noissimerlan\n.ortivnisnoruenlapmacoppihfoecafrusehtnogniniatsmuresevitisoPa\n828\nS.Wrightet al.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\n829\nCNSAntibodiesinPediatricEpilepsy\nTable 3. Comparisonofclinicalfeaturesandoutcomesofnewonsetepilepsyantibodypositiveandnegativepatients\nCharacteristic Antibodypositive(n=17) Antibodynegative(n=161) p-Value\nSex M:F–9:8 M:F–72:89\nMedianageofpresentation 5.7years(range0.9–15.5) 6.2(range0.2–15.8)\nTypeofepilepsyatenrollment Generalized 9(53%) Generalized 75(47%) 0.8\nFocal 6(35%) Focal 82(51%) 0.3\nOther 2(12%) Other 4(2%) 0.1\nFrequencyofseizures 1–3 6(35%) 1–3 71(44%) 0.6\nwithinfirst6months 4–25 4(24%) 4–25 34(21%) 0.8\nUncountable 7(41%) Uncountable 56(35%) 0.6\nEtiologyatonset Idiopathic 8(47%) Idiopathic 87(54%) 0.6\nRSinclMR 7(41%) RSinclMR 43(27%) 0.3\nCryptogenic 2(12%) Cryptogenic 31(19%) 0.7\nPreexistingneurologic 3(17.6%) 17(10.6%) 0.4\nsigns/abnormal\nneurologicexamination\nMentalretardation/cognitive 9(52.9%) 33(20.4%) 0.01a\nimpairmentatintake\nHistoryoffebrileseizures 1(5.8%) 32(19.8%) 0.2\nbeforeorafterintake\nFamilyhistory 2(11.7%) 20(12.4%) 1\nStatusepilepticusas 2(11.7%) 9(5.6%) 0.2\npresentingfeature\nAbnormalEEGatintake 14(82%) 126(78%) 1\nCTatintake Normal 8(47%) Normal 85(53%) 0.8\nAbnormal 4(24%) Abnormal 29(18%) 0.5\nNotdone 5(29%) Notdone 48(30%) 1\nPolytherapyduringFU, 4/14(28.5%) 22/143(15.4%) 0.3\nrange(2–16years)\nOnAEDatfinalcontact, 8/14(57%) 44/143(30.7%) 0.07\nrange(2–16years)\nIntractableatlastcontact 3(2withlateonset)(17.6%) 16(8withlateonset)(9.9%) 0.4\nAED,antiepilepticdrug;MR,mentalretardation;RS,remotesymptomatic.\naAnalyzedbyFisher’sexacttest.\nDiscussion proteinsthatarelinkedtogeneticformsofepilepsyorneu-\nrodevelopmental disorders, is an intriguing finding that\nAutoantibodies to neuronal surface antigens have been deservesfurtherstudy.\nreported in adults and children with epilepsy and could Thefrequencyofantibodypositivityinthisstudycohort\nindicate an immune basis with obvious management (9.5%comparedwith2.6%incontrols)wassimilartothat\nimplications.11–13 However, these studies have been com- publishedpreviouslyforbothadultandpediatricepilepsies\nplicated by some use of immunotherapies, and long-term (10–16% in patients and <5% in controls). Patients with\ntreatment and outcome data of untreated antibody-positive acutesymptomaticepilepsyhadbeenexcludedand,impor-\npatientshavenotbeenreported.Wewereabletotestalarge, tantly,thepatientsdidnothaveanyassociatedclinicalfea-\nhistoricalcohortofpatientswithpediatricepilepsyforneu- tures of encephalitis (e.g., confusion, memory loss) at the\nronalsurfaceantibodiesandrelatethefindingstotheirepi- timeofsampling,andnonehadreceivedimmunotherapies.\nlepsy course over time. The frequency of antibodies were\nAllcell-basedassay–positivesamplesobtainedatonsetcon-\nsimilar to those reported previously, but were mainly tran- tainedrelativelylowantibodytiters,8/14boundtothesur-\nsient and occurred sporadically; despite lack of face of hippocampal neurons in vitro, and most available\nimmunotherapies,mostautoantibodypositivepatientshada follow-up samples had normalized by 12 months, whereas\ngoodoutcomeandrespondedtostandardAEDs.Theresults antibodies had appeared de novo in seven patients.\nsuggest,therefore,thatroutineantibodytestingisnotneces- Although samples were taken as close to seizure onset as\nsarily helpful in children with epilepsy and should be possible, the median sampling time of 69 days means that\nrestrictedtothosewithevidenceofneuroinflammatorydis- someweretakenaftertheestablishmentofepilepsyandthe\nease. Nevertheless, the number of patients (n = 11) who results could, therefore, reflect the consequences of the\nhad or developed antibodies to CASPR2 or contactin-2, epileptogenicprocessratherthanbeingtheprimarycause.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\n830\nS.Wrightet al.\nIndeed, low-titer antibodies to VGKC complex or Acknowledgments\nNMDARshavebeenfoundinsomepatientswithoutautoim-\nmune neurologic diseases,21,25 and the fact that NMDARs\nS.WrightwasfundedbyanOxfordUniversity/WellcomeTrustClinical\nwere found in some children with generalized absence epi- ResearchTrainingFellowship.WorkintheOxfordlaboratoryissupported\nlepsy makes them unlikely to be pathogenic in these cases. bytheNIHROxfordBiomedicalResearchCentre.\nHowever, the binding to the surface of live hippocampal\nDisclosure of Conflict of\nneurons,presentin8of17sera,suggestedthattheantibodies\ncould be pathogenic if they reach the brain parenchyma. In Interest\nthe remaining patients whose antibodiesdid not bindtothe\nneuronsortoLGI1,theVGKC-complexAbsmaybemark- AV,BL,PW,andtheNuffieldDepartmentofClinicalNeurosciencesin\nOxfordreceiveroyaltiesandpaymentsforantibodyassays.Theremaining\nersforaneuroinflammatoryprocessratherthanforananti-\nauthorshavenoconflictsofinterest.Weconfirmthatwehavereadthe\nbody-mediated syndrome, as recently discussed.12,22,26 Journal’spositiononissuesinvolvedinethicalpublicationandaffirmthat\nSurprisingly, therefore,antibodiestoCASPR2orcontactin- thisreportisconsistentwiththoseguidelines.\n2,theotherknowncomponentsoftheVGKCcomplex,were\nReferences\nfound in11 pediatric epilepsypatients(seven atonset,four\nduring follow-up), but not in controls. This finding draws\nattention tothe growing areaofshared targets and partially 1. IraniSR,GelfandJM,Al-DiwaniA,etal.Cell-surfacecentralnervous\nsystem autoantibodies: clinical relevance and emerging paradigms.\noverlappingphenotypesbetweenantibodyandgeneticforms AnnNeurol2014;76:168–184.\nofpediatricneurologicdisease.12,27\n2. LeypoldtF,ArmangueT,DalmauJ.Autoimmuneencephalopathies.\nDespite the limitations of a retrospective study with no\nAnnNYAcadSci2014;1338:94–114.\n3. Irani SR, Alexander S, Waters P, etal. Antibodies to Kv1 potas-\naccesstocerebrospinalfluid(CSF)samplesfortesting,this\nsium channel-complex proteins leucine-rich, glioma inactivated 1\nobservationalstudyenabledustoinvestigatethelong-term protein and contactin-associated protein-2 in limbic encephalitis.\noutcome of antibody positivity in a cohort of patients with Morvan’s syndrome and acquired neuromyotonia. Brain 2010;133:\n2734–2748.\npediatricepilepsyinwhomimmunotherapieswerenotused.\n4. LaiM,HuijbersMG,LancasterE,etal.InvestigationofLGI1asthe\nBecause most patients responded well to standard AEDs antigeninlimbicencephalitispreviouslyattributedtopotassiumchan-\nandhadagoodlong-termoutcome,thisquestionsthepatho-\nnels:acaseseries.LancetNeurol2010;9:776–785.\nlogicrelevanceoftheselowpositiveantibodiesparticularly\n5. Irani SR, Bera K, Waters P, etal. N-methyl-D-aspartate antibody\nencephalitis:temporalprogressionofclinicalandparaclinicalobserva-\nas, in most cases, the antibodies were transient and disap- tions in a predominantly non-paraneoplastic disorder of both sexes.\npearedby6or12 monthsfollow-up.Itseemslikelythatthe\nBrain2010;133:1655–1667.\n6. Dalmau J, Gleichman AJ, Hughes EG, etal. Anti-NMDA-receptor\nantibodiesmayhavebeenasecondaryresponsetoneuronal\nencephalitis:caseseriesandanalysisoftheeffectsofantibodies.Lan-\ndamagebeforetheseizurescameundercontrol,ratherthan cetNeurol2008;7:1091–1098.\nthe primary pathogenic agent. Nevertheless, this is not 7. IraniSR,MichellAW,LangB,etal.Faciobrachialdystonicseizures\nprecedeLgi1antibodylimbicencephalitis.AnnNeurol2011;69:892–\nunprecedented and the development of high levels of\n900.\nNMDAR-Abs following herpes simplex virus encephalitis 8. IraniSR,StaggCJ,SchottJM,etal.Faciobrachialdystonicseizures:\n(HSVE)withneurologicdeterioration(movementdisorder, theinfluenceofimmunotherapyonseizurecontrolandpreventionof\ncognitiveimpairmentinabroadeningphenotype.Brain2013;136:3151–\nbehavioralchange,seizures,andworseningofbrainlesions\n3162.\nonmagneticresonanceimaging[MRI]),inpatientswithno 9. MajoieHJ,deBaetsM,RenierW,etal.Antibodiestovoltage-gated\nevidence of reactivation ofthe herpessimplexvirus,28and potassium and calcium channels in epilepsy. Epilepsy Res\ntheir response to immunotherapy,29 demonstrates that this\n2006;71:135–141.\n10. McKnightK,JiangY,HartY,etal.Serumantibodiesinepilepsyand\n“secondary inflammation” may still be pathogenic and seizure-associateddisorders.Neurology2005;65:1730–1736.\nrespondtoimmunotherapy. 11. BrennerT,SillsGJ,HartY,etal.Prevalenceofneurologicautoanti-\nFrom these results, a “mono-immunogenic” cause for b si o a d 2 ie 0 s 1 i 3 n ;5 c 4 o : h 1 o 0 r 2 ts 8– o 1 f 0 p 3 at 5 i . entswithnewandestablishedepilepsy.Epilep-\npediatric epilepsy is unlikely, with neuronal antibodies 12. SuleimanJ,WrightS,GillD,etal.Autoantibodiestoneuronalanti-\nformingonlypartofthecomplexetiologicframeworkthat gensin childrenwithnew-onsetseizuresclassifiedaccordingto the\nrevised ILAE organization of seizures and epilepsies. Epilepsia\nincludesinflammation,structuralabnormalities,andgenetic 2013;54:2091–2100.\nsusceptibility;similardiversefactorsmayexplainthefinal 13. QuekAM,BrittonJW,McKeonA,etal.Autoimmuneepilepsy:clini-\noutcomes.Futurestudiesinvestigatingpredictivebiomark- cal characteristics and response to immunotherapy. Arch Neurol\n2012;69:582–593.\ners in epilepsy need to include all these factors to indicate\n14. BienCG.Valueofautoantibodiesforpredictionoftreatmentresponse\nthe likely progression of disease and treatment response. in patients with autoimmune epilepsy: review of the literature and\nThis would be invaluable to both patients and clinicians,30 suggestions for clinical management. Epilepsia 2013;54(Suppl. 2):\n48–55.\nparticularly in drug-resistant refractory cases with associ-\n15. ArtsWF,GeertsAT,BrouwerOF,etal.Theearlyprognosisofepi-\nated comorbidities, commonly seen in pediatric epilepsy. lepsyinchildhood:thepredictionofapooroutcome.TheDutchstudy\nThisgroupofpatientsmaybenefitmostfromfurtherstudies\nofepilepsyinchildhood.Epilepsia1999;40:726–734.\n16. ArtsWF,BrouwerOF,PetersAC,etal.Courseandprognosisofchild-\ninto antibody presence, antigenic targets, relevance, and\nhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in\nimmunotherapytreatmenttrials. childhood.Brain2004;127:1774–1784.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356\n831\nCNSAntibodiesinPediatricEpilepsy\n17. HauserWA,AndersonVE,LoewensonRB,McRobertsSM.Seizure 26. Hacohen Y, Wright S, Waters P, etal. Paediatric autoimmune\nrecurrenceafterafirstunprovokedseizure.NEnglJMed1982;307: encephalopathies:clinicalfeatures,laboratoryinvestigationsandout-\n522–528. comesinpatientswithorwithoutantibodiestoknowncentralnervous\n18. Callenbach PM, Jol-Van Der Zijde CM, Geerts AT, etal. system autoantigens. J Neurol Neurosurg Psychiatry 2013;84:\nImmunoglobulinsinchildrenwithepilepsy:theDutchStudyofEpi- 748–755.\nlepsyinChildhood.ClinExpImmunol2003;132:144–151. 27. RamanathanS,WongCH,RahmanZ,etal.Myoclonicstatusepilepti-\n19. Stroink H, Brouwer OF, Arts WF, etal. The first unprovoked, cus as a presentation of caspr2 antibody-associated autoimmune\nuntreatedseizureinchildhood:ahospitalbasedstudyoftheaccuracy encephalitis.EpilepticDisord2014;16:477–481.\nofthediagnosis,rateofrecurrence,andlongtermoutcomeafterrecur- 28. HacohenY,DeivaK,PettingillP,etal.N-methyl-D-aspartatereceptor\nrence. Dutch study of epilepsy in childhood. J Neurol Neurosurg antibodies in post-herpes simplex virus encephalitis neurological\nPsychiatry1998;64:595–600. relapse.MovDisord2014;29:90–96.\n20. GeertsA,BrouwerO,StroinkH,etal.Onsetofintractabilityandits 29. MohammadSS,SinclairK,PillaiS,etal.Herpessimplexencephalitis\ncourseovertime:theDutchstudyofepilepsyinchildhood.Epilepsia relapsewithchoreaisassociatedwithautoantibodiestoN-Methyl-D-\n2012;53:741–751. aspartatereceptorordopamine-2receptor.MovDisord2014;29:117–\n21. PatersonRW,ZandiMS,ArmstrongR,etal.Clinicalrelevanceofpos- 122.\nitive voltage-gated potassium channel (VGKC)-complex antibodies: 30. Hegde M, Lowenstein DH. The search for circulating epilepsy\nexperiencefromatertiaryreferralcentre.JNeurolNeurosurgPsychia- biomarkers.BiomarkMed2014;8:413–427.\ntry2014;85:625–630.\n22. HacohenY,Singh R, Rossi M, etal. Clinical relevanceofvoltage-\nSupporting Information\ngated potassium channel-complex antibodies in children. Neurology\n2015;85:967–975.\n23. BeaudoinGMIII,LeeSH,SinghD,etal.Culturingpyramidalneurons Additional Supporting Information may be found in the\nfromtheearlypostnatalmousehippocampusandcortex.NatProtoc\nonlineversionofthisarticle:\n2012;7:1741–1754.\n24. Kaech S, Banker G. Culturing hippocampal neurons. Nat Protoc Table S1. Clinical features of latent antibody-positive\n2006;1:2406–2415. epilepsypatients.\n25. Zandi MS, Paterson RW, Ellul MA, etal. Clinical relevance of\nserum antibodies to extracellular N-methyl-D-aspartate receptor\nepitopes.JNeurolNeurosurgPsychiatry2015;86:708–713.\nEpilepsia,57(5):823–831,2016\ndoi:10.1111/epi.13356",
  "Day, 2011": "JGIM\nClinical Vignettes\nAnti-NMDA-Receptor Encephalitis: Case Report and Literature\nReview of an Under-Recognized Condition\nGregory S. Day, MD, MSc1,3, Sasha M. High, MD2,3, Bianca Cot, MD2,3,\nand David F. Tang-Wai, MDCM, FRCPC1,3\n1DepartmentofMedicine,DivisionofNeurology(UniversityofToronto,Toronto,Ontario,Canada;2DepartmentofMedicine,DivisionofInternal\nMedicine(UniversityofToronto,Toronto,Ontario,Canada;3UniversityHealthNetwork-MountSinaiHospital,Toronto,Ontario,Canada\nAnti-N-methyl-D-aspartate receptor (anti-NMDA-R) en- Resultsofconventionalinvestigationsincludingexamination\ncephalitisisanimmune-mediatedsyndromethatremains ofcerebrospinalfluid(CSF),brainimagingandelectroencepha-\nunder-recognizeddespiteagrowingbodyofliterature.This logram (EEG) are non-specific. Lymphocytic pleocytosis, oligo-\nsyndrome has been predominantly described in young clonal banding, increased CSF protein, hyperintensity on T2\nfemales with a constellation of symptoms, including magneticresonanceimaging(MRI),decreaseduptakeinhippo-\npersonality changes, autonomic dysfunction and neuro- campalstructuresonfunctionalMRIandepileptiformactivityon\nlogic decompensation. It is commonly associated with\nEEGhavebeendescribed1–3.Thelackofspecificlaboratoryand\nmatureovarianteratomas.Wedescribetheclassicpresen- radiologicfindingsexplainwhythissyndromewasnotdescribed\ntation of anti-NMDA-R encephalitis in three dramatically until2007,withthemajorityofpreviouscaseslikelydiagnosed\ndifferent patients: Case A, a young woman with ovarian asviralencephalitis.\nteratoma; Case B, the eldest case reported to date; and This case series describes the classic presentation of anti-\nCaseC,ayoungmalewithnoidentifiabletumor.Wereview NMDA-Rencephalitisinthreediversepatients.Putativepatho-\nthe literature summarizing the differential diagnosis, physiology,diagnosisandmanagementofthisunder-recognized\ninvestigativeapproach,treatmentoptionsandchallenges syndromearediscussedthroughliteraturereview.Havingread\ninherent to this disorder. We advocate good supportive thesevignettestheclinicianshouldrecognizewhentoconsider\ncare,involvementofmultiplehealthdisciplinesanduseof anti-NMDA-R encephalitis in the differential diagnosis of a\nimmune-modulating therapies in patient management. patientwithsuspectedviralencephalitis.\nThesecasesunderscoretheneedforincreasedawareness\nand high diagnostic suspicion when approaching the\nCase A\npatientwithsuspectedviralencephalitis.\nA 21-year-old previously healthy woman was brought to a\nKEYWORDS:encephalitis;NMDA-receptor;teratoma;autoimmune.\nJGenInternMed26(7):811–6 communityhospitalwithconfusion,agitation,auditoryhallu-\nDOI:10.1007/s11606-011-1641-9 cinations and suicidal ideation. She was febrile without focal\n©SocietyofGeneralInternalMedicine2011 neurologic deficits or meningeal signs (Mini-Mental Status\nExamination4[MMSE]>26/30;ModifiedRankinScale5[MRS]=\n2).Laboratoryparameterswerenormal.Shewasdiagnosedwith\nbriefpsychoticdisorderanddischargedhome.\nSymptoms progressed, requiring admission to a psychiatric\nhospital. On admission, hyperventilation was observed. Days\nINTRODUCTION later, the patient became apneic, had a witnessed generalized\ntonic-clonic seizure, and was transferred to our tertiary care\nTheclassicpresentationofanti-NMDA-Rencephalitisinvolves center. Brain computerized tomography (CT) and MRI were\na confluence of psychiatric, neurologic and autonomic symp- normal. CSF showedmildly elevatedlymphocytesand protein.\ntoms, often with a viral prodrome. Psychosis, hallucinations, Treatment with acyclovir was started for presumed viral en-\nmemory loss and personality changes are the earliest symp- cephalitis.Fourdayslater,sheexperiencedanothergeneralized\ntoms; for this reason psychiatry is often consulted. Dyskine- seizure with decreased level of consciousness. She was intu-\nsias(especially orofacial),ataxia,seizuresanddecreasedlevel batedandtransferredtotheICU.\nofconsciousnessmayfollow,promptingreferraltoaninternist. IntheICU,orofacialdyskinesiasandinvoluntarymovementsof\nDays to weeks later, autonomic instability may occur, mani- the upper extremities were observed. Continuous EEG demon-\nfesting as cardiac arrhythmia, hypotension and hypoventila- stratednon-convulsivestatusepilepticus,requiringhighdosesof\ntion,requiringsupportivecareintheintensivecareunit(ICU). anticonvulsantsandgeneralanaesthesia.RepeatserumandCSF\ninvestigationswereunchanged.Aparaneoplasticantibodypanel\nGregoryS.DayandSashaM.Highcontributedequallytothemanuscript. wassentgiventheconstellationofpersonalitychanges,autonomic\ninstability(requiringmechanicalventilation),orofacialdyskinesia\nReceivedOctober29,2010\nRevisedDecember29,2010 and seizures. Anti-NMDA-R antibodies were detected in serum\nAcceptedJanuary13,2011 andCSF.Searchforaprimarytumorrevealeda2.9-centimeter\nPublishedonlineFebruary12,2011 right ovarian cyst. Laparoscopic right oophorectomy was per-\n811\n812 Dayetal.:Anti-NMDA-ReceptorEncephalitis JGIM\nformed;pathologyconfirmedmaturecysticteratoma.Thepatient malignancy.SerialCSFsamplesshowedanon-specificlympho-\nwastreatedwithplasmaexchange(PLEX)followedbyintravenous cyticpleocytosisandoligoclonalbanding,suggestiveofimmune\nimmunoglobulin (IVIG, 2 g/kg divided over 5 days) without upregulationwithintrathecalantibodyproduction.CSFwassent\nimprovementinneurologicalstatus. for anti-NMDA-R antibodies. Empiric high-dose corticosteroids\nThepatient’sprolongedICUcoursewascomplicatedbydiabetes and acyclovir were started to treat possible steroid-responsive\ninsipidus,Staphylococcusaureuspneumonia,Clostridiumdifficile encephalopathyandviralencephalopathy,respectively.Acyclovir\ncolitis and bacteremia. Three months following initial presenta- wasdiscontinuedwhenherpessimplexviruswasnotidentified\ntion, she developed third-degree heart block with hypotension. by polymerase chain reaction (CSF). A course of IVIG (2 g/kg\nInstability persisted despite transvenous pacemaker insertion. divided over 5 days) was completed with no response. Three\nFourteenandone-halfweeksfollowingadmission,shesuffereda weeksintoadmission,thepatientdevelopedglobalaphasiaand\ncardiacarrestanddieddespiteaggressiveresuscitationattempts. flaccid quadriparesis with opsoclonus. He was urgently trans-\nferredtoourtertiarycarecenter.\nWithin24hoursoftransferthepatientexperiencedageneral-\nized tonic-clonic seizure with respiratory compromise requiring\nCase B\nintubationandICUadmission.Repeatbrainimagingwasnormal.\nEEG showed generalized non-specific slowing. His course was\nAhigh-functioning84-year-oldItalianwomanpresentedtoour\ncomplicatedbytreatment-resistantstatusepilepticus,ventilator-\ntertiary care hospital with a six-day history of disorientation,\nassociated pneumonia and Stevens–Johnson syndrome (pre-\nagitationandvisualhallucinations.Physicalexaminationdem-\nsumedsecondarytoanticonvulsants,includingcarbamazepine).\nonstratedimpairedcognitionwithdecreasedattention(MMSE=\nWithin two weeks of transfer, anti-NMDA-R antibodies were\n22/30, MRS=3). Blood tests, toxicology and brain CT were\nconfirmedintheCSF.Afive-daycourseofPLEXwasadministered\nnormal.Urinalysiswaspositiveforleukocytesandnitrites,and\nwithoutimprovement.Hecontinuedtodeteriorateanddeveloped\nurine culture confirmed Escherichia coli sensitive to fluoroqui-\nbradycardia, prolonged QT interval and apnea. Rituximab was\nnolones.Urinarytractinfectionwastreatedwithciprofloxacin.\nadministered(375mg/m2tobegivenweekly,sixcycles).Sixdays\nWhile in hospital the patient experienced insomnia, anxiety\nfollowing the first dose he developed sepsis with hemodynamic\nanddelusionsthatherfoodwasbeingpoisoned.Givenconcern\nfailure. Consistent with advanced directives, cardiopulmonary\nfor non-resolvingdelirium, a lumbarpuncturewas performed;\nresuscitationwasnotprovidedandhedied.\nCSF showedhigh-normal proteinand lymphocytic pleocytosis.\nSixweeksafteradmission,shedevelopedorofacialdyskinesias,\nunilateraldystonicposturingofthelimbsandhyperventilation,\nfollowedbyhypoxicrespiratoryfailurerequiringintubationand Anti-NMDA-Receptor Encephalitis\nICU admission. Brain MRI was normal. EEG showed diffuse\nslowing. Diagnosis of viral encephalitis was presumed. Seven\nThesyndromeofanti-NMDA-Rencephalitiswasfirstcharacterized\nweeks later, phenytoin was started after EEG demonstrated\nin 20076. Over 120 cases have been reported in the literature\nperiodiclateralizedepileptiformdischarges—anon-specificpat-\n(Table1).Initiallydescribedasaparaneoplasticsyndromeaffecting\nternseeninpatientswithseizures,braininfections,tumorsand\nyoungwomenwithovarianteratomas,anti-NMDA-Rencephalitis\nintracranial hemorrhage, amongst other causes. A second\nis associated with mediastinal teratomas, sex-cord stromal\nlumbarpuncturewasperformedwithanti-NMDA-Rantibodies\ntumors,small-celllungcancerandtesticularteratomas1.Inthe\ndetectedintheCSF.Imagingofthethorax,abdomenandpelvis\nlargestcaseseriespublishedtodate1,thesyndromeofanti-NMDA-\nfailed to detect malignancy. Empiric treatment with IVIG was\nRencephalitiswasdescribedin91femalesand9males.Ovarian\nstarted(2g/kgdividedover5days).Noresponsewasobserved\nteratomaswerediagnosedin56females(62%;56/91);small-cell\nwithin two weeks. PLEX was performed without improvement.\ncancerandtesticularteratomawerediagnosedintwomales(22%;\nFourteenweeksintoadmission,thepatientremainedunrespon-\n2/9). Microscopic analysis of ovarian teratomas confirmed the\nsive with complications, including ventilator-associated pneu-\npresenceofcentralnervoussystemtissue,withNMDA-receptors\nmoniaandPseudomonasbacteremia.Inconsultationwithfamily\nexpressedin25tumorsfurtheranalyzed.Animmune-mediated\nandhealth-teammembers(includingpalliativecarespecialists)\nmechanism likely underlies this syndrome: antibodies formed\nthe decision was made to withdraw ventilatory support. The\nagainst neoplastic cells cross-react with native NMDA-receptors\npatientdiedfromrespiratoryfailurewithin24hours.\nleadingtodestructionordown-regulation1.\nIn the normal state, NMDA-receptors are found throughout\nthecentralnervoussystem,mediatingacriticalroleinsynaptic\nCase C transmissionandplasticity.NR1andNR2subtypesbindglycine\nand glutamate, respectively, and together form heteromers with\nA38-year-oldhealthyCaucasianmalecomplainedofasix-month distinct pharmacologic properties, abilities to interact with\nhistoryofintermittentnausea,vomiting,vertigoandimbalance. intracellular messengers and localizations7. In patients with\nNeurologic examination was normal. Three months following anti-NMDA-Rencephalitis,antibodiesdirectedtowardstheNR1\nassessmentheexperiencedageneralizedtonic-clonicseizureand and NR2 heteromers of NMDA-receptors circulate within CSF.\nwas admitted to hospital (MMSE=30/30, MRS=1). Over the NR1andNR2heteromerspredominatewithinthehippocampus,\nfollowingweek,hedevelopedprogressiveconfusion,short-term with less intense reactivity described in the forebrain, basal\nmemorydysfunction,prosopagnosia,agitation,orofacialdyski- ganglia, spinal cord and cerebellum1,8. Thus, antibodies may\nnesias,partialcomplexseizuresandbroad-basedgait.BrainCT preferentially affect areas responsible for memory, personality,\nand MRI were normal. CTand positron emission tomography movement and autonomic control, accounting for the unique\n(PET) of the chest, abdomen and pelvis failed to reveal a confluence of personality changes, impairments in cognition,\nJGIM Dayetal.:Anti-NMDA-ReceptorEncephalitis 813\nTable1. SelectedSummaryofCases,PatientPresentation*\nNumberof Viral MRIFLAIR†/T2 CSFLymphocytic PresenceofNeoplasm\nCases,Median Prodrome Hyperintensity(focalfindings) Pleocytosis‡\nAge(Range)\nWomen Men Women Men\nDalmauetal.20076 12 0 83%(10/12) 75%,9/12(67%,6/9) 100%(12/12) 100%(12/12) –\n27(14–44)years\nDalmauetal.20081 91 9 86%(86/100) 55%,55/100(35%,19/55) 91%(91/100) 62%(56/91) 22%(2/9)\n23(5–76)years\nIizukaetal.200812 4 0 100%(4/4) 25%,1/4(0) 100%(4/4) 75%(3/4) –\n25.8\n(17–33)years\nIshihuraetal.20082 1 0 100%(1/1) MRINormal 100%(1/1) 0 –\n42years\nGableetal.20093 6 4 “Mostpatients” 40%,4/10(25%,1/4) 90%(9/10) 33%(2/6) 0\n18.5\n(11–31)years\nDaviesetal.20109 4 2 Notspecified 17%,1/6(0) 100%(6/6) 50%(2/4) 0\n27(21–41)years\nPrüssetal.201010 6 0 83%(5/6) 67%(4/6)(0) 100%(6/6) 33%(2/6) –\n22.5\n(18–31)years\nDayetal.2011 2 1 100%(3/3) 0 100%(3/3) 50%(1/2) 0\n38(21–84)years\n*CaseswerecompiledthroughMEDLINEsearchofEnglish-languagepublications(2007–2010)usingkeyword“anti-NMDA-receptorencephalitis.”Case\nreviews featuring multiple cases were included. Cases cited in manuscript text were included regardless of number of cases to provide outcome\ninformation\n†Fluid-attenuatedinversionrecovery\n‡Absolutewhitebloodcellcount>5/μL,lymphocyticpredominance\nmotor derangements, bradyarrhythmias and disturbances in in 86% (6/7) of patients managed in a single-center ICU with\nrespiratorydrivethatdefinethesyndrome. diagnosis “encephalitis of unknown origin” and compatible\nAntibodytitresarehigherinpatientswithconfirmedmalignan- clinicalfeatures10.Thediagnosisoughttobeconsideredinthe\ncies and highest in those with the most severe symptoms1. differential of all patients presenting with findings of “viral\nAntibodiesarealsodetectedwithintheCSFofpatientspresenting encephalitis”—regardless of age or sex (previous reports have\nwiththetypicalsyndromewithouttumor(similartoCasesBand emphasized the classic presentation in the “young female”)—\nC).Itisthereforelikelythatotherimmunologictriggerscontribute especiallywhenfindingsout-of-keepingwithpresumeddiagnosis\ntotheproductionofautoantibodies.Onesuchtriggermaybeviral aredetected,asnotedinCaseA,describingapatientwithfever\ninfection, as viral prodrome is reported in the majority of cases incompatiblewithdiagnosisofbriefpsychoticdisorder.Similarly,\n(Table1).Similarassociationswithneoplasmandviralprodromes thepresenceofseizuresearlyintheillnesscourseshouldraise\nare described in other antibody-mediated syndromes including diagnostic suspicion. Complex and generalized seizures are\nlimbic encephalitis, dermatomyositis–polymyositis, myasthenia reported in the majority of cases (76% [76/100] in the largest\ngravisandLambert–Eatonmyasthenicsyndrome. case series1), distinguishing anti-NMDA-R encephalitis from\nmostcausesofviralencephalitis3andsuggestingthatseizures\narepartofthenaturalhistoryofthissyndrome.Investigations\nshouldberequestedwiththeintentofconfirmingthediagnosis\nDiagnosis and Management\nwhileexcludingmimics(Table3).Particular attention should\nbedirectedtowardorgansofgametogenesis,asthepresence\nTheidentificationofNMDA-receptorantibodieshasestablisheda and removal of ovarian or testicular teratomas is associated\nlaboratory diagnosis for the characteristic clinical syndrome. withmorefavorableoutcomes1.Confirmatorytestingshould\nCase A exemplifies the most common presentation of anti- be requested in all patients presenting with psychiatric,\nNMDA-Rencephalitis:ayoungfemaleofreproductiveagewith neurologic and autonomic symptoms / signs that are not\nanovarianteratoma.CaseBdescribesthesyndromeinan84- better explained by another disease process. Although\nyear-oldwoman—theeldestcasereportedtodate.Finally,CaseC routine antibody testing is not yet available, techniques for\nprovides an example of anti-NMDA-R encephalitis in a young isolating antibodies have been published1 and validated—\nmale without evidence of tumor. Although patients’ ages vary sensitivity and specificity is reported to be 100%11. Results\nwidely,symptoms,signsandcoursesaresimilar(Table2). may be obtained through communication with academic\nThese cases highlight several important discussion points. centers investigating paraneoplastic syndromes.\nPerhapsmostimportantisthatanti-NMDA-Rencephalitisisan Empirictreatmentshouldbeinitiatedconcurrentwithinves-\nunder-recognized syndrome. Withthe adventofantibody mar- tigations, with close monitoring for response. No randomized\nkers,thissyndromewasconfirmedin20%ofcasesofencepha- controlledtrialshaveevaluatedanti-NMDA-Rencephalitistreat-\nlitisatonetertiaryreferralcenter9,andretrospectivelydiagnosed ment.Open-labelobservationalstudiesofimmune-modulating\n814 Dayetal.:Anti-NMDA-ReceptorEncephalitis JGIM\nTable2. PatientPresentations,InvestigationsandOutcomes\nSex PatientA B C\nFemale Female Male\nAge 21 84 38\nSymptoms\n-Psychiatric Confusion,agitation,auditory Disorientation,agitation,anxiety,visual Confusion,short-termmemory\nhallucinationsandsuicidal hallucinations,persecutorydelusions dysfunction,prosopagnosia,agitation\nideation\n-Dyskinesias Lip-smacking,chewing Lip-smacking,chewingmovements Lip-smacking,chewingmovements,\nmovements,rotatorymovements opsoclonus\nofupperextremities\n-Hypoventilation Yes,withapnea Yes Yes,withapnea\n-Arrhythmias 3oheartblock No Bradycardia,prolongedQTinterval\nInvestigations\n-CSF Lymphocyticpleocytosis(107 Lymphocyticpleocytosis(22WBC/HPF, Lymphocyticpleocytosis(84WBC/HPF,\nWBC/HPF*,99%lymphocytes), 98%lymphocytes),elevatedprotein 92%lymphocytes)elevatedprotein\noligoclonalbandsnotrequested (170mg/ml†),oligoclonalbandsnot (250mg/ml),oligoclonalbands\nrequested\n-CTHead Normal Microangiopathicchanges Normal\n-MRI Normal Normal Normal\n-EEG Early:normal.Late:non- Early:diffusenon-epileptiformactivity Early:GeneralizedslowingLate:\nconvulsivestatusepilepticus Late:periodiclateralizedepileptiform statusepilepticus\ndischarges\n-Anti-NMDA-R Yes Yes Yes\nantibodiesinCSF\nTumor Ovarianteratoma None None\nTreatment\n-Corticosteroids No Yes Yes\n-IVIG Yes Yes Yes\n-PLEX Yes Yes Yes\n-Rituximab No No Yes\nTimefrom 8weeks 10weeks 5weeks\npresentationtodiagnosis\nDurationofsymptoms\n(ICUadmission) 14.5weeks(14weeks) 14weeks(8weeks) 36weeks(9weeks)\nOutcome Deceased Deceased Deceased\n*Whitebloodcellsperhighpoweredfield\n†Milligramspermilliliter\nTable3. DifferentialDiagnosisofAnti-NMDA-REncephalitis\nEtiology DistinguishingFeatures\nPhysicalExamination LaboratoryMarkers Imaging\nInfectious(e.g.,bacterial -Fever -PositiveCSF/serumcultures -CT:Hydrocephalus\nmeningitis,HSV* -Nuchalrigidity -Specificantibody/antigen -MRI:Temporallobehyperintensity/\nencephalitis,otherviral, -Palpablepurpura detection degeneration(HSVencephalitis),cortical\npriondisease) (Neisseriameningitidis) ribbon/basalgangliaenhancement\n(Creutzfeldt-JakobDisease)\nNeoplastic(e.g.,primary/ -Focalneurologic -Specificmarkers(PSA†,CA-125‡, -CT/MRI:Space-occupying\nsecondarybrainneoplasm, signs CEA§) lesion(s)\ncentralnervoussystem -Monoclonalproliferationonflow\nlymphoma) cytometry,immunohistochemistry\nMetabolic(e.g.,Wernicke’s, -Abnormaleye -Decreasedthiamine -Periventricularenhancement/\nHashimoto’sencephalopathy) movements,ataxic -Anti-thyroidperoxidase/thyroglobulin hemorrhage(Wernicke’s)\ngait(Wernicke’s) antibodies\nAutoimmune(e.g., -Systemicfindings -IncreasedESR‖/CRP¶ -Diffusecorticalchanges,vesselwall\nvasculitis,systemiclupus -Specificrheumatologicseromarkers narrowing(withvessel-wallimaging)\nerythematous)\n*Herpessimplexvirus\n†Prostatespecificantigen\n‡Cancerantigen125\n§Carcinoembryonicantigen\n‖Erythrocytesedimentationrate\n¶C-reactiveprotein\nJGIM Dayetal.:Anti-NMDA-ReceptorEncephalitis 815\nTable4. SelectedSummaryofCases,TreatmentandResponses\nSurgical FirstLineTherapy: SecondLineTherapy: AlternativeTherapies Outcomes*(FR,MR,\nExcisionof Corticosteroids IVIG,PLEX,both Attempted PR,Death)\nTumor\nDalmauetal.20076 75%(9/12) 83%(10/12) IVIG=50%(6/12) Cyclophosphamide=8% FR=33%(7/12)\nPLEX=50%(6/12) (1/12) MR=8%(1/12)\nBoth=33%(4/12) PR=8%(1/12)\nDeath=25%(3/12)\nDalmauetal.20081 51%(51/100) 76%(76/100) IVIG=62%(62/100) Azathioprine=10%(10/100) FR=47%(47/100)\nPLEX=34%(34/100) Cyclophosphamide=9% MR=28%(28/100)\nBoth=Notspecified (9/100) PR=18%(18/100)\nRituximab=10%(10/100) Death=7%(7/100)\nIizukaetal.200812 75%(3/4) 50%(2/4) IVIG=50%(2/4) – FR=75%(3/4)\nPLEX=0Both=0 MR=25%(1/4)\nPR=0Death=0\nIshihuraetal.20082 0 100%(1/1) IVIG=0PLEX=100% Rituximab=100%(1/1) FR=100%(1/1)\n(1/1)Both=0 MR=0PR=0\nDeath=0\nDaviesetal.20109 33%(2/3) 100%(6/6) IVIG=33%(2/6) Cyclophosphamide=17% FR=33%(2/6)\nPLEX=50%(3/6) (1/6) MR=33%(2/6)\nBoth=17%(1/6) Ketamine=17%(1/6) PR=17%(1/6)\nRituximab=17%(1/6) Death=17%(1/6)\nDayetal.2011 33%(1/3) 67%(2/3) IVIG=100%(3/3) Rituximab=33%(1/3) FR=0MR=0PR=0\nPLEX=100%(3/3) Death=100%(3/3)\nBoth=100%(3/3)\n*FR=fullrecovery(MRS=0);MR=moderaterecovery(MRS=1–2);PR=poorrecovery(MRS=3–5);Death(MRS=6)\ntherapies have shown mixed results1,2,6,9,12 (Table 4). One wishtoexpressourgratitudetoDr.AllanDetskyforhisconstructive\ncomments and advice concerning this manuscript, and Dr. Josep\ntreatmentprotocoltoconsideristouseintravenouscorticoster-\nDalmauandhislaboratoryforserumandCSFanalysisidentifying\noids,progressingtoPLEX,IVIG,orboth.Monoclonal-antibodies\nanti-NMDA-Rantibodies.\ntargetingCD-20lymphocytes(i.e.,rituximab)maybeconsidered Case A was presented in abstract form (author B.C.) at the\nwhen other therapies have failed, although efficacy is unprov- Canadian Society of Internal Medicine 2009 Annual Scientific\nen1,2,9.Theassociationbetweenmalignancyandanti-NMDA-R Meeting(October23,2009).\nencephalitissuggeststhatantibodiesareformedagainsttumor\ncellsexpressingNMDA-receptors.Consistentwiththis,surgical\nConflictsofInterest:Nonedisclosed.\nexcision of tumor “antigen” precedes a reduction in antibody\ntitres1andoffersthemostclinicalbenefitinaffectedpatients1,6.\nCorresponding Author: Gregory S. Day, MD, MSc; Division of\nExcision should be considered in all patients with suspected Neurology, University of Toronto, Toronto Western Hospital, 399\nneoplasmtodecreasepotentialantigenburden.Limitedevidence Bathurst Street, Toronto, ON, Canada M5T 2S8 (e-mail: gregg.\nfromcasereportssuggestsrituximabmaybeusefulforpatients day@utoronto.ca).\nwithoutconfirmedneoplasm2.\nAnti-NMDA-R encephalitis is a complex syndrome with\ncharacteristic symptomatology, variable response to treat- REFERENCES\nment and a broad differential diagnosis. Diagnosis and\n1. Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor\nmanagement necessitates awareness and communication\nencephalitis:caseseriesandanalysisoftheeffectsofantibodies.Lancet\nbetween various medical professionals including internists,\nNeurol2008;7:1091-98.\nneurologists, psychiatrists, intensivists, cardiologists, infec- 2. IshiuraH,MatsudaS,HigashiharaM,etal.Responseofanti-NMDA\ntious disease specialists, radiologists, gynecologic and uro- receptorencephalitiswithouttumortoimmunotherapyincludingRitux-\nlogic surgeons, and pathologists. With care as described, imab.Neurology2008;71:1921-23.\n3. GableMS,GavaliS,RadnerA,etal.Anti-NMDAreceptorencephalitis:\nprognosis remains good with 75% (92/123) of cases recov-\nreportoftencasesandcomparisonwithviralencephalitis.EurJClin\nering with minimal deficits (MRS≤2, Table 4). Mortality of MicrobiolInfectDis2009;28:1421-29.\nour cases (100%) is higher than described (0–25%, Table 4), 4. FolsteinMF,FolsteinSE,McHughPR.“Mini-mentalstate”:apractical\nwith disease courses adversely affected by complications method for grading the cognitive state of patients for the clinician. J\nPsychiatrRes1975:12:189-98.\nassociated with prolonged ICU admission. This observation\n5. vanSwietenJC,KoudstaalPJ,VisserMC,SchoutenHJ,vanGijnJ.\nstresses the importance of prompt diagnosis and treatment,\nInterobserver agreement for the assessment of handicap in stroke\nwith emphasis on supportive care. patients.Stroke1988:19:604-07\n6. Dalmau J, Tüzün E, Wu H, et al. Paraneoplastic anti-N-methyl-D-\naspartatereceptorencephalitis associatedwith ovarian teratoma.Ann\nNeurol2007;61:25–36.\nAcknowledgements: We wish to thank our patients’ families for 7. Lynch DR, Anegawa NJ, Verdoorn T, Pritchett DB. N-methyl-D-\ntheircooperationandwillingnesstoparticipateinphysicianeduca- aspartate receptors: different subunit requirements for binding of\ntion.Wealsowishtoacknowledgetheexcellentcareprovidedbyour glutamate antagonists, glycine antagonists, and channel-blocking\ncolleaguesinmedicine,nursingandaffiliatedservices.Finally,we agents.MolPharmacol1994;45:540–45.\n816 Dayetal.:Anti-NMDA-ReceptorEncephalitis JGIM\n8. TüzünE,ZhouL,BaehringJM,BannykhS,RosenfeldMR,DalmauJ. 10. PrüssH,DalmauJ,HarmsL,etal.RetrospectiveanalysisofNMDAreceptor\nEvidenceforantibody-mediatedpathogenesisinanti-NMDARencepha- antibodiesinencephalitisofunknownorigin.Neurology:75:1735-39.\nlitisassociatedwithovarianteratoma.ActaNeuropathol2009;118:737- 11. WandingerKP,SaschenbreckerS,StoeckerW,DalmauJ.Anti-NMDA-\n43 receptorencephalitis:Asevere,multistage,treatabledisorderpresenting\n9. Davies G, Irani SR, Coltart C, et al. Anti-N-methyl-D-aspartate withpsychosis.JNeuroimmunol2010;Epubaheadofprint:Oct14\nreceptorantibodies:Apotentiallytreatablecauseofencephalitisinthe 12. IizukaT,SakaiF,IdeT,etal.Anti-NMDAreceptorencephalitisinJapan:\nintensivecareunit.CritCareMed2010;38:679-82. Long-termoutcomewithouttumorremoval.Neurology2008;70(7):504-11."
}